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Abstract 
The stereoselective synthesis of fluorescent amino acids, biomolecules and natural products was 
achieved using a chiral pool strategy with α-amino acids. The use of L-aspartic acid gave access to 
a small library of enone derived amino acids via a Horner-Wadsworth-Emmons (HWE) reaction. 
Transformation of the enones via a number of steps gave a series of pyrazoloquinazoline derived 
amino acids. Due to the rigid structure of these amino acids, high quantum yields were observed. 
The lead compound from this series, a dimethylamino substituted pyrazoloquinazoline also 
displayed high excitation and emission wavelengths. It was found that this compound could be 
excited either by a one or a two-photon process. This amino acid was also incorporated into a 
short cell-penetrating pentapeptide in high yield, with no loss of fluorescence. 
 
A second series of fluorescent amino acids bearing benzotriazole side-chains was synthesised from 
L-asparagine in five steps. The conjugation of these was extended using a Suzuki-Miyaura reaction 
that led to a highly fluorescent 4-methoxyphenyl substituted analogue. This new chromophore 
was also rigidified using a copper-catalysed C-H insertion reaction, which yielded a new carbazole 
derived amino acid. 
 
The HWE reaction used in the first project was investigated as a new approach for bioconjugation. 
The aspartic acid derived phosphonate ester was coupled with alanine, and this model dipeptide 
was subjected to successful HWE reactions with various aldehydes, showing this as a possible new 
method for incorporating chromophores within peptides and proteins. 
 
Finally, L-aspartic acid was also used as a starting material to synthesis a small library of enones, 
using a HWE reaction. These were found to be excellent substrates for an acid-mediated 6-endo-
trig cyclisation for the stereoselective synthesis of a series of 2,6-dialkyl-4-oxopiperidines. This 
transformation was then used as the key step for the synthesis of the alkaloids, (+)-myrtine and 
(−)-solenopsin A. 
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1.1 Introduction 
1.1.1 Fluorescence imaging 
Fluorescence imaging is a non-invasive technique that can offer much insight into biological 
processes.1 The success of fluorescence imaging is due in part to the range of different fluorescent 
probes that are available, such as small organic molecules, quantum dots and proteins. The use of 
two-photon excitation techniques have allowed living cells to be imaged with minimal 
morphological change.2 Fluorescence imaging has inherent advantages over other imaging 
techniques such as positron emission tomography (PET) and single-photon emission computed 
tomography (SPECT) that relies upon radioactive nuclei.3 No special handling and disposal 
procedures are required and fluorescent probes are radiologically stable. Carbon-11 that is used 
for PET imaging has a half-life of 20 minutes. Therefore, the shelf life of PET probes based upon 
11C is severely limited.4 Recently, fluorescent probes have also recently found use in surgery.5 It 
has been found that the use of fluorescence-guided surgery can significantly increase the survival 
rate of patients with malignant glioma. 
 
1.1.2 Introduction to photoluminescence 
Electrons within the ground state of a compound can be excited to a higher energy level. As the 
electron returns back to the ground state, it can emit a photon as luminescence. There are many 
methods in which an electron can be excited for luminescence to occur, including 
chemiluminescence, bioluminescence, electroluminescence, radioluminescence, 
sonoluminescence, thermoluminescence and photoluminescence.6,7 Photoluminescence is the 
absorption of a photon of light, leading to excitation and then luminescence as the electron 
relaxes back to the ground state.8 This is summarised with a Perrin-Jablonski diagram (Figure 1).7 
Luminescence occurs either through fluorescence or phosphorescence. Fluorescence is the 
electronic transition from an excited singlet state (S1) back to the ground singlet state (S0). As this 
is an allowed transition, it has a short excited-state lifetime with retention of spin multiplicity.9 
Phosphorescence occurs with intersystem crossing to an excited triplet state (T1) then, transition 
back to the ground singlet state (S0) and release of a photon of light. As this is a forbidden 
transition, this results in a long excited-state lifetime and involves a change of spin multiplicity. 
With photoluminescence, the photon emitted is at a longer wavelength than the photon that was 
absorbed. This is due to energy losses within the compound after excitation resulting in the light 
emitted being lower in energy. This difference between excitation and emission wavelengths is 
known as the Stokes shift. 
11 
 
 
 
Figure 1 Perrin-Jablonski diagram. 
 
Emission of a photon as fluorescence only occurs from the first excited singlet state (S1). This is 
known as Kasha’s rule.10 Azulene is the only known exception to this rule as it emits fluorescence 
from the second excited singlet state (S2). This is due to the large energy gap between the S2 and 
S1 levels.10 As excitation does not significantly alter the compound’s vibrational energy levels, this 
causes the emission and absorption spectra to become mirror images.11 This is known as the 
mirror image rule. A further rule regarding fluorescence is the Kasha-Vavilov rule.12 This states 
that the quantum yield of photoluminescence is independent of the excitation wavelength, 
however, there are expectations to this rule.10 
 
Vibrational energy levels as well as electronic energy levels are also present in a compound. This 
results in fine-structure of the absorption and emission spectra from vibronic transitions. The 
absorption and emission spectra of anthracene is an example of this (Figure 2 b).11 As anthracene 
is excited to the first excited state, numerous vibrational levels can be occupied. With excitation 
to V0 energy level of S1, this is defined as a 0-0 vibronic transition (Figure 2 a). The 0-0 vibronic 
excitation involves absorption of a photon at 376 nm. Excitation to the V1 level involves a 0-1 
vibronic transition which corresponds to absorption at 356 nm. The 0-2 transition to the V2 level 
is observed with absorption at 339 nm. From the mirror image rule, these vibronic transitions are 
present in the emission spectrum (Figure 2 b). Emission to the V0 level from a 0-0 transition is 
observed at 378 nm. With relaxation to the V1 state from a 0-1 transition, an emission at 400 nm 
is observed. Emission at 423 nm is observed for a 0-2 transition to the V2 level of the ground singlet 
state.11 If the chromophore can freely rotate, then rotational energy levels will also be present. 
12 
 
With rotational energy levels being very small, this leads to broadening of both the absorption 
and emission spectra. Therefore, vibronic fine structure is not observed in non-rigid compounds. 
 
  
Figure 2  Vibrational energy levels (left). Absorption and emission spectrum of anthracene in 
ethanol (5 μM) (right). 
 
The photoluminescent properties of a fluorophore can be quantified.13,14 The molar attenuation 
coefficient is used to quantify how efficiently a compound can absorb photons. Quantum yield is 
used to determine how efficiently the compound converts absorbed photons into fluorescence. 
The molar attenuation coefficient and quantum yield can be combined to give a value known as 
brightness. This is used to quantify the total fluorescence intensity of the fluorophore. 
 
The photoluminescence properties of a fluorophore can alter in different environments and this 
is known as solvatochromism.15 As a fluorophore is excited, it gains a larger dipole moment. The 
surrounding solvent dipoles will reorient to stabilise the dipole moment. With increasing solvent 
polarity, the effect of this energy reduction becomes more pronounced. Therefore, in more polar 
solvents the emission becomes red-shifted and lower in energy. An example of this is with 4-
dimethylamino-4ʹ-nitrostilbene (1) (Figure 3). In pentane, it emits with a maximum of 465 nm. 
When 1 was dissolved in dioxane, the emission maximum was at 598 nm and when it was dissolved 
in DMF, the emission maximum occurred at 830 nm. 
 
 
Figure 3 4-Dimethylamino-4ʹ-nitrostilbene (1). 
 
If a compound has an electron-donating group conjugated to an electron-accepting group, an 
intramolecular charge transfer (ICT) state can form. The formation of an ICT state is dependent 
upon solvent polarity. In polar solvents, the separated charges can be stabilised, resulting in the 
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ICT becoming more favourable. In non-polar solvents, these charges cannot be stabilised, resulting 
in a locally excited state (LE) being more favourable. Therefore, in polar solvents, emission will 
occur only from the ICT state and in non-polar solvents, emission will only occur from the LE state. 
For some intermediate solvents, such as methanol, emission may occur from both ICT and LE 
states giving dual emission. For formation of the ICT state, rotation of the functional groups 
present is sometimes required. This rotation gives a twisted internal charge transfer (TICT) state. 
In addition, the quantum yield of a compound can vary in different solvents. Typically, the use of 
high polar hydrogen-bonding solvents reduces the quantum yield of compounds.16 
 
1.1.3 Two-photon excitation  
Commonly a single photon is used in exciting a compound to its excited state. However, multiple 
photons can also be used to excite a compound (Figure 4). With multiple photons being used to 
excite the compound, the total energy required to reach the excited state is divided between the 
photons. For example, with a two-photon process, this corresponds to a doubling of the excitation 
wavelength. If a compound requires photons of 350 nm to reach the first excited state with a one-
photon process, then 700 nm can be used for a two-photon process.  
 
 
Figure 4 Two-photon excitation. 
 
For biological imaging, multi-photon excitation offers many advantages over traditional one-
photon excitation, such as reduced phototoxicity, reduced photobleaching and greater tissue 
penetration.17 Reduced phototoxicity can be achieved with the use of higher excitation 
wavelengths. Some fluorophores are excited with UV light and this can be detrimental to the 
biological system being studied. For example, mammalian cells undergo apoptosis when irradiated 
with UV light.18 Whereas, if a two-photon process is used, the resulting higher excitation 
wavelengths could avoid cell apoptosis. The advantages of two-photon microscopy have been 
demonstrated with the monitoring of mitochondrial distribution in hamster embryos.19 After 8 h 
of one-photon microscopy, it was found that embryo development had ceased. Whereas, the use 
14 
 
of two-photon microscopy over a 24 h time span with frequent imaging, resulted in viable 
embryos, still capable of foetus development. Furthermore, photobleaching is also reduced with 
the use of two-photon excitation.2 As fluorescence emission increases quadratically with 
excitation intensity, photobleaching only occurs within the vicinity of the focal plane, minimising 
damage. 
 
From its high sensitivity and real-time analysis, fluorescence has been used to investigate 
biological processes.20 There exists an “imaging window” between 650 nm and 1450 nm where 
tissue penetration is the largest, as the components of tissue have low absorbance at these 
wavelengths (Figure 5).21 Therefore, having fluorophores that operate at these wavelengths 
allows for deep tissue penetration. An example of this has been demonstrated with quantum 
dots.22 The use of two-photon excitation (900 nm) allowed for high-resolution fluorescence 
imaging up to depths of 2 mm. This was not achievable using a one-photon process with light of 
450 nm.  
 
 
Figure 5 Imaging window. Reprinted with permission from (Chem. Mater., 2012, 24, 812–827). 
Copyright (2012) American Chemical Society. 
 
1.1.4 Quenching of fluorescence 
Fluorescence can be quenched through a number of different processes and this results in a 
decrease of intensity. The inclusion of heavy atoms can lead to a reduction of the fluorescence 
quantum yield (Table 1).9 This is due to increased efficiency of intersystem crossing to the triplet 
state from spin-orbit coupling, although from this, increased phosphorescence is observed. For 
naphthalene, a quantum yield of 0.55 is measured but with the inclusion of an iodine atom, this is 
decreased to 0.0005.23 It should be noted that the quantum yield of phosphorescence is increased 
to 0.38.24 This “heavy atom effect” has also been shown to operate both externally and over long 
distances.25 
15 
 
 
Compound φF φP 
Naphthalene 0.55 0.051 
1-Fluoronaphthalene 0.84 0.056 
1-Chloronaphthalene 0.058 0.30 
1-Bromonapthalene 0.0026 0.27 
1-Iodonaphthalene <0.0005 0.38 
Table 1 Fluorescence and phosphorescence quantum yield values for halogenated naphthalene. 
 
The inclusion of nitro functional groups into polyaromatic compounds can also lead to 
fluorescence quenching, resulting in the fluorescence of aromatic nitro compounds not being 
detectable.9,26 It has been determined that 1-nitronaphthalene has the largest intersystem 
crossing rate of any organic molecule.27 This results in many aromatic nitro compounds being 
phosphorescent.9 For example, carbazole (2) has excellent fluorescent properties.9 However, with 
3-nitrocarbazole (3), no fluorescence is detected.28 Instead, high levels of phosphorescence is 
observed with 3 when measured in a solid matrix at 77 K. However, for some nitroaromatics, the 
intersystem crossing is not fully efficient. So, some quenching may be due to high rates of S1 to S0 
non-radiative internal conversion resulting from the strong electron-withdrawing nature of the 
nitro group.9 
 
 
 
Figure 6 Quantum yields of 2 and 3. 
 
Quenching of fluorescence can also occur with excited-state proton transfer.29 The acidity and 
basicity properties of a compound can differ between the ground state and excited state. For 
example, phenol has a pka of 10.6 in the ground state. This pKa value is decreased to 3.6 when 
phenol is excited.9 Therefore, the fluorescence of compounds such as naphthol can be quenched 
in water from proton transfer.30 Fluorescence can also be diminished with collisions with 
quenchers. Dissolved oxygen is a well-known quencher for aromatic hydrocarbons.31 Similar 
quenching is observed between 1-chloronaphthalene and ethyl iodide and between anthracene 
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and diethylaniline.32,33 The presence of nitro-aromatic compounds has also been shown to quench 
fluorescence, with a photo-induced electron transfer from the fluorophore to the aromatic nitro 
compound.33 This quenching mechanism has been used in the detection of nitro-containing 
explosive compounds such as 2,4,6-trinitrotoluene. 
 
1.1.5 Methods for improving the fluorescence of chromophores 
To improve the photoluminescence properties of a compound, a number of strategies can be 
implemented. For example, the conjugation present in the fluorophore can be increased. The 
increased conjugation from biphenyl (4) to para-terphenyl (5) leads to higher quantum yield, 
molar attenuation coefficient and longer absorption and emission wavelengths (Figure 7).34 
 
 
Figure 7 Photoluminescent properties of 4 and 5. 
 
The quantum yield and molar attenuation coefficient is also increased in more rigid and planar 
compounds.35–37 The influence of rigidity on the quantum yield value is demonstrated with 4,4ʹ-
di-tert-butylbiphenyl (6) and fluorene (7). Due to the increase in rigidity, the quantum yield 
increased from 0.26 to 0.70 (Figure 8).38 The same phenomenon is also observed in donor-π-
acceptor systems. While alkene 8 has a quantum yield of 0.15, the more rigid alkyne 9 has a value 
of 0.83.39 
 
 
 
Figure 8 Quantum yield values of compounds 6–9. 
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The strategy of rigidifying compounds has shown to be very successful at creating improved 
fluorophores for biological imaging. This was shown with far-red cyanine dye 10 (Figure 9).37  
Although, the compound is heavily used in fluorescence microscopy, it has a small quantum yield 
value in aqueous solutions This is due to excited state trans-cis polyene rotation which quenches 
the fluorescence. To overcome this, the fluorophore was rigidified and this gave octacyclic 
compound 11. With this increased rigidity, a substantial increase of the quantum yield from 0.15 
for 10 to 0.69 for 11 in PBS solution was observed. 
 
 
Figure 9 Photoluminescent properties of 10 and 11. 
 
As mentioned, it is preferable for fluorophores to have high absorption and emission wavelengths 
for imaging. A method to increase these wavelengths is with push and pull electronic systems. For 
example, alkyne 12 has an emission wavelength of 361 nm in ethyl acetate (Figure 10).39 When a 
push-pull system is introduced by incorporating an electron-donating methoxy functional group 
9, the emission wavelength is increased to 396 nm. When the more electron-donating 
dimethylamino group is used 13, the emission wavelength is increased to 515 nm. The excitation 
wavelengths of these compounds are also increased. 
 
 
12 
λEx = 304 nm, λem. = 361 nm in EtOAc 
 
9 
λEx = 319 nm, λem. = 396 nm in EtOAc 
 
13 
λEx. = 360 nm, λem. = 515 nm in EtOAc 
Figure 10 Excitation and emission wavelengths of compounds 9, 12 and 13. 
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1.1.6 Introduction to fluorescent amino acids 
Fluorescence imaging is highly important for investigating peptide-protein and protein-protein 
interactions using environmentally sensitive and highly fluorescent dyes that are available.40,41 
When studying biological processes, the proteinogenic amino acids, L-phenylalanine, L-tyrosine 
and L-tryptophan 14–16 can be used as fluorophores (Figure 11).13,14,42 From its small quantum 
yield and low molar attenuation coefficient, fluorescence from L-phenylalanine is only detected in 
proteins without L-tryptophan and L-tyrosine residues.14 Therefore, L-phenylalanine has very 
limited applications. L-Tyrosine has much greater fluorescence intensity than L-phenylalanine, but 
it lacks environmental sensitivity.14 Whereas, with its bigger brightness value and high 
environmental sensitivity, L-tryptophan has found more application in fluorescent microscopy.14 
The study of protein structure has been studied with time-resolved fluorescence using L-
tryptophan residues.43 This is carried out with proteins containing only a single L-tryptophan 
residue. Otherwise, the replacement of all but one L-tryptophan residue can be achieved with 
mutagenesis. It has also been shown that the fluorescence from L-tryptophan residues can be used 
in the diagnosis of cataracts.34 
 
 
 
Figure 11 Structure and fluorescent properties of amino acids 14–16 and absorption, emission 
spectra of tryptophan in MeOH (10 μM). 
 
However, due to the issues associated with naturally occurring amino acids such as low brightness, 
nonspecific labelling and low excitation wavelengths, it is often it is best to install a superior 
fluorophore. Fluorescent protein such as green fluorescent protein can be used to label peptides 
and proteins. Although, the size of a fluorescent protein may affect the folding and function of the 
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protein being studied.14,40 Small, highly fluorescent amino acids can also be used. Due to their 
small size, they may not affect the nature of protein being studied.14,20,40,41,45 Furthermore, they 
can be specifically placed anywhere in the protein/peptide to give site-specific information. 
 
1.1.7 Synthesis of fluorescent amino acids 
Fluorescent amino acids have been prepared using a number of different approaches.45 Most 
syntheses of fluorescent amino acids have used a chiral pool strategy, that took advantage of the 
diverse range of natural α-amino acids available. This approach avoids the use of enantioselective 
catalysts and chiral resolution. 
 
One approach that had been used for the synthesis of fluorescent amino acids was 
functionalisation of the α-amino group.46 For example, it was shown that L-amino acids 18a–18f 
could be prepared from the proteinogenic amino acids with 3-(6-iodo-2-
pyridinyl)[1,2,3]triazolo[1,5-a]pyridine in high yields (Scheme 1).46 High excitation (333–357 nm) 
and emission wavelengths (405–451 nm) were obtained from this library of compounds. It was 
then investigated if these amino acids could be used as metal sensors. It is known that Cu(II) and 
Zn(II) can diminish or enhance fluorescence respectively.47 When copper(II) was added to the 
amino acids, the fluorescence was strongly quenched. There was no enhancement in fluorescence 
with the addition of zinc(II). It was also shown that fluorescence was enhanced and blue-shifted 
by 20 nm with the addition of oxalic acid. As the fluorophore was installed onto the α-amino group, 
this limited the use of amino acids 18a–18f in peptide synthesis. 
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Scheme 1 Synthesis of fluorescent amino acids 18a–18f. 
 
Fluorescent amino acids are more commonly synthesised by modification of the side-arms of the 
natural amino acids. Lysine, 2,3-diaminopropionic acid, serine, tyrosine and aspartic acid have all 
been used to prepare fluorescent amino acids. For example, D-lysine has been used in the 
synthesis of dimethylamino substituted naphthalimide derived amino acid 21 (Scheme 2).48 This 
was achieved by a condensation reaction of Boc protected D-lysine 19 with dimethylamino 
substituted naphthalic anhydride and gave 20 in 66% yield. The fluorescent properties of amino 
acid 20 was next investigated. It was found that the deprotected amino acid had an excitation 
wavelength of 450 nm and an emission wavelength of 533 nm in methanol. In water, a 
bathochromic shift was observed with amino acid emitting at 548 nm. A Fmoc protected analogue 
21 was then prepared from 20 in 71% yield over two-steps. This allowed for the synthesis of a 
tripeptide by solid-phase peptide synthesis (SPPS) using 21. It was thought that the use of D-amino 
acid 21 in peptide synthesis would be highly attractive due to its resistance to enzymatic 
degradation. 
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Scheme 2 Synthesis and photophysical properties of naphthalimide derived amino acid 20. 
 
The amino acid, L-2,3-diaminopropionic acid, has been used for the preparation of fluorescent 
amino acids.49 Dansyl derived fluorescent amino acid 24 was prepared by the reaction of protected 
analogue 22 with dansyl chloride (Scheme 3).50 After deprotection with TFA, target compound 24 
was isolated in a 58% yield over the two steps. It had been shown that dansyl fluorophore 25 has 
favourable fluorescent properties in methanol.51 Amino acid 24 was incorporated into human 
superoxide dismutase protein. Unfolding of this protein in the presence of guanidinium chloride 
was investigated by fluorescence microscopy. 
 
 
Scheme 3 Synthesis of dansyl derived amino acid 24. 
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L-2,3-Diaminopropionic acid has also been used for the synthesis of phthalimide derived amino 
acid 29 (Scheme 4).52 This was accomplished by protection of the commercially available amino 
acid 26 with allyl bromide and removal of the Boc protecting group with TFA gave 27 in 73% yield. 
This allowed for coupling with the dimethylamino substituted phthalic anhydride. It was found 
that the reaction of 27 with the anhydride did not result in ring closure when standard conditions 
were used. No cyclisation occurred even when the reaction was heated in piperidine or toluene. 
HBTU and HOBt were used to complete cyclisation and this gave 28 in a 63% yield. Removal of the 
allyl protecting group was achieved with tetrakis(triphenylphosphine)palladium and phenylsilane 
and this resulted in formation of Fmoc amino acid 29 in a 100% yield. The dimethylamino 
substituted phthalimide heterocycle (DAP) 30 had some interesting fluorescent properties.53 In 
MeOH, 30 has an absorption wavelength of 396 nm and an emission maximum of 534 nm, which 
makes it a useful fluorophore for studying protein-protein interactions.52 The quantum yield of 30 
is sensitive to solvent polarity. In THF it had a value of 0.52, which decreased to 0.12 in MeCN. This 
observed decrease in quantum yield with solvent polarity was due to a nonradiative twisted 
intramolecular charge transfer (TICT) state.53 This is not evident with 4-aminophthalimide (31) as 
a TICT state isn’t possible and therefore, it's quantum yield value is independent of solvent polarity. 
 
 
Scheme 4 Synthesis of phthalimide derived amino acid 29. 
 
L-Serine has also been used for the synthesis of fluorescent amino acids. Fluorescent amino acid 
32 has been prepared from serine using a Fukuyama-Mitsunobu reaction (Scheme 5).54 A 
sulfonamide protecting group was used to lower the pKa of 2-aminonaphthalene 32 and allowed 
for a successful Mitsunobu reaction.55 Synthesis of 34 was achieved with the reaction of 32 with 
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nosyl chloride under basic conditions and this gave intermediate 33. This was used in the next step 
without any purification. A L-serine analogue was then coupled with 33 using DIAD and 
triphenylphosphine, which gave 34 in 88% yield over the two-steps. It was then shown that 34 
could be deprotected stepwise. The trityl protecting group was removed with trifluoroacetic acid 
and the nosyl group was then removed with thiophenol and potassium carbonate in DMF. This 
gave 35 in 80% yield over the two-steps. The methyl ester was then hydrolysed with 2 M HCl at 
60 °C, which gave fully deprotected analogue 36 in 99% yield. Amino acid 36 was found to possess 
a high quantum yield and solvatochromic properties.56 
 
 
Scheme 5 Synthesis of 2-aminonaphthyl amino acid 36 and fluorescent properties in EtOH. 
 
L-Serine analogue 37 was also used as a starting material for the synthesis of xanthone derived 
amino acid 41 through a palladium catalysed Negishi coupling (Scheme 6).57 This was achieved by 
activation of serine analogue 37 with tosyl chloride under basic conditions. This gave 38 in 64% 
yield. Iodine functionalised amino acid 39 was prepared from 38 with sodium iodide using a 
Finkelstein-type reaction in 80% yield. The reaction of amino acid 39 with activated zinc gave the 
organozinc reagent required for the Negishi reaction. This was performed with dichlorobis(tri-o-
tolylphosphine)palladium(II) and a xanthone triflate in DMF and gave 40 in a 31% yield. Enzymatic 
hydrolysis of the methyl ester gave amino acid 41 in a 84% yield. Amino acid 41 displayed typical 
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xanthone fluorescent characteristics. This included more enhanced fluorescence intensity in water 
than organic solvents.58 This is due to ultrafast intersystem crossing resulting in very limited 
fluorescence in most solvents. In water, the quantum yield can be 100 times larger from a delayed 
fluorescence mechanism. 
 
 
Scheme 6 Synthesis of xanthone-substituted amino acid 41. 
 
Bicyclic oxazolidone 44 has also been used to prepare fluorescent amino acids (Scheme 7).59 44 
was prepared in four-steps from L-serine analogue 37. Initially, the reaction of serine analogue 37 
with 2,2,3,3-tetramethoxybutane under acidic conditions gave 42 in 75% yield. When 42 was 
reacted with KHMDS in THF this gave alkene 43 in 95% yield. Bicyclic intermediate 44 was prepared 
by ester hydrolysis of 43 with LiOH, followed by lactonisation with EDC and DMAP in a 77% yield 
over the two-steps.60 
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Scheme 7 Synthesis of intermediate 44. 
 
With 45 prepared, it was then functionalised with  N-dansyl 2-aminoethanethiol 46.61 This was by 
a 1,4-conjugate addition under basic conditions that gave 47 in a 92% yield. Acid hydrolysis of 47 
with 4 M HCl gave fluorescent D-amino acid 48 in 96% yield. The Fmoc protecting group was 
installed on amino acid 48 with FmocOSu and sodium hydrogen carbonate, which gave Fmoc 
analogue 49 in 48% yield. 
 
 
Scheme 8 Synthesis of Fmoc protected dansyl derived amino acid 49. 
 
Dansyl derived amino acid 49 was then incorporated into a short cell-penetrating peptide 50 
(Figure 12). As the synthesised peptide contained only natural amino acids, this resulted in 50 
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being stable for up to 4 h in human plasma and being non-cytotoxic up to 200 μM.61 The potential 
of this fluorescent peptide was demonstrated with the imaging of HeLa cells. 
 
 
 
Figure 12 Peptide 50 and fluorescence imaging of HeLa cells, control (left) and with peptide 
(right).61 Reprinted with permission from (Chem. Eur. J., 2018, 24, 7991). Copyright (2018) Wiley-
VCH Verlag GmbH & Co. KGaA, Weinheim. 
 
As L-tyrosine is already fluorescent, only a few modifications are required to prepare an amino 
acid that has excellent fluorescent properties. For example, amino acid 53 was prepared using a 
palladium catalysed Heck reaction (Scheme 9).62 Starting from commercially available 3ʹ,5ʹ-diiodo-
L-tyrosine (51) this was protected by esterification and standard Boc-protection, which gave 52. A 
Heck reaction was performed using 52 and 4’-methoxystyrene, which gave 53 in 52% yield. With 
the increased conjugation, amino acid 53 was a better fluorophore than L-tyrosine. It had a higher 
quantum yield and molar attenuation coefficient values and longer excitation and emission 
wavelengths. 
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Scheme 9 Synthesis of amino acid 53 via a Heck cross-coupling reaction and fluorescent 
properties in DMSO. 
 
It was also demonstrated that flavone derived amino acid 59 could be synthesised from L-tyrosine 
(54) (Scheme 10).63 This was achieved by Friedel-Crafts acylation of 54 using acetyl chloride and 
gave 55 in 77% yield. Tyrosine derivative 55 was protected with di-tert-butyl dicarbonate and this 
gave 56 in 94% yield. An aldol condensation was then carried out with 57, 4-
dimethylaminobenzaldehyde and sodium hydroxide in ethanol and this gave chalcone 58 in 78% 
yield. Flavone 59 was synthesised from 58 using the Algar-Flynn-Oyamada reaction with sodium 
hydroxide and hydrogen peroxide in 33% yield. Target amino acid 59 was prepared by Boc group 
deprotection with HCl in dioxane. The Fmoc protecting group was installed on 59 under basic 
conditions and this gave 60 in 73% yield. With SPPS, Fmoc amino acid 60 was incorporated into 
two peptide chains. The peptide chains were based upon Melittin, a 26-mer peptide chain that is 
found in the venom of the honeybee (Apis mellifera).64 For one peptide the hydrophobic leucine 
residue was replaced at the 9-position, for the other peptide a tryptophan residue at the 19-
position was replaced. These fluorescent peptides were then used in image HeLa cells using two-
photon excitation with a wavelength of 830 nm.  
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Scheme 10 Synthesis of dimethylamino substituted flavone derived amino acid 59. 
 
One interesting aspect regarding the fluorescence of 59 is the dual emission that is observed. This 
is due to an excited state intramolecular proton transfer (ESIPT) (Table 2).65 This is demonstrated 
with compound 61. In its excited state, a proton transfer takes place and this resulted in tautomer 
62. The fluorescence from this state is emitted at a higher wavelength. Depending upon the 
solvent used, fluorescence will either take place from LE 61 or ESIPT state 62. Less polar solvents 
favour the ESIPT state. For 61 in toluene, the emission is almost exclusively from the ESIPT state 
(95% of total emission) with an emission maximum wavelength of 566 nm. As the solvent polarity 
is increased, the proportional emission from the ESIPT is decreased. When 61 is dissolved in MeCN, 
most of the emission comes from the LE state with an emission maximum of 516 nm. In aqueous 
buffer solution and methanol, emission is exclusively from LE state 61 with emission maxima at 
533 and 550 nm, respectively. 
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Solvent 
LE emission 
(nm) 
ESIPT emission 
(nm) 
% ESIPT 
emission 
φF 
Toluene 466 566 95 0.226 
EtOAc 487 567 75 0.095 
Acetone 503 573 61 0.101 
MeCN 516 575 30 0.154 
MeOH 533 N/A 0 0.262 
PBS solution 550 N/A 0 0.004 
Table 2 Excited state 61, ESIPT state 62 and photoluminescent properties. 
 
To improve the fluorescent properties in aqueous environments of 59, the dimethylamino 
functional group was replaced with a methoxy functional group. This was accomplished using the 
same synthetic approach. Ketone 56 was reacted with 4-methoxybenzaldehyde and this gave 63 
in 87% yield (Scheme 11).66 Subsequent Algar-Flynn-Oyamada reaction with sodium hydroxide 
and hydrogen peroxide gave 64 in 63% yield. Removal of the Boc protecting group with HCl in 
dioxane gave methoxy substituted flavone derived amino acid 65 in 58% yield.  
 
 
Scheme 11 Synthesis of methoxy substituted flavone derived amino acid 65. 
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As the fluorescent properties of 65 were studied, differences were found in comparison with 
61.63,66,67 The fluorescence quantum yield of methoxy analogue 65 had far less sensitivity to 
solvent polarity (Table 3). With 65 dissolved in methanol, a quantum yield of 0.067 was measured.  
This value increased to 0.078 when 65 was dissolved in aqueous PBS solution. Dual emission was 
still observed with approximately a 1:1 ratio of emission from LE and ESIPT states when 65 was 
dissolved in methanol. 
 
 
Solvent 
Excitation 
Wavelength (nm) 
LE emission 
(nm) 
ESIPT emission 
(nm) 
% Emission 
from ESIPT 
φF 
1,4-Dioxane 355 416 540 96 0.159 
DMF 355 421 539 90 0.068 
EtOH 360 429 535 66 0.072 
MeOH 357 434 535 51 0.067 
PBS 
solution 
355 442 N/A 0 0.078 
Table 3 Solvatochromic properties of methoxy substituted flavone derived amino acid 65. 
 
Based on the favourable properties of 65, it was incorporated into a peptide corresponding to the 
zinc finger domain of the nucleocapsid protein of the human immunodeficiency virus.66 Two 
fluorescent-tagged peptide chains were prepared with amino acid 65. Either the alanine residue 
at position 30 or the tryptophan residue at position 37 was replaced with 65. These fluorescent 
peptides were then used for the imaging of HeLa cells with two-photon FLIM (Figure 13). With 
each pixel in the image, the fluorescence lifetime was determined with a biexponential fit. From 
this, the image was coloured to represent the fluorescence lifetime of that pixel. No lifetimes 
under 2.5 and 1.7 ns were found, from which it was concluded that no unbound peptide was 
present within the cells. The lifetimes found suggested that the fluorescent peptides were bound 
to nucleic acids. 
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Figure 13 2-Photon FLIM imaging with fluorescent peptide tagged with 65. Reprinted with 
permission from (J. Phys. Chem., 2015, 119, 2585–2595). Copyright (2014) American Chemical 
Society. 
 
The commercially available amino acid, 4ʹ-nitro-L-phenylalanine (66) has also been used to 
synthesise fluorescent amino acids (Scheme 12).68 For example, the synthesis of fluorescent amino 
acid 71 was achieved from 66 in six steps. Initially, 66 was protected with di-tert-butyl dicarbonate 
and then diazomethane and gave 67 in 51% yield over the two steps. Reduction of 67 was carried 
out with 10% palladium on carbon and hydrogen in methanol and gave amino acid 68 in 94% yield. 
An Ullmann-Jourdan condensation was then carried out with 68 and 2-chloroenzoic acid and gave 
69 in 78% yield. Formation of an acridone ring system was carried out with 69 and hot 
polyphosphoric acid (PPA). This resulted in Boc deprotection and gave 70 in a 74% yield. The Boc 
protecting group was re-installed with di-tert-butyl dicarbonate and sodium hydroxide, which 
resulted in ester hydrolysis and gave 71 in a 59% yield. Unlike, xanthone derived amino acid 41, 
amino acid 71 had excellent fluorescent properties. It had excellent quantum yields in water (φF = 
0.95), MeOH (φF = 0.74), DMSO (φF = 0.76) but a low quantum yield in THF (φF = 0.21). In water, 
71 could be excited with light at 388 and 407 nm. This is very useful as it allowed for 71 to be 
excited selectively over tryptophan and tyrosine when used for investigating peptides and 
proteins. From vibronic transitions, two emission maxima were observed in water at 424 and 445 
nm. 
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Scheme 12 Synthesis and of acridone derived amino acid 71 and fluorescent properties in water. 
 
As acridone derived amino acid 71 had useful fluorescent properties an improved synthesis was 
published.69 It was found that 71 could be synthesised in five steps with an 87% overall yield from 
L-tyrosine (15) (Scheme 13). Protected analogue 72 was prepared in three steps and with a 96% 
overall from 15. Coupling of 72 with 2-methyl anthranilate was achieved using a Buchwald-Hartwig 
reaction and gave 73 in a 92% yield. It was also found that the efficiency of the Friedel-Crafts 
cyclisation could be improved using 13.5 M sulfuric acid and gave 74 in a 98% yield. From this 
more efficient synthesis of 74, large quantities of the amino acid could be synthesised, allowing 
for milligram quantities of a fluorescent protein to be prepared. The protein calmodulin was 
selectively labelled with 74 at the 13, 41, 100 and 113 positions.69 Then, it's binding to a peptide 
was investigated by fluorescence spectroscopy. It was found that the fluorescence emission of the 
protein became more redshifted as higher equivalents of peptide were introduced to the protein, 
signifying protein-peptide interactions. 
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Scheme 13 Improved synthesis of acridone derived amino acid 74. 
 
L-Aspartic acid has also been used for the synthesis of fluorescent amino acids.70 Protected 
analogue 75 was used in the synthesis of coumarin derived amino acid 78 (Scheme 14). This was 
achieved by synthesis of β-ketoester 76 from 75 in 77% yield. Removal of the protecting groups 
by hydrogenolysis, using 10% palladium on carbon gave 77 in 97% yield. The allowed for the key 
step, a Pechmann condensation with benzene-1,3-diol. The reaction was facilitated with 
methanesulfonic acid and gave coumarin derived amino acid 78 in a 47% yield. The imaging of 
HeLa cells was then carried out with a 17-mer peptide chain containing 78. 
 
 
Scheme 14 Synthesis of coumarin derived amino acid 78 and fluorescent properties in EtOH. 
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Although, the majority of fluorescent amino acids are synthesised from enantiopure starting 
materials, in some cases chirality is introduced by either resolution or enantioselective catalysis. 
It has been shown that the GMO enzyme Ochrobactrum anthropi can be used to resolve a racemic 
mixture of amino acids (Scheme 15).71 Racemic benzylidene protected alanine amide 79 was 
alkylated with use of a phase transfer catalyst and this phenylalanine derivative 80 in 71% yield 
over two steps. Treatment of racemic amino acid 80 with GMO Ochrobactrum anthropi resulted 
in amide hydrolysis of the S-enantiomer and gave 4ʹ-cyano-L-phenylalanine 81 in 33% yield 
with >99% ee and the R-enantiomer 80D was returned in 48% yield. Compared to phenylalanine 
(14), amino acid 81 had a quantum yield that was five times larger and had an excitation 
wavelength of 235 nm with emission at 295–305 nm. In addition, it was found that the emission 
of 81 was sensitive to its environment. Amino acid 81 was then utilised in SPPS for the preparation 
of a decapeptide. This was used for investigating peptide-membrane interactions. 
 
 
Scheme 15 Enzymatic resolution of 80. 
 
Enantioselective catalysis was used in the synthesis of charge transfer based fluorescent amino 
acid 86 (Scheme 16).72 A cinchonidine organic catalyst was used in the coupling reaction of 
prochiral amino acid 82 with α-bromoketone 83. It was reported that reaction temperature was 
crucial in allowing for an efficient transformation. At temperatures below −30 °C, the alkylation 
reaction did not occur and at elevated temperatures the stereoselectivity of the reaction was 
diminished. When the reaction was performed at −25 °C, a yield of 83% was achieved for 85 with 
87% ee. Target amino acid 86 was prepared after acid hydrolysis and Fmoc protection in 96% yield 
over the two steps. It was found that the fluorescence emitted from amino acid 86 was highly 
sensitive to solvent polarity.73 In heptane, the emission maximum was recorded at 409 nm. A 
bathochromic shift was observed when 86 was dissolved in water with an emission maximum at 
542 nm. Amino acid 86 was then incorporated into the 15-mer peptide, S-tag, which was used to 
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bind to the S-protein. From fluorescent measurements, the binding affinity constants of the 
modified S-tags to the S-protein were determined.  
 
 
Scheme 16 Synthesis of charge-transfer amino acid 86. 
 
1.1.8 Summary 
There is much interest in the application of fluorescent amino acids for biological imaging and in 
particular investigating protein-protein and protein-peptide interactions.4,20,39,40,44 This is due to 
the wide diversity of environmentally sensitive fluorescent amino acids available and their high 
brightness. In addition, when a fluorescent amino acid is incorporated into a protein or peptide 
unlike GFP its small size will not affect the folding or the function of the protein.40 
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2.1 Synthesis of Novel Fluorescent Pyrazoloquinazoline 
Functionalised α-Amino Acids 
2.1.1 Previous work in the Sutherland group 
Previous work within the group has focused on the synthesis of a diverse range of fluorescent α-
amino acids (Figure 14). Originally, a fluorescent enone amino acid 87 was prepared with a HWE 
reaction between a β-keto phosphonate ester and 4-dimethylamino-1-naphthaldehyde. The 
charge transfer between the electron-rich amino group and the electron-deficient enone system 
resulted in a high excitation wavelength (393 nm) and a high emission maximum (540 nm).74 With 
the enone being highly reactive due to conjugation with the dimethylamino group, it was 
proposed that this compound may not be suitable for long-term storage. Therefore, it was thought 
more robust fluorescent amino acids could be attained if the enone functional group was 
converted into a more stable heterocycle.75 It was first shown that these enone derived amino 
acids could undergo reaction with phenylhydrazine for the preparation of the dihydropyrazole ring 
system. Subsequent oxidation of the dihydropyrazole ring with DDQ gave the aromatic pyrazole 
heterocycle 88. The reaction of different enones with phenylhydrazine and DDQ gave a small 
library of pyrazole substituted amino acids. From this library, it was found that naphthyl-
substituted pyrazole amino acid 88 was the most fluorescent amino acid.  
 
Next, it was shown that pyridine heterocycles could be constructed from enone derived amino 
acids.76 This was achieved by reaction of the enones with ethyl vinyl ether in an ytterbium 
catalysed, inverse electron-demand hetero-Diels-Alder reaction, giving dihydropyran derived 
amino acids 89. A modified Knoevenagel-Stobbe reaction with hydroxylamine was then used to 
convert the dihydropyran into the pyridine heterocycle. Using this methodology, a small library of 
pyridine derived amino acids were synthesised. From this library, the 4-methoxyphenyl 
substituted pyridine derived amino acid 90 exhibited the best photoluminescence properties. This 
was due to the charge-transfer between the electron-rich methoxy group and the electron-
deficient pyridine ring system. The 4-methoxyphenyl substituted pyridine derived amino acid had 
high values for both its molar attenuation coefficient (25,920 cm−1 M−1) and quantum yield (0.46) 
resulting in a brightness value of 11,923 cm−1 M−1.  
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Figure 14 Previously synthesised fluorescent amino acids. 
 
The emission of 4-methoxyphenyl substituted pyridine derived amino acid 90 was found to be 
highly sensitive to solvent polarity. In non-polar THF, the amino acid had an emission maximum of 
308 nm (Figure 15). However, when dissolved in highly polar PBS solution, the emission maximum 
increased to 423 nm. 
 
 
Figure 15 Emission spectra of amino acid 90 in a range of solvents. 
 
The environmental sensitivity observed for 4-methoxyphenylpyridine 90 is due to an ICT state.11 
After excitation, electron flow from the methoxy group to the pyridine ring system gives ICT state 
91 (Figure 16). This can only occur in polar solvents, as the highly polar ICT state is stabilised with 
solvent interactions. For non-polar states, emission occurs from a locally excited (LE) state that 
resembles the ground state. The presence of shoulder peaks in the emission spectra in chloroform 
and PBS solution is an indication of 90 possessing both LE and ICT states. 
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Figure 16 Ground state 90 and internal charge-transfer (ICT) state 91 for 90. 
 
2.1.2 Aim of the project 
The amino acids previously developed did exhibit some interesting fluorescent properties. 
However, it was proposed that if more rigid and planar amino acids were synthesised, the 
photoluminescence properties could be improved. Therefore, it was thought that incorporating 
rigidity into one of the previously synthesised fluorescent amino acids, a superior fluorophore 
could be prepared. From the previously prepared amino acids, the pyrazole functionalised amino 
acid 92 was the obvious substrate for introducing rigidity. This was due to the presence of a 
heteroatom in close proximately to the adjoined phenyl ring that would be useful for tethering 
the two rings together 93 (Figure 17). There is a class of heterocycle known as 
pyrazoloquinazolines 94 that exhibit useful bioactivities, such as being antagonists for adenosine 
receptor 95, AMPA receptor 96 and Gly/NMDA antagonist 97.77–80 It was proposed that this would 
make an excellent template for a new generation of rigid, planar fluorescent α-amino acids. 
 
 
Figure 17 Conceptual design of the rigid pyrazoloquinazoline amino acid 94 and bioactive 
pyrazoloquinazoline compounds 95–97.77,78,80,81   
 
The aims of this project were to develop a synthetic route to pyrazoloquinazoline derived amino 
acid 94 and then prepare a small library of analogues. After a library was synthesised, the 
photoluminescence properties of the pyrazoloquinazoline derived amino acids would be 
measured with UV-Vis absorption and fluorescence spectroscopy. Amino acids 94, 98–101 were 
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chosen as target compounds for this library (Figure 18). The target compounds include the highly 
conjugated benzo-fused pyrazoloquinazoline 98, the electron-deficient fluorine substituted 
pyrazoloquinazoline 99 and the electron-rich dimethoxy- and dimethylamino substituted 
pyrazoloquinazoline amino acids 100 and 101. 
 
 
Figure 18 Target pyrazoloquinazoline amino acid compounds. 
 
2.1.3 Synthesis of pyrazoloquinazoline derived amino acid 
A synthetic route to pyrazoloquinazoline derived amino acid 94 was designed with the following 
retrosynthetic analysis (Scheme 17). It was proposed that a double disconnection could be 
achieved between the carbonyl carbon and the two adjoining nitrogen atoms. This disconnection 
gives 2-aminophenyl substituted pyrazole 102. Preparation of the urea group could be achieved 
with triphosgene, carbonyl diimidazole or disuccinimidyl carbonate.82,83 Amine 102 could be 
prepared from nitro derivative 103 with a functional group interconversion. Previous work within 
the group has shown that pyrazole derived amino acids can be synthesised from enones.75 Thus, 
amino acid 103 could be prepared from enone derived amino acid 104, hydrazine hydrate and 
then subsequent oxidation. Enone 104 could be prepared from the HWE reaction with β-keto-
phosphonate ester 105 and 2-nitrobenzaldehyde. Analogues of enone 104 could be obtained by 
using different 2-nitrobenzaldehydes, allowing for the synthesis of target compounds 94, 98–101. 
It has previously been shown that β-keto-phosphonate ester 105 can be synthesised from L-
aspartic acid (106).74 Hence, all pyrazoloquinazoline derived amino acids 94, 98–101 could be 
synthesised from L-aspartic acid (106). 
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Scheme 17 Retrosynthetic analysis of pyrazoloquinazoline amino acid 94. 
 
Literature conditions were followed for the synthesis of β-keto-phosphonate ester 108 from L-
aspartic acid (106) (Scheme 18).74–76,84 This involved treatment of L-aspartic acid (106) with thionyl 
chloride in MeOH, which gave dimethyl-L-aspartate in quantitative yield. The trityl protecting 
group was installed with triphenylmethyl chloride under basic conditions, which produced 
dimethyl N-trityl-L-aspartate (107) in quantitative yield. The bulky trityl protecting group was 
required for the regioselective synthesis of β-keto-phosphonate ester amino acid 108. Due to the 
large bulk of the trityl group, this shields the α-ester functional group from nucleophilic attack. 
When the anion of dimethyl methylphosphonate was reacted with protected amino acid 107, this 
gave 108 in excellent yield as a single regioisomer. 
 
 
Scheme 18 Synthesis of β-keto-phosphonate ester 108 from L-aspartic acid (106). 
 
HWE reactions were then carried out with β-keto-phosphonate ester 108 with various 2-
nitrobenzaldehydes under mild conditions (Scheme 19). Due to the strong electron-withdrawing 
nitro group being in conjugation with the aldehyde, the reactions were highly efficient. Most of 
the reactions were completed within 24 h and gave enone amino acids 109a–109e in good to 
excellent yields (52%–92%). Formation of the E-enone was confirmed by 1H NMR spectroscopy 
with the appearance of doublets at 6.53 ppm and 7.89 ppm, with a large coupling constant of 16.2 
Hz. 
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Scheme 19 Synthesis of enones 109a–109e using a HWE reaction. 
 
While it was required for the preparation of β-keto-phosphonate ester 108, the trityl group 
inhibits subsequent reactions of the enone due to its steric bulk.76 Hence, prior to the formation 
of the pyrazole ring, the trityl protecting group was replaced with a smaller protecting group. To 
achieve this, enones 109a–109e were initially treated with trifluoroacetic acid (Scheme 20). The 
Boc protecting group was then installed with di-tert-butyl dicarbonate under basic conditions and 
this gave enones 110a–110e, from good to excellent yields over the two-steps. 
 
 
Scheme 20 Synthesis of Boc-protected enones 110a–110e. 
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It was proposed a more efficient synthesis to Boc enones 110a–110e could be achieved by 
reprotection of the β-keto phosphonate ester 108 followed by HWE reaction of this with various 
aldehydes. This would allow the introduction of the different aromatic groups at a later stage of 
the synthetic route. This was investigated by trityl deprotection of phosphonate ester 108 with 
TFA and then subsequent Boc protection with di-tert-butyl decarbonate, which gave 111 (Scheme 
21). This transformation was achieved in high yield. 
 
 
Scheme 21 Synthesis of Boc protected β-keto-phosphonate ester 111 from trityl protected β-
keto-phosphonate ester 108. 
 
The HWE reaction was then trialled with Boc protected β-keto-phosphonate ester 111 and 2-
nitrobenzaldehydes (Scheme 22). From this, it was found that good yields were achieved for 
enones 110a-110e, in short reaction times. Only when the electron-rich, 4-dimethyl-2-
nitrobenzaldehyde was used did the reaction require multiple days to reach completion. The 
lowest yield was obtained when using the electron-poor, 5-fluoro-2-nitrobenzaldehyde aldehyde. 
 
 
Scheme 22 HWE reaction with Boc protected β-keto-phosphonate ester 111. 
 
As previously mentioned, work within the group has demonstrated that pyrazole derived amino 
acid 114 can be prepared from enone 112 (Scheme 23).75 This was achieved by reaction of 112 
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with phenylhydrazine under acidic conditions, which gave dihydropyrazole 113. Treatment of 113 
with the oxidising agent DDQ gave pyrazole derived amino acid 114 in 76% yield over the two-
steps. 
 
 
Scheme 23 Previous synthesis of pyrazole amino acid 114.75 
 
Due to the presence of the acid-labile Boc protecting group, these acidic conditions were not used. 
As forcing conditions were required to react enone 112 with phenylhydrazine, therefore forcing 
conditions were initially tried with enone 110a (Table 4). When the reaction was attempted with 
a large excess of hydrazine hydrate under reflux conditions, no desired target compound was 
obtained due to the reaction of the ester with hydrazine (entry 1). It has previously been reported 
that hydrazine will form the hydrazide by reaction with methyl esters in alcoholic solvents.85 The 
number of equivalents of hydrazine hydrate was then reduced from 10 to 5 under the same 
conditions but, this still resulted in reaction with the ester functional group (entry 2). However, 
when the reaction temperature was reduced to room temperature and only one equivalent of 
hydrazine was used, it was found that the ester protecting group was still intact. Unfortunately, 
there was incomplete conversion from the enone to the dihydropyrazole (entry 3). Therefore, 
while keeping the reaction at room temperature, the quantity of hydrazine hydrate was gradually 
increased (entries 4 and 5). This resulted in an increase in yield for dihydropyrazole 115a. From 
this, it was observed that 5 equivalents of hydrazine hydrate gave the best yield of 115a (entry 6). 
It was then found that full conversion of enone 110a occurred within 4 hours when 5 equivalents 
of hydrazine were used (entry 7). This gave dihydropyrazole 115a in 86% yield. 
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Entry 
N2H4.H2O 
(equiv.) 
Temperature 
Time 
(h) 
Yield 
(%) 
1 10 reflux 17 0 
2 5 reflux 3 0 
3 1 rt 16 0 
4 2 rt 16 31 
5 4 rt 16 60 
6 5 rt 16 83 
7 5 rt 4 86 
Table 4 Optimisation study for the formation of dihydropyrazole 115a. 
 
Dihydropyrazoles 115a–115e were prepared from enone derived amino acids 110a–110e using 
these optimised conditions. In all cases, full conversion to the cyclised products was achieved 
within 4 h. It was found by 1H NMR spectroscopy that all the cyclised products were obtained in a 
1:1 mixture of diastereomers. 
 
 
Scheme 24 Synthesis of dihydropyrazole derived amino acids 115a–115e. 
 
The oxidation to pyrazole derived amino acid 116a from 115a was next investigated. There are 
many oxidising reagents available for this transformation. It was reported by Huang et al. that 
1,3,5-triaryl-4-alkylpyrazoles can be prepared from dihydropyrazole precursors with manganese 
dioxide at room temperature.86 When these conditions were attempted with dihydropyrazole 
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115a, only a 4% yield of pyrazole 116a was obtained (Table 5, entry 1). It was also reported that 
both 10% palladium on carbon and dihydropyran can be used as oxidising agents in pyrazole 
formation.87,88 When these oxidants were used with dihydropyrazole 115a, there was no 
conversion to pyrazole 116a (entries 2 and 3). When dihydropyrazole 115a was reacted with 
benzoquinone, pyrazole 116a was isolated in a 28% yield (entry 4). When the oxidation reaction 
was performed with the stronger oxidising agent DDQ, the yield was reduced to 18% (entry 5). 
Performing the reaction with DDQ at lower temperature (−15 °C) gave an optimised yield of 65% 
(entry 6). 
 
 
Entry Reagent 
Temperature 
(°C) 
Time 
(h) 
Yield 
(%) 
1 MnO2 20 24 4 
2 10% Pd/C 20 24 0 
3 dihydropyran 60 24 0 
4 benzoquinone 20 24 28 
5 DDQ 20 2.5 18 
6 DDQ −15 3 65 
Table 5 Optimisation study for the oxidation of dihydropyrazole 115a to the pyrazole 116a. 
 
Pyrazole derived amino acids 116a–116e were then prepared from dihydropyrazoles 115a–115e 
with the optimised conditions (Scheme 25). It was found that higher yields were obtained for 
pyrazoles 116b, 116c and 116e when the DDQ oxidation was conducted at a lower temperature. 
The DDQ oxidation for 115a and 115d was also attempted at lower temperatures but there was 
no improvement in yield. With all these compounds 116a–116e, a characteristic singlet was 
observed by 1H NMR spectroscopy between 6.11–6.41 ppm for the H-4ʹ hydrogen atom, which 
confirmed pyrazole ring formation. 
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Scheme 25 Pyrazole products 116a–116e. 
 
With pyrazole derived amino acids 116a–116e having been prepared, the reduction of the 
aromatic nitro group was next investigated. Initially, tin dichloride was used for the reduction of 
2-nitrophenyl substituted pyrazole 116a to amine 117a (Scheme 26). From this, it was found due 
to the acidity of the reaction conditions, this did not result in a very efficient transformation. 
 
 
Scheme 26 Synthesis of 2-aminophenyl substituted pyrazole 117a with tin dichloride. 
 
Nitro group reduction was then attempted by hydrogenation with 10% palladium on carbon 
(Scheme 27). When 2-nitrophenyl substituted pyrazole amino acids 116a–116e were subjected to 
hydrogenation conditions, full conversion to amines 117a–117e were observed after 16 h. This 
was confirmed by 1H NMR spectroscopy with the aromatic hydrogen atoms appearing upfield in 
the spectra of the products. As the transformations yielded no byproducts, simple removal of the 
palladium catalyst by filtration through Celite® allowed the material to be used in the next step 
without further purification. The reaction of amines 117a–117e with triphosgene and 
triethylamine in dichloromethane gave 118a–118e in good yields (48%–75%) over the two-steps, 
with only 118b being prepared in a low yield (23%), even after multiple attempts. Formation of 
pyrazoloquinazoline derived amino acids 118a–118e was confirmed by 1H NMR spectroscopy with 
a characteristic NH signal at 10.40–11.30 ppm from the urea moiety. Due to the success of these 
conditions for the preparation of pyrazoloquinazolines 118a–118e, the use of carbonyl 
diimidazole or disuccinimidyl carbonate were not investigated. 
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Scheme 27 Synthesis of pyrazoloquinazoline amino acids 118a–118e. 
 
Before measurement of the photoluminescence properties of these pyrazoloquinazoline derived 
amino acids 118a–118e, the protecting groups were removed. To achieve this, 
pyrazoloquinazoline 118a was subjected to 6 M hydrochloric acid under reflux conditions (Scheme 
28). This removed both the Boc protecting group and methyl ester after 16 h and gave 94 in 47% 
yield after recrystallisation. 
 
 
Scheme 28 Acid deprotection of amino acid 94. 
 
The same deprotection conditions were also used with benzo-fused pyrazoloquinazoline 118b and 
9ʹ-fluoropyrazoloquinazoline 118c compounds (Scheme 29). After 16 h, amino acids 98 and 99 
were isolated after recrystallisation in 40% yield. 
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Scheme 29 Preparation of amino acids 98 and 99.  
 
The one-step acid deprotection was then attempted with dimethoxy and dimethylamino 
substituted pyrazoloquinazoline derived amino acids 118d and 118e. For these amino acids, this 
resulted in decomposition of the material. It was proposed that the electron-rich nature of these 
amino acids made them more susceptible to decomposition under harsh acidic reaction 
conditions. Hence, a milder deprotection strategy was implemented for the preparation of amino 
acids 100 and 101. It had previously been shown within the group that ester hydrolysis can be 
accomplished with the mild base caesium carbonate.74 In preparing enone derived amino acid 
120, caesium carbonate was used to hydrolysis the ester group of 119. With the ester group 
hydrolysed, TFA was used for deprotection of the Boc group and this gave 120 in 46% yield over 
the two-steps (Scheme 30). Therefore, it was envisioned that similar conditions could be used for 
deprotection of amino acids 118d and 118e.  
 
 
Scheme 30 Two-step deprotection strategy of enone derived amino acid 119.74 
 
Pyrazoloquinazoline derived amino acids 118d and 118e were both subjected to this two-step 
deprotection method. It was found that caesium carbonate gave the carboxylic acids from the 
methyl esters cleanly in both cases within 16 h (Scheme 31). Boc group deprotection was achieved 
for both analogues with 2 M hydrochloric acid at room temperature and this gave 100 and 101 in 
70% and 78% yield, respectively. Owing to the high yields obtained with this approach, amino acid 
118a was also deprotected with these conditions and this resulted in an increase in yield from 
47% to 80% for 94. 
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Scheme 31  Two-step deprotection of pyrazoloquinazoline amino acids 94, 100 and 101. 
 
 
2.1.4 Photoluminescence of pyrazoloquinazoline derived amino acids 
With a library of pyrazoloquinazoline amino acids 94, 98–101 synthesised, the photoluminescence 
properties of these compounds were studied. Initially, UV/Vis absorption and fluorescence 
spectroscopy were used to record the absorbance and emission spectra of all amino acids in 
methanol (5 μM). When pyrazoloquinazoline derived amino acid 94 was studied by absorption 
spectroscopy, a structured spectrum was obtained with multiple absorption maxima at 225, 257, 
272, 307 and 321 nm (Figure 19).  As mentioned previously, fluorophores that are planar in the 
ground state generally give rise to more structured absorption spectra, due to vibronic 
transitions.35,36  
 
 
Figure 19 UV-Vis absorption spectra of pyrazoloquinazoline amino acid 94 in MeOH (5 μM). 
 
The molar attenuation coefficient of these maxima were calculated. This was accomplished by 
measuring the absorption of 94 at different concentrations and using the Beer-Lambert Law 
(Figure 20). Five concentrations were used in order to determine an accurate value, with the 
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gradient of a concentration and absorption plot being the molar attenuation coefficient. For 94, 
the absorbance maximum at 321 nm had a molar attenuation coefficient of 8,253 cm−1 M−1. 
 
  
Figure 20 Calculation of the molar attenuation coefficient of amino acid 94 in MeOH. 
 
This process was repeated for all the other maxima (Table 6). As all the molar attenuation values 
are very large, it can be concluded that all the absorption maxima account for π → π* electronic 
transitions. The absorption spectra obtained for pyrazoloquinazoline amino acid 94 closely 
resembles the absorption spectra of 9,10-anthraquinone. The absorption spectra of 9,10-
anthraquinone has absorption maxima at 253 nm (51,500 cm−1 M−1), 263 nm (20,000 cm−1 M−1), 
272 nm (20,000 cm−1 M−1) and 325 nm (5,600 cm−1 M−1) and it has been reported that all these 
bands are due to π → π* electronic transitions.89–91 For 9,10-anthraquinone, a further weak 
absorption band is observed at 405 nm (90  cm−1 M−1) and this due to an n → π* transition. No such 
transition was observed for pyrazoloquinazoline derived amino acid 94. 
 
Wavelength (nm) Molar Attenuation Coefficient (cm−1 M−1) 
225 34,810 
257 13,279 
272 9,337 
307 8,280 
321 8,253 
Table 6 Molar attenuation coefficients for amino acid 94 in MeOH. 
 
To understand how these absorption bands affect the emission of amino acid 94, a 5 μM sample 
in MeOH was excited at these wavelengths and the emission spectra were recorded (Figure 21). 
With all these excitation wavelengths, the same emission spectrum was obtained. Therefore, as it 
can be concluded that emission is occurring from the lowest excited level, amino acid 94 obeys 
Kasha’s rule.10 However, it was found that emission spectra varied in intensity depending upon 
the excitation wavelength. It was found that exciting amino acid 94 at 321 nm gave the most 
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intense fluorescence. While this absorbance maximum has the longest wavelength, it is also the 
lowest in energy. Therefore, this electronic transition at 321 nm must be the S0 to S1 transition.8,10 
It can be concluded that the transition at 307 nm while also being excited to the S1 state, is to the 
higher vibrational level. The absorption maximum at 272 nm is the electronic transition to the 
second excited state, S0 to S2. With all these different excitation wavelengths giving different 
fluorescence emission intensity, it can be concluded that amino acid 94 does not fulfil Vavilov’s 
rule, as the quantum yield value does vary with excitation wavelength.10 Furthermore, with the 
most intense fluorescence being emitted by excitation at 321 nm, it is the S0 to S1 electronic 
transition that is the most efficient at producing fluorescence. 
 
 
Figure 21 Emission spectra of amino acid 94 in MeOH (5 μM) at different excitation wavelengths.  
 
The absorption and emission spectra of pyrazoloquinazoline derived amino acids 94, 98–101 were 
recorded in MeOH (5 μM) (Figure 22, Figure 23, Figure 24 and Figure 25). These amino acids were 
excited at the wavelength that gave the most intense fluorescence. All amino acids obeyed the 
“mirror image” rule with respect to their S1 absorption band and their emission band. For amino 
acids 94, 98–101, vibronic fine structure was observed in both the absorption and emission 
spectra owing to the rigidity and planarity of these compounds. However, for the dimethylamino 
substituted pyrazoloquinazoline amino acid 101, no vibronic fine structure was observed. 
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Figure 22 Absorption and emission spectra of amino acid 94 in MeOH (5 μM), excited at 321 nm. 
 
  
Figure 23 Absorption and emission spectra of amino acid 99 in MeOH (5 μM), excited at 328 nm. 
 
  
Figure 24 Absorption and emission spectra of amino acid 100 in MeOH (5 μM), excited at 337 nm. 
 
  
Figure 25 Absorption and emission spectra of amino acid 101 in MeOH (5 μM), excited at 349 nm. 
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When benzo-fused pyrazoloquinazoline amino acid 98 was studied with UV-Vis spectrometry, it 
also gave an absorption spectrum with multiple maxima (Figure 26). It had absorption maxima at 
228 nm, 269 nm, 279 nm, 334 nm and 350 nm when dissolved in MeOH. When amino acid 98 was 
then excited with these wavelengths, the resulting emission spectra were recorded. As with 94, 
99–101, the same emission spectrum was produced regardless of excitation wavelength. Unlike 
the other amino acids, excitation of 98 to the S2 electronic level with light of 279 nm, gave the 
most intense fluorescence. When 98 was excited to the S1 level with a wavelength 350 nm there 
was a reduction in the fluorescence intensity. 
 
 
Figure 26  Absorption and emission spectra of amino acid 98 in MeOH (5 μM). 
 
Several trends of the normalised emission spectra of the pyrazoloquinazoline derived amino acids 
94, 98–101 were noted (Figure 27). The inclusion of electron-donating groups or increased 
conjugation resulted in a bathochromic shift of the emission spectrum. For example, 94 has an 
emission maximum of 342 nm. This is increased to 372 nm as conjugation is increased, with the 
benzo-fused pyrazoloquinazoline amino acid 98. When electron-donating groups are added, the 
emission maximum is also increased. Addition of two methoxy groups increased the emission 
maximum to 363 nm and the addition of a dimethylamino group increased the emission maximum 
to 414 nm. The emission maximum is also increased when the electron-withdrawing fluorine atom 
was substituted into the pyrazoloquinazoline ring system and this gave an emission maximum of 
353 nm. 
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Figure 27 Emission spectra of pyrazoloquinazoline amino acids 94, 98–101 in MeOH (5 μM). 
 
The photoluminescence properties of these amino acids were furthered quantified by calculating 
the quantum yield values 94, 98–101. This was done using the comparative method with two 
known standards, L-tryptophan and anthracene.92 The absorption and emission spectra of the 
amino acids and the two standards were measured at five different concentrations (Figure 28).  
 
  
Figure 28 Calculation of the quantum yield value of pyrazoloquinazoline amino acid 94 in MeOH 
at 321 nm, relative to the known standard anthracene. 
 
From a plot of integrated fluorescence intensity against the absorption, a gradient value was 
calculated, and used in Equation 1. With the use of a known standard, a quantum yield value for 
a test compound can be found. 
 
Φx= ΦST (
Gradx
GradST
) (
ηx
2
ηST
2 ) 
Equation 1 Calculation of quantum yield. Where ΦX is the quantum yield of the test sample, ΦST is 
the quantum yield of the known standard, GradX is the gradient from the test compound plot, 
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GradST is the gradient from the known standard plot and η is the refractive index of the solvent 
used in the fluorescence measurements. 
 
Quantum yield values, molar attenuation coefficients and brightness values were calculated for 
all pyrazoloquinazoline amino acids 94, 98–101 (Table 7). As expected, with these amino acids 
being highly planar and rigid, high quantum yields and brightness values were obtained.35,93 The 
quantum yield value and brightness value was also calculated for pyrazole amino acid 88, so that 
these two classes of amino acids could be compared. From this, it was found that 
pyrazoloquinazoline amino acids were much brighter. Pyrazole amino acid 88 had a quantum yield 
value of 0.04, whereas amino acid 98 had a quantum yield value of 0.47. Therefore, it can be 
concluded that rigidity did enhance the photoluminescent properties of amino acid 88 and hence, 
amino acids 94, 98–101 have more potential for fluorescence imaging. 
 
Compound 
Excitation 
Wavelength 
(nm) 
Molar 
Attenuation 
Coefficient 
(cm−1 M−1) 
Emission 
Maximum 
(nm) 
Stokes 
Shift 
(nm) 
Quantum 
Yield  
(φF) 
Brightness 
(cm−1 M−1) 
 
321 8,253 342 21 0.42 3,466 
 
279 
(350) 
24,830 
(7,731) 
373 
(372) 
94 
(22) 
0.27 
(0.47) 
6,704 
(3,634) 
 
328 9,977 353 25 0.47 4,689 
 
337 11,209 363 26 0.56 6,277 
 
349 12,202 415 66 0.48 5,857 
 
251 23,650 356 105 0.04 946 
Table 7 Photoluminescence properties of amino acids 94, 98–101 and amino acid 88. 
 
After the photoluminescent properties were measured, it was concluded that the dimethylamino 
substituted amino acid 101 had the best optical properties. For example, it had a high excitation 
wavelength, emission maxima and brightness value. Therefore, the photoluminescence properties 
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of 101 were investigated further. The fluorescence lifetime of amino acid 101 was measured to 
determine if it would be a suitable fluorophore for FLIM (Figure 29).17,94 It was found that 101 had 
an amplitude weighted lifetime of 1.81 ns, which is consistent with other similar fluorophores of 
this type.95 It has been reported that flavanols, catechin and epicatechin, have been used in two-
photon fluorescence lifetime imaging.17 The flavanol catechin has a fluorescence lifetime of 1.1 ns 
and a quantum yield of 0.02 in MeOH at 37 °C. Based on these literature examples, it can be 
concluded that amino acid 101 may be a suitable fluorophore for FLIM microscopy. 
 
 
Figure 29 Lifetime measurement of amino acid 101 in MeOH (10 μM). 
 
The photoluminescence characteristics of 101 in different solvents was next investigated. The 
absorption and emission spectra of 101 were measured in THF, MeCN, DMSO, MeOH and PBS 
(Figure 30). It was found there was only very slight variations in the absorption spectra, whereas 
for the emission spectra, 101 did display solvatochromic behaviour. A bathochromic shift was 
observed when amino acid 101 was dissolved in more polar solvents. When dissolved in THF, a 
emission maximum of 374 nm was obtained. This increased to 379 nm in MeCN, 382 nm in DMSO, 
415 nm in MeOH and 424 nm in aqueous PBS solution. This bathochromic shift is due to solvent 
relaxation around the excited compound. With this variation in emission wavelength, this would 
allow amino acid 101 to be used as an environment-sensitive fluorescence probe.72 
 
  
Figure 30 UV-Vis absorption and emission spectra of amino acid 101 in different solvents. 
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The quantum yield value of 101 was next calculated in the various solvents, except for THF and 
MeCN. It was proposed when 101 was dissolved in these non-polar solvents aggregation occurred. 
Therefore, quantum yield measurements in these solvents would not be reliable. This 
phenomenon has previously been reported with the fluorophores PRODAN and FR0 in hexane.96 
From measuring quantum yield values for 101 in DMSO, MeOH and PBS, it was found that the 
quantum yield value decreased as solvent polarity increased. In DMSO, a value of 0.92 was 
recorded. This decreased to 0.48 in MeOH and 0.01 in PBS. This decrease in quantum yield could 
be due to hydrogen bonding between 101 and the solvents, quenching the fluorescence.16,30 With 
this significant difference in quantum yield, this would allow 101 to be used in binding titration 
experiments. It was shown that fluorescence titration could be performed with a chromophore of 
similar fluorescent properties.67 This was incorporated into a peptide and exhibited weak 
fluorescence in aqueous solutions. Upon addition of peptide to vesicles, this resulted in 
fluorescence being turned on with interactions with the hydrophobic membrane. It was found 
that a ratio of one peptide per 100 lipids resulted in maximum fluorescence intensity, thus 
indicating full saturation of the membrane surface. Therefore, amino acid 101 has the potential 
to be used in similar applications. 
 
Table 8 Summary of the photoluminescence properties of amino acid 101 in various solvents. 
 
With the rigid structure of amino acid 101, it was next investigated how its emission varied with 
temperature. It is known that the photoluminescence properties of some fluorophores change 
with temperature. For example, the quantum yield of pentamethine cyanine 10 varies with 
temperature, due to photoisomerisation via trans-to-cis polyene rotation (Figure 31).37 This 
rotation is more efficient at higher temperatures resulting in greater energy loss. However, the 
quantum yield of rigid analogue 11 shows no variance with temperature, as trans-to-cis polyene 
rotation is no longer possible. 
 
Solvent 
Excitation 
Wavelength 
(nm) 
Emission 
Maximum 
(nm) 
Stokes 
shift 
(nm) 
Molar 
Attenuation 
Coefficient 
(cm−1 M−1) 
Quantum 
Yield  
(φF) 
Brightness 
(cm−1 M−1) 
THF 347 374 26 6,820 N/A N/A 
MeCN 342 379 31 4,380 N/A N/A 
DMSO 348 382 40 14,582 0.92 13,415 
MeOH 349 415 66 12,202 0.48 5,857 
PBS 341 424 76 6,313 0.01 63 
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Figure 31 Chemical structures of pentamethine cyanine 10 and restrained indocyanine 11. 
 
The emission spectra of amino acid 101 and pyrazole derived amino acid 88 were recorded in 
MeOH between 10–60 °C (Figure 32). From this, it was found that the emission intensity of 101 
was consistent throughout the temperature range. However, for 88, the fluorescence intensity 
did decrease when the temperature was increased. At higher temperatures, the π conjugation 
between pyrazole and naphthyl rings was disrupted through increased bond rotation. As the 
phenyl ring is tethered to the pyrazole ring in 101, this rotation isn’t possible and resulted in the 
fluorescence intensity being constant over the studied temperature range. 
 
(a)
 
(b)
 
(c)
 
(d) 
 
Figure 32 (a) Emission spectra of amino acid 101 in MeOH (5 μM). (b) Emission spectra of pyrazole 
88 in MeOH (5 μM). (c) Comparison of emission intensity of 101 and 88. (d) Structures of 101 and 
88. 
 
It was next investigated whether amino acid 101 could be excited using a two-photon process. For 
biological imaging this would be highly advantageous as this would allow amino acid 101 to be 
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excited at 700 nm instead of 350 nm. With excitation at 700 nm, this would result in reduced 
photobleaching and phototoxicity.17,18,21 This work was carried out by David Nobis and Eilidh 
Malcolm of the Steven Magennis research group at the University of Glasgow. Evidence of two-
photon excitation was achieved with a log-log plot of laser power and fluorescence intensity. For 
a two-photon process, a gradient of two is required.11 A sample of amino acid 101 in MeOH (203 
μM) was excited with light at 800 nm (with a full width at half maximum (FWHM) of 135 nm) at 
four different laser powers: 79, 157, 117 and 228 mW and the emission intensity was recorded. 
This was plotted with a log-log plot and the resulting gradient was 1.96 ± 0.03. This is indicative of 
a two-photon process (Figure 33). 
 
 
Figure 33 Log-log plot of 101 with light centred at 800 nm with FWHM of 135 nm. 
 
As it was shown that 100 can be excited by a two-photon process, the efficiency of this process 
was assessed by calculating the cross-sectional area. This was achieved by using Equation 2 and a 
known standard.97 
 
σ2
SΦS
σ2
RΦR
= 
ηR(nλemission
S )
2
nλexcitation
R CRFS〈PR〉2
ηS(nλemission
R )
2
nλexcitation
S CSFR〈PS〉2
 
Equation 2 Calculation for cross-sectional area. Where Φ is the quantum yield of the 
fluorescence, η accounts for the wavelength dependence of the detection efficiency, n is the 
refractive index of the solvent, C is the concentration, F is the integrated fluorescence signal and P 
is the excitation power. The superscripts R and S denote reference and sample respectively. 
The equation is simplified by performing the measurements with the same solvent and at the 
same wavelength (700 nm ± 10 nm). This allows for the following ηR= ηS  and nλemission= 
nλexcitation = n simplifications and gives Equation 3. 
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σ2
SϕS
σ2
RϕR
= 
CRFS〈PR〉2
CSFR〈PS〉2
 
Equation 3 Simplified calculation for cross-sectional area. 
 
Rhodamine B was used as the standard as it has a molar attenuation coefficient of 106,000 cm−1 
M−1, a two-photon cross-section area of 240 GM (at 700 nm) and a quantum yield value of 0.70.98,99 
The cross-section of 101 was calculated at three different concentrations and this gave a value of 
0.38 ± 0.06 GM. From these measurements, the emission spectrum of 101 is obtained from the 
two photon-excitation (Figure 34). This emission spectrum obtained is very similar to the emission 
spectrum obtained with a one-photon excitation process. 
 
 
Figure 34 Emission of 101 with 1-photon and 2-photon excitation. 
 
2.1.5 Synthesis of a fluorescent cell-penetrating peptide 
The synthetic utility of amino acid 101 for use in SPPS was next investigated by its incorporation 
into a short peptide. From previous work within the group, it was shown that amino acid 90 could 
be incorporated into a short peptide chain.76 The peptide sequence chosen was five residues long 
and consisted of Val-Pro-Thr-Leu-Lys. It was based upon the Bax-binding domain of the Ku70 
protein. Although it consisted of only five amino acid residues, it was shown to have cell-
penetrating properties and low cytotoxicity. Therefore, this peptide sequence was also used for 
amino acid 101 in SPPS. 
 
When amino acid 90 was used in SPPS, it was protected with the Fmoc protecting group (Scheme 
32).76 This was done to allow for protecting group removal with piperidine during peptide 
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synthesis. The Fmoc protecting group was installed with fluorenylmethyloxycarbonyl chloride 
under basic conditions to give 121 in a 40% yield. 
 
 
Scheme 32 Synthesis of Fmoc amino acid 121. 
 
For the synthesis of a peptide containing 101, the preparation of Fmoc protected amino acid 122 
was attempted. It was found that the reaction of 101 with fluorenylmethyloxycarbonyl chloride 
under basic conditions gave 122 (Scheme 33). However, attempted purification with column 
chromatography with silica gel, eluting with dichloromethane and methanol was not successful. 
Therefore, this approach to the Fmoc amino acid was abandoned. 
 
 
Scheme 33 Attempted synthesis of Fmoc amino acid 122. 
 
From the literature, there are examples of synthetic amino acids being prepared for peptide 
synthesis with selective ester hydrolysis of Fmoc esters. For example, in the preparation of novel 
amino acids capable of NO release, Fmoc sydnonimine amino acid 123 was selectively hydrolysed 
with sodium hydroxide to give Fmoc acid 124 in a yield of 80% (Scheme 34).100 
 
 
Scheme 34 Selective hydrolysis of Fmoc protected sydnonimine amino ester 124.100 
 
It was also shown that calcium chloride can be used in the selective hydrolysis of methyl esters.101 
For example, a combination of calcium chloride and sodium hydroxide was used to hydrolyse ester 
125 to acid 124 without Fmoc deprotection in a 98% yield (Scheme 35).  
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Scheme 35 Selective ester hydrolysis of 124 with sodium hydroxide and calcium chloride.101 
 
Therefore, it was proposed that selective ester hydrolysis of 127 would give an easier purification 
of 122. It was found that 127 could be prepared from 118e using literature conditions in 75% yield 
(Scheme 36).100 
 
 
Scheme 36 Synthesis of Fmoc ester 127. 
 
With access to 127, selective ester hydrolysis and preparation of 122 was next investigated. Based 
on literature precedent (Scheme 34 and 35) for base hydrolysis of Fmoc-protected amino esters 
and our experience of amino ester hydrolysis Cs2CO3 was chosen for this reaction. When this was 
attempted with caesium carbonate in MeOH and water, this resulted in a heterogeneous reaction 
mixture (Scheme 37). It was found that addition of dioxane gave a homogenous reaction mixture, 
but the hydrolysis was very slow and there was minimal conversion to 122. When an extra 
equivalent of caesium carbonate was added and the reaction mixture was stirred at room 
temperature for 16 h, this resulted in both ester hydrolysis and Fmoc deprotection. 
 
 
Scheme 37 Attempted synthesis of Fmoc acid 122. 
 
With the difficulties in synthesising 122 and with amino acid being incorporated last in the peptide, 
it was proposed that amino acid 101 could be incorporated as Boc-derivative 129. As the cleavage 
of the peptide chain from the resin is accomplished with trifluoroacetic acid, it was thought that 
this would also remove the Boc group. This approach was investigated by synthesising 
pentapeptide 128. This was achieved by SPPS synthesis with TentaGelTM S RAM resin on a 0.100 
mmol scale (Scheme 38). Peptide couplings were carried out using a four-fold excess of the amino 
acid, amide coupling reagent (HCTU) and eight equivalents of N,N-diisopropylethylamine. Fmoc 
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deprotection was carried out using 20% piperidine in DMF. The structure and purity of 
pentapeptide 128 was confirmed with analytical HPLC and LCMS. 
 
 
Scheme 38 Synthesis of 128 using automated SPPS. 
 
With access to pentapeptide 128, the use of 101 in peptide synthesis was then explored. Boc acid 
129 was prepared by ester hydrolysis of 118e with caesium carbonate in a yield of 71%. The 
peptide coupling was carried out manually, using two equivalents of 129 and at room temperature 
for 16 h (Scheme 39). From HPLC analysis, it was shown that the reaction resulted in the formation 
of only one product and LCMS confirmed the structure of hexapeptide 130. After cleavage from 
the resin with trifluoroacetic acid and triisopropylsilane and purification by prep-HPLC, 
hexapeptide 131 was obtained in 72% yield (based on starting resin). 
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Scheme 39 Synthesis of fluorescent cell-penetrating hexapeptide 131. 
 
As 131 had been successfully prepared, its photoluminescence properties were next investigated, 
to ascertain if the fluorescent characteristics of 101 had altered by incorporation into a peptide. 
This was achieved by measurement of the absorption and emission spectra of 131 in MeOH (5 
μM). It was found that there were small differences in the absorption spectra between amino acid 
101 and peptide 131 (Figure 35). A hypsochromic shift in the emission spectrum of peptide 131 
compared to amino acid 101 was observed. Amino acid 101 had an emission maximum of 414 nm, 
whereas peptide 131 has an emission maximum of 389 nm. It also had a shoulder peak at 
approximately 405 nm. 
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Figure 35 Absorption and emission spectra of amino acid 101 (blue) and peptide 131 (red). 
 
The molar attenuation coefficient and quantum yield were then measured for 131 (Table 9). It 
was found that the brightness value for the fluorophore as part of a peptide increased from 5,857 
to 6,900 cm−1 M−1. The increase in brightness was solely due to an increase in the molar 
attenuation coefficient value from 12,202 to 15,333 cm−1 M−1. Alongside this increase in 
brightness, there was also a decrease in the Stokes shift of the fluorophore from 65 nm to 40 nm. 
 
 
Excitation 
Wavelength 
(nm) 
Molar 
Attenuation 
Coefficient 
(cm−1 M−1) 
Emission 
Maximum 
(nm) 
Stokes 
Shift 
(nm) 
Quantum 
Yield 
(φF) 
Brightness 
(cm−1 M−1) 
Amino 
acid 101 
349 12,202 414 65 0.48 5,857 
Peptide 
131 
349 15,333 389 40 0.45 6,900 
Table 9 Summary of photoluminescence for amino acid 101 and peptide 131. 
 
The emission spectrum of peptide 131 was also measured in an aqueous solution of PBS (Figure 
36). This resulted in a bathochromic shift, with the emission maximum increasing from 389 nm in 
MeOH to 412 nm in PBS solution. So, when incorporated within a peptide, the fluorophore showed 
greater solvatochromic sensitivity than amino acid 101. 
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Figure 36 Solvatochromic behaviour of peptide 131. 
 
2.1.5 Summary 
To conclude, a synthetic route to pyrazoloquinazoline functionalised amino acids was developed. 
This allowed access to five pyrazoloquinazoline derived amino acids 94, 98–101 (Figure 37). The 
photoluminescence characteristics of these five amino acids were analysed by absorption and 
fluorescence spectroscopy. Their molar attenuation coefficient, quantum yield and brightness 
values were measured and calculated. It was found that the incorporation of rigidity into the 
fluorophore significantly improved the fluorescent characteristics of 94, 98–101 compared to 
pyrazole 88. For example, all pyrazoloquinazoline amino acids 94, 98–101 had quantum yield 
values between 0.42 to 0.56, whereas pyrazole amino acid 88 had a quantum yield of 0.04. The 
improved photoluminescence properties are due to the restricted rotation of the fluorophore in 
the excited state as this reduces non-radiative decay processes, thus giving a more fluorescent 
compound.102 This restricted rotation was further investigated with a temperature study where 
the fluorescence of 88 decreased with increasing temperature, due to faster bond rotation. 
Whereas for 101, no decrease in fluorescence was observed due to restricted rotation. From this 
library of pyrazoloquinazoline derived amino acids, the dimethylamino substituted amino acid 101 
showed the best optical properties. In particular, the highest emission wavelength and the largest 
Stokes shift.  
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Figure 37 Structures of synthesised amino acids and their key fluorescent properties. 
 
As amino acid 101 had the best photophysical properties, it was chosen for further study. It 
exhibited solvatochromic properties, with potential application as an environmentally sensitive 
chromophore. It was found that 101 could be excited by two-photon spectroscopy and it had a 
two-photon cross-section area of 0.38 ± 0.06 GM. It was then shown that 101 could be used in 
SPPS, with the preparation of a fluorescent cell-penetrating hexapeptide 131 in 72% yield (Figure 
38). The fluorescence properties of peptide 131 showed a small hypsochromic shift compared to 
amino acid 101. 
 
 
Figure 38 Fluorescent cell-penetrating hexapeptide 131 and its photoluminescence properties.  
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2.2 Synthesis of Novel Fluorescent Benzotriazole Functionalised α-
Amino Acids 
2.2.1 Introduction 
The compound AT-1012 (134) is an antagonist for the α3β4 nicotinic acetylcholine receptor 
(nAChR). Preparation of a radio-labelled analogue of this compound was previously attempted 
from ortho-nitroaniline 132 within the group.103 A tin dichloride reduction of the aromatic nitro 
group gave diaminophenyl 133 (Scheme 40). The radioactive iodine-125 atom was to be installed 
via the diazonium salt using a resin supported nitrite reagent.104 After 16 h at 60 °C, full 
consumption of diaminophenyl starting material was achieved, but there was no radio-labelled 
product 134, instead, a benzotriazole product was isolated in 64% yield (see box). The formation 
of benzotriazoles from ortho-diaminobenzenes upon treatment with sodium nitrite, under acidic 
conditions has been widely reported in the literature.105–109 
 
 
Scheme 40 Attempted synthesis of AT-1012. 
 
Further work within the group utilised the nitrite resin-bound reagent for the mild synthesis of 
benzotriazoles.110 For example, N-benzyl benzotriazole 137 could be prepared from ortho-
diaminobenzene 136 under mildly acidic conditions at ambient temperature with no release of 
toxic nitrogen oxides (Scheme 41).105 
 
 
Scheme 41 Formation of N-benzyl benzotriazole 137 with the resin-supported nitrite reagent. 
 
  
69 
 
2.2.2 Aim of the project 
Considering this elegant heterocycle synthesis, it was proposed that this methodology could be 
used to prepare benzotriazole substituted amino acids. There are three aims to this project. Firstly, 
this methodology would be used for the preparation of simple benzotriazole-derived amino acids 
138–140 (Figure 39). 
 
 
Figure 39 Simple benzotriazole target compounds. 
 
After the development of this approach, the use of cross-coupling chemistry would be used to 
prepare conjugated products 141–143 (Figure 40). The fluorescent properties of these conjugated 
amino acids 141–143 should be much superior to original amino acids 138–140, due to the 
extended π system.111 
 
 
Figure 40 Conjugated benzotriazole compounds. 
 
Finally, the benzotriazole core would be rigidified to improve the photophysical properties of the 
amino acids (Figure 41). This could be achieved by tethering the phenyl ring with the benzotriazole 
heterocycle to give 144. A nitrogen atom could be used to tether the two rings together to give a 
carbazole triazole fused ring system 145. It is expected that this increase in rigidity would improve 
properties such as quantum yield. 
 
 
Figure 41 Rigid benzotriazoles. 
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2.2.3 Synthesis of benzotriazole-derived amino acids 
From retrosynthetic analysis, it was proposed that benzotriazole-derived amino acid 138 could be 
prepared from 2-nitroaniline amino acid 147 (Scheme 42). After nitro group reduction to amine 
146, the previously developed conditions for benzotriazole ring formation could be applied to give 
138.110 
 
 
Scheme 42 Retrosynthetic analysis of benzotriazole amino acid 138. 
 
In preparing amino acid 147, three approaches were considered (Scheme 43). The first of these 
involved a Mitsunobu reaction with L-serine 148 and 2-nitroaniline. It has previously been shown 
that L-serine can be used in Mitsunobu reactions without racemisation and that anilines can be 
used as nucleophiles for Mitsunobu reactions.112,113 Typically nucleophiles in the Mitsunobu 
reaction must be acidic, with a pKa of 11 or below.55 Alternatively, a nucleophilic aromatic 
substitution with 3-amino-L-alanine 150 and 2-fluoronitrobenzene could be used to give 147. 3-
Amino-L-alanine could be prepared from L-asparagine (151) using a Hofmann rearrangement. 
Finally, a ring-opening reaction of chiral aziridine 149 with 2-nitroaniline to give amino acid 147 
could also be used.114 
 
 
Scheme 43 Retrosynthetic analysis of amino acid 147. 
 
Synthesis of intermediate 2-nitroaniline 152 was first attempted with a Mitsunobu reaction with 
L-serine analogue 37 (Scheme 44). From this reaction, it was found that after 16 h there was no 
product formation. Instead, starting material 37 and alkene 153 were isolated in 42% yield and 
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45% yield, respectively. This showed that an elimination reaction was taking place, instead of the 
desired substitution reaction.  
 
 
Scheme 44 Attempted Mitsunobu synthesis of amino acid 152. 
 
A new approach was required. Therefore, it was proposed that the preparation of amino acid 147 
by nucleophilic substitution would be investigated next. The Hofmann rearrangement of amino 
acids is well documented.115–118 The reaction was first attempted with the hypervalent iodine 
species (diacetoxyiodo)benzene (PIDA) in THF, but this only resulted in a 22% yield after 20 h 
(Table 10, entry 1).116 It has been reported in the literature that bis-
[(trifluoroacetoxy)iodo)benzene (PIFA) can also be an effective reagent for the Hofmann 
rearrangement.119 When PIFA was used to prepare 155 in THF an increased yield of 34% was 
obtained (entry 2). With low yields being obtained for this transformation other conditions were 
investigated. It has been reported that the inclusion of pyridine is beneficial for the 
transformation.115 When pyridine was used in combination with PIFA in aqueous acetonitrile a 
yield of 49% for 155 was obtained (entry 3). It has been reported that very high yields can be 
obtained when the Hofmann rearrangement of 154 is carried out in a solvent mixture of ethyl 
acetate, acetonitrile and water.117,118 When this transformation was first carried out with PIFA, no 
product was given (entry 4). However, when PIDA was used, a quantitative yield of 155 was 
achieved (entry 5). It was found that 155 had very low solubility, resulting in precipitation during 
the reaction and easy isolation. 
 
 
Entry Reagent Pyridine Solvent Temperature Time (h) Yield (%) 
1 PIDA No THF 0 °C to rt 20 22 
2 PIFA No THF 0 °C to rt 20 34 
3 PIFA Yes MeCN, H2O rt 20 49 
4 PIFA No EtOAc, MeCN, H2O 15 °C to rt 3 0 
5 PIDA No EtOAc, MeCN, H2O 15 °C to rt 3 100 
Table 10 Optimisation of Hofmann rearrangement. 
72 
 
 
With 155 being prepared, the carboxylic acid was then protected as the methyl ester with thionyl 
chloride in methanol, which gave methyl 3-amino-L-alaninate 156 in quantitative yield (Scheme 
45).120 Compound 156 was then used in a nucleophilic aromatic substitution with 2-
fluoronitrobenzenes with triethylamine.121 The reaction was monitored by TLC and from this, it 
was observed that complete consumption of starting material was achieved after 16 h with the 
formation of a yellow compound. It is known that ortho and para-nitroanilines have a strong 
yellow colour, due to their strong absorbance in the visible region. For example, 2-nitroaniline has 
a strong absorbance at 405 nm with a molar attenuation coefficient of 6000 cm−1M−1.122 Hence, it 
can be concluded that the reaction was progressing to o-nitroaniline 157 due to the development 
of this yellow compound. From the reaction, yields of 62–92% of the coupled products were 
obtained with a 16 h reaction time. The structure of the products was confirmed by 1H, 13C NMR 
spectroscopy and mass spectrometry. Coupled products 157a–157c were reduced to 1,2-
diaminophenyl derived amino acids 158a–158c with tin dichloride. As this reaction resulted in the 
loss of the push-pull system in the phenyl ring, the yellow nitroaniline colour disappeared during 
the course of the reaction. It was also observed with 1H NMR spectroscopy that the hydrogen 
atoms on the disubstituted phenyl ring migrated upfield as the phenyl ring became more electron-
rich. Anilines 158a–158c were immediately reacted with the resin-bound nitrite and p-tosic acid, 
which gave N-Cbz protected benzotriazoles 159a–159c. Originally these reactions were run at 
room temperature, but it was found better yields could be obtained by lowering the reaction 
temperature. When the reactions were run at −10 °C for 3 h, good yields (49–69%) over the two-
steps were achieved for the synthesis of 159a–159c. Formation of these benzotriazoles gave a 
characteristic downfield signal (7.77–8.03 ppm) with 1H NMR spectroscopy of the aromatic 
hydrogen atom ortho to the triazole ring. This helped identify the formation of the benzotriazole 
products. It was proposed that brominated analogue 159c would be a highly valuable synthetic 
building block, due to its aryl halide functionality, which could be used for palladium cross-
coupling chemistry. 
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Scheme 45 Synthesis of benzotriazole-derived amino acids. 
 
To access the parent amino acids, compounds 159a–159c were deprotected. This was achieved in 
one-step by treatment with 6 M hydrochloric acid (Scheme 46). It was found that this gave 
analogues 160a–160c in 63%–94% yields after purification by recrystallisation from methanol and 
diethyl ether. 
 
 
Scheme 46 One-step acid deprotection to amino acids 160a–160c. 
 
It was found that these simple benzotriazoles, 160a–160c were not fluorescent. Therefore, 
investigations began on further functionalisation of the benzotriazole derived amino acids. It was 
proposed that the conjugation of these benzotriazole amino acids could be increased using the 
Suzuki-Miyaura reaction. Due to the wide range of boronic acid coupling partners available, a wide 
range of conjugated products could be synthesised. With this increase in conjugation, it was 
proposed that some of these Suzuki-Miyaura products would be fluorescent. Initially, the Suzuki 
cross-coupling reaction was attempted using, [1,1ʹ-bis(diphenylphosphino)ferrocene]palladium(II) 
dichloride, 4-methoxyphenylboronic acid and caesium carbonate in a solvent mixture of water 
and dioxane (Scheme 47). It was found after reaction at 80 °C for 20 h, that none of the desired 
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Suzuki product 161f could be isolated, as the methyl ester had been hydrolysed by the caesium 
carbonate base. 
 
 
Scheme 47 Attempted Suzuki-Miyaura reaction with caesium carbonate. 
 
To remedy this, the hydrolytic base caesium carbonate was replaced with the non-hydrolytic base 
potassium fluoride (Scheme 48). After reaction at 80 °C for 20 h, coupled product 161f was 
isolated in an excellent 84% yield.  
 
 
Scheme 48 Suzuki-Miyaura reaction with potassium fluoride. 
 
Having developed the optimised conditions for the Suzuki-Miyaura reaction, the substrate scope 
was then investigated (Scheme 49). The reaction of bromide analogue 159c with a range of 
boronic acids gave coupled products 161a–161k. Simple aryl boronic acids gave coupled products 
161a–161c in excellent 83–91% yields. The sulfur-containing thiophene heterocycle could also be 
coupled to the benzotriazole using 3-thiopheneboronic acid in good yield. The functional groups, 
hydroxy, methoxy, dioxole, nitro and amine were all tolerated in this reaction, giving the coupled 
products 161e–161k, from low to excellent yield (39–84%). It should be noted that while the 
majority of these reactions required a catalyst loading of 7.5 mol%, in synthesising compound 161j, 
15 mol% was required to reach full conversion. It is proposed that this reaction was less efficient 
due to the presence of an ortho-substituent. 
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Scheme 49 Synthesis of Suzuki coupled products. 
 
Before the photoluminescence properties of these coupled products 161a–161k was assessed, 
the protecting groups were removed. Owing to the successful deprotection of the simple 
benzotriazole amino acids 160a–160c with a one-pot acidic deprotection, this was attempted for 
amino acid 161a (Scheme 50). It was observed under these conditions that the protected amino 
acid degraded, yielding no product. 
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Scheme 50 Attempted one-pot deprotection of amino acid 161a. 
 
Therefore, a mild two-step deprotection strategy was next investigated to gain access to the target 
amino acids. Following a literature procedure, ester hydrolysis of 161a with caesium carbonate 
gave acid 162a in 58% yield (Scheme 51). It was reported that the hydrolysis was carried out in a 
solution of methanol and water.74,75 When this was attempted, this resulted in a heterogeneous 
reaction mixture and no ester hydrolysis occurred. It was found that the addition of a minimal 
amount of 1,4-dioxane resulted in a homogenous reaction mixture and gave hydrolysed product 
163a cleanly. The reaction was also trialled in a solvent mixture of 1,4-dioxane and water, but this 
resulted in no ester hydrolysis. 
 
 
Scheme 51 Ester hydrolysis of 161a with caesium carbonate. 
 
To avoid the use of acidic conditions, hydrogenolysis of the Cbz group was attempted, following a 
previously reported procedure (Scheme 52).123 When the reaction was trialled with 162a in 
methanol, using 10% palladium on carbon, a very low yield of deprotected amino acid 163a was 
obtained. 
 
 
Scheme 52 Hydrogenolysis of Cbz amino acid 162a in methanol. 
 
From the literature, it had been reported that hydrogenolysis mediated deprotection of the Cbz 
group can be achieved when THF is used as the solvent.124 Therefore, this was attempted with Cbz 
protected benzotriazole amino acid 162a (Scheme 53). After 6 h under hydrogenation conditions, 
complete deprotection was achieved and the target amino acid 163a was isolated in 83% yield. It 
was found that forming the HCl amino acid salt was crucial in the amino acid having good solubility 
and allowing for a more straightforward purification by recrystallisation. 
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Scheme 53 Hydrogenolysis of Cbz protected amino acid 162a in THF. 
 
With the success of preparing amino acid 163a with hydrogenolysis, this approach was then 
investigated for the other substrates. It was found that the 4-methoxyphenyl substituted 
benzotriazole amino acid 161f could also be deprotected using this protocol (Scheme 54), giving 
deprotected amino acid 163f in excellent yield over the two steps. 
 
 
Scheme 54 Deprotection of benzotriazole amino acid 163f with hydrogenolysis. 
 
When other benzotriazole amino acids were subjected to these hydrogenolysis conditions, no Cbz 
deprotection was achieved. For example, when thiophene derived benzotriazole amino acid 162d 
was subjected to hydrogenolysis conditions for 6 h, only starting material was returned (Scheme 
55). The hydrogenolysis of amino acid 162d was also attempted with palladium black. Again, this 
only returned starting material. 
 
 
Scheme 55 Attempted hydrogenolysis of amino acid 163d. 
 
It has been reported that the acidic removal of Cbz protecting groups can be achieved in very short 
reaction times.125 This was demonstrated for 2-[(2S)-1-benzyloxycarbonyl-2-pyrrolidinyl]pyridine, 
where the Cbz protecting group was removed in an excellent yield of 92%, after a reaction time of 
1 h.125 Hence, these literature conditions were trialled for amino acid 162d (Scheme 56). It was 
found that after a reaction time of 1 h, full deprotection of the Cbz group was achieved with target 
compound 163d being isolated in 73% yield. In performing the reaction, it was found that the 
addition of a minimal amount of 1,4-dioxane was crucial in ensuring a homogenous reaction 
mixture. 
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Scheme 56 Acid deprotection of Cbz-protected amino acid 163d. 
 
Having developed an effective deprotection protocol, the other amino acids 163b–163k were 
trialled under these conditions (Scheme 57). Nine of the ten benzotriazole amino acids tested gave 
excellent yields for the target compounds 163b, 163d–163k, with only highly lipophilic biaryl 
substituted benzotriazole amino acid 163c not successful. For amino acid 161c, ester hydrolysis to 
the N-Cbz protected carboxylic acid proceeded well. However, the resulting carboxylic acid had 
very poor solubility in most solvents. When the acidic removal of the Cbz group was attempted, 
using the optimised conditions, this resulted in a heterogeneous reaction mixture. Even with 
extended heating, the reaction would not become homogenous and therefore no deprotection 
occurred. When large amounts of 1,4-dioxane were added to the reaction mixture, a homogenous 
reaction mixture could be achieved but this then led to slow Cbz removal. With extended reaction 
times, the material then degraded under these forcing conditions before deprotection was 
complete. 
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Scheme 57 Two-step deprotection of benzotriazole amino acids. 
 
2.2.3 Optical properties of benzotriazole-derived amino acids 
With target benzotriazole derived amino acids 163a, 163b 163d–163k being synthesised, the 
photoluminescence properties were then measured (Table 11). Fluorescence spectroscopy was 
carried out with the benzotriazoles being excited by the wavelengths corresponding to their 
absorption maxima from their absorption spectra. As with the pyrazoloquinazoline amino acids 
94, 98–101, the Stokes shift, molar attenuation coefficient, quantum yields and brightness of 
these benzotriazole amino acids 163a, 163b 163d–163k were calculated. No fluorescence was 
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observed for amino acids 160a–160c and 163j and 163k, with only scattered excitation and Raman 
scattering being recorded. This was confirmed using methanol as a blank sample, which gave 
identical emission spectra.11 Therefore brightness and quantum yield values could not be 
calculated for these compounds.  
 
For amino acids 163a, 163b 163d–163l, mega-Stokes shifts were observed between the excitation 
and emission wavelength maxima.126  Due to the lack of rigidity and planarity, the quantum yields 
of these benzotriazole derived amino acids were lower and more varied than pyrazoloquinazoline 
derived amino acids 94, 98–101. In addition, no vibronic fine structure was observed due to 
rotation between the aryl rings being allowed. The presence of rotational energy levels led to 
broad absorption and emission spectra. Like the previously reported pyridine-derived amino acids, 
the highest quantum yield values were obtained for naphthyl and 4-methoxyphenyl analogues 
163b and 163f. 4-Methoxyphenyl substituted benzotriazole 163f had one of the highest molar 
attenuation coefficients, which made it the brightest compound from this series. Alongside, the 
high brightness value, 4-methoxyphenyl substituted benzotriazole amino acid 163f also had a 
Stokes shift of 162 nm making it the lead compound of this series. 
 
It should be noted that the 4-methoxyphenyl 163f and 4-hydroxyphenyl substituted benzotriazole 
amino acid 163e displayed very different fluorescent properties. While the 4-methoxyphenyl 
substituted benzotriazole was a very bright fluorophore, the 4-hydroxyphenyl substituted 
benzotriazole showed almost no fluorescence. This is due to excited-state proton transfer, the 
same phenomenon has been observed for hydroxyl- and methoxyflavones.127 Another 
observation is the significant decrease in brightness between 4-methoxyphenyl substituted 
benzotriazole 163f and benzodioxole substituted benzotriazole amino acid 163g. This trend was 
also observed with the previously synthesised pyridine amino acids.128 
 
Both 4-dimethyaminophenyl- and 4-morpholinephenyl substituted benzotriazole amino acids 
163h and 163l had limited fluorescence. It has been reported that fluorescent properties can be 
improved by the replacement of dialkylamino functional groups with azetidine rings.129 Therefore, 
the fluorescence properties of a 4-azetidinephenyl substituted benzotriazole amino acid would be 
of interest. 
  
81 
 
Compound 
Excitation 
Wavelength 
(nm) 
Molar 
Attenuation 
Coefficient 
(cm−1M−1) 
Emission 
Maximum 
(nm) 
Stokes 
shift 
(nm) 
Quantum 
yield (φF) 
Brightness 
(cm−1M−1) 
 
282 4,824 N/A N/A N/A N/A 
 
290 6,117 N/A N/A N/A N/A 
 
294 4,601 N/A N/A N/A N/A 
 
250 22,633 363 120 0.0024 55 
 
280 10,309 417 131 0.18 1866 
 
251 19,903 384 127 0.03 533 
 
260 26,729 436 176 0.0081 216 
 
256 23,034 418 162 0.17 3857 
 
258 18,504 454 196 0.02 350 
 
290 17,212 382 92 0.0016 27 
 
285 19,212 384 99 0.0043 82 
 
290 24,360 N/A N/A N/A N/A 
 
224 
312 
26,308 
17,224 
N/A N/A N/A N/A 
Table 11 Photoluminescence properties of the synthesised amino acids 160a–160c, 163a, 163b 
and 163d–163k. 
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Figure 42 Absorption and emission spectra of amino acid 160a, in MeOH (excitation at 282 nm). 
 
Figure 43 Absorption and emission spectra of amino acid 160b, in MeOH (excitation at 290 nm). 
 
  
Figure 44 Absorption and emission spectra of amino acid 160c, in MeOH (excitation at 294 nm). 
 
  
Figure 45 Absorption and emission spectra of amino acid 163a, in MeOH (excitation at 250 nm). 
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Figure 46 Absorption and emission spectra of amino acid 163b, in MeOH (excitation at 280 nm). 
 
  
Figure 47 Absorption and emission spectra of amino acid 163d, in MeOH (excitation at 251 nm).  
  
 
  
Figure 48 Absorption and emission spectra of amino acid 163e, in MeOH (excitation at 260 nm).  
 
  
Figure 49 Absorption and emission spectra of amino acid 163f, in MeOH (excitation at 256 nm).  
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Figure 50 Absorption and emission spectra of amino acid 163g, in MeOH (excitation at 258 nm).  
 
  
Figure 51 Absorption and emission spectra of amino acid 163h, in MeOH (excitation at 287 nm).  
 
  
Figure 52 Absorption and emission spectra of amino acid 163i, in MeOH (excitation at 285 nm). 
 
 
  
 
Figure 53 Absorption and emission spectra of amino acid 163j, in MeOH (excitation at 290 nm). 
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Figure 54 Absorption and emission spectra of amino acid 163k, in MeOH (excitation at 260 nm). 
 
Compound 163f the lead compound in this series, was studied further with a brief solvatochromic 
study (Figure 55). The absorption and emission spectra of the amino acid were measured in THF, 
methanol and PBS solution. It was found that the absorption spectra were very similar in all the 
solvents. However, it was observed that the emission spectra of the amino acid displayed strong 
solvent effects. As the solvent polarity increased, the emission maximum also increased. In THF, 
an emission maximum of 372 nm was recorded, while in methanol, the emission maximum was 
observed at 417 nm. In aqueous PBS solution, the emission maximum was found at 449 nm. 
Furthermore, there is evidence of a change in the excited state between polar and non-polar 
solvents with a shoulder peak present in the emission spectrum recorded in methanol. From this, 
it can be concluded that in non-polar solvents the compound exists in a locally excited state before 
the emission of a photon, whereas in polar solvents an ICT state present. 
 
  
Figure 55 Solvatochromic study of 163f. 
 
2.2.4 Carbazole derived amino acids 
With the photoluminescence properties of pyrazole amino acids being significantly improved by 
introducing rigidity to the structure, it was proposed a similar approach could be undertaken for 
the benzotriazole derived amino acids. With amino acid 141, the phenyl ring could distort out of 
the plane of the benzotriazole ring system, leading to reduced conjugation and fluorescence 
(Figure 56). Therefore, a tether 144 could be incorporated, constraining the phenyl and 
benzotriazole rings into the same plane. As carbazoles are well-established tricyclic aromatic 
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heterocycles, it was thought this ring system could be used to introduce rigidity into these 
benzotriazole fluorophores 145. 
 
 
Figure 56 Introducing rigidity into benzotriazole amino acids. 
 
There are several ways to prepare carbazoles from 2-nitrobiphenyl (164) (Figure 57) and it was 
proposed that one of these methods would be applicable for benzotriazole derived amino acids. 
Carbazole (165) can be prepared in one-step from 164 via a Cadogan cyclisation at high 
temperatures with triphenylphosphine.130 The reaction proceeds through a nitrene intermediate 
as the triphenylphosphine is oxidised to the triphenylphosphine oxide. Once the nitrene is formed, 
an intramolecular cyclisation can take place giving the carbazole. This has the advantage of 
reducing the nitro group and performing the cyclisation reaction in the same step. However, 
extremely harsh conditions are generally needed for this reaction to occur. If 164 is reduced to 2-
aminobiphenyl (166) much milder chemistry can be implemented to form the desired carbazole. 
From 166, azide compound 168 can be prepared from the diazonium salt.131 Then, 168 can 
undergo a Sundberg cyclisation reaction to give carbazole (165).131 Otherwise, after the amino 
group of 166 has been protected with a suitable nitrogen protecting group, it has been shown that 
carbazole 170 can be accessed with treatment of 169 with a hypervalent iodine species.30–32 
 
 
Figure 57 Synthetic approaches to carbazoles 
 
Lately, there has been a plethora of research in the use of the hypervalent iodine species in 
carbazole cyclisation chemistry. For example, it has been shown that this transformation can be 
carried out with the use of a palladium catalyst and PIDA (Scheme 58). Under mild conditions, N-
benzyl protected carbazole 172 was formed in 94% yield from aniline 171. 
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Scheme 58 Palladium catalysed carbazole formation with benzyl-protected aniline 171. 
 
It was then later reported, that the same cyclisation can also be performed with a copper catalyst 
and a tosyl-protected aniline (Scheme 59).134 At 50 °C, the tosyl-aniline 173 was converted to 
carbazole 174 in excellent yield with copper(II) triflate and PIDA 
 
 
Scheme 59 Copper catalysed carbazole formation with tosyl-protected aniline 173. 
 
In an attempt to form the carbazole ring, a Cadogan cyclisation reaction was first attempted with 
2-nitrophenyl substituted benzotriazole amino acid 161j (Scheme 60). No product formation was 
observed. A Graebe–Ullmann reaction may be occurring resulting in decomposition of the 
material.135,136 
 
 
Scheme 60 Attempted Cadogan cyclisation of benzotriazole 161j. 
 
With substrate 161j unable to perform the Cadogan cyclisation reaction, an alternative approach 
was required. It was proposed that metal-catalysed carbazole ring formation with a hypervalent 
iodine oxidant had the greatest prospect of success, owing to the very mild reaction conditions 
needed for ring closure. For this approach to be investigated, the 2-nitrophenyl substituted 
benzotriazole compound was converted to 2-aminophenyl substituted benzotriazole 176 (Scheme 
61). This was achieved by tin dichloride reduction of the aromatic nitro group to give 176 in 69% 
yield. Protection of 176 was then carried out with 4-methylbenzenesulfonyl chloride (TsCl) under 
basic conditions, this gave the Ts protected analogue 177 in a 91% yield from 176.  
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Scheme 61 Synthesis of protected aniline 177. 
 
With access to 177, the formation of the carbazole ring system with a transition metal catalyst 
and PIDA was next investigated.132,134 The transformation was first attempted using palladium-
catalysed conditions (Scheme 62). However, no formation of 178 was observed, even with 
extended reaction times and heating.134 
 
 
Scheme 62 Attempted carbazole formation with palladium catalyst.134 
 
The transformation was then attempted using copper-catalysed conditions (Scheme 63). Full 
conversion of 177 to the carbazole product was observed after a reaction time of 0.1 h at 50 °C 
and this gave 178 in 81% yield. 
 
 
Scheme 63 Copper catalysed carbazole ring formation. 
 
Prior to the measurement of any photoluminescent properties, the protecting groups of 178 had 
to be removed. From the literature, it was found that magnesium metal can be used to remove 
aromatic tosyl groups when dissolved in alcoholic solvents.137–139 For example, the reaction of 
compound 179 with magnesium metal gave 180 in a 95% yield (Scheme 64).137 
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Scheme 64 Selective tosyl deprotection of compound 179. 
 
When similar conditions were used with 178, tosyl deprotection did occur, which gave 181, in 50% 
yield (Scheme 65). However, it was found that this result was not reproducible, and a sufficient 
amount of product could not be prepared for subsequent steps with this approach. 
 
 
Scheme 65 Tosyl deprotection of carbazole 178. 
 
Therefore, the other protecting groups of 178 were removed instead using a combination of 
caesium carbonate and 6 M HCl, which gave 182 in a good 45% overall yield (Scheme 66). 
 
 
Scheme 66 Ester hydrolysis and Cbz deprotection of 182. 
 
The photoluminescence properties of 182 were then measured in methanol (10 μM) (Figure 58). 
The Stokes shift, molar attenuation coefficient, quantum yield and brightness values were 
calculated for 182. These values were then compared with the phenyl substituted benzotriazole 
amino acid 163a (Table 12). With the introduction of the nitrogen tether, the photoluminescence 
properties were improved. Carbazole 182 has longer excitation and emission wavelengths, a larger 
Stokes shift and is significantly brighter. 
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Compound 
Excitation 
Wavelength 
(nm) 
Molar 
Attenuation 
Coefficient 
(cm−1M−1) 
Emission 
Maximum 
(nm) 
Stokes 
shift 
(nm) 
Quantum 
yield (φF) 
Brightness 
(cm−1M−1) 
 
243 22,633 363 120 0.0024 55 
 
270 18,399 411 141 0.034 622 
Table 12 Comparison of benzotriazole 163a and carbazole amino acid 182.  
 
 
Figure 58 Absorption and emission spectra of carbazole 182 (MeOH, 10 μM), excited at 270 nm. 
 
2.2.5 Summary 
In conclusion, a route to benzotriazole derived amino acids has been established. Originally this 
allowed for the synthesis of three simple benzotriazole amino acids 160a–160c. As expected, none 
of these amino acids were fluorescent. As a bromide analogue had been synthesised, this allowed 
for further functionalisation via the Suzuki-Miyaura reaction. This gave a small library of 
polyaromatic benzotriazole substituted amino acids 163a, 163b and 163d–163k, and from this 
library, many of these displayed interesting photoluminescence properties. To improve these 
properties, more rigid analogues were studied. It was found that 2-nitrophenyl substituted 
benzotriazole 161j could be reduced to 2-aminophenyl substituted benzotriazole 176. After tosyl 
protection of 176, could undergo a copper-catalysed C-H functionalisation reaction, which gave 
carbazole 178 in high yield. Initial work suggests that the fluorescence properties of this carbazole 
derived amino acids is superior to the original benzotriazole functionalised amino acids. One 
drawback of this synthesis was the use of the tosyl protecting group. While this allowed for the 
efficient formation of the carbazole ring system its removal afterwards was challenging. It was 
found that magnesium metal was capable of removing the protecting group, but the 
transformation was not reproducible. Therefore, other protecting groups should be considered 
for this route. 
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2.2.6 Future work for benzotriazole derived amino acids 
It has been shown that aromatic tosyl groups can be removed with excess caesium carbonate 
(Scheme 67).140 Therefore, tosyl deprotection of carbazole 178 could be trialled using these 
conditions to give the fully deprotected amino acid. 
 
 
Scheme 67 Deprotection of indole 183 with caesium carbonate. 
 
Otherwise, for the carbazole ring formation alternative protecting groups could also be 
investigated. For the copper catalysed cyclisation, the acetamide was reported to be a suitable 
protecting group.134  With the palladium catalysed carbazole ring formation, methyl, benzyl, allyl 
and t-butyl were all shown to be suitable protecting groups for the ring-closing reaction.132 The 
use of one of these alternative protecting groups may allow for easier preparation of 181.  
 
In addition to amino acid 181, other heterocycles could be pursued to increase rigidity within the 
benzotriazole side-chain. It has been reported that dibenzothiophene derived amino acid 187 can 
be synthesised from proline derivative 185, in 77% yield over the two-steps (Scheme 68).141 This 
was achieved using a Suzuki-Miyaura reaction of amino acid 185 with (2-phenylthio)phenylboronic 
acid, which gave coupled product 186. Palladium catalysis with a carboxylic acid ligand under high 
temperatures gave 187 from 186. A similar approach could be investigated with 5ʹ-bromo 
substituted benzotriazole 159c. 
 
 
Scheme 68 Synthesis of dibenzothiophene amino acid 187. 
 
A dibenzofuran ring system could be another ring system for installing rigidity into benzotriazole 
amino acid.  It has been recently reported that dibenzofuran (190) could be prepared from silyl 
phenol 188 (Scheme 69).142 With palladium catalysis, phenol 188 was converted to ortho-silyl 
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ether 189 in good yield. A gold-catalysed intramolecular arylation then gave 190 from silyl ether 
189. 
 
 
Scheme 69 Preparation of dibenzofuran (190). 
 
From this, a synthetic route to give a dibenzofuran analogue can be proposed (Scheme 70). 
Starting with 5ʹ-bromo substituted analogue 159c, etherification with 2-(trimethylsilyl)phenol 
would give silyl 191. Then a gold catalysed cyclisation would result in benzofuran product 192. An 
alternative ring-closing strategy would be the Pschorr reaction from 2-nitrophenol using literature 
conditions.110,143  
 
 
Scheme 70 Synthetic route to dibenzofuran derived amino acid 192.  
 
2.2.7 General future work for fluorescent amino acids 
As discussed above, the replacement of dimethylamino functional groups with azetidine rings can 
improve photoluminescence properties.129 For example, when the dimethylamino functional 
group was replaced with an azetidine ring in fluorophores 193 and 195 the quantum yield was 
greatly increased (Figure 59). 
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Figure 59 Comparison of photoluminescence properties of dimethylamino- and azetidine 
functionalised fluorophores. 
 
For this reason, it would be interesting to prepare azetidine analogues of amino acids previously 
synthesised in the group (Figure 60). Once the target 197–201 azetidine functionalised amino 
acids had been synthesised, their photoluminescence properties would be measured and 
compared to the current library. 
 
 
Figure 60 Potential azetidine functionalised target compounds. 
 
Finally, the chemistry developed for the synthesis of 178 (Scheme 63), could be used for the 
synthesis of carbazole functionalised amino acid 208 from 4ʹ-nitro-L-phenylalanine (66) (Scheme 
71). This could be achieved by reduction of the protected analogue 202 with tin dichloride to give 
aniline 203, followed by protection with TsCl to produce 204. Then, a selective ortho-iodination 
reaction using NIS, iron() chloride and [BMIM]NTf2 would give halogenated product 205.144 The 
Suzuki-Miyaura reaction could be used with iodide functionalised amino acid 205 and a range of 
boronic acids to give a library of polyaromatic derived amino acids 206.43,44 A ring-closing reaction 
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could then be carried out with the previously used conditions to give a collection of carbazole 
products 207. Assessment of the photoluminescence properties of these carbazole derived amino 
acids 207 would be carried out after the removal of protecting groups. From the literature, it has 
already been shown that carbazole compounds possess favourable fluorescent properties.147,148 It 
is also envisioned that dibenzofuran and dibenzothiophene derived amino acids 209 and 210 could 
also be prepared from L-tyrosine and 4ʹ-mercapto-L-phenylalanine respectively.118,141,149 
 
 
Scheme 71 Proposed synthesis of carbazole functionalised amino acid 208. 
  
95 
 
2.3 Bioconjugation 
2.3.1 Introduction 
Bioconjugation is the coupling of two compounds with a covalent bond, with one of these being a 
biomolecule.150,151 This allows for the properties of the biomolecule to be improved. 
Polyethyleneglycol can be conjugated to therapeutic proteins to extend their in vivo half-lives.152  
Biomolecules can also be functionalised through bioconjugation for the introduction of organic 
fluorophores, quantum dots and biotin.153–155  This facilitates the study of biological processes.  
 
2.3.2 Bioconjugation with native amino acids 
Bioconjugation of proteins can be achieved by coupling with side-chains of amino acids.151 The 
amino acids: lysine, cysteine, tryptophan, histidine, tyrosine, arginine, aspartic acid, glutamic acid 
and methionine have all been targets for bioconjugation reactions.151 
 
Lysine residue 188 of human kappa antibodies 211 was selectively modified with biotin using a 
fluorophenyl ester 212 (Scheme 72).156 By performing the coupling at 4 °C in an aqueous phosphate 
buffer solution, biotinylation was selective even in the presence of approximately 40 other lysine 
residues. The selectivity achieved was due to the neighbouring His189 and Asp151 residues 
accelerating the rate of labelling at the Lys188 site. Further control of site selectivity was 
accomplished with lower reaction temperatures and performing the reaction with flow chemistry. 
 
 
Scheme 72 Bioconjugation of the human kappa antibody. 
 
The amino acid cysteine is an attractive target for bioconjugation owing to the very high 
nucleophilicity of the thiol side-arm and its low abundance in living systems.151 Fluorophore QuatCy 
(214) has been found to react with cysteine (Scheme 73) and with cysteine residues in proteins at 
37 °C.157 It was shown that QuatCy is highly selective and will not react with lysine, proline and 
tyrosine residues. When QuatCy was reacted with the protein vimentin, an abundant intracellular 
protein with only one cysteine residue, Cys328, the adduct was fully formed within 1 h.157 
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Scheme 73 Reaction of QuatCy (214) with N-acetamide cysteine. 
 
2.3.3 Bioorthogonal reactions  
A major disadvantage of using native amino acids for bioconjugation is that if the targeted 
functionality is present multiple times within the protein, then control of site selectivity is very 
challenging.156,158 Hence, bioorthogonal chemistry has been developed to allow the specific 
labelling of protein residues.  
 
Staudinger ligation is one such method where a biomolecule can be selectively 
functionalised.157,159,160 An azide-functionalised biomolecule can react with 2-
(diphenylphosphino)phenyl acetate resulting in an amide bond. For example, the reaction of 
azidonucleoside 216 with phosphine 217, gave 218 in 95% HPLC yield (Scheme 74). 
 
 
Scheme 74 Staudinger ligation of azidonucleoside 216. 
 
The use of this conjugation strategy has been highlighted with the ligation of phosphine dye 219 
with protein murine dihydrofolate reductase.161 For this protein, a native methionine residue had 
been replaced with an azidohomoalanine residue to allow for the Staudinger ligation to take place.  
The mechanism of this process is demonstrated with the reaction of 219 with 220 (Scheme 75).161 
Before the Staudinger reaction, the lone pair of electrons present on the phosphorus quenches the 
fluorescence. This 219 a quantum yield of 0.011, after the ligation amide 221 has a quantum yield 
of 0.65 in PBS solution. 
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Scheme 75 Staudinger ligation of phosphine 219 with “turn on” fluorescence. 
 
Another bioorthogonal reaction used extensively in bioconjugation coupling is the Huisgen 
cycloaddition with alkynes and azides, giving the corresponding triazole heterocycle.153,162–166 The 
reaction can occur under very mild conditions and can be catalysed with copper. The reaction of 
azide 222 with alkyne 223 using a copper sulfate catalyst gave 224 in 91% yield (Scheme 76). Due 
to the rapid reaction, high yields, wide scope and generation of minimal byproducts, this process 
can be considered a click reaction.167 
 
 
Scheme 76 Huisgen cycloaddition of azide 222 and alkyne 223. 
 
As copper is toxic to bacterial and mammalian cells, the Huisgen reaction must occur under copper-
free conditions if this reaction is to be used in biological systems. The use of cyclooctynes allows for 
triazole ring formation under metal-free conditions. This is due to the large ring strain present (18 
kcal mol-1).165 Using a cyclooctyne functionalised with biotin 225 allowed for live-cell labelling of 
Jurkat cells incubated with an azide functionalised protein (Figure 61). No negative effects were 
observed of the cells during treatment with cyclooctyne 225. 
 
 
Figure 61 Cyclooctyne functionalised biotin 225. 
 
In addition to the Staudinger ligation and Huisgen reactions, the Wittig reaction has also been 
studied for bioconjugation. It has been reported that hexapeptide 226 could be functionalised with 
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Wittig reagent 228 (Scheme 77).168 This is achieved with a Malaprade oxidation of the terminal 
serine residue of 226 with sodium periodate, which gave aldehyde 227. The intermediate aldehyde 
could be used in the next reaction with 228 without any purification.169,170 It was then shown that 
this methodology could also be applied to the protein interleukin 8, which also has an N-terminal 
serine residue.168 
 
 
Scheme 77 Wittig modification of hexapeptide 226. 
 
It was also reported that aldehyde 230, an analogue of the FK506 drug molecule, was coupled with 
biotin Wittig reagent 231 in a cellular environment (Figure 62).171 HeLa cells were incubated with 
230 for 8 h and then 231 was added. After 15 h, it was found that a successful Wittig coupling had 
taken place. 
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Figure 62 Aldehyde analogue of drug molecule FK506 230 and biotin Wittig reagent 231. 
 
2.3.4 Aims of the project 
From these excellent results, it was proposed that the HWE reaction could also be used in 
orthogonal bioconjugation reactions. Therefore, the aim of this project was to assess if a β-keto 
phosphonate ester analogue of 111 used earlier could also be used in bioconjugation. This will be 
investigated by synthesising a dipeptide phosphonate ester 232 and evaluating its performance in 
model HWE reactions with a range of aldehydes (Figure 63). It was then investigated if the use of 
electron-rich aldehydes for the HWE reaction would result in the synthesis of fluorescent charge-
transfer enones. This would allow for the synthesis of fluorescent enone derived peptides for use 
in biological imaging.74,128 
 
 
Figure 63 Dipeptide phosphonate ester 232. 
 
2.3.5 Synthesis 
L-Aspartic acid β-methyl ester hydrochloride (233) was fully protected using acid-labile protecting 
groups (Scheme 78). This was achieved by the reaction of 233 with tert-butyl acetate and perchloric 
acid to give tert-butyl ester 234 in 44% yield.172 The trityl protected amino acid 235 was prepared 
in 95% yield by reaction of 234 with trityl chloride in the presence of triethylamine in acetonitrile. 
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Scheme 78 Preparation of protected amino acid 235. 
 
Formation of β-keto phosphonate ester 236 from protected amino acid 235 was next investigated 
(Scheme 79). Using the previously mentioned conditions, 2.2 equivalents of dimethyl 
methylphosphonate, 2.3 equivalents of butyllithium, at -78 °C in THF resulted in a low yield of 42% 
of 236. To improve the yield of 236, different reaction conditions were trialled. A synthesis of 236 
was reported when 235 was reacted with 4.5 equivalents of phosphorus anion in tert-butyl methyl 
ether, which gave a yield of 66%.173 When the reaction was attempted using 4.5 equivalents of 
phosphorus anion in THF, a reduced yield of 31% for phosphonate ester 236 was obtained. 
 
 
Scheme 79 Synthesis of phosphonate ester 236 in THF. 
 
From the literature, the synthesis of β-keto phosphonate esters 238 from protected amino acids 
237 was reported (Table 13).174 When the reaction was first trialled in THF with the glutamate 
analogue and a reaction concentration of 0.5 M, a yield of 28% was achieved (entry 1). The reaction 
molarity was decreased from 0.5 M to 0.1 M and this resulted in an increased yield of 52% (entry 
2). When the reaction was trialled in diethyl ether with a reaction concentration of 0.05 M, an 
improved yield of 84% was obtained (entry 3). The same transformation was then trialled on the 
aspartate analogue. The reaction was conducted in diethyl ether with a reaction concentration of 
0.05 and a yield of 71% was obtained for the desired β-keto phosphonate ester (entry 4). It was 
then found that the same yield could be achieved when toluene was used as the reaction solvent 
with a higher reaction concentration of 0.1 M (entry 5). 
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Entry n Solvent M Yield of 238 
1 2 THF 0.5 28% 
2 2 THF 0.1 52% 
3 2 Et2O 0.05 84% 
4 1 Et2O 0.05 71% 
5 1 PhMe 0.1 71% 
Table 13 Literature optimization for the synthesis of phosphonate ester 238. 
 
Therefore, from these literature results, the synthesis of β-keto phosphonate ester 236 was trialled 
in toluene. When amino acid 235 was subjected to these reaction conditions this gave 236 in 71% 
yield (Scheme 80). 
 
 
Scheme 80 Synthesis of phosphonate ester 236 in toluene. 
 
For the β-keto phosphonate ester to be used in amide coupling reactions, the acid-labile tert-butyl 
ester group had to be removed and the trityl protecting group replaced. It was found that both 
protecting groups of 236 were removed with 50% TFA in dichloromethane after 4 h (Scheme 81). 
The deprotected intermediate was then reacted with di-tert-butyl dicarbonate in the presence of 
triethylamine, which gave 237 in 88% yield over the two steps. 
 
 
Scheme 81 Synthesis of Boc phosphonate ester 237. 
 
To investigate peptide coupling of phosphonate ester 237, L-alanine tert-butyl ester hydrochloride 
was used as the coupling partner (Table 14). Various coupling reagents were then trialled to 
optimise this reaction. HBTU and HATU gave moderate yields for dipeptide 238 (entries 1 and 2). 
The use of the coupling reagent PyBOP® gave 238 in 68% yield after a reaction time of 16 h (entry 
3). It was then found that the reaction time could be decreased from 16 h to 1 h (entry 4). The low 
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yields observed with HBTU and HATU were due to removal of the tetramethylurea (TMU) byproduct. 
TMU was removed with aqueous washes, but 238 also partitioned into the aqueous layer.  
 
 
Entry Coupling reagent Reaction  
time (h) 
Yield 
1 HBTU 16 52% 
2 HATU 16 53% 
3 PyBOP® 16 68% 
4 PyBOP® 1 71% 
Table 14 Peptide coupling optimisation of phosphonate ester 238. 
 
Dipeptide 238 was then trialled in HWE reactions with a range of benzaldehydes (Scheme 82). The 
reaction of 238 with benzaldehyde with standard conditions gave enone 239a in 88% yield. When 
more electron-rich aldehydes were used the efficiency of this reaction decreased. For example, 
when 4-anisaldehyde was used this gave enone 239b in 42% yield. Using the highly electron-rich 
aldehyde, 4-dimethylaminonaphthaldehyde, the reaction was very slow. To achieve full conversion, 
an extra equivalent of base, higher temperatures and extended reaction time were all required. 
This resulted in formation of 239c in 28% yield with a 2:1 mixture of E/Z isomers. 
 
 
Scheme 82 HWE reactions with dipeptide 238. 
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To access deprotected dipeptide 240, protected enone 239b was reacted with 50% trifluoroacetic 
acid in dichloromethane, this gave 240 in 72% yield (Scheme 83). 
 
 
Scheme 83 Deprotection of enone 239b. 
 
As this approach had generated a chromophore with a potential charge-transfer motif, the 
photoluminescent properties were investigated. The absorbance and emission of 240 were 
recorded in methanol (10 μM) (Figure 64). From UV/Vis spectroscopy it was found that peptide 240 
absorbed strongly at 324 nm. When 240 was excited at 326 nm no fluorescence was detected. The 
emission spectrum of 240 was compared to a control spectrum of methanol and from this, it was 
concluded that only Raman scattering was being detected. 
 
   
Figure 64 Absorption and emission spectra of 240 in methanol (10 μM), excited at 326 nm. 
 
2.3.6 Summary 
In conclusion, β-keto phosphonate ester dipeptide 238 was synthesised and shown to be an 
effective substrate for model HWE reactions, giving enones 239a–239c. This demonstrates that the 
HWE reaction could be used in bioconjugation reactions, analogous to the previously reported 
Wittig bioconjugation reactions.168,171 However, some optimisation, particularly for electron-rich 
aldehydes is required. 
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2.3.7 Future work 
In order for the HWE reaction to be used in bioconjugation, the reactions conditions need to be 
optimised. More forcing conditions using barium hydroxide as base, in aqueous THF have been 
reported in the literature.175,176 However, as the aim of this work is to perform HWE reaction for 
bioconjugation, it would be preferable to use the mildest and non-toxic conditions possible, as then 
the reaction could take place within living cells. There have been multiple reports of HWE reactions 
being carried out in water, using potassium carbonate as base, giving the enones in good yield.177–
179 In the event of solubility issues, the HWE reaction has also been carried out in water/IPA and 
water/THF mixtures180,181   
 
Once optimised this procedure could be used to couple proteins or peptides with aldehyde 
functionalised compounds through a HWE reaction. From previous group work, it has both been 
shown that enone 87 has very favourable photoluminescent properties and that peptides are 
effective at imaging human fibroblast cells.74,128 In the literature it has been shown that Wittig 
bioconjugation reactions can take place within the cellular environment.170 Therefore, it is 
envisioned that Boc-protected phosphonate ester 237 could be installed upon cell-penetrating 
peptide 128, to give 241 (Scheme 84). After deprotection and resin cleavage, peptide 242 could be 
incubated into a cell. The subsequent addition of aldehydes, such as 4-
dimethylaminonaphthaldehyde would form enone 243 in the cellular environment with turn-on 
fluorescence for cell imaging. 
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Scheme 84 Proposed synthesis of fluorescent enone hexapeptide. 
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2.4 Acid-mediated stereoselective synthesis of 2,6-trans-4-
oxopiperidines from amine-functionalised enones 
2.4.1 Introduction 
Both trans-2,6-dialkyl-4-oxopiperidines and trans-2,6-dialkylpiperidines are found in natural 
products and in bioactive compounds (Figure 65). For example (+)-myrtine (244) is a naturally 
occurring bicyclic alkaloid isolated from the shrub Vaccinium myrtillus (Ericaceae) containing the 
trans-2,6-alkyl-4-oxopiperidine ring system.182,183 (−)-Cermizine C (245), isolated from the moss 
Lycopodium cernuum is another bicyclic alkaloid that has a trans-2,6-dialkylpiperidine ring 
system.184 The alkaloid (−)-solenopsin A (246), which consists of a trans-2,6-dialkylpiperidine ring 
is believed to be the active compound in the venom of fire ants.185,186 Finally the trans-2,6-
dialkylpiperidine ring systems have also been found in highly bioactive compounds. For example, 
himbacine (247) has shown activity in the treatment of Alzheimer’s disease.187 
 
 
Figure 65 Structures of trans-2,6-dialkyl-4-oxopiperidines and trans-2,6-dialkylpiperidines 
natural products and bioactive compounds. 
 
As well as undergoing functionalisation to afford fluorescent amino acids 249, the previously 
mentioned enone derived amino acids 248 can also undergo a 6-endo-trig cyclisation process 
(Scheme 85). This is via an aza-1,4-conjugate addition of the enone system with the α-nitrogen 
atom to give the cyclised product. The products of these transformations are 2,6-disubstituted-4-
oxopiperidines 250. After cyclisation, the ketone can be functionalised to give the 2,4,6-
trisubstituted piperidines products. 
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Scheme 85 6-endo-trig cyclisation via an aza-1,4-conjugate addition. 
 
2.4.2 Previous work in the Sutherland group 
Work within the Sutherland group began by exploring a reductive amination process to induce a 
6-endo-trig cyclisation to give the corresponding 4-oxopipecolic acids (Scheme 86).84 Starting from 
the trityl protected amino acid 251, cyclisation was achieved first by deprotection of the trityl-
protecting group under mildly acidic conditions that gave the amine. This amine was then 
protected with benzaldehyde, which gave 252. A chemoselective reduction of the imine in the 
presence of a ketone functional group induced cyclisation. Various reducing conditions were 
tested, and it was found that the sodium cyanoborohydride in methanol was the most efficient, 
yielding the trans-2,6-disubstituted-4-oxopipecolic acid product 253 after 1 h at room 
temperature in good yields. 
 
 
Scheme 86 Synthesis of trans-2,6-disubstituted-4-oxopipecolic acid 253. 
 
The scope of the reaction was broad with both alkyl and aryl-substituted enones being cyclised to 
pipecolic acids 253a and 253b. Generally, good yields were obtained over the three steps with 
only the very large and highly conjugated substituents giving low yields of the cyclised products 
253c (Figure 66).  
 
 
Figure 66 4-Oxopipecolic acid compounds 253a–253c, produced via reductive amination. 
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It was proposed that the diastereoselectivity observed was due to a Zimmerman-Traxler chair-like 
transition state with both the benzyl and R-group adopting in equatorial positions and the methyl 
ester in an axial position 254 (Figure 67). It was envisioned that the absence of the nitrogen 
protecting group would allow both the ester and R-group to occupy the favoured equatorial 
positions 255. This allows for the cis-2,6-disubstituted-4-oxo-pipecolic acid to become the 
favoured product of the aza-1,4-conjugate cyclisation. 
 
 
Figure 67 Transition states with N-protecting group 254 and without N-protecting group 255. 
 
To investigate this hypothesis, trityl protected enone 255 was deprotected with trifluoroacetic 
acid and this gave free amine 256 (Scheme 87).188 Then a range of different bases were tested to 
induce the 6-endo-trig cyclisation. Butyl lithium and lithium bis(trimethylsilyl)amide both yielded 
no product. The inorganic base sodium carbonate yielded no product when the reaction was 
carried out in dichloromethane but gave a modest yield of 41% of 257 (of both diastereoisomers) 
when performed in methanol. When the organic base, diisopropylethylamine was used the yield 
increased to 85% and a diastereotopic ratio of 75:25 in favour of the cis isomer was obtained with 
a phenyl substituent. Hence, without the N-protecting group present, the cis isomer becomes the 
favoured over the trans isomer. 
 
 
Scheme 87 Base-mediated cyclisation of enone 255. 
 
After the reaction was developed, it was shown that a wide range of cis-2,6-disubstituted-4-
oxopipecolic acids 257a–257d could be produced (Figure 68). Enones with aryl and alkyl side-
chains were suitable substrates for this 6-endo-trig cyclisation process giving good isolated yields 
of the cyclised product. Electron deficient aryl substrates gave the lowest yields 257d for this 
process. 
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Figure 68 Base-mediated cyclisation products 257a–257d. 
 
It was proposed that cis-2,6-disubstituted-4-oxopiperidines 259 could be prepared using the same 
reaction conditions (Scheme 88). These compounds would be useful synthetic intermediates for 
the natural products, spruce alkaloid 260 and (+)-241 D 261.189 While the cis-2,6-disubstituted-4-
oxopiperidines were produced under basic conditions it was observed that this reaction was less 
diastereoselective, giving approximately a 1:1 mixture of both diastereomers. 
 
 
Scheme 88 Base-mediated cyclisation to 2,6-cis-4-oxopiperidines 259 from 258 and the natural 
products spruce alkaloid 260 and (+)-241D 261. 
 
Nevertheless, from this transformation, a library of cis-2,6-disubstituted-4-oxopiperidines were 
synthesised in yields from 41% to 46% (Figure 69). Alkyl 259a, aryl 259b and heterocyclic 259c 
side-arms were all tolerated in this transformation. 
 
 
Figure 69 cis-2,6-Disubstituted-4-oxopiperidines products from base mediated cyclisation. 
 
Finally, the utility of this methodology was demonstrated with the synthesis of (+)-241D and 
spruce alkaloid. 259b underwent a diastereoselective reduction with sodium borohydride to give 
spruce alkaloid 260 in an excellent yield of 87% (Scheme 89). A yield of 84% was for the 
preparation of 261. 
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Scheme 89 Synthesis of 260 by diastereoselective reduction with sodium borohydride. 
 
2.4.3 Aims of the project 
In optimising conditions for the synthesis of cis-2,6-disubstituted-4-oxopiperidines 259, various 
cyclisation conditions were trialled. A similar cyclisation process was reported with sulfoxide 262 
(Scheme 90).190 It was reported that the sulfoxide protecting group was removed using one 
equivalent of hydrochloric acid followed by 6-endo-trig cyclisation with triethylamine and this 
gave cyclised product 263 in 84% yield.  
 
 
Scheme 90 Cyclisation of sulfoxide protected enone 262.  
 
As the above conditions resulted in the efficient transformation of 262 to 263 with an aza-1,4-
conjugate addition, it was therefore thought that the same reaction conditions might be suitable 
for the cyclisation of Boc protected enone 258 to 259. However, when 258a was treated with 
hydrochloric acid at room temperature for one hour in methanol there was no Boc deprotection. 
Instead, it was found that a cyclisation reaction had occurred, which gave a mixture of trans-2,6- 
and cis-2,6-dialkyl-4-oxopiperidines 264a and 265a (Scheme 91). These compounds were isolated, 
and it was found that the combined yield of both isomers was 58% in a 2:1 ratio in favour of 
264a.128 
 
 
Scheme 91 Attempted Boc deprotection of 258a. 
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While an unexpected result, acid-mediated 6-endo-trig cyclisation reactions are known in the 
literature. It was reported that N-Cbz protected enone 266 underwent an acid-mediated 
intramolecular aza-Michael reaction which gave trans-2,6-disubstituted-4-ketalpiperidine 267a in 
67% yield (Scheme 92).191 It was hypothesised that the first step of the reaction is the formation 
of the corresponding ketal, the size of the ketal is critical in determining the selectivity of the 
reaction. When ethylene glycol is used, this forms the cyclic 1,3-dioxolane ketal and this imposes 
steric control in the transition state to give a highly selective reaction. 
 
 
Scheme 92 Acid-mediated cyclisation of Cbz protected enone 266. 
 
The aims of this project were to develop methodology for the acid-mediated cyclisation on Boc-
protected enones 258. Once optimised cyclisation conditions had been developed the synthesis 
of (+)-myrtine (244) and (−)-solenopsin (246) was then investigated.  
 
2.4.4 Synthesis of Boc-protected enones 
The enones required to explore this reaction were synthesised from the corresponding β-keto 
phosphonate ester 274, which was prepared in a seven-step synthesis from L-aspartic acid (106) 
(Scheme 93). At −10 °C, the β-carboxylic acid of 106 was selectively converted to the methyl ester 
with thionyl chloride with no esterification occurred at the α-carboxylic acid. Boc protection under 
basic conditions with di-tert-butyl dicarbonate gave 269 in 89% yield over the two-steps.192 
Reduction of the remaining carboxylic acid group was next investigated. 
 
This was achieved by reaction of 269 with N-hydroxysuccinimide and N,Nʹ-
dicyclohexylcarbodiimide and this gave ester 270. It was reported that 270 could be reduced with 
sodium borohydride.193 It was found the reaction of 270 with sodium borohydride gave alcohol 
271 in a 90% yield over the two steps. Using a literature procedure 271 was converted to alkyl-
iodide 272 in a Appel reaction with iodine and triphenylphosphine with 90% yield.192 Using a 
previously reported procedure hydrodehalogenation of 272 with palladium on carbon gave ester 
273 in 99% yield.194 It should be noted that diisopropylethylamine was added to quench the 
hydrogen iodide formed during the reaction and prevent poisoning of the Pd/C catalyst. β-
Phosphonate ester 274 was prepared from 273 using standard conditions. It was found that 274 
could be prepared in THF with 90% yield.173,174 While the synthesis of 274 required, it was highly 
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efficient (64% overall yield) and therefore multi-gram preparation of this intermediate was 
possible. 
 
 
Scheme 93 Synthetic route to phosphonate ester 274 from L-aspartic acid (106). 
 
With developed HWE conditions, 274 used in reactions with various carbonyl compounds and this 
gave a small library of enones. The majority of the carbonyl compounds tested were commercially 
available, with only 276a and 276b had to be prepared beforehand. Compounds 276a and 276b 
were prepared from commercially available alcohols 275a and 275b (Scheme 94). 
Phenylacetaldehyde 276c was also prepared beforehand from benzyl alcohol 276c for the HWE as 
this aldehyde has a limited shelf-life. Originally all these aldehydes were synthesised with Dess-
Martin periodinane. This resulted in the formation of 276a and 276c in high yield but even with 
multiple attempts 276b was only isolated in 38% yield 
 
 
Scheme 94 Dess-Martin oxidation to give aldehydes 276a–276c. 
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As the use of Dess-Martin periodinane in preparing 276b resulted in low yield, different oxidations 
conditions were investigated. It was found that the Swern oxidation gave 276b in high yield from 
275b (Scheme 95). 
 
 
Scheme 95 Swern oxidation of alcohol 275b to give aldehyde 276b. 
 
It was found that 274 was an excellent substrate for the HWE reaction, allowing for a small library 
of enones to be prepared (Scheme 96). In all the reactions only formation of the E-isomer was 
observed. The reaction of 274 with n-alkyl aldehydes gave the corresponding enones 258a–258f 
in 72–97% yield. It was also found that functional aldehydes, such as 276b could be used in this 
reaction and this gave chlorinated enone 258g in 88% yield. The biologically relevant 
trifluoromethyl functional group was also tolerated in this reaction with 4,4,4-trifluorobutanal and 
this gave enone 258h in 88% yield. Enones containing ring systems 258i, 258j and 258m could all 
be prepared from 274 with excellent yields. Branched aldehydes were also tolerated in this 
reaction with isovaleraldehyde and isobutyraldehyde with 274 which gave enones 258k and 258l. 
On the other hand, when 274 was reacted with phenylacetaldehyde and 3,3,3-trifluoropropanal 
very low yields for enones 258n and 258o were given. This was due to base catalysed 
polymerisation of the aldehyde reagents.195 Attempted synthesis of enone 258p, from 3,3-
dimethylbutanal and 274 gave yield of 15%, it was proposed that steric factors resulted in the low 
yield of this reaction. Low yields were also obtained for functionalised enones 258q and 258r. The 
HWE reaction was attempted with 274 and an alkyl ketone.  When pentan-2-one was used in this 
reaction no conversion to enone 258s was observed and only starting materials were returned 
from the reaction mixture. Only enones that were prepared in high yield were used as substrates 
in the subsequent acid-mediated 6-endo-trig reaction. 
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Scheme 96 Synthesised enones 258a–258s from HWE reaction with 274. 
 
2.5.5 Optimisation and substrate scope of the acid-mediated 6-endo-trig reaction 
To optimise the conditions for this reaction, alkyl enone 258a was chosen as the model substrate 
(Table 15). As mentioned previously, treatment with one equivalent of hydrochloric acid at room 
temperature for 1 hour gave both diastereoisomers with a combined yield of 58% (entry 1). 
Increased amounts of hydrochloric acid led to decomposition and removal of the Boc group (entry 
2). Whereas, when a catalytic amount (50 mol%) of hydrochloric acid was used this gave an 
incomplete reaction and a reduced yield of 40% (entry 3). Addition of the acid at 0 °C and slowly 
warming the reaction to 30 °C, gave a cleaner reaction and with a greater overall yield of both 
diastereomers (entry 4). A marginal gain in the combined yield was observed when the acid was 
added at −78 °C and then slowly warmed to room temperature (entry 5). On performing the 
reaction at reduced temperature, whilst there was an increase in yield there was no improvement 
in the selectivity of the reaction. However, under these improved reaction conditions, this allowed 
isolation of 264a in a 49% yield. 
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Entry HCl (eq.) Temperature (°C) Time (h) Combined Yield (%)a 
1 1 20 1 58 
2 5 20 1 0 
3 0.5 20 3 40 
4 1 0 to 20 2 75 
5 1 −78 to 20 2 82 
Table 15 Optimisation of acid-mediated 6-endo-trig cyclisation with 258a. Reactions performed 
on a 0.04 M concentration. aCombined yield of both diastereoisomers after column 
chromatography. 
 
To gain further understanding of this reaction, the cyclisation reaction of 258a was monitored by 
1H NMR spectroscopy (Figure 70). From this, it was found 258a was fully consumed within 2 h. 
Furthermore, it was observed 264a forms first but over time the amount of 264a decreases and 
the amount of 265a increases. 
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Figure 70  1H NMR spectra of 258a subjected to reaction conditions for 24 hours.
264a 265a 
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Initially, a ratio of 3:1 in favour of trans-isomer 264a was measured (Figure 71). As the reaction 
progressed the quantity of cis increased and after 8 h there was approximately a 1:1 ratio of 264a to 
265a. After 24 h the reaction predominantly gave 265a in a 2:1 ratio. The ratio marginally increased 
to 2.3:1 after 48 h of reaction. 
 
 
Figure 71 Plot of diastereomeric ratio of 264a (blue), 265a (red) and reaction time. 
 
The same phenomenon has been previously reported with the cyclisation of enone 277 (Table 16).191 
It was postulated that the formation of trans isomer 278 occurred first, followed by epimerisation to 
the more stable cis isomer 279 with either a retro-Mannich or a retro-Michael reaction. 
 
 
t (h) 278 (%) 279 (%) 
0.3 85 15 
24 40 60 
Table 16 Formation of 278 and 279 with reaction time.191 
 
Further control experiments were performed by subjecting the separated 264a and 265a compounds 
to the reaction conditions for six hours (Figure 72). After this time, both isomers showed conversion 
to the other diastereomer, but this was more pronounced for the less stable trans-isomer. 264a was 
converted to a mixture of the two isomers in a 2:1 ratio in favour of 264a. While 265a gave a final 
ratio of 5:1 in favour of 265a.  
0
25
50
75
100
0 6 12 18 24
D
ia
st
er
eo
is
o
m
er
s 
(%
)
Time  (h)
118 
 
 
Figure 72 1H NMR spectra of isolated trans/cis products 264a and 265a re-subjected to reaction conditions for 6 hours.
265a 264a 
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From these experiments, it was concluded that the cis product 265a is the thermodynamically 
favoured isomer and the trans product 264a is the kinetically favoured isomer. In the reaction 
264a forms first and then this is epimerised to 265a. From this it was decided, a reaction time of 
2 hours was optimal to ensure a maximum yield of 264 is obtained. As this would be enough time 
for the starting material to be fully consumed and to minimise formation of the 265 isomer. 
 
With the optimised reaction conditions established, the scope of this reaction was next 
investigated (Scheme 97). Enones with long alkyl side-arms were found to be excellent substrates 
for this reaction and after 2 h gave trans-2,6-dialkyl-4-oxopiperidines 264a–264f in 47–56% yield. 
The cyclisation was also shown to accommodate functional groups, and this allowed for the 
preparation of 264g in 56% yield. The synthesis of functional piperidines such as 264g allowed for 
further functionalisation. These conditions were found not to be applicable for enone 258h, with 
extended reaction times being required for full consumption of the starting material. From these 
extended reaction times, this led to a complicated product mixture from which no pure 4-
oxopiperidine product could be isolated. It was found that enones containing ring systems 258i 
and 258j were also good substrates for this reaction, with the compounds 264i and 264j being 
formed in 51–54% yield. It was noted that increased steric bulk next to the newly forming ring as 
with sec-butyl 264k and iso-propyl 264l analogues resulted in the loss of stereoselectivity. This can 
be explained with A-values. With methyl and ethyl substituents the A-values are 1.70 and 1.75 
kcal/mol respectively this indicates only minimal additional steric interactions is introduced as the 
alkyl substituent becomes longer. Therefore, n-propyl, n-butyl, n-pentyl, n-hexyl, n-nonyl and n-
undecyl substituents all impart similar steric influence upon the ring system. However, for 
branched alkyl substituents there is a significant increase in the steric bulk. This is represented 
with the A-value increasing from 1.75 for an ethyl substituent to 2.15 kcal/mol for an iso-propyl 
substituent 258l, as there is more steric bulk being in close proximity to the 4-oxopiperidine ring 
system. This explains the loss of stereoselectivity when compounds 264k and 264l are prepared, 
as the competing cis isomers 265k and 265l can place both substituents into equatorial positions. 
The conjugated enone 264m was also tried with these reaction conditions. It was found that even 
with extended reaction times no cyclised products formed. It was hypothesised that the highly 
conjugated substrate is too stable to undergo cyclisation under these conditions. 
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Scheme 97 Acid-mediated cyclisation of enones 258a–258m. 
 
2.5.6 Synthesis of natural products, (+)-myrtine and (−)-solenopsin A 
As it was found that N-Boc protected enones 258a–258l can be efficiently converted to 2,6-trans-
alkyl-4-oxopiperidines 264a–264l under acidic conditions. The synthetic utility of these cyclic 
compounds was next explored with the synthesis of alkaloid natural products. The natural 
products (+)-myrtine (244) and (−)-solenopsin A (246) were chosen as target compounds. It was 
proposed that 244 could be synthesised from chlorinated enone 264g by removal of the Boc group 
and then nitrogen alkylation. After Boc deprotection under acidic conditions, attempts to perform 
the N-alkylation using sodium hydride following a literature precedent, resulted in decomposition 
of the substrate and no product formation (Scheme 98).196 
 
 
Scheme 98 Attempted synthesis of (+)-myrtine 244 with sodium hydride. 
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It was also reported that milder base, sodium hydrogen carbonate could also be used in 
intramolecular N-alkylations.197,198 When sodium hydrogen carbonate was used in this reaction, 
this gave 244 cleanly with no decomposition in 62% yield over the two steps. (Scheme 99). 
 
 
Scheme 99 Synthesis of (+)-myrtine (244) from 4-oxopiperidine 264g. 
 
 (−)-Solenopsin A (246) was prepared from 4-oxopiperidine 264f. Initially, removal of the ketone 
was attempted with literature high-pressure hydrogenation conditions (Scheme 100).196 However, 
when this was attempted this only returned starting material and there was no formation of 246. 
 
 
Scheme 100 Attempted synthesis of (−)-solenopsin A (246) with high-pressure hydrogenation. 
 
Therefore, a two-step approach to remove the ketone was performed. This involved synthesis of 
dithiane intermediate 280, as the thioketal could be removed with a nickel catalyst.191 Treatment 
of piperidine 264f with 1,3-propanedithiol under Lewis acid conditions gave 280 in a 90% yield. 
The use of boron trifluoride resulted both in the installation of the cyclic dithioketal and removal 
of the Boc-protecting group (Scheme 101). Reduction of 280 with Raney® nickel gave 246 in 77% 
yield. Therefore, natural product 246 can be prepared from 264f in 69% yield over two-steps. 
 
 
Scheme 101 Synthesis of (−)-solenopsin A (246) with Raney® nickel. 
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2.5.7 Future work 
Tri-substituted piperidines are found both in bio-active molecules, for example, eucatropine (281) 
is a mydriatic. Therefore, it would be of interest to synthesise 281 and other related compounds 
(Figure 73).199,200 
 
 
Figure 73 Chemical structure of eucatropine (281). 
 
It is proposed that tri-substituted-2,6,6-piperidones 283 could be prepared from 274 and various 
ketones with the HWE reaction (Scheme 102). Initial investigations have found that the enone 282 
could not be prepared using potassium carbonate as base. However, there are examples in 
literature where this transformation can be achieved with the use of sodium hydride.201–203 
Therefore, it is envisioned the use of sodium hydride could facilitate the preparation of 282. Using 
the developed acid-mediated 6-endo-trig procedure would allow access to tri-substituted-2,6,6-
piperidones 283. 
 
 
Scheme 102 Potential synthetic route to 2,6,6-trialkyl-4-oxopiperidines 283. 
 
As mentioned, previous work in the group has established a one-pot, three-step method for the 
synthesis of pipecolic acids 253. Therefore, it would be of interest if these compounds could be 
prepared more efficiently using this acid-mediated procedure. The enones needed for this 
transformation can be easily prepared from phosphonate ester 111. Then, the optimisation of the 
cyclisation step could then be carried out. Currently, it has been shown that pipecolic acid 285 can 
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be synthesised from enone 284 in low yield (Scheme 103). This result would serve as a starting 
point for optimisation of this process. 
 
 
Scheme 103 Synthesis of 4-oxopipecolic acid 285. 
 
2.5.8 Summary 
In summary, an acid-mediated stereoselective reaction has been developed and a library of eleven 
trans-2,6-dialkyl-4-oxopiperidines were synthesised. This complements the work already 
developed by the group (Figure 74). It was also shown that these products can isomerise under 
reaction conditions. Mechanistic studies showed that the trans compound is the kinetic product, 
whilst the cis compound is the thermodynamic product. Furthermore, despite the reaction being 
performed under acidic conditions, no significant Boc deprotected or ketal products were isolated, 
with the Boc-protected 4-oxopiperidines being isolated as the major product (54–95% yield). 
 
 
Figure 74 Group methodology to cyclic 4-oxopipecolic acid and 4-oxopiperidines. 
 
With this understanding, it was shown that this methodology could be used for the efficient 
synthesis of two natural products (−)-solenopsin A (244) and (+)-myrtine (246) (Figure 75). Both 
compounds were synthesised from L-aspartic acid in eleven steps with overall yields of 18% and 
20%, respectively. 
 
 
Figure 75 Natural products accessed via the acid-mediated 6-endo-trig methodology. 
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3.0 Experimental 
3.1 General experimental 
All reagents and starting materials were obtained from commercial sources and used as received. 
Dry solvents were purified using a PureSolv 500 MD solvent purification system. All reactions were 
performed under an atmosphere of argon unless otherwise mentioned. Brine refers to a saturated 
solution of sodium chloride. Flash column chromatography was carried out using Fisher matrix 
silica 60. Macherey-Nagel aluminium-backed plates pre-coated with silica gel 60 (UV254) were 
used for thin-layer chromatography and visualised by staining with KMnO4, vanillin or ninhydrin. 
1H NMR and 13C NMR spectra were recorded on a Bruker DPX 400 or 500 spectrometer with 
chemical shift values in ppm relative to TMS (δH = 0.00 ppm and δC = 0.0 ppm), or solvent signals 
as the internal standard, for 1H NMR spectra: CHCl3 δH = 7.26 ppm, DMSO-d5, δH = 2.50 ppm or 
CD2HOH δH = 3.31 ppm. For 13C NMR spectra CDCl3 δC = 77.2 ppm DMSO-d6 δC = 39.5 ppm and 
MeOD-d4 δC = 49.0 ppm. Proton and carbon assignments are based on two-dimensional COSY, 
HSQC, HMBC and DEPT experiments. Mass spectra were obtained using a JEOL JMS-700 
spectrometer for EI and CI or Bruker Microtof-q for ESI. Infrared spectra were obtained neat using 
a Shimadzu IR Prestige-21 spectrometer. Melting points were determined on a Reichert platform 
melting point apparatus. Optical rotations were determined as solutions irradiating with the 
sodium D line (λ= 589 nm) using an Autopol V polarimeter. [α]D values are given in units 10-1 deg 
cm−1 g−1. UV-Vis spectra were recorded on a Pekin Elmer Lambda 25 instrument. Fluorescence 
spectra were recorded on a Shimadzu RF- 5301PC spectrofluorophotometer. Emission data were 
measured using excitation and emission bandpass filters of 3 nm. Quantum yields were 
determined using a comparative method against two standards.92 Anthracene (Φ = 0.27, in 
ethanol) and ʟ-tryptophan (Φ = 0.14 in water) were used as standard references.42,204 The 
integrated fluorescence intensity of each compound was determined from the emission spectra 
given. Measurements were performed at five different concentrations. Concentrations were 
chosen to ensure the absorption value was below 0.1 to avoid re-absorption effects. Integrated 
fluorescence intensity was plotted as a function of the measured absorbance and a linear fit is 
calculated with an intercept of zero. The resultant gradient was then used to calculate the 
quantum yield. 
 
Φx= ΦST (
Gradx
GradST
) (
ηx
2
ηST
2 ) 
 
Calculation of quantum yield. Subscript ST signifies the quantities associated with the quantum 
yield standard. Subscript X signifies the quantities associated with the novel compound. GradX is 
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the determined gradient associated with the novel compound. GradST is the determined gradient 
associated with quantum yield standard. η is the refractive index of the solvent used in the 
fluorescence measurements. η = 1.333 for water, 1.361 for ethanol and 1.331 for methanol.205,206 
 
3.2 Experimental for pyrazoloquinazoline derived amino acids 
Dimethyl (2S)-2-aminobutandioate hydrochloride (286)207 
 
 
 
To a suspension of L-aspartic acid (106) (5.00 g, 37.6 mmol) in methanol (30 mL) at 0 °C under 
argon was added dropwise thionyl chloride (4.00 mL, 52.6 mmol). The reaction mixture was 
warmed to room temperature and then heated under reflux for 3 h. The solution was 
concentrated in vacuo to give a colourless oil and triturated with diethyl ether which gave 
dimethyl (2S)-2-aminobutandioate hydrochloride as a colourless solid (7.55 g, 100%). Mp 115–
116 °C (lit.207 114–115 °C); [α]D
24 +22.0 (c 1.0, MeOH); δH (400 MHz, DMSO-d6) 2.99 (1H, dd, J 18.0, 
5.5 Hz, 3-HH), 3.05 (1H, dd, J 18.0, 5.5 Hz, 3-HH), 3.66 (3H, s, OMe), 3.74 (3H, s, OMe), 4.35 (1H, t, 
J 5.5 Hz, 2-H), 8.72 (3H, s, CHNH3+); δC (101 MHz, DMSO-d6) 34.0 (CH2), 48.4 (CH), 52.2 (CH3), 53.0 
(CH3), 168.7 (C), 169.6 (C); m/z (CI) 162 (MH+, 100%), 148(5), 102 (20). 
 
Dimethyl (2S)-2-(tritylamino)butandioate (107)173 
 
 
 
To a solution of dimethyl (2S)-2-aminobutandioate hydrochloride (286) (7.46 g, 37.7 mmol) in 
dichloromethane (150 mL) at 0 °C was added dropwise triethylamine (11.0 mL, 75.4 mmol) and 
triphenylmethylchloride (10.5 g, 37.7 mmol). The reaction mixture was allowed to warm to room 
temperature and stirred for 24 h. The reaction mixture was washed with 2 M citric acid (100 mL), 
water (100 mL), brine (100 mL), then dried (MgSO4) and concentrated in vacuo to give a colourless 
oil. The crude product was purified by column chromatography (elution with 50% diethyl ether in 
petroleum ether) which gave 107 as a colourless solid (15.2 g, 100%). Mp 71–72 °C (lit. 70–71 °C); 
[α]D
24 +36.6 (c1.0, CHCl3); δH (400 MHz, CDCl3) 2.51 (1H, dd, J 14.7, 7.0 Hz, 3-HH), 2.66 (1H, dd, J 
14.7, 5.4 Hz, 3-HH), 2.93 (1H, d, J 10.1 Hz, NH), 3.25 (3H, s, OMe), 3.67 (3H, s, OMe), 3.68–3.73 
(1H, m, 2-H), 7.15–7.20 (3H, m, ArH), 7.23–7.28 (6H, m, ArH), 7.46–7.51 (6H, m, ArH); δC (101 MHz, 
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CDCl3) 39.0 (CH2), 50.5 (CH), 50.7 (CH3), 52.4 (CH3), 69.9 (C), 125.2 (3 × CH), 126.6 (6 × CH), 127.5 
(6 × CH), 144.4 (3 × C), 169.7 (C), 172.6 (C); m/z (EI) 403 (M+, 1%), 326 (35), 243 (100), 165 (30), 83 
(70). 
 
Methyl (2S)-5-(dimethyloxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate (108)173 
 
 
 
A solution of dimethyl methylphosphonate (3.00 mL, 27.3 mmol) in THF (50 mL) was cooled to –
78 °C under an argon atmosphere. n-Butyl lithium (2.5 M in hexane, 11.0 mL, 28.6 mmol) was 
added dropwise and the reaction mixture stirred for 1 h. In a separate reaction vessel, a solution 
of dimethyl (2S)-2-(tritylamino)butandioate (107) (5.00 g, 12.4 mmol) in THF (100 mL) was cooled 
to –78 °C and then the dimethyl methylphosphonate/n-butyl lithium solution was cannulated into 
the flask and the reaction mixture stirred at –78 °C for 2 h to give a yellow solution. The reaction 
was quenched with a saturated solution of ammonium chloride (3 mL) and allowed to warm to 
room temperature. The mixture was concentrated in vacuo. The resulting residue was diluted with 
ethyl acetate (100 mL), washed with water (2 × 100 mL), brine (100 mL) then dried (MgSO4) and 
concentrated in vacuo. The crude product was purified by column chromatography (elution with 
40% ethyl acetate in dichloromethane) which gave 108 as a colourless solid (5.71 g, 93%). Mp 117–
118 °C (lit.173 117–118.5 °C); [α]D
24  +31.1 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.78 (1H, dd, J 16.7, 
6.9 Hz, 3-HH), 2.85–2.95 (2H, m, 3-HH and NH), 3.06 (2H, d, JH–C–P 22.7 Hz, 5-H2), 3.29 (3H, s, OCH3), 
3.65–3.73 (1H, m, 2-H), 3.76 (3H, s, OCH3), 3.79 (3H, s, OCH3), 7.15–7.21 (3H, m, ArH), 7.26 (6H, t, 
J 7.7 Hz, ArH), 7.47 (6H, d, J 7.7 Hz, ArH); δC (101 MHz, CDCl3) 41.8 (d, JC–P 128 Hz, CH2), 48.8 (CH2), 
52.0 (CH3), 52.9 (CH3), 53.0 (CH3), 53.1 (CH), 71.3 (C), 126.6 (3 × CH), 127.9 (6 × CH), 128.8 (6 × CH), 
145.7 (3 × C), 174.0 (C), 199.3 (C); m/z (CI) 496 (MH+, 1%), 301 (5), 254 (90), 243 (100), 237 (55), 
167 (45). 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-5-(dimethoxyphosphoryl)-4-oxopentanoate (111) 
 
 
 
To a solution of methyl (2S)-5-(dimethoxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate (108) (1.95 
g, 3.94 mmol) in dichloromethane (40 mL) was added trifluoroacetic acid (3.02 mL, 39.4 mmol). The 
reaction mixture was stirred at room temperature for 2 h and then concentrated in vacuo. The 
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resulting residue was dissolved in water (50 mL) and washed with diethyl ether (2 × 50 mL). The 
aqueous layer was concentrated in vacuo to give the TFA salt. This was dissolved in 
dichloromethane (40 mL), cooled to 0 °C and, di-tert-butyl dicarbonate (1.81 mL, 7.87 mmol) and 
triethylamine (1.12 mL, 7.87 mmol) was added. The reaction mixture was warmed to room 
temperature and stirred for 16 h. The reaction mixture was diluted with dichloromethane (10 mL), 
washed with 1 M aqueous hydrochloric acid (50 mL) and brine (50 mL). The organic layer was dried 
(MgSO4) and concentrated in vacuo. Purification by flash chromatography using silica gel, eluting 
with 2% methanol in dichloromethane gave methyl (2S)-2-(tert-butoxycarbonylamino)-5-
(dimethoxyphosphoryl)-4-oxopentanoate (111) as a clear oil (1.27 g, 91%). νmax/cm−1 (neat) 3291 
(NH), 2957 (CH), 1713 (C=O), 1506, 1368, 1252, 1165, 1026; [α]D
22 +25.2 (c 1.0, CHCl3); δH (400 MHz, 
CDCl3) 1.42 (9H, s, 3 × CH3), 3.09 (2H, d, J 22.7 Hz, 5-H2), 3.13 (1H, dd, J 18.4, 4.3 Hz, 3-HH), 3.29 (1H, 
dd, J 18.4, 4.7 Hz, 3-HH), 3.71 (3H, s, OCH3), 3.75 (3H, s, OCH3), 3.78 (3H, s, OCH3), 4.50 (1H, ddd, J 
8.4, 4.7, 4.3 Hz, 2-H), 5.45 (1H, d, J 8.4 Hz, NH); δC (101 MHz, CDCl3) 28.4 (3 × CH3), 41.6 (d, JC-P 128 
Hz, CH2) 45.9 (CH2), 49.5 (CH), 52.7 (CH3), 53.2 (d, JC-O-P 5.4 Hz, CH3), 53.3 (d, JC-O-P 5.1 Hz, CH3), 80.2 
(C), 155.5 (C), 171.7 (C), 199.9 (C); m/z (ESI) 376.1121 (MNa+. C13H24NNaO8P requires 376.1132). 
 
Methyl (2S,5E)-6-(2ʹ-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (109a) 
 
 
 
Methyl (2S)-5-(dimethyoxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate (108) (2.50 g, 5.05 
mmol), 2-nitrobenzaldehyde (1.53 g, 10.1 mmol) and potassium carbonate (0.733 g, 5.30 mmol) 
were stirred in anhydrous acetonitrile (50 mL) at 50 °C under argon for 20 h. The reaction mixture 
was concentrated in vacuo. The resulting residue was dissolved in ethyl acetate (50 mL) and 
washed with water (50 mL) and brine (50 mL). The organic layer was dried (MgSO4) and 
concentrated in vacuo to give the crude product. Purification by flash chromatography using silica 
gel, eluting with 50% diethyl ether in petroleum ether (40–60) gave methyl (2S,5E)-6-(2’-
nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (109a) as a yellow solid (2.21 g, 92%). Mp 137–
139 °C; νmax/cm−1 (neat) 2922 (CH) 1736 (C=O), 1692 (C=O), 1524, 1343, 1201, 1172, 745, 706; 
[α]D
24 +39.9 (c 1.1, CHCl3); δH (500 MHz, CDCl3) 2.81 (1H, dd, J 15.7 6.9 Hz, 3-HH), 2.90–2.94 (2H, 
m, 3-HH and NH), 3.33 (3H, s, OCH3), 3.81 (1H, ddd, J 9.8 6.9 5.1 Hz, 2-H), 6.53 (1H, d, J 16.1 Hz, 5-
H), 7.17 (3H, tt, J 7.3 1.3 Hz, ArH), 7.24–7.27 (6H, m, ArH) 7.49–7.51 (6H, m, ArH), 7.55–7.58 (1H, 
m, 4ʹ-H), 7.61 (1H, dd, J 7.8 1.5 Hz, 6ʹ-H), 7.65–7.68 (1H, m, 5ʹ-H), 7.89 (1H, d, J 16.1 Hz, 6-H), 8.07 
(1H, dd, J 8.2 1.2 Hz, 3ʹ-H); δC (121 MHz, CDCl3) 45.2 (CH2), 52.2 (CH3), 53.7 (CH), 71.4 (C) 125.2 
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(CH), 126.7 (3 × CH), 128.1 (6 × CH), 128.9 (6 × CH), 129.2 (CH),130.6 (CH), 130.9 (C), 131.3 (CH), 
133.8 (CH), 138.7(CH), 145.9 (3 × C), 148.5 (C), 174.5 (C), 197.4 (C); m/z (ESI) 543.1869 (MNa+. 
C32H28N2NaO5 requires 543.1890).  
 
Methyl (2S,5E)-6-(1ʹ-nitronaphthalen-2ʹ-yl)-4-oxo-2-(tritylamino)hex-5-enoate (109b) 
 
 
 
Methyl (2S,5E)-6-(1ʹ-nitronaphthalen-2ʹ-yl)-4-oxo-2-(tritylamino)hex-5-enoate (109b) was 
synthesised as described for methyl (2S,5E)-6-(2’-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate 
(109a) using methyl (2S)-5-(dimethyoxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate (108) (0.100 
g, 0.202 mmol), 1-nitro-2-naphthaldehyde (0.0812 g, 0.404 mmol) and potassium carbonate 
(0.0307 g, 0.222 mmol) in anhydrous acetonitrile (4 mL). Purification by flash chromatography 
using silica gel, eluting with 50% diethyl ether in petroleum ether (40–60) gave methyl (2S,5E)-6-
(1ʹ-nitronaphthalen-2ʹ-yl)-4-oxo-2-(tritylamino)hex-5-enoate (109b) as a yellow solid (0.0604 g, 
52%). Mp 115–118 °C; νmax/cm−1 (neat) 1735 (C=O), 1732 (C=O), 1612, 1595, 1526; [α]D
24 +45.2 (c 
1.4, CHCl3); δH (400 MHz, CDCl3) 2.74 (1H, dd, J 15.7, 6.8 Hz, 3-HH), 2.84 (1H, dd, J 15.7, 4.8 Hz, 3-
HH), 2.93 (1H, d, J 9.2 Hz, NH), 3.36 (3H, s, OCH3), 3.75–3.83 (1H, m, 2-H), 6.78 (1H, d, J 16.0 Hz, 5-
H), 7.19 (3H, tt, J 7.2, 1.2 Hz, 3 × ArH), 7.25–7.30 (6H, m, 6 × ArH), 7.48–7.54 (7H, m, 6-H and 6 × 
ArH), 7.62–7.71 (3H, m, 3ʹ-H, 6ʹ-H and 7ʹ-H), 7.76–7.80 (1H, m, 5ʹ-H), 7.90–7.96 (1H, m, 8ʹ-H), 7.99 
(1H, d, J 8.8 Hz, 4ʹ-H); δC (126 MHz, CDCl3) 45.5 (CH2), 52.2 (CH3), 53.6 (CH), 71.4 (C), 122.4 (CH), 
122.5 (CH), 123.9 (C), 124.6 (C), 126.7 (3 × CH), 128.1 (6 × CH), 128.3 (CH), 128.8 (CH), 128.9 (6 × 
CH), 129.5 (CH), 131.2 (CH), 131.3 (CH), 134.6 (C), 135.0 (CH), 145.9 (3 × C), 148.8 (C), 174.4 (C), 
196.9 (C); m/z (ESI) 593.2023 (MNa+. C36H30N2NaO5 requires 593.2047). 
 
Methyl (2S,5E)-6-(5ʹ-fluoro-2ʹ-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (109c) 
 
 
 
Methyl (2S,5E)-6-(5ʹ-fluoro-2ʹ-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (109c) was 
synthesised as described for methyl (2S,5E)-6-(2’-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate 
(109a) using methyl (2S)-5-(dimethyoxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate (108) (2.00 
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g, 4.04 mmol), 5-fluoro-2-nitrobenzaldehyde (1.37 g, 8.08 mmol) and potassium carbonate (0.614 
g, 4.44) in anhydrous acetonitrile (40 mL). Purification by flash chromatography using silica gel, 
eluting with 50% diethyl ether in petroleum ether (40–60) gave methyl (2S,5E)-6-(5ʹ-fluoro-2ʹ-
nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (109c) as a yellow solid (1.88 g, 86%). Mp 108–
110 °C; νmax/cm−1 (neat) 1734 (C=O), 1729 (C=O), 1523, 1341, 1276, 1213; [α]D
28 +36.1 (c 0.8, CHCl-
3); δH (500 MHz, CDCl3) 2.80 (1H, dd, J 15.7, 7.0 Hz, 3-HH), 2.90 (1H, dd, J 15.7, 5.0 Hz, 3-HH), 2.95 
(1H, d, J 9.5 Hz, NH), 3.33 (3H, s, OCH3), 3.76–3.87 (1H, m, 2-H), 6.50 (1H, d, J 16.0 Hz, 5-H), 6.14–
7.20 (4H, m, ArH), 7.21–7.29 (7H, m, ArH), 7.50 (6H, d, J 7.5 Hz, ArH), 7.88 (1H, d, J 16.0 Hz, 6-H), 
8.10 (1H, dd, J 9.1 5.0 Hz, ArH); δC (126 MHz, CDCl3) 45.4 (CH2), 52.1 (CH3), 53.6 (CH), 71.3 (C), 
116.0 (d, 2JCF 24.6 Hz, CH), 117.4 (d, 2JCF 23.4 Hz, CH), 126.6 (3 × CH), 128.0 (6 × CH), 128.1 (d, 3JCF 
10.2 Hz, CH), 128.8 (6 × CH),  131.7 (CH), 134.1 (d, 3JCF 9.2 Hz, C), 137.6 (CH), 144.4 (C), 145.7 (3 × 
C), 164.9 (d, 1JCF 258.4 Hz, C), 174.3 (C), 196.9 (C); m/z (ESI) 561.1774 (MNa+. C32H27FN2NaO5 
requires 561.1796). 
 
Methyl (2S,5E)-6-(4ʹ,5ʹ-dimethyoxy-2ʹ-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (109d) 
 
 
 
Methyl (2S,5E)-6-(4ʹ,5ʹ-dimethyoxy-2ʹ-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (109d) was 
synthesised as described for methyl (2S,5E)-6-(2’-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate 
(109a) using methyl (2S)-5-(dimethyoxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate (108) (0.825 
g, 1.67 mmol), 6-nitroveratraldehyde (0.705 g, 3.34 mmol) and potassium carbonate (0.254 g, 1.84 
mmol) in anhydrous acetonitrile (20 mL). Purification by flash chromatography using silica gel, 
eluting with 80% diethyl ether in petroleum ether (40–60) gave methyl (2S,5E)-6-(4ʹ,5ʹ-
dimethyoxy-2ʹ-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (109d) as a yellow solid (0.822 g, 
85%). Mp 106–108 °C; νmax/cm−1 (neat) 3072 (NH), 2943 (CH), 1733 (C=O), 1663 (C=O), 1519, 1280, 
1067; [α]D
32 +36.4 (c 0.7, CHCl3); δH (400 MHz, CDCl3) 2.84 (1H, dd, J 15.7, 6.9 Hz, 3-HH), 2.93–2.97 
(2H, m, 3-HH and NH), 3.32 (3H, s, OCH3), 3.82 (1H, m, 2-H), 3.98 (3H, s, OCH3), 3.99 (3H, s, OCH3), 
6.46 (1H, d, J 16.2 Hz, 5-H), 6.95 (1H, s, 6ʹ-H), 7.17 (3H, tt, J 7.3, 1.1 Hz, ArH), 7.23–7.26 (6H, m, 
ArH), 7.49–7.51 (6H, m, ArH), 7.66 (1H, s, 3ʹ-H), 8.01 (1H, d, J 16.2 Hz, 6-H); δC (126 MHz, CDCl3) 
44.8 (CH2), 52.2 (CH3), 53.8 (CH), 56.7 (CH3), 56.7 (CH3), 71.4 (C), 108.2 (CH), 109.9 (CH), 125.4 (C), 
126.7 (3 × CH) 128.1 (6 × CH), 129.0 (6 × CH), 130.4 (CH), 139.8 (CH), 141.5 (C), 145.9 (3 × C), 150.3 
(C), 153.4 (C), 174.5 (C), 197.7 (C); m/z (ESI) 603.2073 (MNa+. C34H32N2NaO7 requires 603.2102). 
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Methyl (2S,5E)-6-(4ʹ-dimethylamino-2ʹ-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (109e) 
 
 
 
Methyl (2S,5E)-6-(4ʹ-dimethylamino-2ʹ-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (109e) 
was synthesised as described for methyl (2S,5E)-6-(2’-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-
enoate (109a) using methyl (2S)-5-(dimethyoxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate (108) 
(0.512 g, 1.03 mmol), 4-(dimethylamino)-2-nitrobenzaldehyde (0.401 g, 0.207 mmol) and 
potassium carbonate (0.157 g, 1.14 mmol) in anhydrous acetonitrile (10 mL). Purification by flash 
chromatography using silica gel, eluting with 50% diethyl ether in petroleum ether (40–60) gave 
methyl (2S,5E)-6-(1ʹ-nitronaphthalen-2-yl)-4-oxo-2-(tritylamino)hex-5-enoate (109e) as a yellow 
solid (0.0604 g, 52%). Mp 117–118 °C; νmax/cm−1 (neat) 3059 (NH), 2947 (CH), 1737 (C=O), 1593 
(C=C), 1537, 1179; [α]D
23+70.3 (c 0.2, CHCl3); δH (400 MHz, CDCl3) 2.77 (1H, dd, J 15.5, 6.8 Hz, 3-
HH), 2.85–2.94 (2H, m, 3-HH and NH), 3.08 (6H, s, NMe2), 3.30 (3H, s, OCH3), 3.71–3.84 (1H, m, 2-
H), 6.48 (1H, d, J 16.1 Hz, 5-H), 6.85 (1H, dd, J 9.0, 1.8 Hz, 5ʹ-H), 7.12–7.20 (3H, m, ArH), 7.20–7.28 
(7H, m, ArH), 7.50 (6H, d, J 7.9 Hz, ArH), 7.54 (1H, d, J 9.0 Hz, 6ʹ-H) 7.78 (1H, d, J 16.1, 6-H); δC (101 
MHz, CDCl3) 40.3 (2 × CH3), 44.9 (CH2), 52.1 (CH3), 53.8 (CH), 71.4 (C), 107.0 (CH), 115.7 (CH), 116.0 
(C), 126.6 (3 × CH), 127.0 (CH), 128.0 (6 × CH), 129.0 (6 × CH), 129.4 (CH), 138.4 (CH), 146.0 (3 × C), 
150.7 (C), 151.5 (C), 174.6 (C), 197.6 (C); m/z (ESI) 586.2297 (MNa+. C34H33N3NaO5 requires 
586.2312). 
 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(2ʹ-nitrophenyl)-4-oxohex-5-enoate (110a) 
 
 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-5-(dimethoxyphosphoryl)-4-oxopentanoate (111) 
(0.100 g, 0.283 mmol), 2-nitrobenzaldehyde (0.0855 g, 0.566 mmol) and potassium carbonate 
(0.0430 g, 0.311 mmol) were stirred in anhydrous acetonitrile (3 mL) at 50 °C under argon for 16 h. 
The reaction mixture was concentrated in vacuo. The resulting residue was dissolved in ethyl 
acetate (50 mL) and washed with water (50 mL) and brine (50 mL). The organic layer was dried 
(MgSO4) and concentrated in vacuo to give the crude product. Purification by flash chromatography 
using silica gel, eluting with 30% ethyl acetate in petroleum ether gave methyl (2S, 5E)-2-(tert-
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butoxycarbonylamino)-6-(2ʹ-nitrophenyl)-4-oxohex-5-enoate (110a) as a yellow solid (0.0836 g, 
78%). Mp 84–86 °C; νmax/cm−1 (neat) 3560 (NH), 2981 (CH), 1720 (C=O), 1694 (C=O), 1621, 1605, 
1525, 1339, 1159, 1091, 979, 747; [α]D
29 +37.7 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.39 (9H, s, 3 × 
CH3), 3.22 (1H, dd, J 18.0, 4.4 Hz, 3-HH), 3.42 (1H, dd, J 18.0, 4.4 Hz, 3-HH), 3.70 (3H, s, OCH3), 4.60 
(1H, dt, J 8.8, 4.4 Hz, 2-H), 5.55 (1H, d, J 8.8 Hz, NH), 6.55 (1H, d, J 16.2 Hz, 5-H), 7.54 (1H, ddd, J 8.5, 
7.0, 2.0 Hz, 4ʹ-H), 7.60–7.66 (2H, m, 5ʹ-H and 6ʹ-H), 7.98 (1H, d, J 16.2 Hz, 6-H), 8.02 (1H, dd, J 8.5, 
0.9 Hz, 3ʹ-H); δC (126 MHz, CDCl3) 28.3 (3 × CH3), 42.5 (CH2), 49.5 (CH), 52.7 (CH3), 80.0 (C), 125.1 
(CH), 129.1 (CH), 130.1 (CH), 130.5 (C), 130.8 (CH), 133.8 (CH), 139.3 (CH), 148.4 (C), 155.5 (C) 171.9 
(C), 197.3 (C); m/z (ESI) 401.1304 (MNa+. C18H22N2NaO7 requires 401.1319). 
 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(1ʹ-nitronaphthalen-2ʹ-yl)-4-oxohex-5 
-enoate (110b) 
 
 
 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(1ʹ-nitronaphthalen-2ʹ-yl)-4-oxohex-5-enoate 
(110b) was synthesised as described for methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(2ʹ-
nitrophenyl)-4-oxohex-5-enoate (110a) using methyl (2S)-2-(tert-butoxycarbonylamino)-5-
(dimethoxyphosphoryl)-4-oxopentanoate (111) (0.0830 g, 0.235 mmol), 3-nitro-2-naphthaldehyde 
(0.0944 g, 0.469 mmol) and potassium carbonate (0.0436 g, 0.260 mmol) in anhydrous acetonitrile 
(3 mL). Purification by flash chromatography using silica gel, eluting with 50% to 80% diethyl ether 
in petroleum ether gave methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(1ʹ-nitronaphthalen-2ʹ-yl)-
4-oxohex-5-enoate (110b) as a yellow solid (0.0757 g, 75%). Mp 88–90 °C; νmax/cm−1 (neat) 3373 
(NH), 2982 (CH), 1735 (C=O), 1692 (C=O), 1669 (C=O), 1523, 1367,1298, 1167, 747; [α]D
26 +30.2 (c 
0.7, CHCl3); δH (500 MHz, CDCl3) 1.45 (9H, s, 3 × CH3), 3.24 (1H, dd, J 18.0, 4.2 Hz, 3-HH), 3.45 (1H, 
dd, J 18.0, 4.2 Hz, 3-HH), 3.76 (3H, s, OCH3), 4.65 (1H, dt, J 8.6, 4.2 Hz, 2-H), 5.55 (1H, d, J 8.6 Hz, 
NH), 6.85 (1H, d, J 16.1 Hz, 5-H), 7.62 (1H, d, J 16.1 Hz, 6-H), 7.63–7.70 (2H, m, 6ʹ-H and 7ʹ-H), 7.72 
(1H, d, J 8.7 Hz, 3ʹ-H), 7.75–7.81 (1H, m, 5ʹ-H), 7.90–7.95 (1H, m, 8ʹ-H), 8.00 (1H, d, J 8.7 Hz, 4ʹ-H); 
δC (126 MHz, CDCl3) 28.5 (3 × CH3), 43.2 (CH2), 49.6 (CH), 52.9 (CH3), 80.3 (C), 122.4 (CH), 122.5 (CH), 
123.7 (C), 124.6 (C), 128.3 (CH), 128.9 (CH), 129.5 (CH), 130.3 (CH), 131.3 (CH), 134.7 (C), 135.8 (CH), 
148.9 (C), 155.7 (C), 171.9 (C), 196.9 (C); m/z (ESI) 451.1457 (MNa+. C22H24N2NaO7 requires 
451.1476). 
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Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(5ʹ-fluoro-2ʹ-nitrophenyl)-4-oxohex-5-enoate 
(110c) 
 
 
 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(5ʹ-fluoro-2ʹ-nitrophenyl)-4-oxohex-5-enoate 
(110c) was synthesised as described for methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(2ʹ-
nitrophenyl)-4-oxohex-5-enoate (110a) using methyl (2S)-2-(tert-butoxycarbonylamino)-5-
(dimethoxyphosphoryl)-4-oxopentanoate (111) (0.100 g, 0.313 mmol), 5-fluoro-2-
nitrobenzaldehyde (0.0960 g, 0.566 mmol) and potassium carbonate (0.0430 g, 0.311 mmol) in 
anhydrous acetonitrile (3 mL). Purification by flash chromatography using silica gel, eluting with 
50% diethyl ether in petroleum ether gave methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(5ʹ-
fluoro-2ʹ-nitrophenyl)-4-oxohex-5-enoate (110c) as a yellow solid (0.0470 g, 42%). Mp 83–86 °C; 
νmax/cm−1 (neat) 2921 (CH), 1748 (C=O), 1701 (C=O), 1614, 1583, 1526, 1343, 1161, 729; [α]D
30 +24.2 
(c 1.3, CHCl3); δH (400 MHz, CDCl3) 1.45 (9H, s, 3 × CH3), 3.30 (1H, dd, J 18.0, 4.2 Hz, 3-HH), 3.47 (1H, 
dd, J 18.0, 4.2 Hz, 3-HH), 3.76 (3H, s, OCH3), 4.67 (1H, dt, J 8.6, 4.2 Hz, 2-H), 5.64 (1H, d, J 8.6 Hz, 
NH), 6.62 (1H, d, J 16.1 Hz, 5-H), 7.29 (1H, ddd, J 9.2, 6.9, 2.8 Hz, 4ʹ-H), 7.36 (1H, dd, J 8.8, 2.8 Hz, 6ʹ-
H), 8.04 (1H, d, J 16.1 Hz, 6-H), 8.19 (1H, dd, J 9.2, 5.0 Hz, 3ʹ-H); δC (101 MHz, CDCl3) 28.3 (3 × CH3), 
42.7 (CH2), 49.5 (CH), 52.7 (CH3), 80.1 (C), 116.1 (d, 2JCF 24.6 Hz, CH), 117.5 (d, 2JCF 23.4 Hz, CH), 128.1 
(d, 3JCF 10.0 Hz, CH), 130.9 (CH), 133.9 (d, 3JCF 9.2 Hz, C), 138.4 (CH), 144.3 (d, 4JCF 2.9 Hz, C), 155.5 
(C), 164.9 (d, 1JCF 258.0 Hz, C), 171.8 (C), 197.0 (C); m/z (ESI) 419.1215 (MNa+. C18H21FN2NaO7 
requires 419.1225). 
 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(4ʹ,5ʹ-dimethoxy-2ʹ-nitrophenyl)-4 
-oxohex-5-enoate (110d) 
 
 
 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(4ʹ,5ʹ-dimethoxy-2ʹ-nitrophenyl)-4-oxohex-5-
enoate (110d) was synthesised as described for methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(2ʹ-
nitrophenyl)-4-oxohex-5-enoate (110a) using methyl (2S)-2-(tert-butoxycarbonylamino)-5-
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(dimethoxyphosphoryl)-4-oxopentanoate (111) (0.321 g, 0.909 mmol), 6-nitroveratraldehyde 
(0.384 g, 1.82 mmol) and potassium carbonate (0.138 g, 0.999 mmol) in anhydrous acetonitrile (9 
mL). Purification by flash chromatography using silica gel, eluting with 50% to 80% diethyl ether in 
petroleum ether gave methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(4ʹ,5ʹ-dimethoxy-2ʹ-
nitrophenyl)-4-oxohex-5-enoate (110d) as a yellow solid (0.275 g, 69%). Mp 75–78 °C; νmax/cm−1 
(neat) 3384 (NH), 2981 (CH), 1747 (C=O), 1707 (C=O), 1670 (C=O), 1521, 1331, 1280, 1218, 1165, 
1066; [α]D
29 +28.8 (c 1.1, CHCl3); δH (500 MHz, CDCl3) 1.37 (9H, s, 3 × CH3), 3.21 (1H, dd, J 17.8, 4.3 
Hz, 3-HH), 3.39 (1H, dd, J 17.8, 4.0 Hz, 3-HH), 3.68 (3H, s, OCH3), 3.92 (3H, s, OCH3), 3.94 (3H, s, 
OCH3), 4.58–4.59 (1H, m, 2-H), 5.53 (1H, d, J 8.7 Hz, NH), 6.46 (1H, d, J 16.1 Hz, 5-H), 6.93 (1H, s, 6ʹ-
H), 7.58 (1H, s, 3ʹ-H), 8.05 (1H, d, J 16.1 Hz, 6-H); δC (126 MHz, CDCl3) 28.3 (3 × CH3), 42.1 (CH2), 49.5 
(CH), 52.6 (CH3), 56.5 (CH3) 56.6 (CH3), 79.9 (C), 108.0 (CH), 109.8 (CH), 124.9 (C), 129.1 (CH), 140.1 
(CH), 141.3 (C), 150.2 (C), 153.2 (C), 155.5 (C), 171.9 (C), 197.4 (C); m/z (ESI) 461.1517 (MNa+. C20H26-
N2NaO9 requires 461.1531). 
 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(4'-dimethylamino-2ʹ-nitrophenyl)-4- 
oxohex-5-enoate (110e) 
 
 
 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(4ʹ-dimethylamino-2ʹ-nitrophenyl)-4-oxohex-5-
enoate (110e) was synthesised as described for methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(2ʹ-
nitrophenyl)-4-oxohex-5-enoate (110a) using methyl (2S)-2-(tert-butoxycarbonylamino)-5-
(dimethoxyphosphoryl)-4-oxopentanoate (111) (0.697 g, 1.97 mmol), 4-(dimethylamino)-2-
nitrobenzaldehyde (0.767 g, 3.95 mmol) and potassium carbonate (0.300 g, 2.17 mmol) in 
anhydrous acetonitrile (10 mL). The reaction was stirred at 50 °C under argon for 72 h. Purification 
by flash chromatography using silica gel, eluting with 60% to 100% diethyl ether in petroleum ether 
gave methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(4ʹ-dimethylamino-2ʹ-nitrophenyl)-4-oxohex-
5-enoate (110e) as a red solid (0.603 g, 82%). Mp 102–104 °C; νmax/cm−1 (neat) 3378 (NH), 2953 
(CH), 1750 (C=O), 1717 (C=O), 1590, 1541, 1368, 1168; [α]D
25 +49.1 (c 0.4, CHCl3); δH (500 MHz, 
CDCl3) 1.39 (9H, s, 3 × CH3), 3.04 (6H, s, 2 × CH3), 3.15 (1H, dd, J 17.8, 4.3 Hz, 3-HH), 3.38 (1H, dd, J 
17.8, 4.3 Hz, 3-HH), 3.69 (3H, s, OCH3), 4.57 (1H, dt, J 8.8, 4.3 Hz, 2-H), 5.55 (1H, d, J 8.8 Hz, NH), 
6.47 (1H, d, J 16.0 Hz, 5-H), 6.80 (1H, dd, J 8.9, 2.7 Hz, 5'-H), 7.08 (1H, d, J 2.7 Hz, 3'-H), 7.51 (1H, d, 
J 8.9 Hz, 6'-H), 7.83 (1H, d, J 16.0 Hz, 6-H); δC (126 MHz, CDCl3) 28.3 (3 × CH3), 40.1 (2 × CH3), 42.1 
(CH2), 49.6 (CH), 52.6 (CH3), 79.9 (C), 106.7 (CH), 115.3 (C), 115.5 (CH), 125.4 (CH), 129.2 (CH), 138.8 
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(CH), 150.6 (C), 151.4 (C), 155.5 (C), 172.1 (C), 197.3 (C); m/z (ESI) 444.1725 (MNa+. C20H27N3NaO7 
requires 444.1741). 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-[5ʹ-(2ʹʹ-nitrophenyl)-1ʹH-pyrazol-3ʹ-yl]propanoate 
(116a) 
 
 
 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(2ʹ-nitrophenyl)-4-oxohex-5-enoate (110a) (0.277 
g, 0.733 mmol) was dissolved in methanol (15 mL) and hydrazine monohydrate (65%, 0.176 mL, 
3.67 mmol) was added at 0 °C. The reaction mixture was stirred at room temperature for 4 h, 
poured into 1 M aqueous hydrochloric acid (50 mL) and extracted with dichloromethane (3 × 30 
mL). The combined organic layers were washed with water (50 mL), brine (50 mL) and concentrated 
in vacuo to give dihydropyrazole 115a as a yellow solid (0.247 g, 86%). Dihydropyrazole 115a (0.194 
g, 0.494 mmol) was dissolved in anhydrous dichloromethane (20 mL), cooled to −15 °C and 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (0.112 g, 0.494 mmol) was added. After stirring at −15 °C 
for 3 h, the reaction mixture was concentrated. Purification by flash chromatography using silica 
gel, eluting with 0% to 20% acetonitrile in dichloromethane gave methyl (2S)-2-(tert-
butoxycarbonylamino-3-[5ʹ-(2ʹʹ-nitrophenyl)-1ʹH-pyrazol-3ʹ-yl]propanoate (116a) as a yellow solid 
(0.126 g, 65%). Mp 88–90 °C; νmax/cm−1 (neat) 3298 (NH), 2923 (CH), 1743 (C=O), 1694 (C=O), 1528, 
1366, 1160, 752; [α]D
29 +12.4 (c 1.1, CHCl3); δH (500 MHz, CDCl3) 1.42 (9H, s, 3 × CH3), 3.19 (1H, dd, 
J 14.8, 5.5 Hz, 3-HH), 3.25 (1H, dd, J 14.8, 5.5 Hz, 3-HH), 3.76 (3H, s, OCH3), 4.54–4.70 (1H, m, 2-H), 
5.42 (1H, d, J 8.1 Hz, NH), 6.23 (1H, s, 4ʹ-H), 7.46 (1H, td, J 8.0, 1.4 Hz, 4ʹʹ-H), 7.59 (1H, td, J 8.0, 1.2 
Hz, 5ʹʹ-H), 7.68 (1H, dd, J 8.0, 1.4 Hz, 6ʹʹ-H), 7.72 (1H, dd, J 8.0, 1.2 Hz, 3ʹʹ-H); δC (126 MHz, CDCl3) 
28.3 (3 × CH3), 29.4 (CH2), 52.7 (CH3), 53.1 (CH), 80.4 (C), 104.7 (CH), 123.6 (CH), 126.5 (C), 128.7 
(CH), 130.8 (CH), 132.0 (CH),  141.6 (C), 145.4 (C), 149.0 (C), 155.5 (C), 172.1 (C); m/z (ESI) 413.1423 
(MNa+. C18H22N4NaO6 requires 413.1432). 
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Methyl (2S)-2-(tert-butoxycarbonylamino)-3-[5ʹ-(1ʹʹ-nitronaphthalen-2ʹʹ-yl)-1ʹH-pyrazol-3ʹ- 
yl]propanoate (116b) 
 
 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-[5ʹ-(1ʹʹ-nitronaphthalen-2ʹʹ-yl)-1ʹH-pyrazol-3ʹ-
yl]propanoate (116b) was synthesised as described for methyl (2S)-2-(tert-butoxycarbonylamino-3-
[5ʹ-(2ʹʹ-nitrophenyl)-1ʹH-pyrazol-3ʹ-yl]propanoate (116a) using methyl (2S,5E)-2-(tert-
butoxycarbonylamino)-6-(1ʹ-nitronaphthalen-2ʹ-yl)-4-oxohex-5-enoate (110b) (0.469 g, 1.10 mmol) 
and hydrazine monohydrate (0.264 mL, 5.48 mmol) in methanol (15 mL). This gave dihydropyrazole 
115b as a yellow solid (0.490 g, 100%). 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (0.122 g, 0.538 
mmol) was added to a solution of dihydropyrazole 115b (0.238 g, 0.538 mmol) in dichloromethane 
(20 mL) at −40 °C and stirred for 3 h. Purification by flash chromatography using silica gel, eluting 
with 0% to 20% acetonitrile in dichloromethane gave methyl (2S)-2-(tert-butoxycarbonylamino)-3-
[5ʹ-(1ʹʹ-nitronaphthalen-2ʹʹ-yl)-1ʹH-pyrazol-3ʹ-yl]propanoate (116b) as a yellow solid (0.0581 g, 
25%). Mp 86–90 °C; νmax/cm−1 (neat) 3312 (NH), 2922 (CH), 1741 (C=O), 1697 (C=O), 1530, 1368, 
1162, 751, 732; [α]D
20 +26.0 (c 0.6, CHCl3); δH (400 MHz, CDCl3) 1.42 (9H, s, 3 × CH3), 3.24 (1H, dd, J 
15.2, 6.0 Hz, 3-HH), 3.32 (1H, dd, J 15.2, 5.3 Hz, 3-HH), 3.77 (3H, s, OCH3), 4.67 (1H, m, 2-H), 5.46 
(1H, d, J 6.9 Hz, NH), 6.41 (1H, s, 4ʹ-H), 7.53–7.66 (2H, m, 6ʹʹ-H and 7ʹʹ-H), 7.70 (1H, d, J 8.4 Hz, 5ʹʹ-
H), 7.83 (1H, d, J 8.6 Hz, 3ʹʹ-H), 7.88 (1H, d, J 8.0 Hz, 8ʹʹ-H), 7.95 (1H, d, J 8.6 Hz, 4ʹʹ-H); δC (101 MHz, 
CDCl3) 28.4 (3 × CH3), 29.4 (CH2), 52.9 (CH3), 53.2 (CH), 80.7 (C), 104.6 (CH), 121.7 (CH), 124.8 (C), 
125.6 (CH), 127.6 (CH), 128.1 (CH), 128.9 (CH), 130.4 (CH), 133.2 (2 × C), 141.5 (C), 145.5 (C), 145.7 
(C), 155.6 (C), 172.1 (C); m/z (ESI) 463.1573 (MNa+. C22H24N4NaO6 requires 463.1588). 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-[5ʹ-(5ʹʹ-fluoro-2ʹʹ-nitrophenyl)-1ʹH-pyrazol- 
3ʹ-yl]propanoate (116c) 
 
 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-[5ʹ-(5ʹʹ-fluoro-2ʹʹ-nitrophenyl)-1ʹH-pyrazol-3ʹ-
yl]propanoate (116c) was synthesised as described for methyl (2S)-2-(tert-butoxycarbonylamino-3-
[5ʹ-(2ʹʹ-nitrophenyl)-1ʹH-pyrazol-3ʹ-yl]propanoate (116a) using (2S,5E)-2-(tert-
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butoxycarbonylamino)-6-(5ʹ-fluoro-2ʹ-nitrophenyl)-4-oxohex-5-enoate (110c) (0.479 g, 1.21 mmol) 
and hydrazine monohydrate (0.291 mL, 6.05 mmol) in methanol (15 mL). This gave dihydropyrazole 
115c as a yellow solid (0.474 g, 95%). 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (0.0320 g, 0.141 
mmol) was added to a solution of dihydropyrazole 115c (0.0579 g, 0.141 mmol) in dichloromethane 
(10 mL) at −30 °C and stirred for 3 h. Purification by flash chromatography using silica gel, eluting 
with 0% to 20% acetonitrile in dichloromethane gave methyl (2S)-2-(tert-butoxycarbonylamino)-3-
[5ʹ-(5ʹʹ-fluoro-2ʹʹ-nitrophenyl)-1ʹH-pyrazol-3ʹ-yl]propanoate (116c) as a yellow solid (0.0260 g, 45%). 
Mp 82–84 °C; νmax/cm−1 (neat) 3287 (NH), 2981 (CH), 1741 (C=O), 1696 (C=O), 1529, 1366, 1161, 
887, 734; [α]D
26 +20.2 (c 0.8, CHCl3); δH (500 MHz, CDCl3) 1.42 (9H, s, 3 × CH3), 3.18 (1H, dd, J 15.0, 
5.1 Hz, 3-HH), 3.26 (1H, dd, J 15.0, 5.1 Hz, 3-HH), 3.76 (3H, s, OMe), 4.64 (1H, br s, 2-H), 5.44 (1H, d, 
J 5.0 Hz, NH), 6.22 (1H, s, 4ʹ-H), 7.12 (1H, ddd, J 8.9, 7.3, 2.6 Hz, 4ʹʹ-H), 7.41 (1H, dd, J 9.0, 2.6 Hz, 6ʹʹ-
H), 7.76 (1H, dd, J 8.9, 5.0 Hz, 3ʹʹ-H); δC (126 MHz, CDCl3) 28.4 (3 × CH3), 29.5 (CH2), 52.9 (CH3), 53.1 
(CH), 80.8 (C), 104.9 (CH), 115.6 (d, 2JCF 23.5 Hz, CH), 117.8 (d, 2JCF 24.5 Hz, CH), 126.5 (d, 3JCF 9.7 Hz, 
CH), 130.1 (d, 3JCF 9.2 Hz, C), 141.1 (C), 145.2 (d, 4JCF 2.7 Hz, C), 145.4 (C), 155.6 (C), 163.9 (d, 1JCF 
254.6 Hz, C), 172.0 (C); m/z (ESI) 431.1321 (MNa+. C18H21FN4NaO6 requires 431.1337). 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-[5ʹ-(4ʹʹ,5ʹʹ-dimethoxy-2ʹʹ-nitrophenyl)-1ʹH-pyrazol-
3ʹ-yl]propanoate (116d) 
 
 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-[5ʹ-(4ʹʹ,5ʹʹ-dimethoxy-2ʹʹ-nitrophenyl)-1ʹH-pyrazol-3ʹ-
yl]propanoate (116d) was synthesised as described for methyl (2S)-2-(tert-butoxycarbonylamino-3-
[5ʹ-(2ʹʹ-nitrophenyl)-1ʹH-pyrazol-3ʹ-yl]propanoate (116a) using methyl (2S,5E)-2-(tert-
butoxycarbonylamino)-6-(4ʹ,5ʹ-dimethoxy-2ʹ-nitrophenyl)-4-oxohex-5-enoate (110d) (0.573 g, 1.31 
mmol) and hydrazine monohydrate (0.315 mL, 6.55 mmol) in methanol (15 mL). This gave 
dihydropyrazole 115d as a yellow solid (0.532 g, 90%). 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
(0.145 g, 0.637 mmol) was added to a solution of dihydropyrazole 115d (0.288 g, 0.637 mmol) at 
−15 °C and stirred for 3 h. Purification by flash chromatography using silica gel, eluting with 0% to 
20% acetonitrile in dichloromethane gave methyl (2S)-2-(tert-butoxycarbonylamino)-3-[5ʹ-(4ʹʹ,5ʹʹ-
dimethoxy-2ʹʹ-nitrophenyl)-1ʹH-pyrazol-3ʹ-yl]propanoate (116d) as a yellow solid (0.0955 g, 34%). 
Mp 79–82 °C; νmax/cm−1 (neat) 3395 (NH), 2925 (CH), 1711 (C=O), 1522, 1337, 1268, 1221, 1163, 
1045, 790; [α]D
29 +9.1 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 1.42 (9H, s, 3 × CH3), 3.10–3.32 (2H, m, 3-
H2), 3.76 (3H, s, OCH3), 3.95 (3H, s, OCH3), 3.96 (3H, s, OCH3), 4.65 (1H, br s, 2-H), 5.51 (1H, d, J 8.1 
137 
 
Hz, NH), 6.18 (1H, s, 4ʹ-H), 7.04 (1H, s, 6ʹʹ-H), 7.44 (1H, s, 3ʹʹ-H); δC (126 MHz, CDCl3) 28.3 (3 × CH3), 
29.7 (CH2), 52.7 (CH3), 53.1 (CH), 56.4 (CH3), 56.5 (CH3), 80.4 (C), 105.4 (CH), 107.7 (CH), 113.0 (CH), 
121.3 (C), 141.3 (C), 142.1 (C), 145.5 (C), 148.6 (C), 152.2 (C), 155.5 (C), 172.1 (C); m/z (ESI) 473.1632 
(MNa+. C20H26N4NaO8 requires 473.1643). 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-[5'-(4''-dimethylamino-2''-nitrophenyl)-1'H-
pyrazol-3'-yl]propanoate (116e) 
 
 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-[5'-(4''-dimethylamino-2''-nitrophenyl)-1'H-pyrazol-
3'-yl]propanoate (116e) was synthesised as described for methyl (2S)-2-(tert-
butoxycarbonylamino-3-[5ʹ-(2ʹʹ-nitrophenyl)-1ʹH-pyrazol-3ʹ-yl]propanoate (116a) using methyl 
(2S)-2-(tert-butoxycarbonylamino)-5-(dimethoxyphosphoryl)-4-oxopentanoate (110e) (0.291 g, 
0690 mmol) and hydrazine monohydrate (0.166 mL, 3.45 mmol) in methanol (10 mL). This gave 
dihydropyrazole 115e as a yellow solid (0.263 g, 88%). 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
(0.695 g, 3.06 mmol) was added to a solution of dihydropyrazole 115e (1.33 g, 3.06 mmol) in 
dichloromethane (60 mL) at −40 °C and stirred for 3 h. Purification by flash chromatography using 
silica gel, eluting with 3% methanol in dichloromethane gave methyl (2S)-2-(tert-
butoxycarbonylamino)-3-[5'-(4''-dimethylamino-2''-nitrophenyl)-1'H-pyrazol-3'-yl]propanoate 
(116e) as a yellow solid (0.960 g, 72%). Mp 107–110 °C; νmax/cm−1 (neat) 3301 (NH), 2983 (CH), 1713 
(C=O), 1625 (C=O), 1531, 1367, 1163; [α]D
26 +24.6 (c 0.7, CHCl3); δH (400 MHz, CDCl3) 1.42 (9H, s, 3 
× CH3), 3.02 (6H, s, 2 × CH3), 3.18 (2H, d, J 5.2 Hz, 3-H2), 3.73 (3H, s, OCH3), 4.61 (1H, br s, 2-H), 5.50 
(1H, d, J 6.5, NH), 6.11 (1H, s, 4ʹ-H), 6.82 (1H, dd, J 8.8, 2.7 Hz, 5ʹʹ-H), 6.95 (1H, d, J 2.7 Hz, 3''-H), 
7.43 (1H, d, J 8.8 Hz, 6''-H); δC (101 MHz, CDCl3) 28.4 (3 × CH3), 29.9 (CH2), 40.3 (2 × CH3), 52.7 (CH3), 
53.2 (CH), 80.3 (C), 104.6 (CH), 106.5 (CH), 112.5 (C), 115.1 (CH), 131.7 (CH), 143.6 (C), 149.9 (C), 
150.3 (2 × C), 155.6 (C), 172.3 (C); m/z (ESI) 456.1840 (MNa+. C20H27N5NaO6 requires 456.1854). 
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Methyl (2S)-2-(tert-butoxycarbonylamino)-3-(5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c] 
quinazolin-5ʹ-yl)propanoate (118a) 
 
 
 
To a solution of methyl (2S)-2-(tert-butoxycarbonylamino-3-[5ʹ-(2ʹʹ-nitrophenyl)-1ʹH-pyrazol-3ʹ-
yl]propanoate (116a) (0.0871 g, 0.223 mmol) in methanol (5 mL) was added 10% palladium on 
carbon (0.0120 g, 0.0112 mmol). The reaction mixture was purged with hydrogen for 0.5 h and then 
stirred under an atmosphere of hydrogen at room temperature for 16 h. The reaction mixture was 
filtered through Celite®, which was washed with methanol. The filtrate was concentrated in vacuo 
and the resulting aniline was dissolved in dichloromethane (10 mL). Triphosgene (0.0265 g, 0.089 
mmol) and triethylamine (0.063 mL, 0.0446 mmol) was added at −10 °C. After stirring at room 
temperature for 1 h, the reaction mixture was diluted with dichloromethane (40 mL), washed with 
1 M aqueous hydrochloric acid (50 mL), water (50 mL) and brine (50 mL). The organic layer was 
dried (MgSO4) and concentrated in vacuo to give the crude product. Purification by flash 
chromatography using silica gel, eluting with 90% ethyl acetate in petroleum ether gave methyl 
(2S)-2-(tert-butoxycarbonylamino)-3-(5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-
yl)propanoate (118a) as a white solid (0.0448 g, 52%). Mp 123–126 °C; νmax/cm−1 (neat) 3248 (NH), 
2978 (CH), 1715 (C=O), 1598, 1491, 1343, 1162, 734; [α]D
30 +13.4 (c 1.3, CHCl3); δH (500 MHz, CDCl3) 
1.38 (9H, s, 3 × CH3), 3.32 (1H, dd, J 14.8, 7.0 Hz 3-HH), 3.40 (1H, dd, J 14.8, 5.0 Hz, 3-HH), 3.76 (3H, 
s, OCH3), 4.67–4.80 (1H, m, 2-H), 5.44 (1H, d, J 8.3 Hz, NH), 6.75 (1H, s, 1ʹ-H), 7.24 (1H, t, J 7.4 Hz, 
9ʹ-H), 7.36–7.48 (2H, m, 7ʹ-H and 8ʹ-H), 7.72 (1H, d, J 7.4 Hz, 10ʹ-H), 11.24 (1H, s, NH); δC (126 MHz, 
CDCl3) 28.4 (3 × CH3), 31.5 (CH2), 52.7 (CH3), 53.1 (CH), 80.2 (C), 101.0 (CH), 112.7 (C), 116.6 (CH), 
123.8 (CH), 124.1 (CH), 130.5 (CH), 133.8 (C), 142.0 (C), 146.6 (C), 154.3 (C), 155.5 (C), 172.3 (C); m/z 
(ESI) 409.1467 (MNa+. C19H22N4NaO5 requires 409.1482). 
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Methyl (2S)-2-(tert-butoxycarbonylamino)-3-(5ʹ-oxo-5ʹ,6ʹ-dihydrobenzo[h]pyrazole 
[1ʹ,5ʹ-c]quinazolin-2ʹ-yl)propanoate (118b) 
 
 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-(5ʹ-oxo-5ʹ,6ʹ-dihydrobenzo[h]pyrazole[1ʹ,5ʹ-
c]quinazolin-2ʹ-yl)propanoate (118b) was synthesised as described for methyl (2S)-2-(tert-
butoxycarbonylamino)-3-(5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-yl)propanoate (118a) 
using methyl (2S)-2-(tert-butoxycarbonylamino)-3-[5ʹ-(1ʹʹ-nitronaphthalen-2ʹʹ-yl)-1ʹH-pyrazol-3ʹ-
yl]propanoate (116b) (0.133 g, 0.301 mmol) with 10% palladium on carbon (0.0160 g, 0.0151 mmol) 
in methanol (10 mL). The resulting aniline was reacted with triphosgene (0.0357 g, 0.120 mmol) 
and triethylamine (0.0854 mL, 0.602 mmol) in dichloromethane (10 mL). Purification by flash 
chromatography using silica gel, eluting with 30% to 60% ethyl acetate in dichloromethane gave 
methyl (2S)-2-(tert-butoxycarbonylamino)-3-(5ʹ-oxo-5ʹ,6ʹ-dihydrobenzo[h]pyrazole[1ʹ,5ʹ-
c]quinazolin-2ʹ-yl)propanoate (116b) as a white solid (0.0300 g, 23%). Mp 140–142 °C; νmax/cm−1 
(neat) 3278 (NH), 2975 (CH), 1709 (C=O), 1344, 1165; [α]D
23 +17.6 (c 0.3, CHCl3); δH (400 MHz, CDCl3) 
1.41 (9H, s, 3 × CH3), 3.31–3.47 (2H, m, 3-H), 3.82 (3H, s, OCH3), 4.72–4.86 (1H, m, 2-H), 5.60 (1H, d, 
J 8.3 Hz, NH), 6.72 (1H, s, 1ʹ-H), 7.51–7.61 (3H, m, 9ʹ-H, 11ʹ-H and 12ʹ-H), 7.70 (1H, t, J 8.0 Hz, 8ʹ-H), 
7.82 (1H, d, J 8.0 Hz, 10ʹ-H), 8.39 (1H, d, J 8.0 Hz, 7ʹ-H), 10.50 (1H, s, NH); δC (101 MHz, CDCl3) 28.4 
(3 × CH3), 31.4 (CH2), 52.8 (CH3), 53.1 (CH), 80.2 (C), 100.9 (CH), 108.5 (C), 120.4 (CH), 120.9 (CH), 
121.7 (C), 124.6 (CH), 127.8 (CH), 127.9 (CH), 128.9 (CH), 129.7 (C), 133.9 (C), 142.4 (C), 146.0 (C), 
154.7 (C), 155.6 (C), 172.5 (C); m/z (ESI) 459.1634 (MNa+. C23H24N4NaO5 requires 459.1639). 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-(9ʹ-fluoro-5ʹ-oxo-5ʹ,6ʹ-dihydropyrazole 
[1ʹ,5ʹ-c]quinazolin-2ʹ-yl)propanoate (118c) 
 
 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-(9ʹ-fluoro-5ʹ-oxo-5ʹ,6ʹ-dihydropyrazole[1ʹ,5ʹ-
c]quinazolin-2ʹ-yl)propanoate (118c) was synthesised as described for methyl (2S)-2-(tert-
butoxycarbonylamino)-3-(5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-yl)propanoate (118a) 
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using methyl (2S)-2-(tert-butoxycarbonylamino)-3-[5ʹ-(5ʹʹ-fluoro-2ʹʹ-nitrophenyl)-1ʹH-pyrazol-3ʹ-
yl]propanoate (116c) (0.142 g, 0.347 mmol) with 10% palladium on carbon (0.0185 g, 0.0174 mmol) 
in methanol (10 mL). The resulting aniline was reacted with triphosgene (0.0412 g, 0.139 mmol) 
and triethylamine (0.0982 mL, 0.694 mmol) in dichloromethane (10 mL). Purification by flash 
chromatography using silica gel, eluting with 50% ethyl acetate in dichloromethane gave methyl 
(2S)-2-(tert-butoxycarbonylamino)-3-(9ʹ-fluoro-5ʹ-oxo-5ʹ,6ʹ-dihydropyrazole[1ʹ,5ʹ-c]quinazolin-2ʹ-
yl)propanoate (118c) as a white solid (0.105 g, 75%). Mp 135–137 °C; νmax/cm−1 (neat) 3250 (NH), 
2979 (CH), 1720 (C=O), 1497, 1367, 1268, 1169; [α]D
26 +16.2 (c 0.9, CHCl3); δH (500 MHz, CDCl3) 1.39 
(9H, s, 3 × CH3), 3.32 (1H, dd, J 14.7, 7.3 Hz, 3-HH), 3.41 (1H, dd, J 14.7, 5.0 Hz, 3-HH), 3.77 (3H, s, 
OCH3), 4.69–4.78 (1H, m, 2-H), 5.41 (1H, d, J 8.3 Hz, NH), 6.75 (1H, s, 1ʹ-H), 7.20 (1H, td, J 8.7, 2.5 
Hz, 8ʹ-H), 7.37–7.42 (1H, m, 10ʹ-H), 7.46 (1H, dd, J 8.7, 4.2 Hz, 7ʹ-H), 11.30 (1H, s, NH); δC (126 MHz, 
CDCl3) 28.3 (3 × CH3), 31.4 (CH2), 52.6 (CH3), 53.0 (CH), 80.2 (C), 101.6 (CH), 109.6 (d, 2JCF 24.6 Hz, 
CH), 113.6 (d, 3JCF 9.2 Hz, C), 118.3 (d, 2JCF 23.4 Hz, CH), 118.4 (d, 3JCF 8.5 Hz, CH), 130.1 (d, 4JCF 1.7 
Hz, C), 141.0 (C), 146.3 (C), 154.4 (C), 155.4 (C), 158.9 (d, 1JCF 244.5 Hz, C), 172.1 (C); m/z (ESI) 
427.1378 (MNa+. C19H21FN4NaO5 requires 427.1388). 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-(8ʹ,9ʹ-dimethoxy-5ʹ-oxo-5ʹ,6ʹ- 
dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-yl)propanoate (118d) 
 
 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-(8ʹ,9ʹ-dimethoxy-5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-
c]quinazolin-2ʹ-yl)propanoate (118d) was synthesised as described for methyl (2S)-2-(tert-
butoxycarbonylamino)-3-(5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-yl)propanoate (118a) 
using methyl (2S)-2-(tert-butoxycarbonylamino)-3-[5ʹ-(4ʹʹ,5ʹʹ-dimethoxy-2ʹʹ-nitrophenyl)-1ʹH-
pyrazol-3ʹ-yl]propanoate (116d) (0.0280 g, 0.0622 mmol) with 10% palladium on carbon (0.00330 
g, 0.00311 mmol) in methanol (5 mL). The resulting aniline was reacted with triphosgene (0.00740 
mg, 0.0249 mmol) and triethylamine (0.0176 mL, 0.124 mmol) in dichloromethane (5 mL). 
Purification by flash chromatography using silica gel, eluting first with 60% ethyl acetate in 
dichloromethane and then with 3% methanol in dichloromethane gave methyl (2S)-2-(tert-
butoxycarbonylamino)-3-(8ʹ,9ʹ-dimethoxy-5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-
yl)propanoate (118d) as a white solid (0.0156 g, 58%). Mp 128–130 °C; νmax/cm−1 (neat) 3250 (NH), 
2929 (CH), 1719 (C=O), 1509, 1278, 1226, 1165, 1021; [α]D
28 +1.6 (c 0.9, CHCl3); δH(500 MHz, CDCl3) 
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1.39 (9H, s, 3 × CH3), 3.29 (1H, dd, J 14.8, 7.4 Hz, 3-HH), 3.37 (1H, dd, J 14.8, 4.9 Hz, 3-HH), 3.77 (3H, 
s, OCH3), 3.93 (3H, s, OCH3), 3.97 (3H, s, OCH3), 4.68–4.80 (1H, m, 2-H), 5.42 (1H, d, J 8.3 Hz, NH), 
6.59 (1H, s, 1ʹ-H), 6.83 (1H, s, 7ʹ-H), 7.04 (1H, s, 10ʹ-H), 11.05 (1H, s, NH); δC (126 MHz, CDCl3) 28.4 
(3 × CH3), 31.6 (CH2), 52.7 (CH3), 53.1 (CH), 56.5 (CH3), 56.7 (CH3), 80.2 (C), 99.2 (CH), 99.3 (CH), 
105.0 (CH), 105.3 (C), 128.7 (C), 142.2 (C), 146.6 (C), 146.7 (C), 152.1 (C), 154.4 (C), 155.6 (C), 172.4 
(C); m/z (ESI) 469.1676 (MNa+. C21H26N4NaO7 requires 469.1694). 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-(8'-dimethylamino-5'-oxo-5'-6'- 
dihydropyrazolo[1',5'-c]quinazolin-2'-yl)propanoate (118e) 
 
 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-(8'-dimethylamino-5'-oxo-5'-6'-dihydropyrazolo[1',5'-
c]quinazolin-2'-yl)propanoate (118e) was synthesised as described for methyl (2S)-2-(tert-
butoxycarbonylamino)-3-(5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-yl)propanoate (118a) 
using methyl (2S)-2-(tert-butoxycarbonylamino)-3-[5'-(4''-dimethylamino-2''-nitrophenyl)-1'H-
pyrazol-3'-yl]propanoate (116e) (0.0814 g, 0.188 mmol) with 10% palladium on carbon (0.0100 g, 
0.00940 mmol) in methanol (10 mL). The resulting aniline was reacted with triphosgene (0.0223 g, 
0.0752 mmol) and triethylamine (0.0532 mL, 0.376 mmol) in dichloromethane (10 mL). Purification 
by flash chromatography using silica gel, eluting with 80% to 100% ethyl acetate in dichloromethane 
gave methyl (2S)-2-(tert-butoxycarbonylamino)-3-(8'-dimethylamino-5'-oxo-5'-6'-
dihydropyrazolo[1',5'-c]quinazolin-2'-yl)propanoate (118e) as a yellow solid (0.0384 g, 48%). Mp 
174–176 °C; νmax/cm−1 (neat) 3271 (NH), 2978 (CH), 1705 (C=O), 1628 (C=O), 1528, 1373, 1157, 910, 
725; [α]D
27 +6.0 (c 0.7, CHCl3); δH(400 MHz, CDCl3) 1.39 (9H, s, 3 × CH3), 3.01 (6H, s, 2 × CH3), 3.26 
(1H, dd, J 14.4, 7.2 Hz, 3-HH), 3.33 (1H, dd, J 14.4, 4.8 Hz, 3-HH), 3.76 (3H, s, OCH3), 4.64–4.77 (1H, 
m, 2-H), 5.44 (1H, d, J 8.2 Hz, NH), 6.36–6.46 (2H, m, 1'-H and 7'-H), 6.56 (1H, dd, J 8.8, 1.5 Hz, 9'-
H), 7.47 (1H, d, J 8.8 Hz, 10'-H), 10.44 (1H, s, NH); δC (101 MHz, CDCl3) 28.4 (3 × CH3), 31.4 (CH2), 
40.4 (2 × CH3), 52.6 (CH3), 53.1 (CH), 80.0 (C), 96.9 (CH), 98.0 (CH), 102.0 (C), 109.3 (CH), 124.8 (CH), 
135.6 (C), 142.9 (C), 146.8 (C), 151.9 (C), 154.1 (C), 155.6 (C), 172.5 (C); m/z (ESI) 452.1900 (MNa+. 
C21H27N5NaO5 requires 452.1904). 
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(2S)-2-Amino-3-(5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-yl)propanoic acid 
hydrochloride (94) 
 
 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-(5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-
yl)propanoate (118a) (0.0417 g, 0.108 mmol) was dissolved in methanol (3.5 mL) and a solution of 
caesium carbonate (0.0457 g, 0.140 mmol) in water (1.5 mL) was added. The reaction mixture was 
stirred at room temperature for 16 h before being concentrating in vacuo. The resulting residue 
was dissolved in water (20 mL), acidified to pH 1 with 1 M aqueous hydrochloric acid and extracted 
with dichloromethane (3 × 30 mL). The organic layers were combined and washed with brine (50 
mL), dried (MgSO4) and concentrated in vacuo. The resulting residue was dissolved in 2 M aqueous 
hydrochloric acid (5 mL) and stirred at room temperature for 2 h. The reaction mixture was 
concentrated in vacuo and the resulting residue was purified by recrystallisation from methanol 
and diethyl ether to give (2S)-2-amino-3-(5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-
yl)propanoic acid hydrochloride (94) as a white solid (0.0268 g, 80%). Mp 280–283 °C 
(decomposition); νmax/cm−1 (neat) 3373 (NH), 2479 (CH), 1701 (C=O), 1599, 1490, 1355, 1119, 973; 
[α]D
27 –6.6 (c 0.5, MeOH); δH (500 MHz, CD3OD) 3.43 (1H, dd, J 16.3, 8.3 Hz, 3-HH), 3.56 (1H, dd, J 
16.3, 3.9 Hz, 3-HH), 4.44 (1H, dd, J 8.3, 3.9 Hz, 2-H), 7.02 (1H, s, 1ʹ-H), 7.25–7.36 (2H, m, 7ʹ-H and 9ʹ-
H), 7.48–7.54 (1H, m, 8ʹ-H), 7.93 (1H, d, J 7.8 Hz, 10ʹ-H); δC (126 MHz, CD3OD) 30.0 (CH2), 53.4 (CH), 
102.2 (CH), 113.7 (C), 117.0 (CH), 125.1 (CH), 125.3 (CH), 132.0 (CH), 135.6 (C), 143.5 (C), 147.0 (C), 
154.3 (C), 171.3 (C); m/z (ESI) 295.0795 (MNa+. C13H12N4NaO3 requires 295.0802). 
 
(2S)-2-Amino-3-(5ʹ-oxo-5ʹ,6ʹ-dihydrobenzo[h]pyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-yl)propanoic acid 
hydrochloride (98) 
 
 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-(5ʹ-oxo-5ʹ,6ʹ-dihydrobenzo[h]pyrazole[1ʹ,5ʹ-
c]quinazolin-2ʹ-yl)propanoate (118b) (0.0293 g, 0.0671 mmol) was suspended in 6 M aqueous 
hydrochloric acid (5 mL). The reaction mixture was stirred under reflux for 16 h. After cooling to 
room temperature, the reaction mixture was concentrated in vacuo and recrystallisation from 
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methanol and diethyl ether gave (2S)-2-amino-3-(5ʹ-oxo-5ʹ,6ʹ-dihydrobenzo[h]pyrazolo[1ʹ,5ʹ-
c]quinazolin-2-yl)propanoic acid hydrochloride (98) as an off-white solid (0.0089 g, 37%). Mp 278–
279 °C (decomposition); νmax/cm−1 (neat) 3178 (NH), 2975 (CH), 1725 (C=O), 1509, 1350, 1177, 801; 
[α]D
23 –7.0 (c 0.2, MeOH); δH (500 MHz, CD3OD) 3.48 (1H, dd, J 16.4, 8.3 Hz, 3-HH), 3.61 (1H, dd, J 
16.4, 3.9 Hz, 3-HH), 4.55 (1H, dd, J 8.3, 3.9 Hz, 2-H), 7.10 (1H, s, 1ʹ-H), 7.64–7.72 (2H, m, 8ʹ-H and 9ʹ-
H), 7.77 (1H, d, J 8.7 Hz, 11ʹ-H), 7.92 (1H, d, J 8.7 Hz, 12ʹ-H), 7.95 (1H, dd, J 8.1, 1.0 Hz, 10ʹ-H), 8.50 
(1H, d, J 8.1 Hz, 7ʹ-H); δC (126 MHz, CD3OD) 29.9 (CH2), 53.1 (CH), 102.1 (CH), 109.6 (C), 121.7 (CH), 
122.5 (CH), 123.3 (C), 125.9 (CH), 128.6 (CH), 129.1 (CH), 130.1 (CH), 131.7 (C), 135.7 (C), 144.0 (C), 
147.4 (C), 154.6 (C), 170.9 (C); m/z (ESI) 345.0948 (MNa+. C17H14N4NaO3 requires 345.0958). 
 
(2S)-2-Amino-3-(9ʹ-fluoro-5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-yl)propanoic acid 
hydrochloride (99) 
 
 
 
(2S)-2-Amino-3-(9ʹ-fluoro-5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-yl)propanoic acid 
hydrochloride (99) was synthesised as described for (2S)-2-amino-3-(5ʹ-oxo-5ʹ,6ʹ-
dihydrobenzo[h]pyrazolo[1ʹ,5ʹ-c]quinazolin-2-yl)propanoic acid hydrochloride (98) using methyl 
(2S)-2-(tert-butoxycarbonylamino)-3-(9ʹ-fluoro-5ʹ-oxo-5ʹ,6ʹ-dihydropyrazole[1ʹ,5ʹ-c]quinazolin-2ʹ-
yl)propanoate (118c) (0.0469 g, 0.116 mmol). Recrystallisation from methanol and diethyl ether 
gave (2S)-2-amino-3-(9ʹ-fluoro-5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-yl)propanoic acid 
hydrochloride (99) as a white solid (0.0150 g, 40%). Mp 275–276 °C (decomposition); νmax/cm−1 
(neat) 3175 (NH), 2950 (CH), 1710 (C=O), 1506, 1358, 1268, 1191, 828; [α]D
27  −14.5  (c 0.1, MeOH); 
δH (400 MHz, DMSO-d6) 3.19–3.45 (2H, m, 3-H2), 4.34 (1H, t, J 6.5 Hz, 2-H), 7.18 (1H, s, 1ʹ-H), 7.35–
7.47 (2H, m, 8ʹ-H and 10ʹ-H), 7.94 (1H, dd, J 8.8, 1.6 Hz, 7ʹ-H), 8.35 (2H, br s, NH2), 11.93 (1H, s, NH); 
δC (101 MHz, DMSO-d6) 29.0 (CH2), 51.6 (CH), 102.4 (CH), 109.7 (d, 2JCF 24.9 Hz, CH), 113.0 (d, 3JCF 
9.6 Hz, C), 117.8 (d, 3JCF 8.9 Hz, CH), 118.0 (d, 2JCF 24.9 Hz, CH), 131.0 (d, 4JCF 1.4 Hz, C), 140.6 (d, 4JCF 
3.3 Hz, C), 143.9 (C), 151.6 (C), 157.8 (d, 1JCF 239.5 Hz, C), 169.9 (C); m/z (ESI) 313.0706 (MNa+. 
C13H11FN4NaO3 requires 313.0707). 
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(2S)-2-Amino-3-(8ʹ,9ʹ-dimethoxy-5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-yl)propanoic 
acid hydrochloride (100) 
 
 
 
(2S)-2-Amino-3-(8ʹ,9ʹ-dimethoxy-5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-yl)propanoic 
acid hydrochloride (100) was synthesised as described for (2S)-2-amino-3-(5ʹ-oxo-5ʹ,6ʹ-
dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-yl)propanoic acid hydrochloride (94) using methyl (2S)-2-
(tert-butoxycarbonylamino)-3-(8ʹ,9ʹ-dimethoxy-5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-
yl)propanoate (118d) (0.0226 g, 0.0507 mmol) and caesium carbonate (0.0215 g, 0.0658 mmol). 
Recrystallisation from methanol and diethyl ether gave (2S)-2-amino-3-(8ʹ,9ʹ-dimethoxy-5ʹ-oxo-
5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-yl)propanoic acid hydrochloride (100) as a white solid 
(0.0152 g, 82%). Mp 268–270 °C (decomposition); νmax/cm−1 (neat) 3375 (NH), 2919 (CH), 1715 
(C=O), 1507, 1284, 1229, 1011, 791; [α]D
25 −7.6 (c 0.4, MeOH); δH (500 MHz, CD3OD) 3.45 (1H, dd, J 
16.0, 9.3 Hz, 3-HH), 3.59 (1H, dd, J 16.0, 3.5 Hz, 3-HH), 3.86 (3H, s, OCH3), 3.94 (3H, s, OCH3), 4.57 
(1H, dd, J 9.3, 3.5 Hz, 2-H), 6.56 (1H, s, 1ʹ-H), 6.89 (1H, s, 10ʹ-H), 7.25 (1H, s, 7ʹ-H); δC (126 MHz, 
CD3OD) 30.1 (CH2), 53.6 (CH), 56.5 (CH3), 56.9 (CH3), 99.4 (CH), 100.8 (CH), 105.8 (C), 106.4 (CH), 
130.1 (C), 143.4 (C), 146.7 (C), 147.8 (C), 153.4 (C), 154.0 (C), 171.0 (C); m/z 355.0998 (MNa+. 
C15H16N4NaO5 requires 355.1013). 
 
(2S)-2-(tert-butoxycarbonylamino)-3-(8'-dimethylamino-5'-oxo-5'-6'- 
dihydropyrazolo[1',5'-c]quinazolin-2'-yl)propanoic acid (129) 
 
 
 
Methyl (2S)-2-(tert-butoxycarbonylamino)-3-(8ʹ-dimethylamino-5'-oxo-5'-6'-dihydropyrazolo[1',5'-
c]quinazolin-2'-yl)propanoate (118e) (0.188 g, 0.438 mmol) was dissolved in methanol (8.5 mL) and 
a solution of caesium carbonate (0.187 g, 0.575 mmol) in water (3.5 mL) was added. The reaction 
mixture was stirred at room temperature for 20 h and then concentrated in vacuo. The resulting 
residue was dissolved in water (50 mL) and acidified to pH 1 with 1 M aqueous hydrochloric acid. 
Solid sodium chloride was added and extracted with dichloromethane (3 × 50 mL). The organic 
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layers were combined and washed with brine (50 mL). The brine was re-extracted with 
dichloromethane (30 mL). The organic layers were dried (MgSO4) and concentrated in vacuo to give 
(2S)-2-(tert-butoxycarbonylamino)-3-(8'-dimethylamino-5'-oxo-5'-6'-dihydropyrazolo[1',5'-
c]quinazolin-2'-yl)propanoic acid (129) as a yellow solid (0.143 g, 78%). Mp 295–297 °C; νmax/cm−1 
(neat) 3414 (NH), 2976 (CH), 1708 (C=O), 1629, 1533, 1387, 1163; [α]D
23 +15.3 (c 0.9, CHCl3); δH (400 
MHz, CD3OD) 1.39 (9H, s, 3 × CH3), 3.03 (6H, s, 2 × CH3), 3.13 (1H, dd, J 14.6, 9.2 Hz, 3-HH), 3.28–
3.33 (1H, m, 3-HH), 4.52 (1H, dd, J 9.2, 4.8 Hz, 2-H), 6.41 (1H, d, J 2.3 Hz, 7ʹ-H), 6.65 (1H, s, 1ʹ-H), 
6.69 (1H, dd, J 8.9, 2.3 Hz, 9ʹ-H), 7.61 (1H, d, J 8.9 Hz, 10ʹ-H); δC (101 MHz, CD3OD) 28.7 (3 × CH3), 
31.9 (CH2), 40.3 (2 × CH3), 54.7 (CH), 80.6 (C), 97.4 (CH), 99.1 (CH), 103.0 (C), 110.3 (CH), 125.9 (CH), 
137.3 (C), 143.9 (C), 147.2 (C), 153.5 (C), 156.0 (C), 157.9 (C), 175.2 (C); m/z  438.1738 (MNa+. 
C20H25N5NaO5 requires 438.1748). 
 
(2S)-2-Amino-3-(8ʹ-dimethylamino-5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-c]quinazolin-2ʹ-
yl)propanoic acid hydrochloride (101) 
 
 
 
(2S)-2-(tert-Butoxycarbonylamino)-3-(8'-dimethylamino-5'-oxo-5'-6'-dihydropyrazolo[1',5'-
c]quinazolin-2'-yl)propanoic acid (129) (0.0375 g, 0.0903 mmol) was dissolved in 2 M aqueous 
hydrochloric acid (5 mL) and stirred at room temperature for 2 h. The reaction mixture was 
concentrated in vacuo and the resulting residue was purified by recrystallisation from methanol 
and diethyl ether. This gave (2S)-2-amino-3-(8ʹ-dimethylamino-5ʹ-oxo-5ʹ,6ʹ-dihydropyrazolo[1ʹ,5ʹ-
c]quinazolin-2ʹ-yl)propanoic acid hydrochloride (101) as a yellow solid (0.0322 g, 100%). Mp 208–
210 °C (decomposition); νmax/cm−1 (neat) 3423 (NH), 2854 (CH), 1713 (C=O), 1612, 1497, 1335, 1211, 
810; [α]D
32 –10.7 (c 0.3, MeOH); δH (400 MHz, CD3OD) 3.11 (6H, s, 2 × CH3), 3.40 (1H, dd, J 16.6, 8.3 
Hz, 3-HH), 3.52 (1H, dd, J 16.6, 3.9 Hz, 3-HH), 4.49 (1H, dd, J 8.3, 3.9 Hz, 2-H), 6.66 (1H, d, J 2.3 Hz, 
7'-H), 6.80 (1H, s, 1'-H), 6.91 (1H, dd, J 8.9, 2.2 Hz, 9'-H), 7.80 (1H, d, J 8.9 Hz, 10'-H); δC (126 MHz, 
CD3OD) 29.9 (CH2), 43.9 (2 × CH3), 53.1 (CH), 103.8 (C), 109.1 (C), 113.9 (CH), 127.1 (CH), 136.9 (CH), 
137.0 (CH), 143.2 (C), 146.9 (C), 149.3 (C), 154.4 (C), 170.8 (C); m/z 338.1224 (MNa+. C15H17N5NaO3 
requires 338.1224). 
 
  
146 
 
Hexapeptide 131 
 
 
 
The pentapeptide was synthesised on a Biotage Initiator+ Alstra peptide synthesiser using a 
Fmoc/tBu protecting group strategy on a 0.1 mmol synthetic scale using Rink Amide ChemMatrix® 
resin. The resin-bound peptide was synthesised by first loading Fmoc-Lys(Boc)-OH to the resin and 
by introducing the amino acids (4 equivalents) successively with a combination of 0.5 M 2-(6-
chloro-1-H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) in DMF 
(4 equivalents) and 2 M diisopropylethylamine in NMP (8 equivalents). Fmoc groups were 
removed using 20% piperidine in DMF. The resin-bound pentapeptide (0.296 g, 0.100 mmol) was 
treated with 20% piperidine in DMF (2 mL) and shaken for 0.25 h. The solution was filtered, and 
the resin-bound peptide was washed with dichloromethane (3 × 2 mL), isopropanol (3 × 2 mL) and 
DMF (3 × 2 mL). The resin-bound peptide was suspended in DMF (2 mL) followed by addition of 
(2S)-2-(tert-butoxycarbonylamino)-3-(8'-dimethylamino-5'-oxo-5'-6'-dihydropyrazolo[1',5'-
c]quinazolin-2'-yl)propanoic acid (129) (0.0834 g, 0.200 mmol), diisopropylethylamine (0.0700 mL, 
0.400 mmol) and 0.5 M HCTU in DMF (0.400 mL, 0.200 mmol). The mixture was shaken for 18 h. 
The solution was filtered, and the resin-bound peptide was washed with dichloromethane (3 × 2 
mL), isopropanol (3 × 2 mL) and DMF (3 × 2 mL). The resin-bound peptide was treated with 
trifluoroacetic acid/water/triisopropylsilane (2 mL, 95:2.5:2.5) and shaken for 2 h. The cleavage 
cocktail was evaporated using a stream of nitrogen and peptide 131 was precipitated from a 
solution of ice-cold diethyl ether (2 mL), centrifuged at 4500 rpm for 5 minutes and the precipitate 
was washed with ice-cold diethyl ether (3 × 2 mL). Peptide 131 was purified on a reverse-phase 
Dionex HPLC system equipped with Dionex P680 pumps and a Dionex UVD170U UV-Vis detector 
(monitoring at 214 nm and 280 nm), using a Phenomenex, Gemini, C18, 5 μm, 250 × 21.2 mm 
column. Gradients were run using a solvent system consisting of A (H2O + 0.1% TFA) and B (MeCN 
+ 0.1% TFA), and collected fractions were lyophilised on a Christ Alpha 2-4 LO plus freeze dryer to 
give a yellow solid (0.0614 g, 0.0720 mmol, 72%). Peptide 131 was analysed on a Shimadzu 
reverse-phase HPLC (RP-HPLC) system equipped with Shimadzu LC-20AT pumps, a Shimadzu SIL-
20A autosampler and a Shimadzu SPD-20A UV-Vis detector (monitoring at 214 nm and 280 nm) 
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using a Phenomenex, Aeris, 5 μm, peptide XB-C18, 150 × 4.6 mm column at a flow rate of 1 
mL/minute. RP-HPLC gradients were run using a solvent system consisting of solution A (5% MeCN 
in H2O + 0.1% TFA) and B (5% H2O in MeCN + 0.1% TFA). Two gradients were used to characterise 
131, a gradient from 0–100% solution B over 20 minutes (Figure 1) and a gradient from 0–100% 
solution B over 50 minutes (Figure 2). Analytical RP-HPLC data is reported as column retention 
time (tR) in minutes (Table 1). High-resolution mass spectrometry (HRMS) was performed on a 
Bruker microTOF-Q II (ESI+). HRMS data are reported as mass to charge ratio (m/z) = observed / 
MW. 
 
20 Minute gradient 50 Minute gradient Calculated MW Observed MW 
TR (min) Purity (%) TR (min) Purity (%) 
853.5043 [M+H]+ 853.5045 [M+H]+ 
11.56 99 20.25 98 
 
Table 1: RP-HPLC gradients and HRMS data. 
 
Figure 1: Analytical HPLC 20-minute gradient. 
 
Figure 2: Analytical HPLC 50-minute gradient. 
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3.3 Experimental for benzotriazole derived amino acids 
(2S)-2-[(Benzyloxycarbonyl)amino]-3-aminopropionic acid (155)208 
 
 
 
To a suspension of Nα-(benzyloxycarbonyl)amino-L-asparagine (154) (5.00 g, 18.8 mmol) in 
acetonitrile (24 mL), ethyl acetate (24 mL) and water (12 mL) was added (diacetoxyiodo)benzene 
(7.26 g, 22.5 mmol) and this reaction mixture was stirred at 16 °C for 0.5 h. The reaction mixture 
was warmed to room temperature for and stirred for a further 3 h. The resulting solid filtered and 
washed with cold ethyl acetate (50 mL) and diethyl ether (50 mL) to give (2S)-2-
[(benzyloxycarbonyl)amino]-3-aminopropionic acid (155) (4.48 g, 100%) as a white solid. Mp 208–
211 °C; [α]D
23 −7.9 (c 1.2, 1 M NaOH), lit.208 [α]D
23 −7.7 (c 0.4, 1 M NaOH); δH (400 MHz, DMSO-
d6/TFA) 2.99–3.06 (1H, m, 3-HH), 3.21–3.28 (1H, m, 3-HH), 4.30 (1H, dt, J 8.9, 4.6 Hz, 2-H), 5.07 
(2H, s, OCH2Ph), 7.28–7.37 (5H, m, Ph), 7.70 (1H, d, J 8.9 Hz, NH), 7.91 (2H, s, NH2); δC (101 MHz, 
DMSO-d6/TFA) 40.4 (CH2), 51.9 (CH), 66.0 (CH2), 128.0 (2 × CH), 128.0 (CH), 128.5 (2 × CH), 136.8 
(C), 156.4 (C), 170.9 (C); m/z (ESI) 261 (MNa+. 100%). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-aminopropanoate hydrochloride (156)209 
 
 
 
To a suspension of (2S)-2-[(benzyloxycarbonyl)amino]-3-aminopropionic acid (155) (4.48 g, 18.8 
mmol) in methanol (30 mL) at 0 °C under argon was added thionyl chloride (1.78 mL, 24.4 mmol) 
dropwise. After warming to room temperature, the reaction mixture was stirred for 16 h, 
concentrated in vacuo to give the crude product. This was triturated with diethyl ether to give 
methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-aminopropanoate hydrochloride (156) (4.74 g, 100%) 
as a white solid. Mp 165–168 °C, lit.209 169–171 °C; [α]D
22 −41.4 (c 1.1, MeOH), lit.2 [α]D
21 −43.1 (c 
2.5, MeOH); δH (400 MHz, CD3OD) 3.23 (1H, dd, J 13.2, 8.8 Hz, 3-HH), 3.45 (1H, dd, J 13.2, 5.1 Hz, 
3-HH), 3.78 (3H, s, OCH3), 4.51 (1H, dd, J 8.8, 5.1 Hz, 2-H), 5.14 (2H, s, OCH2Ph), 7.30–7.40 (5H, m, 
Ph); δC (101 MHz, CD3OD) 41.3 (CH2), 53.1 (CH), 53.4 (CH3), 68.2 (CH2), 129.0 (2 × CH), 129.2 (CH), 
129.5 (2 × CH), 137.8 (C), 158.7 (C), 170.9 (C); m/z (ESI) 275 (MNa+. 100%). 
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Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-nitrophenyl)amino]propanoate (157a)  
 
 
 
To a solution of methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-aminopropanoate hydrochloride 
(156) (0.250 g, 0.991 mmol) in acetonitrile (7.5 mL) was added 2-fluoronitrobenzene (0.310 mL, 
2.97 mmol) and triethylamine (0.410 mL, 2.97 mmol). The reaction mixture was degassed with 
argon for 0.15 h and heated under reflux for 16 h. The reaction mixture was cooled to room 
temperature and concentrated in vacuo. The resulting residue was dissolved in ethyl acetate (50 
mL), washed with 1 M aqueous hydrochloric acid (50 mL), water (50 mL) and brine (50 mL). The 
organic layer was dried and concentrated in vacuo to give the crude product. Purification by flash 
chromatography using silica gel, eluting with 0% to 20% ethyl acetate in dichloromethane gave 
methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-nitrophenyl)amino]propanoate (157a) as a 
yellow solid (0.330 g, 89%). Mp 82–84 °C; νmax/cm−1 (neat) 3348 (NH), 1721 (C=O), 1512, 1265, 
1234, 741; [α]D
25 +50.8 (c 0.3, CHCl3); δH (400 MHz, CDCl3) 3.64–3.74 (5H, m, 3-H2 and OCH3), 4.57 
(1H, dt, J 6.7, 5.7 Hz, 2-H), 5.04 (2H, s, OCH2Ph), 5.63 (1H, d, J 6.7 Hz, NH), 6.69 (1H, br t, J 8.6 Hz, 
4ʹ-H), 6.98 (1H, d, J 8.6 Hz, 6ʹ-H), 7.27–7.51 (6H, m, 5ʹ-H and Ph), 8.16 (1H, dd, J 8.6, 1.2 Hz, 3ʹ-H), 
8.22 (1H, t, J 5.6 Hz, NH); δC (101 MHz, CDCl3) 44.6 (CH2), 53.1 (CH3), 53.6 (CH), 67.4 (CH2), 113.7 
(CH), 116.3 (CH), 127.0 (CH), 128.3 (2 × CH), 128.4 (CH), 128.7 (2 × CH), 132.8 (C), 136.0 (C), 136.4 
(CH), 144.9 (C), 155.9 (C), 170.8 (C); m/z (ESI) 396.1158 (MNa+. C18H19N3NaO6 requires 396.1166). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-nitro-4ʹ-methylphenyl)amino]propanoate 
(157b) 
 
 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-nitro-4ʹ-methylphenyl)amino]propanoate (157b) 
was synthesised as described for methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-
nitrophenyl)amino]propanoate (157a) using methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-
aminopropanoate hydrochloride (156) (2.85 g, 11.3 mmol), 4-fluoro-3-nitrotoluene (5.26 g, 33.9 
mmol) and triethylamine (4.72 mL, 33.9 mmol) in acetonitrile (50 mL). Purification by flash 
chromatography using silica gel, eluting with 0% to 20% ethyl acetate in dichloromethane gave 
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methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-nitro-4ʹ-methylphenyl)amino]propanoate (157b) 
as a viscous orange oil (2.70 g, 62%). νmax/cm−1 (neat) 3364 (NH), 2955 (CH), 1721 (C=O), 1520 
(C=C), 1273, 1227, 1057; [α]D
24
 +50.4 (c 1.1, CHCl3); δH (400 MHz, CDCl3) 2.18 (3H, s, CH3), 3.61–3.74 
(5H, m, 3-H2 and OCH3), 4.59 (1H, q, J 6.3 Hz, 2-H), 5.04 (2H, s, OCH2Ph), 5.90 (1H, d, J 6.3 Hz, NH), 
6.82 (1H, d, J 8.5 Hz, 6ʹ-H), 7.16 (1H, d, J 8.5 Hz, 5ʹ-H), 7.20–7.32 (5H, m, Ph), 7.87 (1H, s, 3ʹ-H), 8.05 
(1H, t, J 6.3 Hz, NH); δC (101 MHz, CDCl3) 19.8 (CH3), 44.4 (CH2), 52.8 (CH3), 53.4 (CH), 67.1 (CH2), 
113.6 (CH), 125.6 (C), 126.1 (CH), 128.0 (2 × CH), 128.1 (CH), 128.4 (2 × CH), 132.2 (C), 136.0 (C), 
137.6 (CH), 142.9 (C), 155.9 (C), 170.8 (C); m/z (ESI) 410.1313 (MNa+. C19H21N3NaO6 requires 
410.1323). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(4ʹ-bromo-2ʹ-nitrophenyl)amino]propanoate 
(157c) 
 
 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(4ʹ-bromo-2ʹ-nitrophenyl)amino]propanoate (157c) 
was synthesised as described for methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-
nitrophenyl)amino]propanoate (157a) using methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-
aminopropanoate hydrochloride (156) (3.97 g, 13.8 mmol), 5-bromo-2-fluoronitrobenzene (5.09 
mL, 41.3 mmol) and triethylamine (5.76 mL, 41.3 mmol) in acetonitrile (50 mL). Purification by 
flash chromatography using silica gel, eluting with 0% to 20% ethyl acetate in dichloromethane 
gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(4ʹ-bromo-2ʹ-nitrophenyl)amino]propanoate 
(157c) as a yellow solid (5.75 g, 92%). Mp 86–89 °C; νmax/cm−1 (neat) 3364 (NH), 2955 (CH), 1721 
(C=O), 1612 (C=O), 1504, 1227, 1065; [α]D
25 +14.3 (c 1.1, CHCl3); δH (400 MHz, CDCl3) 3.60–3.76 (5H, 
m, 3-H2 and OCH3), 4.60 (1H, dt, J 6.9, 5.8 Hz, 2-H), 5.06 (1H, d, J 12.2 Hz, OCHHPh), 5.11 (1H, d, J 
12.2 Hz, OCHHPh), 6.06 (1H, d, J 6.9 Hz, NH), 6.81 (1H, d, J 9.1 Hz, 6ʹ-H), 7.20–7.30 (5H, m, Ph), 
7.36 (1H, dd, J 9.1, 1.5 Hz, 5ʹ-H), 8.16 (1H, d, J 1.5 Hz, 3ʹ-H), 8.19 (1H, t, J 6.0 Hz, NH); δC (101 MHz, 
CDCl3) 44.2 (CH2), 52.8 (CH3), 53.2 (CH), 67.0 (CH2), 107.0 (C) 115.3 (CH), 127.9 (2 × CH), 128.1 (CH), 
128.3 (2 × CH), 128.6 (CH), 132.5 (C), 135.8 (C), 138.7 (CH), 143.6 (C), 155.9 (C), 170.4 (C); m/z (ESI) 
474.0276 (MNa+. C18H1879BrN3NaO6 requires 474.0271). 
 
  
151 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (159a) 
 
 
 
To a solution of methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-nitrophenyl)amino] propanoate 
(157a)  (0.320 g, 0.857 mmol) in methanol (12 mL) was added tin(II) dichloride dihydrate (0.970 g, 
4.29 mmol). The reaction mixture was heated under reflux and stirred under argon for 24 h. After 
cooling to room temperature, the reaction was concentrated in vacuo and the resulting residue 
was dissolved in ethyl acetate (50 mL) and mixed with a saturated solution of aqueous sodium 
hydrogen carbonate (30 mL). The biphasic mixture was filtered through Celite® and the organic 
layer was separated from the aqueous layer. The product was further extracted from the aqueous 
layer with ethyl acetate (2 × 20 mL). The combined organic layers were washed with brine (50 mL), 
dried (MgSO4), filtered and concentrated in vacuo. Purification by flash chromatography using 
silica gel, eluting with 10% diethyl ether in dichloromethane gave methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[(2’-aminophenyl)amino]propanoate (158a) as a pink solid (0.244 
g, 83%). This material was then used immediately for the next step. To a stirring solution of methyl 
(2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-aminophenyl)amino]propanoate (158a) (0.244 g, 0.711 
mmol) in acetonitrile (6 mL) at −10 °C was added p-toluenesulfonic acid (0.216 g, 1.14 mmol) and 
polymer-supported nitrate (0.609 g, containing 2.13 mmol of NO2−). The reaction mixture was 
stirred at −10 °C for 3 h. Afterwards, the reaction mixture was diluted with dichloromethane (50 
mL) and the resin was removed by filtration. The filtrate was washed with sat. aqueous sodium 
carbonate (50 mL) and brine (50 mL), dried (MgSO4) and concentrated in vacuo to give the crude 
product. Purification by flash chromatography using silica gel, eluting with 0% to 10% diethyl ether 
in dichloromethane gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(1H-benzo[d][1.2.3]triazol-
1ʹ-yl)propanoate (159a) as a white solid (0.148 g, 59%). Mp 82–85 °C; νmax/cm−1 (neat) 3325 (NH), 
2955 (CH), 1713 (C=O), 1504, 1211, 1057, 741; [α]D
25 +37.0 (c 0.4, CHCl3); δH (400 MHz, CDCl3) 3.75 
(3H, s, OCH3), 4.88 (1H, dt, J 7.0, 4.4 Hz, 2-H), 5.05‒5.18 (4H, m, 3-H2 and OCH2Ph), 5.66 (1H, d, J 
7.0 Hz, NH), 7.29‒7.45 (8H, m, 5ʹ-H, 6ʹ-H, 7ʹ-H and Ph), 8.03 (1H, br d, J 8.0, 4ʹ-H); δC (101 MHz, 
CDCl3) 48.7 (CH2), 53.3 (CH3), 54.4 (CH), 67.4 (CH2), 109.2 (CH), 120.2 (CH), 124.2 (CH), 127.9 (CH), 
128.3 (2 × CH), 128.5 (CH), 128.7 (2 × CH), 133.9 (C), 136.0 (C), 145.8 (C), 155.8 (C), 169.5 (C); m/z 
(ESI) 377.1223 (MNa+. C18H18N4NaO4 requires 377.1220). 
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Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-methyl-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (159b) 
 
 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-methyl-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (159b) was synthesised as described for methyl (2S)-2-[(benzyloxycarbonyl)amino]-
3-(1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (159a) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[(2ʹ-nitro-4ʹ-methylphenyl)amino]propanoate (157b) (2.70 g, 6.96 
mmol). This gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-methyl-1H-
benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (159b) as a white solid (0.997 g, 69%). Mp 79–83 °C; 
νmax/cm−1 (neat) 3314 (NH), 2951 (CH), 1717 (C=O), 1500, 1215, 1057, 1022, 741; [α]D
25 +36.5 (c 1.0, 
CHCl3); δH (400 MHz, CDCl3) 2.48 (3H, s, CH3), 3.73 (3H, s, OCH3), 4.86 (1H, dt, J 7.0, 4.6 Hz, 2-H), 
5.01–5.17 (4H, m, 3-H2 and OCH2Ph), 5.68 (1H, d, J 7.0 Hz, NH), 7.21 (1H, dd, J 8.5, 1.4 Hz, 6ʹ-H), 
7.22–7.31 (6H, m, 7ʹ-H and Ph), 7.76 (1H, br s, 4ʹ-H); δC (101 MHz, CDCl3) 21.6 (CH3), 48.6 (CH2), 
53.3 (CH3), 54.3 (CH), 67.3 (CH2), 108.7 (CH), 119.1 (CH), 128.3 (2 × CH), 128.4 (CH), 128.7 (2 × CH), 
130.1 (CH), 132.4 (C), 134.2 (C), 136.1 (C), 146.4 (C), 155.8 (C), 169.5 (C); m/z (ESI) 391.1374 (MNa+. 
C19H20N4NaO4 requires 391.1377). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (159c) 
 
 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (159c) was synthesised as described for methyl (2S)-2-[(benzyloxycarbonyl)amino]-
3-(1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (159a) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[(4ʹ-bromo-2ʹ-nitrophenyl)amino] propanoate (157c) (9.00 g, 19.9 
mmol). This gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-
benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (159c) as a pink solid (4.25 g, 66%). Mp 110–114 °C; 
νmax/cm−1 (neat) 3321 (NH), 2954 (CH), 1717 (C=O), 1512, 1211, 1057, 752; [α]D
22  −22.2 (c 1.0, 
CHCl3); δH (500 MHz, CDCl3) 3.77 (3H, s, OCH3), 4.84 (1H, dt, J 6.6, 4.5 Hz, 2-H), 5.00–5.20 (4H, m, 
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3-H2 and OCH2Ph), 5.69 (1H, d, J 6.6 Hz, NH), 7.22–7.47 (7H, m, 6ʹ-H, 7ʹ-H and Ph), 8.15 (1H, d, J 
1.0 Hz, 4ʹ-H); δC (126 MHz, CDCl3) 48.6 (CH2), 53.3 (CH3), 54.2 (CH), 67.3 (CH2), 110.4 (CH), 117.4 
(C), 122.6 (CH), 128.3 (2 × CH), 128.4 (CH), 128.6 (2 × CH), 131.2 (CH), 132.8 (C), 135.8 (C), 146.7 
(C), 155.6 (C), 169.1 (C); m/z (ESI) 455.0325 (MNa+. C18H1779BrN4NaO4 requires 455.0325). 
 
(2S)-2-Amino-3-(1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid hydrochloride (160a) 
 
 
 
A solution of methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (159a)  (0.0834 g, 0.236 mmol) in 6 M hydrochloric acid solution (10 mL) was heated 
under reflux for 20 h. After cooling to room temperature, the reaction mixture was concentrated 
in vacuo. Purification by recrystallisation from methanol and diethyl ether gave (2S)-2-amino-3-
(1H-benzo[d][1.2.3]triazol-1’-yl)propanoic acid hydrochloride (160a) as a pale brown solid (0.0537 
g, 94%). Mp 190–192 °C; νmax/cm−1 (neat) 2893 (CH), 1728 (C=O), 1234, 1165, 756; [α]D
24 +11.9 (c 
0.7, MeOH); δH (400 MHz, CD3OD) 4.79 (1H, dd, J 5.8, 4.1 Hz, 2-H), 5.26 (1H, dd, J 15.5, 4.1 Hz, 3-
HH), 5.37 (1H, dd, J 15.5, 5.8 Hz, 3-HH), 7.49 (1H, ddd, J 8.4, 7.0, 0.9 Hz, 5ʹ-H), 7.63 (1H, ddd, J 8.5, 
7.0, 0.9 Hz, 6ʹ-H), 7.84 (1H, dt, J 8.5, 0.9 Hz, 7ʹ-H), 8.05 (1H, dt, J 8.4, 0.9 Hz, 4ʹ-H); δC (101 MHz, 
CD3OD) 48.0 (CH2), 53.5 (CH), 111.1 (CH), 120.3 (CH), 126.0 (CH), 129.5 (CH), 134.9 (C), 146.8 (C), 
168.9 (C); m/z (ESI) 229.0706 (MNa+. C9H10N4NaO2 requires 229.0696). 
 
(2S)-2-Amino-3-(5ʹ-methyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid hydrochloride (160b) 
 
 
 
(2S)-2-Amino-3-(5’-methyl-1H-benzo[d][1.2.3]triazol-1’-yl]propanoic acid hydrochloride (160b) 
was synthesised as described for (2S)-2-amino-3-(1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (160a) using methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-methyl-1H-
benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (159b) (0.159 g, 0.432 mmol) and 6 M aqueous 
hydrochloric (10 mL) to give (2S)-2-amino-3-(5’-methyl-1H-benzo[d][1.2.3]triazol-1’-yl)propanoic 
acid hydrochloride (160b) as a white solid (0.0911 g, 82%) Mp 180–184 °C; νmax/cm−1 (neat) 2835 
(CH), 1744 (C=O), 1505, 1435, 1227, 810; [α]D
19 +17.9 (c 1.0, MeOH); δH (400 MHz, CD3OD) 2.52 (3H, 
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s, CH3), 4.80 (1H, dd, J 5.6, 4.2 Hz, 2-H), 5.25 (1H, dd, J 15.4, 4.2 Hz, 3-HH), 5.34 (1H, dd, J 15.4, 5.6 
Hz, 3-HH), 7.47 (1H, dd, J 8.6, 1.5 Hz, 6ʹ-H), 7.73 (1H, dd, J 8.6, 0.8 Hz, 7ʹ-H), 7.77 (1H, dd, J 1.5, 0.8 
Hz, 4ʹ-H); δC (101 MHz, CD3OD) 21.4 (CH3), 48.0 (CH2), 53.5 (CH), 110.8 (CH), 119.0 (CH), 131.6 (CH), 
133.4 (C), 136.6 (C), 147.2 (C), 168.9 (C); m/z (ESI) 243.0847 (MNa+. C10H12N4NaO2 requires 
243.0852). 
 
(2S)-2-Amino-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid hydrochloride (160c) 
 
 
 
(2S)-2-Amino-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid hydrochloride (160c) 
was synthesised as described for (2S)-2-amino-3-(1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid 
hydrochloride (160a) using (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-
benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (159c) (0.137 g, 0.317 mmol) and 6 M aqueous 
hydrochloric acid (6 mL) to give (2S)-2-amino-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoic acid hydrochloride (160c) as a white solid (0.0641, 63%). Mp 168‒172 °C; νmax/cm−1 
(neat) 3402 (NH), 2847 (OH), 1744 (C=O), 1474, 1211, 802; [α]D
22 +9.1 (c 0.7, MeOH); δH (500 MHz, 
CD3OD) 4.74 (1H, dd, J 5.9, 4.0 Hz, 2-H), 5.24 (1H, dd, J 15.5, 4.0 Hz, 3-HH), 5.34 (1H, dd, J 15.5, 5.9 
Hz, 3-HH), 7.73 (1H, dd, J 8.8, 1.7 Hz, 6ʹ-H), 7.78 (1H, dd, J 8.8, 0.5 Hz, 7ʹ-H), 8.26 (1H, dd, J 1.7, 0.5 
Hz, 4ʹ-H); δC (126 MHz, CD3OD) 48.3 (CH2), 53.6 (CH), 112.9 (CH), 119.0 (C), 123.1 (CH), 132.7 (CH), 
134.0 (C), 148.1 (C), 169.0 (C); m/z (ESI) 284.9978 (MH+. C9H1079BrN4O2 requires 284.9982). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-phenyl-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (161a) 
 
 
 
To a microwave vial containing phenylboronic acid (0.0463 g, 0.379 mmol), potassium fluoride 
(0.0441 g, 0.759 mmol) and [1,1ʹ-bis(diphenylphosphino)ferrocene]palladium(II) dichloride-
dichloromethane complex (0.0155 g, 0.0189 mmol) was added a solution of methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (159c) 
(0.109 g, 0.253 mmol) in 1,4-dioxane (3.6 mL) and water (0.4 mL). The reaction mixture was 
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degassed with argon for 0.15 h, the vial was sealed under argon and stirred at 80 °C for 20 h. The 
reaction mixture was filtered through Celite® and washed with ethyl acetate (50 mL). The filtrate 
was washed with 1 M aqueous hydrochloric acid (50 mL), water (50 mL) and brine (50 mL), dried 
(MgSO4) and concentrated in vacuo to give the crude product. Purification by flash 
chromatography using silica gel, eluting with 5% diethyl ether in dichloromethane gave methyl 
(2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-phenyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (161a) 
as a white solid (0.0912 g, 84%). Mp 136–138 °C; νmax/cm−1 (neat) 3323 (NH), 2952 (CH), 1718 
(C=O), 1507, 1214, 1060, 757, 698; [α]D
23 +8.3 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.78 (3H, s, OCH3), 
4.90 (1H, dt, J 7.0, 4.3 Hz, 2-H), 5.05–5.25 (4H, m, 3-H2 and OCH2Ph), 5.63 (1H, d, J 7.0 Hz, NH), 
7.30–7.43 (6H, m, ArH and Ph), 7.44–7.55 (3H, m, 3 × ArH), 7.59–7.70 (3H, m, 3 × ArH), 8.20 (1H, 
br s, 4ʹ-H); δC (101 MHz, CDCl3) 48.6 (CH2), 53.3 (CH3), 54.3 (CH), 67.3 (CH2), 109.2 (CH), 117.9 (CH), 
127.5 (2 × CH), 127.6 (CH), 128.1 (CH), 128.3 (2 × CH), 128.4 (CH), 128.6 (2 × CH), 129.0 (2 × CH), 
133.2 (C), 135.9 (C), 138.0 (C), 140.4 (C), 146.5 (C), 155.7 (C), 169.3 (C); m/z (EI) 430.1654 (M+. 
C24H22N4O4 requires 430.1641). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(naphthalen-2ʹʹ-yl)-1H-benzo[d][1.2.3]triazol-
1ʹ-yl]propanoate (161b) 
 
 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(naphthalen-2ʹʹ-yl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl]propanoate (161b) was synthesised as described for methyl (2S)-2-[(benzyloxycarbonyl)amino]-
3-(5ʹ-phenyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (161a) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (159c) 
(0.105 g, 0.242 mmol), 2-naphthylboronic acid (0.0834 g, 0.485 mmol), [1,1ʹ-
bis(diphenylphosphino)ferrocene]palladium(II) dichloride-dichloromethane complex (0.0148 g, 
0.0182 mmol) and potassium fluoride (0.0422 g, 0.726 mmol) in dioxane (3.6 mL) and water (0.4 
mL). Purification with flash chromatography using silica gel, eluting with 5% diethyl ether in 
dichloromethane gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(naphthalen-2ʹʹ-yl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161b) as a white solid (0.105 g, 91%). Mp 72–74 °C; 
νmax/cm−1 (neat) 3335 (NH), 2950 (CH), 1713 (C=O), 1508, 1211, 1018, 777, 729; [α]D
20 +11.7 (c 1.0, 
CHCl3); δH (400 MHz, CDCl3) 3.81 (3H, s, OCH3), 4.93 (1H, dt, J 7.1, 4.3 Hz, 2-H), 5.02–5.30 (4H, m, 
3-H2 and OCH2Ph), 5.76 (1H, d, J 7.1 Hz, NH), 7.25–7.62 (11H, m, 6 × ArH and Ph), 7.81 (1H, d, J 8.4 
Hz, ArH), 7.90 (1H, br d, J 8.3 Hz, 7ʹ-H), 7.93 (1H, d, J 8.1 Hz, ArH), 8.13 (1H, br s, 4ʹ-H); δC (101 MHz, 
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CDCl3) 48.7 (CH2), 53.3 (CH3), 54.3 (CH), 67.3 (CH2), 108.7 (CH), 120.8 (CH), 125.4 (CH), 125.7 (CH), 
126.0 (CH), 126.3 (CH), 127.5 (CH), 128.1 (CH), 128.2 (2 × CH), 128.4 (2 × CH), 128.6 (2 × CH), 130.7 
(CH), 131.7 (C), 133.2 (C), 133.8 (C), 135.9 (C), 137.1 (C), 139.1 (C), 146.0 (C), 155.7 (C), 169.4 (C); 
m/z (ESI) 503.1671 (MNa+. C28H24N4NaO4 requires 503.1690).  
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(biphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl]propanoate (161c) 
 
 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(biphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl]propanoate (161c) was synthesised as described for methyl (2S)-2-[(benzyloxycarbonyl)amino]-
3-(5ʹ-phenyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (161a) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (159c) 
(0.105 g, 0.242 mmol), 4-biphenylboronic acid (0.0959 g, 0.484 mmol), [1,1ʹ-
bis(diphenylphosphino)ferrocene]palladium(II) dichloride-dichloromethane complex (0.0148 g, 
0.0182 mmol) and potassium fluoride (0.0422 g, 0.726 mmol) in dioxane (3.6 mL) and water (0.4 
mL). Purification with flash chromatography using silica gel, eluting with 5% diethyl ether in 
dichloromethane gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(biphenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161c) as a white solid (0.102 g, 83%). Mp 176–178 °C; 
νmax/cm−1 (neat) 3307 (NH), 2954 (CH), 1715 (C=O), 1481, 1214, 764, 732; [α]D
24 +13.6 (c 1.0, CHCl3), 
δH (400 MHz, CDCl3) 3.79 (3H, s, OCH3), 4.91 (1H, dt, J 7.1, 4.3 Hz, 2-H), 5.05–5.25 (4H, m, 3-H2 and 
OCH2Ph), 5.65 (1H, d, J 7.1 Hz, NH), 7.29–7.42 (6H, m, ArH and Ph), 7.44–7.53 (3H, m, 3 × ArH), 
7.64–7.70 (7H, m, 7 × ArH), 8.25 (1H, dd, J 1.3, 0.7 Hz, 4ʹ-H); δC (101 MHz, CDCl3) 48.7 (CH2), 53.3 
(CH3), 54.3 (CH), 67.3 (CH2), 109.4 (CH), 117.8 (CH), 127.1 (2 × CH) 127.5 (CH), 127.7 (2 × CH), 127.9 
(2 × CH), 128.0 (CH), 128.3 (2 × CH), 128.4 (CH), 128.6 (2 × CH), 128.9 (2 × CH), 133.3 (C), 135.9 (C), 
137.5 (C), 139.3 (C), 140.5 (2 × C), 146.5 (C), 155.7 (C), 169.3 (C); m/z (ESI) 529.1831 (MNa+. 
C30H26N4NaO4 requires 529.1846). 
 
  
157 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(thiophen-3ʹʹ-yl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl]propanoate (161d) 
 
 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(thiophen-3ʹʹ-yl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl]propanoate (161d) was synthesised as described for methyl (2S)-2-[(benzyloxycarbonyl)amino]-
3-(5ʹ-phenyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (161a) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (159c) 
(0.111 g, 0.256 mmol), 3-thiopheneboronic acid (0.0654 g, 0.511 mmol), [1,1ʹ-
bis(diphenylphosphino)ferrocene]palladium(II) dichloride-dichloromethane complex (0.0157 g, 
0.0192 mmol) and potassium fluoride (0.0446 g, 0.768 mmol) in dioxane (3.6 mL) and water (0.4 
mL). Purification with flash chromatography using silica gel, eluting with 5% diethyl ether in 
dichloromethane gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(thiophen-3ʹʹ-yl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161d) as a white solid (0.0826 g, 74%). Mp 144–145 °C; 
νmax/cm−1 (neat) 3321 (NH), 2957 (CH), 1744 (C=O), 1713 (C=O), 1514, 1214, 788; [α]D
23 +18.0 (c 1.0, 
CHCl3); δH (400 MHz, CDCl3) 3.77 (3H, s, OCH3), 4.89 (1H, dt, J 7.1, 4.3 Hz, 2-H), 5.02–5.25 (4H, m, 
3-H2 and OCH2Ph), 5.64 (1H, d, J 7.1 Hz, NH), 7.28–7.47 (8H, m, 7ʹ-H, 4ʹʹ-H and 5ʹʹ-H and Ph), 7.49 
(1H, dd, J 2.8, 1.5 Hz, 2ʹʹ-H), 7.62 (1H, dd, J 8.7, 1.3 Hz, 6ʹ-H), 8.20 (1H, dd, J 1.3, 0.7 Hz, 4ʹ-H); δC 
(101 MHz, CDCl3) 48.6 (CH2), 53.3 (CH3), 54.3 (CH), 67.3 (CH2), 109.4 (CH), 116.9 (CH), 120.9 
(CH),  126.5 (CH), 126.7 (CH), 127.5 (CH), 128.3 (2 × CH2), 128.4 (CH), 128.6 (2 × CH2), 132.5 (C), 
133.1 (C), 135.9 (C), 141.5 (C), 146.4 (C), 155.7 (C), 169.3 (C); m/z (ESI) 459.1081 (MNa+. 
C22H20N4NaO4S requires 459.1097). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-hydroxyphenyl)-1H-benzo[d][1.2.3]triazol-
1ʹ-yl]propanoate (161e) 
 
 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-hydroxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl]propanoate (161e) was synthesised as described for methyl (2S)-2-[(benzyloxycarbonyl)amino]-
3-(5ʹ-phenyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (161a) using methyl (2S)-2-
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[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (159c) 
(0.106 g, 0.244 mmol), 4-hydroxyphenylboronic acid (0.0672 g, 0.487 mmol), [1,1ʹ-
bis(diphenylphosphino)ferrocene]palladium(II) dichloride-dichloromethane complex (0.0150 g, 
0.0183 mmol) and potassium fluoride (0.0425 g, 0.732 mmol) in dioxane (3.6 mL) and water (0.4 
mL). Purification with flash chromatography using silica gel, eluting with 15% diethyl ether in 
dichloromethane gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-hydroxyphenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161e) as a white solid (0.0887 g, 81%). Mp 103–106 °C; 
νmax/cm−1 (neat) 3318 (NH) 2955 (CH), 1740 (C=O), 1690 (C=O), 1522, 1211, 1063, 754, 698; [α]D
23 
−11.4 (c 1.0, MeOH); δH (400 MHz, CD3OD), 3.77 (3H, s, OCH3), 4.80–4.85 (1H, m, 2-H), 4.98 (2H, s, 
OCH2Ph), 5.09 (1H, dd, J 14.5, 8.1 Hz, 3-HH), 5.21 (1H, dd, J 14.5, 4.9 Hz, 3-HH), 6.90 (2H, d, J 8.7 
Hz, 3ʹʹ-H and 5ʹʹ-H), 7.18–7.32 (5H, m, Ph), 7.51 (2H, d, J 8.7 Hz, 2ʹʹ-H and 6ʹʹ-H), 7.64–7.76 (2H, m, 
6ʹ-H and 7ʹ-H), 8.05 (1H, br s, 4ʹ-H); δC (101 MHz, CD3OD), 47.4 (CH2), 51.9 (CH3), 54.2 (CH), 66.3 
(CH2), 109.9 (CH), 115.1 (CH), 115.4 (2 × CH), 127.4 (2 × CH), 127.5 (CH), 127.6 (CH), 128.0 (2 × CH), 
128.2 (2 × CH), 131.4 (C), 132.8 (C), 136.5 (C), 138.3 (C), 146.0 (C), 156.6 (C), 157.2 (C), 169.7 (C); 
m/z (ESI) 469.1466 (MNa+. C24H22N4NaO5 requires 469.1482).  
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-methoxyphenyl)-1H-benzo[d][1.2.3]triazol-
1ʹ-yl]propanoate (161f) 
 
 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-methoxyphenyl)-1H-benzo[d][1.2.3]triazol-
1ʹ-yl]propanoate (161f) was synthesised as described for methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(5ʹ-phenyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (161a) using 
methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (159c) (0.200 g, 0.462 mmol), 4-methoxyphenylboronic acid (0.105 g, 0.693 mmol), 
[1,1ʹ-bis(diphenylphosphino)ferrocene]palladium(II) dichloride-dichloromethane complex 
(0.0289 g, 0.0346 mmol) and potassium fluoride (0.0805 g, 1.39 mmol) in dioxane (3.6 mL) and 
water (0.4 mL). Purification with flash chromatography using silica gel, eluting with 15% diethyl 
ether in dichloromethane gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-
methoxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161f) as a white solid (0.179 g, 84%). 
Mp 139–142 °C; νmax/cm−1 (neat) 3333 (NH), 2932 (CH), 1721 (C=O), 1604, 1512, 1342, 1250, 1026; 
[α]D
21 +7.6 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.77 (3H, s, OCH3), 3.87 (3H, s, OCH3), 4.89 (1H, dt, J 
7.2, 4.3 Hz, 2-H), 5.04–5.22 (4H, m, 3-H2 and OCH2Ph), 5.68 (1H, d, J 7.2 Hz, NH), 7.02 (2H, d, J 8.8 
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Hz, 3ʹʹ-H and 5ʹʹ-H), 7.28–7.40 (5H, m, Ph), 7.43 (1H, br d, J 8.7 Hz, 7ʹ-H), 7.55 (2H, d, J 8.8 Hz, 2ʹʹ-H 
and 6ʹʹ-H), 7.59 (1H, dd, J 8.7, 1.5 Hz, 6ʹ-H), 8.13 (1H, dd, J 1.5, 0.7 Hz, 4ʹ-H); δC (101 MHz, CDCl3) 
48.6 (CH2), 53.2 (CH3), 54.3 (CH), 55.4 (CH3), 67.3 (CH2), 109.2 (CH), 114.4 (2 × CH), 117.2 (CH), 
127.9 (CH), 128.3 (2 × CH), 128.4 (CH), 128.5 (2 × CH), 128.6 (2 × CH), 132.9 (2 × C), 135.9 (C), 137.6 
(C), 146.5 (C), 155.7 (C), 159.4 (C), 169.3 (C); m/z (ESI) 483.1623 (MNa+. C25H24N4NaO5 requires 
483.1639). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(3ʹʹ,4ʹʹ-methylenedioxyphenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161g) 
 
 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(3ʹʹ,4ʹʹ-methylenedioxyphenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161g) was synthesised as described for methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(5ʹ-phenyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (161a) using 
methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (159c) (0.104 g, 0.239 mmol), 3,4-(methylenedioxy)phenylboronic acid (0.0793 g, 
0.478 mmol), [1,1ʹ-bis(diphenylphosphino)ferrocene]palladium(II) dichloride-dichloromethane 
complex (0.0146 g, 0.0179 mmol) and potassium fluoride (0.0417 g, 0.717 mmol) in dioxane (3.6 
mL) and water (0.4 mL). Purification with flash chromatography using silica gel, eluting with 5% 
diethyl ether in dichloromethane gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(3ʹʹ,4ʹʹ-
methylenedioxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161g) as a white solid (0.0926 
g, 82%). Mp 160–162 °C; νmax/cm−1 (neat) 3322, (NH), 2930 (CH), 1715 (C=O), 1510, 1480, 1225, 
1038, 799, 735; [α]D
24 +13.4 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.78 (3H, s, OCH3), 4.89 (1H, dt, J 
7.0, 4.3 Hz, 2-H), 5.03–5.22 (4H, m, 3-H2 and OCH2Ph), 5.65 (1H, d, J 7.0 Hz, NH), 6.03 (2H, s, OCH2O), 
6.92 (1H, dd, J 7.5, 0.9 Hz, 6ʹʹ-H), 7.04–7.11 (2H, m, 2ʹʹ-H and 5ʹʹ-H), 7.29–7.40 (5H, m, Ph), 7.42 
(1H, br d, J 8.6 Hz, 7ʹ-H), 7.54 (1H, dd, J 8.6, 1.3 Hz, 6ʹ-H), 8.10 (1H, dd, J 1.3, 0.6 Hz, 4ʹ-H); δC (101 
MHz, CDCl3) 48.6 (CH2), 53.3 (CH3), 54.3 (CH), 67.3 (CH2), 101.3 (CH2), 108.0 (CH), 108.7 (CH), 109.2 
(CH), 117.4 (CH), 121.1 (CH), 128.0 (CH), 128.3 (2 × CH), 128.4 (CH), 128.6 (2 × CH), 133.1 (C), 134.7 
(C), 135.9 (C), 137.7 (C), 146.4 (C), 147.4 (C), 148.3 (C), 155.7 (C), 169.3 (C); m/z (ESI) 497.1411 
(MNa+. C25H22N4NaO6 requires 497.1432).  
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Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-dimethylaminophenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161h) 
 
 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-dimethylaminophenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161h) was synthesised as described for methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(5ʹ-phenyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (161a) using 
methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (159c) (0.106 g, 0.245 mmol), 4-dimethylaminobenzeneboronic acid (0.0810 g, 
0.491 mmol), [1,1ʹ-bis(diphenylphosphino)ferrocene]palladium(II) dichloride-dichloromethane 
complex (0.0150 g, 0.0184 mmol) and potassium fluoride (0.0430 g, 0.735 mmol) in dioxane (3.6 
mL) and water (0.4 mL). Purification with flash chromatography using silica gel, eluting with 20% 
diethyl ether in dichloromethane gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-
dimethylaminophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161h) as a white solid (0.0453 
g, 39%). Mp 139–140 °C; νmax/cm−1 (neat) 3347 (NH), 2947 (CH), 1719 (C=O), 1609, 1528, 1489, 
1439, 1213, 1061, 802; [α]D
20 +11.5 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.02 (6H, s, NMe2), 3.76 (3H, 
s, OCH3), 4.89 (1H, dt, J 7.2, 4.2 Hz, 2-H), 5.04–5.22 (4H, m, 3-H2 and OCH2Ph), 5.66 (1H, d, J 7.2 Hz, 
NH), 6.84 (2H, d, J 8.9 Hz, 3ʹʹ-H and 5ʹʹ-H), 7.28–7.39 (5H, m, Ph), 7.41 (1H, br d, J 8.7 Hz, 7ʹ-H), 7.53 
(2H, d, J 8.9 Hz, 2ʹʹ-H and 6ʹʹ-H), 7.61 (1H, dd, J 8.7, 1.4 Hz, 6ʹ-H), 8.13 (1H, dd, J 1.4, 0.6 Hz, 4ʹ-H); 
δC (101 MHz, CDCl3) 40.5 (2 × CH3), 48.6 (CH2), 53.2 (CH3), 54.3 (CH), 67.3 (CH2), 109.0 (CH), 112.9 
(2 × CH), 116.3 (CH), 127.8 (CH), 128.1 (2 × CH), 128.2 (2 × CH), 128.3 (CH), 128.6 (2 × CH), 132.6 
(C), 135.9 (C), 138.1 (2 × C), 146.7 (C), 150.2 (C), 155.7 (C), 169.4 (C); m/z (ESI) 496.1937 (MNa+. 
C26H27N5NaO4 requires 496.1955). 
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Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-morpholinophenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161i) 
 
 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-morpholinophenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161i) was synthesised as described for methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(5ʹ-phenyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (161a) using 
methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (159c) (0.0810 g, 0.187 mmol), 4-morpholinophenylboronic acid (0.116 g, 0.561 
mmol), [1,1ʹ-bis(diphenylphosphino)ferrocene]palladium(II) dichloride-dichloromethane complex 
(0.0115 g, 0.0140 mmol) and potassium fluoride (0.0326 g, 0.561 mmol) in dioxane (3.6 mL) and 
water (0.4 mL). Purification with flash chromatography using silica gel, eluting with 20% diethyl 
ether in dichloromethane gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-
morpholinophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161i) as a white solid (0.0578 g, 
60%). Mp 159–160 °C; νmax/cm−1 (neat) 3302 (NH), 2953 (CH), 1717 (C=O), 1522, 1485, 1227, 1117, 
926, 729; [α]D
20 +5.3 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.23 (4H, t, J 4.5 Hz, 2ʹʹʹ-H2 and 6ʹʹʹ-H2), 3.76 
(3H, s, OCH3), 3.90 (4H, t, J 4.5 Hz, 3ʹʹʹ-H2 and 5ʹʹʹ-H2), 4.88 (1H, dt, J 7.1, 4.3 Hz, 2-H), 5.04–5.24 
(4H, m, 3-H2 and OCH2Ph), 5.76 (1H, d, J 7.1 Hz, NH), 7.04 (2H, d, J 8.5 Hz, 3ʹʹ-H and 5ʹʹ-H), 7.29–
7.39 (5H, m, Ph), 7.43 (1H, d, J 8.7 Hz, 7ʹ-H), 7.55 (2H, d, J 8.5 Hz, 2ʹʹ-H and 6ʹʹ-H), 7.59 (1H, dd, J 
8.7, 1.4 Hz, 6ʹ-H), 8.13 (1H, br s, 4ʹ-H); δC (101 MHz, CDCl3) 48.6 (CH2), 49.3 (2 × CH2), 53.2 (CH3), 
54.3 (CH), 66.7 (2 × CH2), 67.3 (CH2), 109.2 (CH), 116.1 (2 × CH), 116.9 (CH), 127.7 (CH), 128.2 (2 × 
CH), 128.3 (3 × CH), 128.6 (2 × CH), 132.0 (C), 132.9 (C), 135.9 (C), 137.5 (C), 146.6 (C), 150.5 (C), 
155.7 (C), 169.4 (C); m/z (ESI) 538.2039 (MNa+. C28H29N5NaO5 requires 538.2061). 
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Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(2ʹʹ-nitrophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl]propanoate (161j) 
 
 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(2ʹʹ-nitrophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl]propanoate (161j) was synthesised as described for methyl (2S)-2-[(benzyloxycarbonyl)amino]-
3-(5ʹ-phenyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (161a) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (159c) 
(0.601 g, 1.39 mmol), 2-nitrophenylboronic acid (0.463 g, 2.78 mmol), [1,1ʹ-
bis(diphenylphosphino)ferrocene]palladium(II) dichloride-dichloromethane complex (0.170 g, 
0.209 mmol) and potassium fluoride (0.242 g, 4.17 mmol) in dioxane (9 mL) and water (1 mL). 
Purification with flash chromatography using silica gel, eluting with 5% diethyl ether in 
dichloromethane gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-nitrophenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161j) after recrystallisation from diethyl ether as a white 
solid (0.614 g, 93%). Mp 90–92 °C; νmax/cm−1 (neat) 3348 (NH), 2950 (CH), 1720 (C=O), 1528, 1350, 
1219, 1057, 741; [α]D
20 +9.9 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.77 (3H, s, OCH3), 4.90 (1H, dt, J 
6.9, 4.2 Hz, 2-H), 5.04–5.26 (4H, m, 3-H2 and OCH2Ph), 5.65 (1H, d, J 6.9 Hz, NH), 7.29 (1H, dd, J 8.6, 
1.4 Hz, 6ʹ-H), 7.30–7.40 (5H, m, Ph), 7.44 (1H, d, J 8.6 Hz, 7ʹ-H), 7.48 (1H, dd, J 7.5, 1.3 Hz, 6ʹʹ-H), 
7.56 (1H, ddd, J 8.0, 7.5, 1.3 Hz, 4ʹʹ-H), 7.68 (1H, ddd, J 8.0, 7.5, 1.1 Hz, 5ʹʹ-H), 7.96 (1H, dd, J 8.0, 
1.1 Hz, 3ʹʹ-H), 8.01 (1H, br s, 4ʹ-H); δC (101 MHz, CDCl3) 48.7 (CH2), 53.3 (CH3), 54.3 (CH), 67.4 (CH2), 
109.3 (CH), 119.3 (CH), 124.5 (CH), 128.3 (2 × CH), 128.4 (2 × CH), 128.6 (2 × CH), 128.7 (CH), 132.4 
(CH), 132.7 (CH), 133.5 (C), 134.0 (C), 135.7 (C), 135.9 (C), 145.9 (C), 149.2 (C), 155.7 (C), 169.3 (C); 
m/z (ESI) 498.1375 (MNa+. C24H21N5NaO6 requires 498.1384). 
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Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-nitrophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl]propanoate (161k) 
 
 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-nitrophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl]propanoate (161k) was synthesised as described for methyl (2S)-2-[(benzyloxycarbonyl)amino]-
3-(5ʹ-phenyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (161a) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (159c) 
(0.105 g, 0.241 mmol), 4-nitrophenylboronic acid (0.0806 g, 0.483 mmol), [1,1ʹ-
bis(diphenylphosphino)ferrocene]palladium(II) dichloride-dichloromethane complex (0.0148 g, 
0.0181 mmol), potassium fluoride (0.0420 g, 0.723 mmol) in dioxane (3.6 mL) and water (0.4 mL). 
Purification with flash chromatography using silica gel, eluting with 5% diethyl ether in 
dichloromethane gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-nitrophenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161k) as a white solid (0.0805 g, 70%). Mp 178–180 °C; 
νmax/cm−1 (neat) 1983, 1721 (C=O), 1512, 1342, 1219, 748; [α]D
20 −46.3 (c 1.0, CHCl3); δH (400 MHz, 
CDCl3) 3.81 (3H, s, OCH3), 4.90 (1H, dt, J 6.8, 4.2 Hz, 2-H), 5.02–5.30 (4H, m, 3-H2 and OCH2Ph), 5.60 
(1H, d, J 6.8 Hz, NH), 7.30–7.42 (5H, m, Ph), 7.52 (1H, br d, J 8.7 Hz, 7ʹ-H), 7.60 (1H, dd, J 8.7, 1.3 
Hz, 6ʹ-H), 7.77 (2H, d, J 8.9 Hz, 2ʹʹ-H and 6ʹʹ-H), 8.27 (1H, dd, J 1.3, 0.8 Hz, 4ʹ-H), 8.35 (2H, d, J 8.9 
Hz, 3ʹʹ-H and 5ʹʹ-H); δC (101 MHz, CDCl3) 48.7 (CH2), 53.4 (CH3), 54.3 (CH), 67.3 (CH2), 110.0 (CH), 
118.9 (CH), 124.3 (2 × CH), 127.7 (CH), 128.2 (2 × CH), 128.3 (2 × CH), 128.4 (CH), 128.6 (2 × CH), 
134.0 (C), 135.4 (C), 135.9 (C), 146.3 (C), 146.8 (C), 147.3 (C), 155.6 (C), 169.2 (C); m/z (ESI) 
498.1365 (MNa+. C24H21N5NaO6 requires 498.1384). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(2ʹʹ-aminophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl]propanoate (176) 
 
 
To a solution of methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-nitrophenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (161j) (0.604 g, 1.27 mmol) in methanol (20 mL) was 
added tin(II) dichloride dihydrate (1.15 g, 5.08 mmol). The resulting reaction mixture was heated 
under reflux under an atmosphere of argon for 20 h. The solvent was then removed in vacuo and 
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the resulting residue was dissolved in ethyl acetate (50 mL). A saturated aqueous solution of 
sodium hydrogen carbonate (50 mL) was added and the biphasic mixture was filtered through 
Celite®. The organic phase was separated and the aqueous layer was washed with ethyl acetate (2 
× 50 mL). The combined organic layers were combined, washed with water (50 mL), brine (50 mL), 
dried (MgSO4) and concentrated in vacuo to give the crude product. Purification by flash 
chromatography using silica gel, eluting with 15% diethyl ether in dichloromethane gave methyl 
(2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-(2ʹʹ-aminophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (176) as a pale yellow solid (0.390 g, 69%). Mp 48–50 °C; νmax/cm−1 (neat) 3364 (NH), 
2955 (CH), 1713 (C=O), 1616, 1504, 1483, 1211, 1055, 1018, 745; [α]D
20 +17.3 (c 1.0, CHCl3); δH (400 
MHz, CDCl3) 3.73 (2H, br s, NH2), 3.79 (3H, s, OCH3), 4.90 (1H, dt, J 7.1, 4.2, 2-H), 5.04–5.27 (4H, m, 
3-H2 and OCH2Ph), 5.68 (1H, d, J 7.1 Hz, NH), 6.80 (1H, dd, J 8.0, 1.0 Hz, 3ʹʹ-H), 6.86 (1H, td, J 7.5, 
1.0 Hz, 5ʹʹ-H), 7.14 (1H, dd, J 7.5, 1.6 Hz, 6ʹʹ-H), 7.20 (1H, ddd, J 8.0, 7.5, 1.6 Hz, 4ʹʹ-H), 7.27–7.42 
(5H, m, Ph), 7.48 (1H, d, J 8.6 Hz, 7ʹ-H), 7.52 (1H, dd, J 8.6, 1.2 Hz, 6ʹ-H), 8.10 (1H, br s, 4ʹ-H); δC 
(101 MHz, CDCl3) 48.6 (CH2), 53.3 (CH3), 54.3 (CH), 67.3 (CH2), 109.4 (CH), 115.8 (CH), 118.8 (CH), 
120.0 (CH), 126.5 (C), 128.2 (2 × CH), 128.4 (CH), 128.6 (2 × CH), 128.9 (CH), 129.8 (CH), 130.8 (CH), 
133.1 (C), 135.9 (2 × C), 143.7 (C), 146.3 (C), 155.7 (C), 169.3 (C); m/z (ESI) 468.1636 (MNa+. 
C24H23N5NaO4 requires 468.1642). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-{5ʹ-[2ʹʹ-(4ʹʹʹ-methylphenylsulfonylamino)phenyl]-
1H-benzo[d][1.2.3]triazol-1ʹ-yl}propanoate (177) 
 
 
 
To a solution of methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(2ʹʹ-aminophenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (176) (0.347 g, 0.769 mmol) in acetonitrile (10 mL) was 
added pyridine (0.186 mL, 2.31 mmol) and 4-toluenesulfonyl chloride (0.440 g, 2.31 mmol). The 
reaction mixture was stirred at room temperature for 1 h and then concentrated in vacuo. The 
resulting residue was dissolved in ethyl acetate (50 mL), washed with 1 M aqueous hydrochloric 
acid (50 mL), water (50 mL), brine (50 mL), dried (MgSO4) and concentrated in vacuo to give the 
crude product. Purification by flash chromatography using silica gel, eluting with 15% diethyl ether 
in dichloromethane gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-{5ʹ-[2ʹʹ-(4ʹʹʹ-
methylphenylsulfonylamino)phenyl]-1H-benzo[d][1.2.3]triazol-1ʹ-yl}propanoate (177) as a white 
solid (0.417 g, 91%). Mp 72–74 °C; νmax/cm−1 (neat) 3347 (NH), 2953 (CH), 1717 (C=O), 1506, 1335 
1213, 1159, 1092, 754; [α]D
15 +5.8 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.40 (3H, s, CH3), 3.82 (3H, s, 
165 
 
OCH3), 4.90 (1H, dt, J 6.9, 4.3 Hz, 2-H), 5.07–5.25 (4H, m, 3-H2 and OCH2Ph), 5.68 (1H, d, J 6.9 Hz, 
NH), 6.49 (1H, s, NH), 7.00 (1H, dd, J 8.5, 0.9 Hz, 3ʹʹ-H), 7.09–7.17 (3H, m, 3 × ArH), 7.20 (1H, td, J 
7.5, 1.1 Hz, 4ʹʹ-H), 7.28–7.47 (10H, m, 5 × ArH and Ph), 7.69 (1H, d, J 8.0 Hz, 7ʹ-H); δC (101 MHz, 
CDCl3) 21.6 (CH3), 48.7 (CH2), 53.3 (CH3), 54.3 (CH), 67.4 (CH2), 109.8 (CH), 120.4 (CH), 122.3 (CH), 
125.3 (CH), 127.0 (2 × CH), 128.4 (3 × CH), 128.6 (2 × CH), 128.9 (CH), 129.1 (CH), 129.7 (2 × CH), 
130.7 (CH), 133.3 (C), 133.4 (C), 133.5 (C), 133.9 (C), 135.9 (C), 136.1 (C), 144.2 (C), 145.9 (C), 155.7 
(C), 169.3 (C); m/z (ESI) 622.1714 (MNa+. C31H29N5NaO6S requires 622.1731). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4ʹ-(4ʹʹ-toluenesulfonyl)-[1,2,3]triazolo[2,3-
c]carbazol-1(4ʹH)-yl]propanoate (178) 
 
 
 
To a solution of methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-{5ʹ-[2ʹʹ-(4ʹʹʹ-
methylphenylsulfonylamino)phenyl]-1H-benzo[d][1.2.3]triazol-1ʹ-yl}propanoate (177) (0.0450 g, 
0.0750 mmol) in anhydrous dichloroethane (1 mL) at 50 °C was added copper(II) 
trifluoromethanesulfonate (0.00136 g, 0.00375 mmol). To the reaction mixture was added 
(diacetoxyiodo)benzene (0.0364 g, 0.113 mmol) in dichloroethane (1 mL) over 0.1 h. The reaction 
mixture was stirred at 50 °C for 0.15 h before being filtered through Celite®, washed with ethyl 
acetate (20 mL) and concentrated in vacuo to give the crude product. Purification by flash 
chromatography with silica gel, eluting with 5% diethyl ether in dichloromethane gave methyl 
(2S)-2-[(benzyloxycarbonyl)amino]-3-[4ʹ-(4ʹʹ-toluenesulfonyl)-[1,2,3]triazolo[2,3-c]carbazol-
1(4ʹH)-yl]propanoate (178) as a white solid (0.0364 g, 81%). Mp 163–165 °C; νmax/cm−1 (neat) 3368 
(NH), 2954 (CH), 1721 (C=O), 1511, 1379, 1236, 1211, 1190, 1052, 971, 778, 738; [α]D
20 +4.3 (c 1.0, 
CHCl3); δH (400 MHz, CDCl3) 2.26 (3H, s, CH3), 3.77 (3H, s, OCH3), 4.92 (1H, dt, J 7.1, 4.3 Hz, 2-H), 
5.00–5.27 (4H, m, 3-H2 and OCH2Ph), 5.71 (1H, d, J 7.1 Hz, NH), 7.14 (2H, d, J 8.3 Hz, 3ʹʹʹ-H and 5ʹʹʹ-
H), 7.27–7.35 (5H, m, Ph), 7.37 (1H, d, J 8.6 Hz, 10ʹ-H), 7.41–7.48 (1H, m, 7ʹ-H), 7.56 (1H, ddd, J 8.5, 
7.4, 1.2 Hz, 6ʹ-H), 7.88 (1H, d, J 8.6 Hz, 9ʹ-H), 7.95 (1H, d, J 7.4 Hz, 5ʹ-H), 8.16 (2H, d, J 8.3 Hz, 2ʹʹ-H 
and 6ʹʹ-H), 8.57 (1H, br d, J 8.5 Hz, 8ʹ-H); δC (101 MHz, CDCl3) 21.6 (CH3), 48.6 (CH2), 53.3 (CH3), 
54.1 (CH), 67.2 (CH2), 105.1 (CH), 115.4 (CH), 119.2 (CH), 120.3 (CH), 121.6 (C), 123.8 (CH), 125.6 
(C), 126.9 (CH), 127.4 (C), 127.8 (2 × CH), 128.2 (2 × CH), 128.3 (CH), 128.6 (2 × CH), 129.6 (2 × CH), 
134.8 (C), 135.0 (C), 135.7 (C), 135.9 (C), 138.4 (C), 144.9 (C), 155.7 (C), 169.2 (C); m/z (ESI) 
620.1560 (MNa+. C31H27N5NaO6S requires 620.1574).  
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Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-([1,2,3]triazolo[2,3-c]carbazol-1(4ʹH)-
yl)propanoate (181) 
 
 
 
To a solution of methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4ʹ-(4ʹʹ-toluenesulfonyl)-
[1,2,3]triazolo[2,3-c]carbazol-1(4ʹH)-yl]propanoate (178) (0.0359 g, 0.0699 mmol), in anhydrous 
methanol (3 mL) and tetrahydrofuran (1 mL) was added magnesium (0.0168 g, 0.691 mmol). The 
reaction mixture was sonicated for 0.5 h, diluted with dichloromethane (50 mL), washed with 1 M 
aqueous hydrochloric acid (50 mL), aqueous saturated sodium hydrogen carbonate solution (50 
mL) and brine (50 mL), dried (MgSO4) and concentrated in vacuo to give the crude product. 
Purification by flash chromatography using silica gel, eluting with 20% diethyl ether in 
dichloromethane, then recrystallisation from chloroform gave methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-([1,2,3]triazolo[2,3-c]carbazol-1(4ʹH)-yl)propanoate (181) as a 
white solid (0.0133 g, 50%). Mp 196–198 °C, νmax/cm−1 (neat) 3350 (NH), 3173 (CH), 1744 (C=O), 
1690 (C=O), 1533, 1250, 1219, 1117, 1067, 1005, 741; [α]D
20 +6.8 (c 0.1, DMSO); δH (500 MHz, 
DMSO-d6) 3.69 (3H, s, OCH3), 4.78 (1H, ddd, J 9.2, 8.7, 5.0 Hz, 2-H), 4.90 (1H, d, J 12.7 Hz, OCHHPh), 
4.94 (1H, d, J 12.7 Hz, OCHHPh), 5.08 (1H, dd, J 14.4, 9.2 Hz, 3-HH), 5.18 (1H, dd, J 14.4, 5.0 Hz, 3-
HH), 7.10–7.30 (6H, m, 7ʹ-H and Ph), 7.41 (1H, t, J 7.8 Hz, 6ʹ-H), 7.52 (1H, d, J 8.7 Hz, 10ʹ-H), 7.61 
(1H, d, J 7.8 Hz, 5ʹ-H), 7.98 (1H, d, J 8.7 Hz, NH), 8.19 (1H, d, J 7.8 Hz, 8ʹ-H), 8.26 (1H, d, J 8.7 Hz, 9ʹ-
H), 12.5 (1H, s, NH); δC (126 MHz, DMSO-d6) 48.3 (CH2), 52.9 (CH3), 54.3 (CH), 66.0 (CH2), 101.4 
(CH), 112.2 (CH), 117.5 (C), 120.0 (CH). 120.1 (CH), 121.5 (CH), 123.6 (C), 124.9 (CH), 127.9 (2 × 
CH), 128.2 (CH), 128.7 (2 × CH), 129.3 (C), 133.9 (C), 134.0 (C), 137.1 (C), 139.2 (C), 156.2 (C), 170.3 
(C); m/z (ESI) 466.1484 (MNa+. C24H21N5NaO4 requires 466.1486).  
 
(2S)-2-Amino-3-(5ʹ-phenyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid hydrochloride (163a) 
 
 
 
To a solution of methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-phenyl-1H-benzo[d][1.2.3]triazol-
1ʹ-yl)propanoate (159a) (0.0438 g, 0.102 mmol) in a mixture of methanol (4 mL) and 1,4-dioxane 
(2 mL) was added a solution of caesium carbonate (0.0430 g, 0.132 mmol) in water (2 mL). The 
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reaction mixture was stirred at room temperature for 20 h and then concentrated in vacuo. The 
resulting residue was dissolved in water (100 mL) and acidified to pH 1 with 1 M aqueous 
hydrochloric acid. The aqueous layer was extracted with dichloromethane (3 × 30 mL) and the 
combined organic layers were washed with 1 M aqueous hydrochloric acid (50 mL), dried (MgSO4) 
and concentrated in vacuo to give (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-phenyl-1H-
benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid (162a) as a white solid (0.0227 g, 58%). This was used 
for the next reaction without any further purification. To a solution of (2S)-2-
[(benzyloxycarbonyl)amino]-3-(5ʹ-phenyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid (162a)  
(0.0355 g, 0.0852 mmol) in tetrahydrofuran (5 mL) was added 10% palladium on carbon (0.0181 g, 
0.0170 mmol). The solution was purged with hydrogen for 1 h and stirred under an atmosphere of 
hydrogen for 5 h. After addition of 1 M aqueous hydrochloric acid (0.200 mL), the reaction mixture 
was filtered through Celite® with tetrahydrofuran and concentrated in vacuo to give the crude 
product. Purification by recrystallisation from methanol and diethyl ether gave (2S)-2-amino-3-(5ʹ-
phenyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid hydrochloride (163a) as a yellow solid 
(0.0225 g, 83%). Mp 176–178 °C; νmax/cm−1 (neat) 3695 (NH/OH), 2932 (CH), 2068, 1682 (C=O), 
1296, 980; [α]D
20 +1.2 (c 0.5, DMSO); δH (400 MHz, CD3OD) 4.79 (1H, dd, J 5.7, 4.1 Hz, 2-H), 5.28 
(1H, dd, J 15.5, 4.1 Hz, 3-HH), 5.38 (1H, dd, J 15.5, 5.7 Hz, 3-HH), 7.40 (1H, t, J 7.5 Hz, 4ʹʹ-H), 7.49 
(2H, t, J 7.5 Hz, 3ʹʹ-H and 5ʹʹ-H), 7.70 (2H, d, J 7.5 Hz, 2ʹʹ-H and 6ʹʹ-H), 7.89 (1H, d, J 8.7 Hz, 7ʹ-H), 
7.93 (1H, dd, J 8.7, 0.9 Hz, 6ʹ-H), 8.23 (1H, br s, 4ʹ-H); δC (101 MHz, CD3OD) 46.8 (CH2), 52.2 (CH), 
110.0 (CH), 116.5 (CH), 127.1 (2 × CH), 127.5 (CH), 128.2 (CH), 128.8 (2 × CH), 132.9 (C), 138.7 (C), 
140.1 (C), 146.3 (C), 167.6 (C); m/z (ESI) 283.1191 (MH+. C15H15N4O2 requires 283.1190). 
 
(2S)-2-Amino-3-[5ʹ-(naphthalen-2ʹʹ-yl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (163b) 
 
 
 
(2S)-2-[(Benzyloxycarbonyl)amino]-3-(5ʹ-(naphthalen-2ʹʹ-yl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)proponic acid (162b) was synthesised as described for (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-
phenyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid (162a) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[5ʹ-(naphthalen-2ʹʹ-yl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoate 
(161b) (0.103 g, 0.213 mmol) and caesium carbonate (0.0904 g, 0.277 mmol). This gave (2S)-2-
[(benzyloxycarbonyl)amino]-3-(5ʹ-(naphthalen-2ʹʹ-yl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl)proponic 
acid (162b)  as a white solid (0.0994 g, 100%). This was used for the next reaction without any 
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further purification. To a solution of (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-(naphthalen-2ʹʹ-yl)-
1H-benzo[d][1.2.3]triazol-1ʹ-yl)proponic acid (162b)  (0.0994 g, 0.213 mmol) in 1,4-dioxane (1 mL) 
was added 6 M aqueous hydrochloric acid (5 mL). The reaction mixture was heated under reflux 
for 1 h, then concentrated in vacuo to give the crude product. Purification by recrystallisation from 
methanol and diethyl ether gave (2S)-2-amino-3-[5ʹ-(naphthalen-2ʹʹ-yl)-1H-benzo[d][1.2.3]triazol-
1ʹ-yl]propanoic acid hydrochloride (163b) as a white solid (0.0994 g, 78%). Mp 224–226 °C; 
νmax/cm−1 (neat) 2833 (CH), 1734 (C=O), 1568, 1510, 1441, 1400, 1238, 1143, 774; [α]D
20 +8.1 (c 0.5, 
DMSO); δH (400 MHz, CD3OD) 4.74 (1H, dd, J 5.8, 4.0 Hz, 2-H), 5.33 (1H, dd, J 15.4, 4.0 Hz, 3-HH), 
5.42 (1H, dd, J 15.4, 5.8 Hz, 3-HH), 7.38–7.66 (4H, m, 4 × ArH), 7.73 (1H, dd, J 8.7, 1.2 Hz, 6ʹ-H), 
7.76 (1H, d, J 8.5 Hz, ArH), 7.89–8.05 (3H, m, 3 × ArH), 8.09 (1H, br s, 4ʹ-H); δC (101 MHz, CD3OD) 
47.9 (CH2), 52.7 (CH), 109.7 (CH), 119.5 (CH), 125.0 (CH), 125.1 (CH), 125.7 (CH), 126.0 (CH), 127.1 
(CH), 127.9 (CH), 128.2 (CH), 130.7 (CH), 131.5 (C), 132.9 (C), 134.0 (C), 137.9 (C), 138.9 (C), 145.8 
(C), 168.1 (C); m/z (ESI) 355.1155 (MNa+. C19H16N4NaO2 requires 355.1165). 
 
(2S)-2-Amino-3-[5ʹ-(thiophen-3ʹʹ-yl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (163d) 
 
 
 
(2S)-2-Amino-3-[5ʹ-(thiophen-3ʹʹ-yl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride 
(163d) was synthesised as described for (2S)-2-amino-3-[5ʹ-(naphthalen-2ʹʹ-yl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163b) using (2S)-2-
[(benzyloxycarbonyl)amino]-3-[5ʹ-(thiophen-3ʹʹ-yl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoate 
(161d) (0.0810 g, 0.186 mmol) and caesium carbonate (0.0785 g, 0.241 mmol). Purification by 
recrystallisation from methanol and diethyl ether gave (2S)-2-amino-3-[5ʹ-(thiophen-3-yl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163d) as a white solid (0.0453 g, 75%). 
Mp 174–176 °C; νmax/cm−1 (neat) 2884 (OH), 1740 (C=O), 1587, 1233, 1207, 775, 590; [α]D
20 +2.5 (c 
0.5, DMSO); δH (400 MHz, CD3OD) 4.81 (1H, dd, J 5.7, 4.1 Hz, 2-H), 5.27 (1H, dd, J 15.5, 4.1 Hz, 3-
HH), 5.37 (1H, dd, J 15.5, 5.7 Hz, 3-HH), 7.54 (1H, dd, J 5.0, 2.8 Hz, 5ʹʹ-H), 7.56 (1H, dd, J 5.0, 1.5 Hz, 
4ʹʹ-H), 7.76 (1H, dd, J 2.8, 1.5 Hz, 2ʹʹ-H), 7.85 (1H, d, J 8.8 Hz, 7ʹ-H), 7.98 (1H, dd, J 8.8, 1.4 Hz, 6ʹ-H), 
8.26 (1H, br s, 4ʹ-H); δC (101 MHz, CD3OD) 46.7 (CH2), 52.2 (CH), 110.1 (CH), 115.4 (CH), 121.0 (CH), 
125.9 (CH), 126.5 (CH), 127.6 (CH), 132.7 (C), 133.3 (C), 141.0 (C), 146.2 (C), 167.5 (C); m/z (ESI) 
289.0750 (MH+. C13H13N4O2S requires 289.0754). 
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(2S)-2-Amino-3-[5ʹ-(4ʹʹ-hydroxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (163e) 
 
 
 
(2S)-2-Amino-3-[5ʹ-(4ʹʹ-hydroxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (163e) was synthesised as described for (2S)-2-amino-3-[5ʹ-(naphthalen-2ʹʹ-yl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163b) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-hydroxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoate 
(161e) (0.0803 g, 0.180 mmol) and caesium carbonate (0.0762 g, 0.234 mmol). Purification by 
recrystallisation from methanol and diethyl ether gave (2S)-2-amino-3-[5ʹ-(4ʹʹ-hydroxyphenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163e) as a white solid (0.0392 g, 65%). 
Mp 188–190 °C; νmax/cm−1 (neat) 3335 (NH/OH), 3007 (CH), 1728 (C=O), 1609, 1483, 1267, 1236, 
816; [α]D
20 +5.8 (c 0.5, MeOH); δH (400 MHz, CD3OD) 4.82 (1H, dd, J 5.6, 4.2 Hz, 2-H), 5.28 (1H, dd, 
J 15.4, 4.2 Hz, 3-HH), 5.38 (1H, dd, J 15.4, 5.6 Hz, 3-HH), 6.91 (2H, d, J 8.7 Hz, 3ʹʹ-H and 5ʹʹ-H), 7.54 
(2H, d, J 8.7 Hz, 2ʹʹ-H and 6ʹʹ-H), 7.86 (2H, m,6ʹ-H and 7ʹ-H), 8.11 (1H, br s, 4ʹ-H); δC (101 MHz, 
CD3OD) 46.8 (CH2), 52.2 (CH), 109.9 (CH), 115.3 (CH), 155.5 (2 × CH), 128.0 (CH), 128.2 (2 × CH), 
131.2 (C), 132.5 (C), 138.8 (C), 146.1 (C), 157.3 (C), 167.5 (C); m/z (ESI) 299.1134 (MH+. C15H15N4O3 
requires 299.1139). 
 
(2S)-2-Amino-3-[5ʹ-(4ʹʹ-methoxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (163f) 
 
 
 
(2S)-2-Amino-3-[5ʹ-(4ʹʹ-methoxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (163f) was synthesised as described for (2S)-2-amino-3-[5ʹ-(naphthalen-2ʹʹ-yl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163b) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-methoxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl]propanoate (161f) (0.155 g, 0.336 mmol) and caesium carbonate (0.142 g, 0.436 mmol). 
Purification by recrystallisation from methanol and diethyl ether gave (2S)-2-amino-3-[5ʹ-(4ʹʹ-
methoxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163f) as a white 
170 
 
solid (0.0906 g, 77%). Mp 214–216 °C; νmax/cm−1 (neat) 2832 (OH), 1744 (C=O), 1612, 1489, 1250, 
810; [α]D
20 +6.5 (c 0.5, MeOH); δH (400 MHz, CD3OD) 3.85 (3H, s, OCH3), 4.79 (1H, dd, J 5.7, 4.1 Hz, 
2-H), 5.27 (1H, dd, J 15.5, 4.1 Hz, 3-HH), 5.37 (1H, dd, J 15.5, 5.7 Hz, 3-HH), 7.04 (2H, d, J 8.8 Hz, 
3ʹʹ-H and 5ʹʹ-H), 7.63 (2H, d, J 8.8 Hz, 2ʹʹ-H and 6ʹʹ-H), 7.81–7.92 (2H, m, 6ʹ-H and 7ʹ-H), 8.15 (1H, 
br s, 4ʹ-H); δC (101 MHz, CD3OD) 46.8 (CH2), 52.2 (CH), 54.4 (CH3), 110.0 (CH), 114.1 (2 × CH), 115.6 
(CH), 128.0 (CH), 128.1 (2 × CH), 132.4 (C), 132.6 (C), 138.4 (C), 146.3 (C), 159.8 (C), 167.6 (C); m/z 
(ESI) 313.1290 (MH+. C16H17N4O3 requires 313.1295). 
 
(2S)-2-Amino-3-[5ʹ-(3ʹʹ,4ʹʹ-methylenedioxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic 
acid hydrochloride (163g) 
 
 
 
(2S)-2-Amino-3-[5ʹ-(3ʹʹ,4ʹʹ-methylenedioxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (163g) was synthesised as described for (2S)-2-amino-3-[5ʹ-(naphthalen-2ʹʹ-yl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163b) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[5ʹ-(3ʹʹ,4ʹʹ-methylenedioxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl]propanoate (161g) (0.0898 g, 0.189 mmol) and caesium carbonate (0.0801 g, 0.246 mmol). 
Purification by recrystallisation from methanol and diethyl ether gave (2S)-2-amino-3-[5ʹ-(3ʹʹ,4ʹʹ-
methylenedioxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163g) as a 
white solid (0.0610 g, 89%). Mp 203–205 °C; νmax/cm−1 (neat) 2886 (OH), 1724 (C=O), 1479, 1248, 
1227, 1038, 800; [α]D
20 +1.6 (c 1.0, DMSO); δH (400 MHz, CD3OD) 4.80 (1H, dd, J 5.7, 4.1 Hz, 2-H), 
5.27 (1H, dd, J 15.5, 4.1 Hz, 3-HH), 5.37 (1H, dd, J 15.5, 5.7 Hz, 3-HH), 6.01 (2H, s, OCH2O), 6.94 
(1H, d, J 7.8, 0.5 Hz, 5ʹʹ-H), 7.14–7.26 (2H, m, 2ʹʹ-H and 6ʹʹ-H), 7.81–7.95 (2H, m, 6ʹ-H and 7ʹ-H), 
8.14 (1H, br s, 4ʹ-H); δC (101 MHz, CD3OD)  46.7 (CH2), 52.2 (CH), 101.3 (CH2), 107.3 (CH), 108.3 
(CH), 109.9 (CH), 116.0 (CH), 120.8 (CH), 128.1 (CH), 132.7 (C), 134.3 (C), 138.5 (C), 146.2 (C), 147.7 
(C), 148.5 (C), 167.5 (C); m/z (ESI) 327.1074 (MH+. C16H15N4O4 requires 327.1088). 
 
(2S)-2-Amino-3-[5ʹ-(4ʹʹ-dimethylaminophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (163h) 
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(2S)-2-Amino-3-[5ʹ-(4ʹʹ-dimethylaminophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (163h) was synthesised as described for (2S)-2-amino-3-[5ʹ-(naphthalen-2ʹʹ-yl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163b) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-dimethylaminophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl]propanoate (161h) (0.0368 g, 0.0777 mmol) and caesium carbonate (0.0329 g, 0.101 mmol).  
Purification by recrystallisation from methanol and diethyl ether gave (2S)-2-amino-3-[5ʹ-(4ʹʹ-
dimethylaminophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163h) as a 
white solid (0.0132 g, 47%). Mp 166–168 °C; νmax/cm−1 (neat) 3393 (NH), 2851 (OH), 1732 (C=O), 
1485, 1234, 808; [α]D
20 +1.6 (c 0.5, MeOH); δH (400 MHz, CD3OD) 3.37 (6H, s, 2 × CH3), 4.84 (1H, dd, 
J 5.4, 4.3 Hz, 2-H), 5.32 (1H, dd, J 15.5, 4.3 Hz, 3-HH), 5.42 (1H, dd, J 15.5, 5.4 Hz, 3-HH), 7.86 (2H, 
d, J 8.7 Hz, 3ʹʹ-H and 5ʹʹ-H), 7.92–8.09 (4H, m, 6ʹ-H, 7ʹ-H, 2ʹʹ-H and 6ʹʹ-H), 8.31 (1H, br s, 4ʹ-H); δC 
(101 MHz, CD3OD) 46.0 (2 × CH3), 46.8 (CH2), 52.2 (CH), 110.7 (CH), 117.3 (CH), 121.1 (2 × CH), 
127.9 (CH), 129.2 (2 × CH), 133.5 (C), 136.3 (C), 142.0 (C), 142.4 (C), 146.1 (C), 167.5 (C); m/z (ESI) 
326.1612 (MH+. C17H20N5O2 requires 362.1612). 
 
(2S)-2-Amino-3-[5ʹ-(4ʹʹ-morpholinophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (163i) 
 
 
 
(2S)-2-Amino-3-[5ʹ-(4ʹʹ-morpholinophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (163i) was synthesised as described for (2S)-2-amino-3-[5ʹ-(naphthalen-2ʹʹ-yl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163b) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-morpholinophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl]propanoate (161i) (0.116 g, 0.224 mmol) and caesium carbonate (0.0948 g, 0.291 mmol). 
Purification by recrystallisation from methanol and diethyl ether gave (2S)-2-amino-3-[5ʹ-(4ʹʹ-
morpholinophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163i) as a white 
solid (0.0957 g, 97%). Mp 172–174 °C; νmax/cm−1 (neat) 3366 (NH), 2866 (OH), 1738 (C=O), 1487, 
1121, 1059, 889, 806; [α]D
20 +3.5 (c 1.0, MeOH); δH (400 MHz, CD3OD) 3.79 (4H, t, J 4.6 Hz, 2ʹʹʹ-H 
and 6ʹʹʹ-H), 4.17 (4H, t, J 4.6 Hz, 3ʹʹʹ-H and 5ʹʹʹ-H), 4.83 (1H, dd, J 5.6, 4.2 Hz, 2-H), 5.31 (1H, dd, J 
15.5, 4.2 Hz, 3-HH), 5.41 (1H, dd, J 15.5, 5.6, 3-HH), 7.89 (2H, d, J 8.8 Hz, 3ʹʹ-H and 5ʹʹ-H), 7.93–8.01 
(4H, m, 6ʹ-H, 7ʹ-H, 2ʹʹ-H and 6ʹʹ-H), 8.31 (1H, br s, 4ʹ-H); δC (101 MHz, CD3OD) 46.8 (CH2), 52.1 (CH), 
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54.9 (2 × CH2), 64.1 (2 × CH2), 110.6 (CH), 117.2 (CH), 121.5 (2 × CH), 127.9 (CH), 129.1 (2 × CH), 
133.4 (C), 136.3 (C), 141.3 (C), 141.9 (C), 146.2 (C), 167.5 (C); m/z (ESI) 368.1708 (MH+. C19H22N5O3 
requires 368.1717). 
 
(2S)-2-Amino-3-[5ʹ-(2ʹʹ-nitrophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (163j) 
 
 
 
(2S)-2-Amino-3-[5ʹ-(2ʹʹ-nitrophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride 
(163j) was synthesised as described for (2S)-2-amino-3-[5ʹ-(naphthalen-2ʹʹ-yl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163b) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[5ʹ-(2ʹʹ-nitrophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoate 
(161j) (0.0577 g, 0.121 mmol) and caesium carbonate (0.0513 g, 0.157 mmol). Purification by 
recrystallisation from methanol and diethyl ether gave (2S)-2-amino-3-[5ʹ-(2ʹʹ-nitrophenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163j) as a white solid (0.0244 g, 56%). 
Mp 186–187 °C; νmax/cm−1 (neat) 2862 (OH), 1744 (C=O), 1524, 1350, 1236; [α]D
20  +0.4 (c 0.5, 
MeOH); δH (400 MHz, CD3OD) 4.82 (1H, dd, J 5.9, 4.0 Hz, 2-H), 5.30 (1H, dd, J 15.5, 4.0 Hz, 3-HH), 
5.39 (1H, dd, J 15.5, 5.9 Hz, 3-HH), 7.57 (1H, dd, J 8.7, 1.5 Hz, 6ʹ-H), 7.59 (1H, dd, J 7.8, 1.2 Hz, 6ʹʹ-
H), 7.65 (1H, ddd, J 8.1, 7.8 Hz, 1.2 Hz, 4ʹʹ-H), 7.77 (1H, td, J 7.8, 1.3 Hz, 5ʹʹ-H), 7.89 (1H, dd, J 8.7, 
0.7 Hz, 7ʹ-H), 7.99 (1H, dd, J 8.1, 1.3 Hz, 3ʹʹ-H), 8.02 (1H, dd, J 1.5, 0.7 Hz, 4ʹ-H); δC (101 MHz, CD3OD) 
46.8 (CH2), 52.1 (CH), 110.0 (CH), 118.2 (CH), 124.0 (CH), 128.7 (CH), 128.8 (CH), 132.0 (CH), 132.5 
(CH), 133.2 (C), 134.9 (C), 135.0 (C), 145.7 (C), 149.4 (C), 167.5 (C); m/z 350.0848 (MNa+. 
C15H13N5NaO4 requires 350.0860).  
 
(2S)-2-Amino-3-[5ʹ-(4ʹʹ-nitrophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (163k) 
 
 
 
(2S)-2-Amino-3-[5ʹ-(4ʹʹ-nitrophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride 
(163k) was synthesised as described for (2S)-2-amino-3-[5ʹ-(naphthalen-2ʹʹ-yl)-1H-
173 
 
benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163b) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[5ʹ-(4ʹʹ-nitrophenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoate 
(161k) (0.0529 g, 0.111 mmol) and caesium carbonate (0.0469 g, 0.144 mmol). Purification by 
recrystallisation from methanol and diethyl ether gave (2S)-2-amino-3-[5ʹ-(4ʹʹ-nitrophenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163k) as a white solid (0.0375 g, 93%). 
Mp 168–170 °C; νmax/cm−1 (neat) 2899 (OH), 1735 (C=O), 1595, 1514, 1344, 750; [α]D
20 +4.8 (c 1.0, 
DMSO); δH (400 MHz, CD3OD) 4.81 (1H, dd, J 5.7, 4.1 Hz, 2-H), 5.31 (1H, dd, J 15.5, 4.1 Hz, 3-HH), 
5.41 (1H, dd, J 15.5, 5.7 Hz, 3-HH), 7.94–8.05 (4H, m, 6ʹ-H, 7ʹ-H, 2ʹʹ-H and 6ʹʹ-H), 8.36 (2H, d, J 8.9 
Hz, 3ʹʹ-H and 5ʹʹ-H), 8.39 (1H, br s, 4ʹ-H); δC (101 MHz, CD3OD) 46.8 (CH2), 52.2 (CH), 110.7 (CH), 
117.8 (CH), 123.8 (2 × CH), 127.9 (CH), 128.1 (2 × CH), 133.7 (C), 136.0 (C), 146.2 (C), 146.4 (C), 
147.4 (C), 167.6 (C); m/z (ESI) 328.1035 (MH+. C15H14N5O4 requires 328.1040). 
 
 (2S)-2-Amino-3-[4ʹ-(4ʹʹ-toluenesulfonyl)-[1,2,3]triazolo[2,3-c]carbazol-1(4ʹH)-yl]propanoic acid 
hydrochloride (182) 
 
 
 
(2S)-2-Amino-3-[4ʹ-(4ʹʹ-toluenesulfonyl)-[1,2,3]triazolo[2,3-c]carbazol-1(4ʹH)-yl]propanoic acid 
hydrochloride (182) was synthesised as described for (2S)-2-amino-3-[5ʹ-(naphthalen-2ʹʹ-yl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid hydrochloride (163b) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[4ʹ-(4ʹʹ-toluenesulfonyl)-[1,2,3]triazolo[2,3-c]carbazol-1(4ʹH)-
yl]propanoate (178)  (0.0319 g, 0.0534 mmol) and caesium carbonate (0.0226 g, 0.0694 mmol). 
Purification by recrystallisation from methanol and diethyl ether gave (2S)-2-(amino)-3-[4ʹ-(4ʹʹ-
toluenesulfonyl)-[1,2,3]triazolo[2,3-c]carbazol-1(4ʹH)-yl]propanoic acid hydrochloride (182) as a 
white solid (0.0117 g, 45%). Mp 180–182 °C; νmax/cm−1 (neat) 2843 (OH), 1734 (C=O), 1597, 1441, 
1389, 1240, 1179, 677; [α]D
20 +4.9 (c 0.2, MeOH); δH (400 MHz, CD3OD) 2.18 (3H, s, CH3), 5.00 (1H, 
br s, 2-H), 5.40 (1H, d, J 4.3 Hz, 3-H2), 7.07 (2H, d, J 8.0 Hz, 2ʹʹ-H and 6ʹʹ-H), 7.31 (1H, t, J 7.6 Hz, 6ʹ-
H), 7.46–7.55 (1H, ddd, J 8.5, 7.6, 0.9 Hz, 7ʹ-H), 7.67 (2H, d, J 8.0 Hz, 3ʹʹ-H and 5ʹʹ-H), 7.73 (1H, d, J 
7.6 Hz, 5ʹ-H), 7.85 (1H, d, J 8.6 Hz, 10’-H), 8.10 (1H, d, J 8.6 Hz, 9ʹ-H), 8.39 (1H, d, J 8.5 Hz, 8ʹ-H); δC 
(101 MHz, CD3OD) 21.4 (CH3), 48.7 (CH2), 49.8 (CH), 108.0 (CH), 116.5 (CH), 120.7 (CH), 122.2 (CH), 
124.2 (C), 125.8 (CH), 127.2 (C), 127.6 (C), 128.0 (2 × CH), 128.2 (CH), 130.7 (2 × CH), 135.8 (C), 
135.9 (C), 136.1 (C), 139.3 (C), 147.1 (C), 169.2 (C); m/z (ESI) 450.1224 (MH+. C22H20N5O4S requires 
450.1231). 
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3.4 Experimental for bioconjugation project 
L-Aspartic acid-α-tert-butyl-β-methyl diester hydrochloride (234)210 
 
 
 
To a suspension of L-aspartic acid 4-methyl ester hydrochloride (233) (2.00 g, 10.9 mmol) in tert-
butyl acetate (75 mL) at 0 °C was added 70% aqueous perchloric acid (2.17 mL, 25.0 mmol) 
dropwise. The reaction mixture was stirred at room temperature for 24 h, poured onto saturated 
aqueous potassium carbonate solution (145 mL) and the resulting mixture was extracted with 
diethyl ether (3 × 100 mL). The combined organic layers were combined and washed with 
saturated aqueous potassium carbonate solution (3 × 50 mL), brine (50 mL), dried (MgSO4) and 
concentrated in vacuo to give a clear oil. The crude product was dissolved in diethyl ether (50 mL), 
cooled to 0 °C and 2 M ethereal HCl (5.5 mL) was added, this afforded a white solid. The solid was 
filtered and washed with cold diethyl ether to give L-aspartic acid-α-tert-butyl-β-methyl diester 
hydrochloride (234) as a white solid (1.14 g, 44%). Spectroscopic data was consistent with the 
literature.210 Mp 126–128 °C; [α]D
15 +8.8 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.49 (9H, s, 3 × CH3), 
3.17 (1H, dd, J 17.6, 5.1 Hz, 3-HH), 3.28 (1H, dd, J 17.6, 5.1 Hz, 3-HH), 4.38 (1H, t, J 5.1 Hz, 2-H), 
8.84 (3H, s, NH3); δC (101 MHz, CDCl3) 27.8 (3 × CH3), 34.1 (CH2), 50.0 (CH3), 52.5 (CH), 84.7 (C), 
166.6 (C), 170.2 (C); m/z (ESI) 204 (MH+ 100%). 
 
N-Trityl-L-aspartic acid-α-tert-butyl-β-methyl diester (235)210 
 
 
 
To a solution of L-aspartic acid-α-tert-butyl-β-methyl diester hydrochloride (234) (1.14 g, 4.75 
mmol) in anhydrous acetonitrile (40 mL) at 0 °C was added triethylamine (1.32 mL, 9.50 mmol) 
and triphenylmethyl chloride (1.32 g, 4.75 mmol). The reaction mixture was stirred at room 
temperature for 16 h, then concentrated in vacuo. The resulting residue was dissolved in ethyl 
acetate (100 mL), washed with 1 M aqueous hydrochloric acid (50 mL), water (50 mL), brine (50 
mL), dried (MgSO4) and concentrated in vacuo. The compound was purified by flash 
chromatography using silica gel, eluting with 10% diethyl ether in petroleum ether. Addition of 
petroleum ether (40–60) precipitated the triphenylmethanol by-product as white crystals, which 
were isolated by filtration. The filtrate was concentrated in vacuo to give N-trityl-L-aspartic acid-
α-tert-butyl-β-methyl diester (235) as a colourless oil (2.08 g, 98%). Spectroscopic data was 
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consistent with the literature.210 [α]D
20 +22.7 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 1.23 (9H, s, 3 × CH3), 
2.39 (1H, dd, J 14.8, 7.4 Hz, 3-HH), 2.50 (1H, dd, J 14.8, 4.2 Hz, 3-HH), 3.01 (1H, d, J 8.5 Hz, NH), 
3.57 (1H, ddd, J 8.5, 7.4, 4.2 Hz, 2-H), 7.13–7.20 (3H, m 3 × ArH), 7.22–7.29 (6H, m, 6 × ArH), 7.45–
7.55 (6H, m, 6 × ArH); δC (126 MHz, CDCl3) 27.8 (3 × CH3), 40.2 (CH2), 51.5 (CH3), 54.0 (CH), 71.4 (C), 
81.2 (C), 126.5 (3 × CH), 127.9 (6 × CH), 128.8 (6 × CH), 146.0 (3 × C), 171.3 (C), 172.4 (C); m/z (ESI) 
468 (MNa+ 100%). 
 
tert-Butyl (2S)-5-(dimethyloxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate (236)173 
 
 
 
A solution of dimethyl methylphosphonate (1.24 mL, 11.5 mmol) in anhydrous toluene (115 mL) 
was cooled to −78 °C under an argon atmosphere. n-Butyl lithium (2.5 M in hexane, 4.58 mL, 11.5 
mmol) was added dropwise and the reaction mixture was stirred for 0.5 h at −78 °C. In a separate 
reaction vessel, a solution of N-trityl-L-aspartic acid-α-tert-butyl-β-methyl diester (235) (2.04 g, 
4.58 mmol) in toluene (50 mL) was cooled to −78 °C and then the dimethyl methylphosphonate 
ester/n-butyl lithium solution was cannulated into the flask and the reaction mixture stirred at 
−78 °C for 3 h. The solution was slowly warmed to room temperature and the reaction was 
quenched with saturated aqueous ammonium chloride (5 mL). The biphasic mixture was 
concentrated in vacuo, dissolved in ethyl acetate (50 mL) and washed with water (2 × 50 mL) and 
brine (50 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography 
using silica gel, eluting with 10% to 30% ethyl acetate in dichloromethane gave tert-butyl (2S)-5-
(dimethyloxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate (236) as a white solid (1.74 g, 71%). 
Mp 90–91 °C, lit.173 90–91 °C; [α]D
20 +7.5 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.26 (9H, s, 3 × CH3), 
2.62 (1H, dd, J 15.4, 5.0 Hz, 3-HH), 2.67 (1H, dd, J 15.4, 3.3 Hz, 3-HH), 3.50–3.59 (3H, m, 5-H2 and 
NH), 3.75 (3H, d, JH-C-O-P 1.6 Hz, OCH3), 3.78 (3H, d, JH-C-O-P 1.6 Hz, OCH3), 7.15–7.21 (3H, m, 3 × ArH), 
7.22–7.33 (6H, m, 6 × ArH), 7.42–7.58 (6H, m, 6 × ArH); δC (101 MHz, CDCl3) 27.8 (3 × CH3), 41.6 (d, 
JC-P 128.5 Hz, CH2), 48.7 (CH2), 53.0 (d, JC-O-P 6.5 Hz, CH3), 53.0 (d, JC-O-P 6.5 Hz, CH3), 53.5 (CH), 71.4 
(C), 81.4 (C), 126.5 (3 × CH), 127.9 (6 × CH), 128.8 (6 × CH), 146.0 (3 × C), 172.4 (C), 199.5 (d, JC-C-P 
6.5 Hz, C); m/z (ESI) 560  (MNa+ 100%). 
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(2S)-5-(Dimethyloxyphosphoryl)-4-oxo-2-(tert-butoxycarbonylamino)pentanoate (237) 
 
 
 
To a solution of tert-butyl (2S)-5-(dimethyloxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate (236) 
(0.172 g, 0.321 mmol) in dichloromethane (2.5 mL) was added trifluoroacetic acid (2.5 mL) and 
this was stirred at room temperature for 4 h. The reaction mixture was concentrated in vacuo and 
the resulting residue was dissolved in water (20 mL) and washed with diethyl ether (2 × 20 mL). 
The aqueous layer was concentrated in vacuo, azeotroping with diethyl ether. This was suspended 
in dichloromethane (5 mL) and di-tert-butyl dicarbonate (0.147 mL, 0.642 mmol) and 
triethylamine (0.0895 mL, 0.642 mmol) were added. The reaction mixture was stirred at room 
temperature for 16 h, with the reaction slowly becoming homogenous. The reaction was 
concentrated in vacuo and the resulting residue was dissolved in ethyl acetate (20 mL), washed 
with brine (2 × 20 mL), dried (MgSO4) and concentrated in vacuo. Trituration with hexane gave 
(2S)-5-(dimethyloxyphosphoryl)-4-oxo-2-(tert-butoxycarbonylamino)pentanoate (237) as a 
colourless oil (0.0960 g, 88%). νmax/cm−1 (neat) 3366 (NH), 2974 (CH), 2164, 1717 (C=O), 1510, 1368, 
1248, 1167, 1036; [α]D
20 +32.8 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.43 (9H, s, 3 × CH3), 2.86–3.51 
(4H, m, 3-H2 and 5-H2), 3.78 (3H, s, OCH3), 3.81 (3H, s, OCH3), 4.53 (1H, br s, 2-H), 5.64 (1H, d, J 7.7 
Hz, NH), 9.24 (1H, br s, OH); δC (101 MHz, CDCl3) 28.3 (3 × CH3), 41.0 (d, JC-P 130 Hz, CH2), 45.9 (CH2), 
49.4 (CH), 53.4 (d, JC-O-P 6.5 Hz, CH3), 53.6 (d, JC-O-P 6.5 Hz, CH3), 80.2 (C), 155.7 (C), 173.4 (C), 199.9 
(C); m/z (ESI) 362.0966 (MNa+. C12H22NNaO8P requires 362.0975). 
 
tert-Butyl (2S,2ʹS)-2-[2ʹ-(tert-butoxycarbonylamino)-5ʹ-(dimethoxyphosphoryl)-4ʹ-
oxopentanamido]propanoate (238) 
 
 
 
To a solution of (2S)-5-(dimethyloxyphosphoryl)-4-oxo-2-(tert-butoxycarbonylamino)pentanoate 
(237) (0.0564 g, 0.166 mmol), tert-butyl L-alaninate (0.0332 g, 0.183 mmol) and 1-
hydroxybenzotriazole hydrate (0.0127 g, 0.0830 mmol) in acetonitrile (5 mL) at 0 °C was added 
PyBop® (0.130 g, 0.249 mmol) and N,N-diisopropylethylamine (0.867 mL, 0.498 mmol). The 
reaction mixture was warmed to room temperature, stirred for 1 h and concentrated in vacuo. 
The resulting residue was dissolved in ethyl acetate (50 mL), washed with 1 M aqueous 
hydrochloric acid (50 mL, for good separation the addition of a minimum amount of brine was 
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required), brine (50 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography using silica gel, eluting first with 20% acetonitrile in dichloromethane and then 
4% methanol in dichloromethane gave tert-butyl (2S,2ʹS)-2-[2ʹ-(tert-butoxycarbonylamino)-5ʹ-
(dimethoxyphosphoryl)-4ʹ-oxopentanamido]propanoate (238) as a colourless oil (0.0552 g, 71%). 
νmax/cm−1 (neat) 3300 (NH), 2978 (CH), 1717 (C=O), 1520 (NH), 1456, 1368, 1250, 1153, 1028; [α]D
20 
+14.8 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.36 (3H, d, J 7.1 Hz, 2-CH3), 1.40–1.52 (18H, m, 6 × CH3), 
2.97 (1H, dd, J 17.7, 5.1 Hz, 3ʹ-HH), 3.10–3.36 (3H, m, 3ʹ-HH and 5ʹ-H2), 3.78 (3H, s, OCH3), 3.81 (3H, 
s, OCH3), 4.37 (1H, quin., J 7.1 Hz, 2-H), 4.55 (1H, dt, J 8.0, 5.1 Hz, 2ʹ-H), 5.63 (1H, d, J 8.0 Hz, NH), 
7.11 (1H, d, J 7.1 Hz, NH); δC (126 MHz, CDCl3) 18.3 (CH3), 27.9 (3 × CH3), 28.3 (3 × CH3), 41.8 (d, JC-
P 129 Hz, CH2), 45.5 (CH2), 48.9 (CH), 50.7 (CH), 53.1 (d, JC-O-P 6.4 Hz, CH3),  53.2 (d, JC-O-P 6.4 Hz, CH3), 
80.4 (C), 81.9 (C), 155.5 (C), 170.2 (C), 171.6 (C), 201.1 (C); m/z (ESI) 489.1966 (MNa+. 
C19H35N2NaO9P requires 489.1972).  
 
tert-Butyl (2S,2ʹS,5ʹE)-2-[2ʹ-(tert-butoxycarbonylamino)-4ʹ-oxo-6ʹ-phenylhex-5ʹ-
enamido]propanoate (239a) 
 
 
 
To a solution of tert-butyl (2S,2ʹS)-2-[2ʹ-(tert-butoxycarbonylamino)-5ʹ-(dimethoxyphosphoryl)-4ʹ-
oxopentanamido]propanoate (238) (0.0298 g, 0.0639 mmol) in anhydrous acetonitrile (2 mL) was 
added potassium carbonate (0.00971 g, 0.0703 mmol) and benzaldehyde (0.0130 mL, 0.128 mmol). 
The reaction mixture was heated to 50 °C for 70 h and then concentrated in vacuo. The resulting 
residue was dissolved in ethyl acetate (50 mL) and washed with water (50 mL), brine (50 mL), dried 
(MgSO4) and concentrated in vacuo. Purification by flash chromatography using silica gel, eluting 
with 50 to 60% diethyl ether in petroleum ether (40–60) gave tert-butyl (2S,2ʹS)-2-[2ʹ-(tert-
butoxycarbonylamino)-4ʹ-oxo-6ʹ-phenylhex-5ʹ-enamido]propanoate (239a) as a clear oil (0.0250 
g, 88%). νmax/cm−1 (neat) 3306 (NH), 2978 (CH), 1728 (C=O), 1657 (C=O), 1526 (NH), 1368, 1152, 
748, 691; [α]D
20 +78.5 (c 0.25, CHCl3); δH (400 MHz, CDCl3) 1.38 (3H, d, J 6.9 Hz, 2-CH3), 1.41–1.50 
(18H, m, 6 × CH3), 2.99 (1H, dd, J 17.8, 5.0 Hz, 3ʹ-HH), 3.54 (1H, br d, J 17.8 Hz, 3ʹ-HH), 4.41 (1H, 
quin., J 6.9 Hz, 2-H), 4.61 (1H, br s, 2ʹ-H), 5.77 (1H, d, J 7.6 Hz, NH), 6.73 (1H, d, J 16.2 Hz, 5ʹ-H), 
7.16 (1H, d, J 6.9 Hz, NH), 7.31–7.46 (3H, m, 3ʹʹ-H, 4ʹʹ-H and 5ʹʹ-H), 7.49–7.63 (3H, m, 6ʹ-H, 2ʹʹ-H 
and 6ʹʹ-H); δC (101 MHz, CDCl3) 18.4 (CH3), 28.0 (3 × CH3), 28.3 (3 × CH3), 42.2 (CH2), 49.0 (CH), 50.6 
(CH), 80.3 (C), 81.9 (C), 125.9 (CH), 128.5 (2 × CH), 129.0 (2 × CH), 130.8 (CH), 134.2 (C), 144.0 (CH), 
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155.5 (C), 170.5 (C), 171.7 (C), 199.0 (C); m/z (ESI) 469.2302 (MNa+. C24H34N2NaO6 requires 
469.2309).  
 
tert-Butyl (2S,2ʹS,5ʹE)-2-[2ʹ-(tert-butoxycarbonylamino)-4ʹ-oxo-6ʹ-(4ʹʹ-methoxyphenyl)hex-5ʹ-
enamido]propanoate (239b) 
 
 
 
tert-Butyl (2S,2ʹS,5ʹE)-2-[2ʹ-(tert-butoxycarbonylamino)-4ʹ-oxo-6ʹ-(4ʹʹ-methoxyphenyl)hex-5ʹ-
enamido]propanoate (239b) was synthesised as described for tert-butyl (2S,2ʹS)-2-[2ʹ-(tert-
butoxycarbonylamino)-4ʹ-oxo-6ʹ-phenylhex-5ʹ-enamido]propanoate (239a) using tert-butyl 
(2S,2ʹS)-2-[2ʹ-(tert-butoxycarbonylamino)-5ʹ-(dimethoxyphosphoryl)-4ʹ-
oxopentanamido]propanoate (238) (0.0503 g, 0.108 mmol), p-anisaldehyde (0.0262 mL, 0.216 
mmol) and potassium carbonate (0.0164 g, 0.119 mmol) in anhydrous acetonitrile (4 mL). 
Purification by flash chromatography using silica gel, eluting with 0 to 20% diethyl ether in 
dichloromethane gave tert-butyl (2S,2ʹS,5ʹE)-2-[2ʹ-(tert-butoxycarbonylamino)-4ʹ-oxo-6ʹ-(4ʹʹ-
methoxyphenyl)hex-5ʹ-enamido]propanoate (239b) as a colourless oil (0.0217 g, 42%). νmax/cm−1 
(neat) 3321 (NH), 2978 (CH), 1655 (C=O), 1599, 1572, 1510 (NH), 1368, 1250, 1169, 1153, 1028, 
733; [α]D
20 +95.6 (c 0.5, CHCl3); δH (400 MHz, CDCl3) 1.37 (3H, d, J 7.1 Hz, 2-CH3), 1.41–1.49 (18H, 
m, 6 × CH3), 2.96 (1H, dd, J 17.7, 5.9 Hz, 3ʹ-HH), 3.50 (1H, br d, 17.7 Hz, 3ʹ-HH), 3.84 (3H, s, OCH3), 
4.40 (1H, quin., J 7.2 Hz, 2-H), 4.59 (1H, br s, 2ʹ-H), 5.78 (1H, d, J 7.8 Hz, NH), 6.61 (1H, d, J 16.2 Hz, 
5ʹ-H), 6.91 (2H, d, J 8.8 Hz, 3ʹʹ-H and 5ʹʹ-H), 7.16 (1H, d, J 7.2 Hz, NH), 7.49 (2H, d, J 8.8 Hz, 2ʹʹ-H and 
6ʹʹ-H), 7.54 (1H, d, J 16.2 Hz, 6ʹ-H); δC (101 MHz, CDCl3) 18.4 (CH3), 28.0 (3 × CH3), 28.3 (3 × CH3), 
42.1 (CH2), 49.0 (CH), 50.6 (CH), 55.4 (CH3), 80.3 (C), 81.8 (C), 114.5 (2 × CH), 123.6 (CH), 126.9 (C), 
130.3 (2 × CH), 143.8 (CH), 155.5 (C), 161.9 (C), 170.6 (C), 171.7 (C), 198.9 (C); m/z (ESI) 499.2405 
(MNa+. C25H36N2NaO7 499.2415).  
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tert-Butyl (2S,2ʹS,5ʹE)-2-[2ʹ-(tert-butoxycarbonylamino)-4ʹ-oxo-6ʹ-(4ʹʹ-
dimethylaminonaphthalen-1ʹ-yl)hex-5ʹ-enamido]propanoate (239c) 
 
 
 
tert-Butyl-(2S,2ʹS,5ʹE) 2-[2ʹ-(tert-butoxycarbonylamino)-4ʹ-oxo-6ʹ-(4ʹʹ-dimethylaminonaphthalen-
1ʹ-yl)hex-5ʹ-enamido]propanoate (239c) was synthesised as described for tert-butyl (2S,2ʹS)-2-[2ʹ-
(tert-butoxycarbonylamino)-4ʹ-oxo-6ʹ-phenylhex-5ʹ-enamido]propanoate (239a) using tert-butyl 
(2S,2ʹS)-2-[2ʹ-(tert-butoxycarbonylamino)-5ʹ-(dimethoxyphosphoryl)-4ʹ-
oxopentanamido]propanoate (238) (0.0580 g, 0.124 mmol), 4-dimethylamino-1-naphthaldehyde 
(0.0297 g, 0.249 mmol) and potassium carbonate (0.0189 g, 0.136 mmol) in anhydrous acetonitrile 
(4 mL). The reaction mixture was heated at 50 °C for 72 h. Potassium carbonate (0.00857 g, 0.0620 
mmol) was added and the reaction continued to be stirred at 70 °C for 48 h. Additional potassium 
carbonate (0.00857 g, 0.0620 mmol) was added and the reaction mixture was heated at 70 °C for 
a further 24 h. The mixture was then concentrated in vacuo. Purification by flash chromatography 
using silica gel, eluting with 60% diethyl ether in petrolumn ether (40–60) gave tert-butyl 
(2S,2ʹS,5ʹE)-2-[2ʹ-(tert-butoxycarbonylamino)-4ʹ-oxo-6ʹ-(4ʹʹ-dimethylaminonaphthalen-1ʹ-yl)hex-
5ʹ-enamido]propanoate (239c) as a yellow oil (0.0189 g, 28%, 71:29 ratio of E/Z isomers). νmax/cm−1 
(neat) 3329 (NH), 2978 (CH), 1713 (C=O), 1667 (C=O), 1512, 1391, 1368, 1155, 1047, 768, 733; 
[α]D
20 +51.4 (c 0.5, CHCl3); NMR data is given for the E-isomer: δH (400 MHz, CDCl3) 1.39 (3H, d, J 
7.2 Hz, 2-CH3), 1.45 (9H, s, 3 × CH3), 1.47 (9H, s, 3 × CH3), 2.96 (6H, s, NMe2), 3.05 (1H, dd, J 16.5, 
5.5 Hz, 3ʹ-HH), 3.60 (1H, br d, J 16.5 Hz, 3ʹ-HH), 4.43 (1H, quin., J 7.2 Hz, 2-H), 4.64 (1H, br s, 2ʹ-H), 
5.82 (1H, d, J 7.2 Hz, NH), 6.76 (1H, d, J 15.8 Hz, 5ʹ-H), 7.04 (1H, d, J 8.0 Hz, 3ʹʹ-H), 7.21 (1H, d, J 7.2 
Hz, NH), 7.41–7.61 (2H, m, 6ʹʹ-H and 7ʹʹ-H), 7.75 (1H, d, J 8.0 Hz, 2ʹʹ-H), 8.18 (1H, dd, J 8.0, 1.3 Hz, 
8ʹʹ-H), 8.23 (1H, dd, J 8.3, 1.3 Hz, 5ʹʹ-H), 8.42 (1H, d, J 15.8 Hz, 6ʹ-H); δC (101 MHz, CDCl3) 18.5 (CH3), 
28.0 (3 × CH3), 28.3 (3 × CH3), 44.9 (2 × CH3), 45.0 (CH2), 49.0 (CH), 50.6 (CH), 81.8 (C), 81.8 (C), 
113.3 (CH), 123.6 (CH), 125.2 (C), 125.2 (CH), 125.3 (CH), 125.7 (CH), 126.1 (CH), 126.8 (CH), 128.3 
(C), 133.1 (C), 140.9 (CH), 152.5 (C), 154.0 (C), 170.6 (C), 171.7 (C), 198.8 (C); m/z (ESI) 562.2867 
(MNa+. C30H41N3NaO6 requires 562.2888). 
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(2S,2ʹS,5ʹE)-2-[2ʹ-Amino-4ʹ-oxo-6ʹ-(4ʹʹ-methoxyphenyl)hex-5ʹ-enamido]propanoic acid 
trifluoroacetate (240) 
 
 
 
To a solution of tert-butyl (2S,2ʹS,2E)-2-[2ʹ-(tert-butoxycarbonylamino)-4ʹ-oxo-6ʹ-(4ʹʹ-
methoxyphenyl)hex-5’-enamido]propanoate (239b) (0.0234 g, 0.0491 mmol) in dichloromethane 
(2 mL) was added trifluoroacetic acid (2 mL). The reaction mixture was stirred at room 
temperature for 4 h. The reaction mixture was concentrated in vacuo and the product was 
precipitated with diethyl ether. The solid was filtered and washed with diethyl ether to give 
(2S,2ʹS,5ʹE)-2-[2ʹ-amino-4ʹ-oxo-6ʹ-(4ʹʹ-methoxyphenyl)hex-5’-enamido]propanoic acid 
trifluoroacetate (240) as a white solid (0.0153 g, 72%). Mp 94–96 °C;  νmax/cm−1 (neat) 3549 (NH), 
3121 (OH), 1674 (C=O), 1597, 1512 (NH), 1396, 1258, 1173, 816; [α]D
20 −11.0 (c 0.1, MeOH); δH (500 
MHz, CD3OD) 1.44 (3H, d, J 7.3 Hz, 2-CH3), 3.26 (1H, dd, J 18.7, 9.8 Hz, 3ʹ-HH), 3.48 (1H, dd, J 18.7, 
3.1 Hz, 3-HH), 4.34 (1H, dd, J 9.8, 3.1 Hz, 2ʹ-H), 4.44 (1H, q, J 7.3 Hz, 2-H), 6.79 (1H, d, J 16.2 Hz, 5ʹ-
H), 6.99 (2H, d, J 8.8 Hz, 3ʹʹ-H and 5ʹʹ-H), 7.63 (2H, d, J 8.8 Hz, 2ʹʹ-H and 6ʹʹ-H), 7.72 (1H, d, J 16.2 
Hz, 6ʹ-H); δH (126 MHz, CD3OD) 16.2 (CH3), 40.5 (CH2), 48.3 (CH), 48.9 (CH), 54.5 (CH3), 114.2 (2 × 
CH), 122.2 (CH), 126.7 (C), 130.2 (2 × CH), 144.8 (CH), 162.4 (C), 168.3 (C), 174.4 (C), 195.9 (C); m/z 
(ESI) 343.1276 (MNa+. C16H20N2NaO5 requires 343.1264). 
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3.5 Experimental for acid-mediated 6-endo-trig project 
3-Cyclohexylpropanal (276a)211 
 
 
 
3-Cyclohexyl-1-propanol (275a) (0.400 mL, 2.56 mmol) was added dropwise to a solution of Dess-
Martin periodinane (1.63 g, 3.84 mmol) in dichloromethane (15 mL) at 0 °C. The resulting reaction 
mixture was stirred at room temperature for 1 h, diluted with dichloromethane (50 mL) and 
washed with 1 M aqueous sodium thiosulfate solution (2 × 30 mL), brine (50 mL), dried (MgSO4) 
and concentrated in vacuo. Purification by flash chromatography using silica gel, eluting with 20% 
diethyl ether in petroleum ether (40–60) gave 3-cyclohexylpropanal (276a) as a clear oil (0.295 g, 
82%). δH (400 MHz, CDCl3) 0.81–0.99 (2H, m, CH2), 1.06–1.34 (4H, m, 2 × CH2), 1.52 (2H, br q, J 7.6 
Hz, 3-H2), 1.58–1.78 (5H, m, CH and 2 × CH2), 2.42 (2H, td, J 7.6, 1.9 Hz, 2-H2), 9.76 (1H, t, J 1.9 Hz, 
1-H); δC (101 MHz, CDCl3) 26.2 (2 × CH2), 26.5 (CH2), 29.4 (CH2), 33.1 (2 × CH2), 37.2 (CH), 41.5 (CH2), 
203.0 (CH); m/z (ESI) 281 (2MH+, 100%) 
 
Phenylacetaldehyde (276c)212 
 
 
 
Phenylacetaldehyde (276c) was synthesised as described for 3-cyclohexylpropanal (276a) using 2-
phenyl-1-ethanol (275c) (0.300 mL, 2.51 mmol), Dess-Martin periodinane (1.59 g, 3.76 mmol) in 
dichloromethane (15 mL). Purification by flash chromatography using silica gel, eluting with 25% 
TBME in cyclohexane gave phenylacetaldehyde (276c) as a clear oil (0.187 g, 59%). Spectroscopic  
data was consistent with literature.212 δH (400 MHz, CDCl3) 3.74 (2H, d, J 2.4 Hz, CH2), 7.24–7.31 
(2H, m, 2 × ArH), 7.34–7.50 (3H, m, 3 × ArH), 9.81 (1H, t, J 2.4 Hz, CH); δC (101 MHz, CDCl3) 50.6 
(CH2), 127.4 (CH), 129.0 (2 × CH), 129.6 (2 × CH), 131.9 (C), 199.3 (CH). 
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5-Chloropentanal (276b)213 
 
 
 
 A solution of oxalyl chloride (0.438 mL, 5.18 mmol) in dichloromethane (15 mL) was added 
dropwise to a solution of DMSO (0.737 mL, 10.37 mmol) in dichloromethane (2.5 mL) at −78 °C. 
The resultant reaction mixture was stirred at −78 °C for 0.1 h. A solution of 5-chloro-1-pentanol 
(275b) (0.500 mL, 4.32 mmol) in dichloromethane (2.5 mL) was added to the reaction mixture. 
The resulting reaction mixture was stirred at −78 °C for 0.2 h. Triethylamine (3.10 mL, 21.6 mmol) 
was added to the reaction mixture and the reaction was warmed to room temperature. The 
reaction mixture was diluted with dichloromethane and washed with water (50 mL), brine (50 mL), 
dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography using silica gel, 
eluting with dichloromethane gave 5-chloropentanal (276b) as a clear oil (0.376 g, 72%). 
Spectroscopic  data was consistent with literature.213  νmax/cm−1 (neat) 2947, 2730, 1721 (C=O), 
1242, 648; δH (400 MHz, CDCl3) 1.72–1.86 (4H, m, 3-H2 and 4-H2), 2.40–2.56 (2H, m, 2-H2), 3.44–
3.61 (2H, m, 5-H2), 9.77 (1H, t, J 1.5 Hz, 1-H); δC (101 MHz, CDCl3) 19.5 (CH2), 31.9 (CH2), 43.1 (CH2), 
44.6 (CH2), 201.9 (CH); m/z (ESI) 281 (2MH+, 100%). 
 
N-Boc-L-aspartic acid-α-methyl ester (269)214 
 
 
 
L-Aspartic acid (106) (5.00 g, 37.6 mmol) was dissolved in methanol (250 mL) and cooled to −10 °C. 
Thionyl chloride (4.77 mL, 41.4mmol) was added dropwise and the resultant reaction mixture was 
stirred for 0.5 h. The solution was concentrated in vacuo and triturated with diethyl ether to give 
ʟ-aspartic acid-α-methyl ester as a white solid (8.27 g, 89%). This was then dissolved in 1,4-dioxane 
(100 mL) and cooled to 0 °C followed by the addition of di-tert-butyl dicarbonate (9.03 g, 41.4 
mmol) and a 10% aqueous solution of sodium carbonate (100 mL). The resulting reaction mixture 
was allowed to warm to room temperature and stirred for 16 h. Once the reaction had reached 
completion, the mixture was concentrated in vacuo and the residue was then dissolved in 
saturated aqueous ammonium chloride (100 mL), washed with dichloromethane (3 × 50 mL) and 
acidified to pH 1 with 1 M aqueous hydrochloric acid. This was extracted with dichloromethane (3 
× 50 mL), the organic fractions were combined, washed with brine (100 mL), dried (MgSO4), 
filtered and concentrated under reduced pressure which gave N-Boc-ʟ-aspartic acid 4-methyl 
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ester (269) as a white solid (8.27 g, 89%). Mp 54–56 °C (lit.,214 56 °C); δH (500 MHz, CDCl3) 1.45 (9H, 
s, 3 × CH3), 2.85 (1H, dd, J 17.2, 3.8 Hz, 3-HH), 3.04 (1H, dd, J 17.2, 3.8 Hz, 3-HH), 3.72 (3H, s, OCH3), 
4.55–4.67 (1H, m, 2-H), 5.55 (1H, d, J 8.0 Hz, NH); δC (126 MHz, CDCl3) 28.4 (3 × CH3), 36.4 (CH2), 
49.9 (CH), 52.3 (CH3), 80.8 (C), 155.8 (C), 171.8 (C), 175.1 (C); m/z (ESI) 270 (MNa+, 100%). 
 
Methyl (3S)-3-(tert-butoxycarbonylamino)-4-hydroxybutanoate (271)215 
 
 
 
To a solution of N-Boc-L-aspartic acid 4-methyl ester (269) (8.27 g, 33.5 mmol) in ethyl acetate 
(200 mL) at 0 °C was added N-hydroxysuccinimide (4.24 g, 36.9 mmol). N,N'-
Dicyclohexylcarbodiimide (7.05 g, 34.2 mmol) in ethyl acetate (20 mL) was then added dropwise. 
The reaction mixture was allowed to warm to room temperature and stirred for 16 h. Once the 
reaction was complete, the reaction mixture was filtered through Celite. The filtrate was washed 
with saturated sodium carbonate solution (100 mL), brine (100 mL), dried (MgSO4) and 
concentrated in vacuo. The resulting residue was then dissolved in tetrahydrofuran (20 mL) and 
added dropwise to a solution of sodium borohydride (2.03 g, 53.6 mmol) in a mixture of 
tetrahydrofuran and water (7.5:1, 85 mL). The reaction mixture was stirred for 0.1 h before 
quenching with saturated aqueous ammonium chloride (5 mL). The reaction mixture was 
extracted with dichloromethane (3 × 50 mL). The organic fractions were combined and washed 
with brine (100 mL), dried (MgSO4), filtered and concentrated in vacuo. Purification by flash 
column chromatography using silica gel, eluting with 30% ethyl acetate in dichloromethane gave 
methyl (3S)-3-(tert-butoxycarbonylamino)-4-hydroxybutanoate (271) as a colourless oil (7.03 g, 
90%). [α]D
26 +5.6 (c 1.0, CHCl3), lit.215 [α]D
23 +6.3 (c 0.5, CHCl3); δH (400 MHz, CDCl3) 1.42 (9H, s, 3 × 
CH3), 2.62 (2H, d, J 6.1 Hz, 2-H2), 2.82 (1H, br s, OH), 3.65–3.73 (5H, m, OCH3 and 4-H2), 3.92–4.04 
(1H, m, 3-H), 5.25 (1H, br s, NH); δC (126 MHz, CDCl3) 28.4 (3 × CH3), 35.9 (CH2), 49.4 (CH), 52.0 
(CH3), 64.4 (CH2), 79.9 (C), 155.9 (C), 172.4 (C); m/z (ESI) 256 (MNa+, 100%). 
 
Methyl (3S)-3-(tert-butoxycarbonylamino)-4-iodobutanoate (272)193 
 
 
 
To a suspension of imidazole (4.11 g, 60.4 mmol) and triphenylphosphine (11.9 g, 45.3 mmol) in a 
mixture of diethyl ether and dichloromethane (2:1, 100 mL) at 0 °C was added iodine (11.5 g, 45.3 
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mmol) in three portions over 0.5 h. After stirring for a further 0.2 h, a solution of methyl (3S)-3-
(tert-butoxycarbonylamino)-4-hydroxybutanoate (271) (7.03 g, 30.2 mmol) in a mixture of diethyl 
ether and dichloromethane (2:1, 50 mL) was added and the resulting mixture was stirred for 3 h 
at room temperature. The reaction mixture was filtered through Celite and the filtrate was 
concentrated in vacuo. Purification by flash column chromatography using silica gel, eluting with 
30% diethyl ether in petroleum ether (40–60) gave methyl (3S)-3-(tert-butoxycarbonylamino)-4-
iodobutanoate (272) (9.33 g, 90%) as a colourless oil. Spectroscopic data were consistent with the 
literature.193 [α]D
33 +7.3 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.40 (9H, s, 3 × CH3), 2.60 (1H, dd, J 16.4, 
6.1 Hz, 2-HH), 2.70 (1H, dd, J 16.4, 5.6 Hz, 2-HH), 3.28–3.45 (2H, m, 4-H2), 3.66 (3H, s, OCH3), 3.81–
3.95 (1H, m, 3-H), 5.11 (1H, d, J 7.2 Hz, NH); δC (101 MHz, CDCl3) 11.1 (CH2), 28.5 (3 × CH3), 38.5 
(CH2), 47.7 (CH), 52.0 (CH3), 79.9 (C), 154.7 (C), 171.1 (C); m/z (ESI) 366 (MNa+, 100%). 
 
Methyl (3R)-3-(tert-butoxycarbonylamino)butanoate (273)216 
 
 
 
A solution of methyl (3S)-3-(tert-butoxycarbonylamino)-4-iodobutanoate (272) (9.33 g, 27.2 
mmol), N,N-diisopropylethylamine (7.11 mL, 40.8 mmol) and 10% Pd/C (2.89 g, 2.72 mmol) in 
methanol (50 mL) were purged with hydrogen for 0.5 h. The reaction mixture was stirred under 
an atmosphere of hydrogen for 18 h at room temperature. The mixture was then filtered through 
Celite and the filtrate was concentrated in vacuo. The resulting residue was dissolved in 
dichloromethane (100 mL) and washed with a saturated solution of sodium hydrogen carbonate 
(50 mL), 1 M hydrochloric acid (50 mL), brine (50 mL), dried over MgSO4, filtered and concentrated 
in vacuo which gave methyl (3R)-3-(tert-butoxycarbonylamino)butanoate (273) as a colourless oil 
(5.87 g, 99%). Spectroscopic data were consistent with the literature.216 [α]D
26 +21.5 (c 1.0, CHCl3); 
δH (500 MHz, CDCl3) 1.20 (3H, d, J 6.8 Hz, 4-H3), 1.43 (9H, s, 3 × CH3), 2.47 (1H, dd, J 15.5, 6.0 Hz, 
2-HH), 2.52 (1H, dd, J 15.5, 5.4 Hz, 2-HH), 3.68 (3H, s, OCH3), 4.03 (1H, br s, 3-H), 4.91 (1H, br s, 
NH); δC (126 MHz, CDCl3) 20.5 (CH3), 28.4 (3 × CH3), 40.7 (CH2), 43.5 (CH), 51.6 (CH3), 79.3 (C), 155.1 
(C), 172.0 (C); m/z (ESI) 240 (MNa+, 100%). 
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(4R)-4-(tert-Butoxycarbonylamino)-1-(dimethyloxyphosphoryl)pentan-2-one (274) 
 
 
 
Dimethyl methylphosphonate (3.74 mL, 34.5 mmol) was dissolved in tetrahydrofuran (100 mL) 
and cooled to −78 °C under an argon atmosphere. n-Butyl lithium (2.5 M, in hexane, 13.8 mL, 34.5 
mmol) was added dropwise and the mixture was stirred for 0.3 h. A solution of methyl (3R)-3-
(tert-butoxycarbonylamino)butanoate (273) (3.00 g, 13.8 mmol) in tetrahydrofuran (20 mL) was 
added dropwise. The resulting mixture was then stirred at −78 °C for 0.5 h and allowed to warm 
to 0 °C over a period of 1 h. The reaction was quenched with a saturated aqueous solution of 
ammonium chloride (4 mL) and extracted with ethyl acetate (2 × 50 mL). The combined organic 
layers were combined, washed with brine (100 mL), dried (MgSO4), filtered and concentrated in 
vacuo. Purification by flash column chromatography using silica gel, eluting with 40% ethyl acetate 
in dichloromethane gave (4R)-4-(tert-butoxycarbonylamino)-1-(dimethyloxyphosphoryl)pentan-
2-one (274) (3.84 g, 90%) as a colourless oil. νmax/cm−1 (neat) 3316 (NH), 2976 (CH), 1704 (C=O), 
1700 (C=O), 1248, 1167, 1023; [α]D
31 +38.3 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.17 (3H, d, J 6.7 Hz, 
5-H3), 1.39 (9H, s, 3 × CH3), 2.71 (1H, dd, J 16.9, 5.9 Hz, 3-HH), 2.80 (1H, dd, J 16.9, 5.9 Hz, 3-HH), 
3.03 (1H, dd, J 22.6, 13.6 Hz, 1-HH), 3.12 (1H, dd, J 22.6, 13.6 Hz, 1-HH), 3.74 (3H, d, J 0.8 Hz, OCH3), 
3.77 (3H, d, J 0.8 Hz, OCH3), 3.93–4.09 (1H, m, 4-H), 4.92 (1H, br s, NH); δC (101 MHz, CDCl3) 20.5 
(CH3), 28.3 (3 × CH3), 41.8 (d, JC-P 127.5 Hz, CH2), 43.2 (CH), 50.1 (CH2), 53.0 (d, JC-O-P 6.5 Hz, CH3), 
53.1 (d, JC-O-P 6.5 Hz, CH3), 79.2 (C), 155.1 (C), 200.5 (C); m/z (ESI) 332.1225 (MNa+. C12H24NNaO6P 
requires 332.1233). 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxonona-5-ene (258a) 
 
 
 
(4R)-4-(tert-Butoxycarbonylamino)-1-(dimethyloxyphosphoryl)pentan-2-one (274) (0.421 g, 1.36 
mmol) was dissolved in anhydrous acetonitrile (14 mL) and potassium carbonate (0.207 g, 1.50 
mmol) was added. The mixture was stirred at room temperature for 0.5 h followed by addition of 
butyraldehyde (0.250 mL, 2.72 mmol). The temperature was increased to 50 °C and the mixture 
stirred for 72 h. The solution was then concentrated in vacuo. the resulting residue was dissolved 
in ethyl acetate (20 mL), washed with water (2 × 15 mL) and brine (15 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash column chromatography using silica gel, eluting with 
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20% diethyl ether in petroleum ether (40–60) gave (2R,5E)-2-(tert-butoxycarbonylamino)-4-
oxonona-5-ene (258a) as a clear colourless oil (0.336 g, 87%). νmax/cm−1 (neat) 3350 (NH), 2968 
(CH), 1689 (C=O), 1516, 1365, 1166, 1053, 977; [α]D
26 +9.3 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 0.94 
(3H, t, J 7.3 Hz, 9-H3), 1.20 (3H, d, J 6.9 Hz, 1-H3), 1.43 (9H, s, 3 × CH3), 1.46–1.55 (2H, m, 8-H2), 2.20 
(2H, qd, J 6.9, 1.5 Hz, 7-H2), 2.64 (1H, dd, J 15.9, 6.5 Hz, 3-HH), 2.86 (1H, dd, J 15.9, 4.5 Hz, 3-HH), 
3.98–4.09 (1H, m, 2-H), 5.02 (1H, br s, NH), 6.09 (1H, dt, J 15.9, 1.5 Hz, 5-H), 6.86 (1H, dt, J 15.9, 
6.9 Hz, 6-H); δC (126 MHz, CDCl3) 13.7 (CH3), 20.5 (CH3), 21.3 (CH2), 28.4 (3 × CH3), 34.5 (CH2), 43.7 
(CH), 45.7 (CH2), 79.1 (C), 130.8 (CH), 148.2 (CH), 155.2 (C), 199.2 (C); m/z (ESI) 278.1725 (MNa+. 
C14H25NNaO3 requires 278.1727). 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxodec-5-ene (258b) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (274) (0.100 g, 0.326 mmol), valeraldehyde (0.070 mL, 
0.652 mmol) and potassium carbonate (0.0496 g, 0.359 mmol) in acetonitrile (4 mL). Purification 
by flash column chromatography using silica gel, eluting with 20% diethyl ether in petroleum ether 
(40–60) gave (2R,5E)-2-(tert-butoxycarbonylamino)-4-oxodec-5-ene (258b) (0.069 g, 78%) as a 
colourless oil. νmax/cm−1 (neat) 3356 (NH), 2961 (CH), 1693 (C=O), 1516, 1366, 1248, 1171, 1053; 
[α]D
20 +6.1 (c 0.9, CHCl3); δH (400 MHz, CDCl3) 0.88 (3H, t, J 7.2 Hz; 10-H3), 1.17 (3H, d, J 6.7 Hz, 1-
H3), 1.27–1.46 (13H, m, 3 × CH3, 8-H2, 9-H2), 2.19 (2H, qd, J 7.1, 1.5 Hz, 7-H2), 2.60 (1H, dd, J 15.9, 
6.6 Hz, 3-HH), 2.82 (1H, dd, J 15.9, 4.9 Hz, 3-HH), 3.94–4.07 (1H, m, 2-H), 4.95 (1H, br s, NH), 6.06 
(1H, dt, J 15.9, 1.5 Hz, 5-H), 6.82 (1H, dt, J 15.9, 7.1 Hz, 6-H); δC (101 MHz, CDCl3) 13.7 (CH3), 20.5 
(CH3), 22.2 (CH2), 28.4 (3 × CH3), 30.1 (CH2), 32.1 (CH2), 43.7 (CH), 45.7 (CH2), 79.1 (C), 130.6 (CH), 
148.4 (CH), 155.1 (C), 199.0 (C); m/z (ESI) 292.1890 (MNa+. C15H27NNaO3 requires 292.1889. 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxoundec-5-ene (258c) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258a) using (4R)-4-(tert-butoxycarbonylamino)-1-
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(dimethyloxyphosphoryl)pentan-2-one (274) (0.047 g, 0.151 mmol), hexanal (0.037 mL, 0.303 
mmol) and potassium carbonate (0.0230 g, 0.166 mmol) in acetonitrile (4 mL). Purification by flash 
column chromatography using silica gel, eluting with 20% diethyl ether in petroleum ether (40–
60) gave (2R,5E)-2-(tert-butoxycarbonylamino)-4-oxoundec-5-ene (258c) as a colourless oil (0.035 
g, 81%). νmax/cm−1 (neat) 3341 (NH), 2928 (CH), 1694 (C=O), 1516, 1366, 1173, 1053; [α]D
24 +5.6 (c 
0.7, CHCl3); δH (400 MHz, CDCl3) 0.89 (3H, t, J 6.9 Hz, 11-H3), 1.20 (3H, d, J 6.7 Hz, 1-H3), 1.24–1.36 
(4H, m, 9-H2 and 10-H2), 1.40–1.52 (11H, m, 8-H2 and 3 × CH3), 2.14 (2H, qd, J 7.1, 1.4 Hz, 7-H2), 
2.63 (1H, dd, J 15.9, 6.5 Hz, 3-HH), 2.85 (1H, dd, J 15.9, 4.6 Hz, 3-HH), 3.95–4.07 (1H, m, 2-H), 4.94 
(1H, br s, NH), 6.08 (1H, dt, J 15.8, 1.4 Hz, 5-H), 6.85 (1H, dt, J 15.8, 7.1 Hz, 6-H); δC (101 MHz, CDCl3) 
14.1 (CH3), 20.6 (CH3), 22.6 (CH2), 27.9 (CH2), 28.6 (3 × CH3), 31.5 (CH2), 32.6 (CH2), 43.9 (CH), 45.8 
(CH2), 79.3 (C), 130.7 (CH), 148.7 (CH), 155.3 (C), 199.3 (C); m/z (ESI) 306.2039 (MNa+. C16H29NNaO3 
requires 306.2040). 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxotetradec-5-ene (258d) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (274) (0.129 g, 0.416 mmol), nonanal (0.143 mL, 0.832 
mmol) and potassium carbonate (0.0632 g, 0.458 mmol) in acetonitrile (4 mL). Purification by flash 
column chromatography using silica gel, eluting with 30% diethyl ether in petroleum ether (40–
60) gave (2R,5E)-2-(tert-butoxycarbonylamino)-4-oxotetradec-5-ene (258d) as a colourless oil 
(0.098 g, 72%). νmax/cm−1 (neat) 3352 (NH), 2924 (CH), 1694 (C=O), 1501, 1366, 1246, 1169, 1053; 
[α]D
29 +6.5 (c 0.8, CHCl3); δH (400 MHz, CDCl3) 0.87 (3H, t, J 6.9 Hz, 14-H3), 1.19 (3H, d, J 6.7 Hz, 1-
H3), 1.22–1.35 (10H, m, 9-H2, 10-H2, 11-H2, 12-H2 and 13-H2), 1.38–1.50 (11H, m, 8-H2 and 3 × CH3), 
2.20 (2H, qd, J 7.0, 1.5 Hz, 7-H2), 2.62 (1H, dd, J 15.9, 6.5 Hz, 3-HH), 2.85 (1H, dd, J 15.9, 4.8 Hz, 3-
HH), 3.95–4.09 (1H, m, 2-H), 4.95 (1H, br s, NH), 6.07 (1H, dt, J 15.9, 1.5 Hz, 5-H), 6.84 (1H, dt, J 
15.9, 7.0 Hz, 6-H); δC (101 MHz, CDCl3) 14.1 (CH3), 20.5 (CH3), 22.7 (CH2), 28.1 (CH2), 28.4 (3 × CH3), 
29.2 (2 × CH2), 29.3 (CH2), 31.8 (CH2), 32.5 (CH2), 43.8 (CH), 45.7 (CH2), 79.2 (C), 130.6 (CH), 148.5 
(CH), 155.2 (C), 199.1 (C); m/z (ESI) 348.2498 (MNa+. C19H35NNaO3 requires 348.2509). 
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(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxopentadec-5-ene (258e) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (274) (0.405 g, 1.31 mmol), decanal (0.500 mL, 2.62 mmol) 
and potassium carbonate (0.199 g, 1.44 mmol) in acetonitrile (8 mL). Purification by flash column 
chromatography using silica gel, eluting with 30% diethyl ether in petroleum ether (40–60) gave 
(2R,5E)-2-(tert-butoxycarbonylamino)-4-oxopentadec-5-ene (258e) (0.345 g, 78%) as a colourless 
oil. νmax/cm−1 (neat) 3327 (NH), 2958 (CH), 1693 (C=O), 1365, 1170, 1053; [α]D
25 +4.2 (c 1.0, CHCl3); 
δH (400 MHz, CDCl3) 0.88 (3H, t, J 6.3 Hz, 15-H3), 1.20 (3H, d, J 6.7 Hz, 1-H3), 1.23–1.34 (12H, m, 9-
H2, 10-H2, 11-H2, 12-H2, 13-H2 and 14-H2), 1.39–1.50 (11H, m, 8-H2 and 3 × CH3), 2.20 (2H, q, J 7.0 
Hz, 7-H2), 2.63 (1H, dd, J 15.7, 6.6 Hz, 3-HH), 2.85 (1H, dd, J 15.7, 4.5 Hz, 3-HH), 3.96–4.08 (1H, m, 
2-H), 4.95 (1H, br s, NH), 6.08 (1H, d, J 15.6 Hz, 5-H), 6.85 (1H, dt, J 15.6, 7.0 Hz, 6-H); δC (126 MHz, 
CDCl3) 14.1 (CH3), 20.5 (CH3), 22.7 (CH2), 28.1 (CH2), 28.4 (3 × CH3), 29.2 (CH2), 29.3 (CH2), 29.4 
(CH2), 29.5 (CH2), 31.9 (CH2), 32.5 (CH2), 43.7 (CH), 45.7 (CH2), 79.2 (C), 130.6 (CH), 148.5 (CH), 
155.2 (C), 199.2 (C); m/z (ESI) 362.2649 (MNa+. C20H37NNaO3 requires 362.2666). 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxoheptadec-5-ene (258f) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (274) (0.750 g, 2.42 mmol), dodecanal (1.08 mL, 4.85 
mmol) and potassium carbonate (0.368 g, 2.66 mmol) in acetonitrile (10 mL). Purification by flash 
column chromatography using silica gel, eluting with 30% diethyl ether in petroleum ether (40–
60) gave (2R,5E)-2-(tert-butoxycarbonylamino)-4-oxoheptadec-5-ene (258f) as a colourless oil 
(0.734 g, 83%). νmax/cm−1 (neat) 3354 (NH), 2925 (CH), 1694 (C=O), 1515, 1366, 1248, 1172, 1053; 
[α]D
22 +4.8 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 0.87 (3H, t, J 6.8 Hz, 17-H3), 1.19 (3H, d, J 6.8 Hz, 1-
H3), 1.22–1.36 (16H, m, 9-H2, 10-H2, 11-H2, 12-H2, 13-H2, 14-H2, 15-H2 and 16-H2), 1.38–1.50 (11H, 
m, 8-H2, 3 × CH3), 2.20 (2H, qd, J 7.1, 1.4 Hz, 7-H2), 2.63 (1H, dd, J 15.9, 6.6 Hz, 3-HH), 2.85 (1H, dd, 
J 15.9, 4.7 Hz, 3-HH), 3.93–4.09 (1H, m, 2-H), 4.96 (1H, br s, NH), 6.07 (1H, dt, J 15.8, 1.4 Hz, 5-H), 
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6.85 (1H, dt, J 15.8, 7.1 Hz, 6-H); δC (101 MHz, CDCl3) 14.3 (CH3), 20.6 (CH3), 22.8 (CH2), 28.2 (CH2), 
28.6 (3 × CH3), 29.3 (CH2), 29.5 (2 × CH2), 29.7 (CH2), 29.8 (2 × CH2), 32.0 (CH2), 32.7 (CH2), 43.8 
(CH), 45.8 (CH2), 79.3 (C), 130.7 (CH), 148.7 (CH), 155.3 (C), 199.3 (C); m/z (ESI) 390.2985 (MNa+. 
C22H41NNaO3 requires 390.2979). 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-10-chloro-4-oxodec-5-ene (258g) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (274) (0.114 g, 0.367 mmol), 5-chloropentanal (0.089 g, 
0.735 mmol), potassium carbonate (0.0558 g, 0.404 mmol) in acetonitrile (4 mL). Purification by 
flash column chromatography using silica gel, eluting with 30% diethyl ether in petroleum ether 
(40–60) gave (2R,5E)-2-(tert-butoxycarbonylamino)-10-chloro-4-oxodec-5-ene (258g) as a 
colourless oil (0.098 g, 88%). νmax/cm−1 (neat) 3357 (NH), 2977 (CH), 1693 (C=O), 1663 (C=O), 1510, 
1366, 1247, 1167, 1053; [α]D
22 +4.7 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.19 (3H, d, J 6.8 Hz, 1-H3), 
1.42 (9H, s, 3 × CH3), 1.57–1.67 (2H, m, 8-H2), 1.74–1.88 (2H, m, 9-H2), 2.25 (2H, qd, J 6.9, 1.5 Hz, 
7-H2), 2.62 (1H, dd, J 15.9, 6.6 Hz, 3-HH), 2.85 (1H, dd, J 15.9, 4.7 Hz, 3-HH), 3.54 (2H, t, J 6.5 Hz, 
10-H2), 3.94–4.08 (1H, m, 2-H), 4.94 (1H, br s, NH), 6.09 (1H, dt, J 15.9, 1.5 Hz, 5-H), 6.83 (1H, dt, J 
15.9, 6.9 Hz, 6-H); δC (101 MHz, CDCl3) 20.6 (CH3), 25.4 (CH2), 28.5 (3 × CH3), 31.7 (CH2), 32.0 (CH2), 
43.8 (CH), 44.7 (CH2), 46.0 (CH2), 79.3 (C), 131.0 (CH), 147.2 (CH), 155.3 (C), 199.0 (C); m/z (ESI) 
326.1484 (MNa+. C15H2635ClNNaO3 requires 326.1493). 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-9,9,9-trifluoro-4-oxonona-5-ene (258h) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (274) (0.0454 g, 0.147 mmol), 4,4,4-trifluorobutanal 
(0.031 mL, 0.294 mmol) and potassium carbonate (0.0223 g, 0.161) in acetonitrile (5 mL). 
Purification with flash chromatography using silica gel, eluting with 30% diethyl ether in petroleum 
ether (40–60) gave (2R,5E)-2-(tert-butoxycarbonylamino)-9,9,9-trifluoro-4-oxonona-5-ene (258h) 
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as a clear oil (0.040 g, 88%). νmax/cm−1 (neat) 3361 (NH), 2979 (CH), 1696 (C=O), 1509, 1367, 1552, 
1138; [α]D
20 +7.5 (c 0.3, CHCl3); δH (400 MHz, CDCl3) 1.19 (3H, d, J 6.8 Hz, 1-H3), 1.42 (9H, s, 3 ×CH3), 
2.18–2.34 (2H, m, 8-H2), 2.44–2.53 (2H, m, 7-H2), 2.62 (1H, dd, J 15.9, 6.7 Hz, 3-HH), 2.85 (1H, dd, 
J 15.9, 4.9 Hz, 3-HH), 3.90–4.11 (1H, m, 2-H), 4.85 (1H, s, NH), 6.14 (1H, dt, J 15.9, 1.6 Hz, 5-H), 
6.49 (1H, dt, J 15.9, 6.7 Hz, 6-H); δC (101 MHz, CDCl3) 20.5 (CH3), 24.9 (q, 4JCF 3.3 Hz, CH2), 28.4 (3 
× CH3), 32.4 (q, 3JCF 29.2 Hz, CH2), 43.7 (CH), 46.4 (CH2), 79.3 (C), 126.5 (q, 2JCF 277 Hz, C), 131.5 
(CH), 143.4 (CH), 155.1 (C), 198.3 (C); m/z (ESI) 332.1446 (MNa+. C14H22F3NNaO3 requires 332.1449). 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-8-cyclohexyl-4-oxooct-5-ene (258i) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (274) (0.044 g, 0.144 mmol), 3-cyclohexylpropanal (0.040 
g, 0.288 mmol) and potassium carbonate (0.0219 g, 0.158 mmol) in acetonitrile (4 mL). Purification 
by flash column chromatography using silica gel, eluting with 30% diethyl ether in petroleum ether 
(40–60) gave (2R,5E)-2-(tert-butoxycarbonylamino)-8-cyclohexyl-4-oxodec-5-ene (258i) as a 
colourless oil (0.037 g, 79%). νmax/cm−1 (neat) 3341 (NH), 2924 (CH), 1694 (C=O), 1512, 1366, 1246, 
1169, 1053; [α]D
24 +5.1 (c 0.9, CHCl3); δH (400 MHz, CDCl3) 0.80–0.96 (2H, m, CH2), 1.09–1.28 (8H, 
m, 1-H3, 8-CH, 2 × CH2), 1.34 (2H, q, J 6.9 Hz, 8-H2), 1.43 (9H, s, 3 × CH3), 1.60–1.78 (4H, m, 2 × CH2), 
2.22 (2H, qd, J 6.9, 1.5 Hz, 7-H2), 2.63 (1H, dd, J 15.8, 6.6 Hz, 3-HH), 2.85 (1H, dd, J 15.8, 4.8 Hz, 3-
HH), 3.97–4.07 (1H, m, 2-H), 4.94 (1H, br s, NH), 6.08 (1H, dd, J 15.9, 1.5 Hz, 5-H), 6.85 (1H, dd, J 
15.9, 6.9 Hz, 6-H); δC (101 MHz, CDCl3) 20.7 (CH3), 26.4 (2 × CH2), 26.7 (CH2), 28.6 (3 × CH3), 30.1 
(CH2), 33.3 (2 × CH2), 35.8 (CH2), 37.3 (CH), 43.9 (CH), 45.8 (CH2), 79.3 (C), 130.6 (CH), 149.0 (CH), 
155.3 (C), 199.3 (C); m/z (ESI) 346.2343 (MNa+. C19H33NNaO3 requires 346.2353). 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxo-8-phenyloct-5-ene (258j) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258a) using (4R)-4-(tert-butoxycarbonylamino)-1-
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(dimethyloxyphosphoryl)pentan-2-one (274) (0.349 g, 1.13 mmol), hydrocinnamaldehyde (0.300 
mL, 2.26 mmol) and potassium carbonate (0.172 g, 1.24 mmol). Purification by flash column 
chromatography using silica gel, eluting with 20% ethyl acetate in petroleum ether (40–60) gave 
(2R,5E)-2-(tert-butoxycarbonylamino)-4-oxo-8-phenyloct-5-ene (258j) (0.288 g, 80%) as a pale 
yellow oil. νmax/cm−1 (neat) 3353 (NH), 2976 (CH), 1692 (C=O), 1496 (C=C), 1247, 1221, 1054; [α]D
23 
+4.1 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.17 (3H, d, J 6.7 Hz, 1-H3), 1.43 (9H, s, 3 × CH3), 2.53 (2H, 
q, J 6.8 Hz, 7-H2), 2.60 (1H, dd, J 15.7, 7.8 Hz, 3-HH), 2.77 (2H, t, J 6.8 Hz, 8-H2), 2.84 (1H, dd, J 15.7, 
4.5 Hz, 3-HH), 3.95–4.08 (1H, m, 2-H), 4.99 (1H, br s, NH), 6.09 (1H, d, J 15.9 Hz, 5-H), 6.87 (1H, dt, 
J 15.9, 6.8 Hz, 6-H), 7.14–7.23 (3H, m, 3 × ArH), 7.25–7.32 (2H, m, 2 × ArH); δC (101 MHz, CDCl3) 
20.5 (CH3), 28.5 (3 × CH3), 34.2 (CH2), 34.4 (CH2), 43.7 (CH), 45.9 (CH2), 79.2 (C), 126.3 (CH), 128.4 
(2 × CH), 128.6 (2 × CH), 131.1 (CH), 140.7 (C), 147.0 (CH), 155.2 (C), 199.0 (C); m/z (ESI) 340.1868 
(MNa+. C19H27NNaO3 requires 340.1883). 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-8-methyl-4-oxonon-5-ene (258k) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (274) (0.141 g, 0.455 mmol), isovaleraldehyde (0.097 mL, 
0.910 mmol) and potassium carbonate (0.0692 g, 0.501 mmol) in acetonitrile (5 mL). Purification 
by flash column chromatography using silica gel, eluting with 40% diethyl ether in petroleum ether 
(40–60) gave (2R,5E)-2-(tert-butoxycarbonylamino)-8-methyl-4-oxonon-5-ene (258k) (0.080 g, 
70%) as a colourless oil. νmax/cm−1 (neat) 3356 (NH), 2963 (CH), 1690 (C=O), 1504, 1366, 1165, 
1250, 1049;  [α]D
29 +7.5 (c 0.5, CHCl3); δH (400 MHz, CDCl3) 0.91 (6H, d, J 6.7 Hz, 8-CH3 and 9-H3), 
1.18 (3H, d, J 6.8 Hz, 1-H3), 1.41 (9H, s, 3 × CH3), 1.67–1.83 (1H, m, 8-H), 2.09 (2H, td, J 7.5, 1.3 Hz, 
7-H2), 2.62 (1H, dd, J 15.9, 6.6 Hz, 3-HH), 2.84 (1H, dd, J 15.9, 4.8 Hz, 3-HH), 3.94–4.08 (1H, m, 2-
H), 4.95 (1H, br s, NH), 6.06 (1H, dt, J 15.7, 1.3 Hz, 5-H), 6.81 (1H, dt, J 15.7, 7.5, 6-H); δC (101 MHz, 
CDCl3) 20.6 (CH3), 22.5 (2 × CH3), 28.0 (CH), 28.5 (3 × CH3), 41.9 (CH2), 43.9 (CH), 45.9 (CH2), 79.3 
(C), 131.8 (CH), 147.3 (CH), 155.3 (C), 199.1 (C); m/z (ESI) 292.1873 (MNa+. C15H27NNaO3 requires 
292.1883). 
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(2R,5E)-2-(tert-Butoxycarbonylamino)-7-methyl-4-oxooct-5-ene (258l) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (274) (0.160 g, 0.517 mmol), isobutyraldehyde (0.095 mL, 
1.04 mmol) and potassium carbonate ( Purification by flash column chromatography using silica 
gel, eluting with 30% diethyl ether in petroleum ether (40–60) gave (2R,5E)-2-(tert-
butoxycarbonylamino)-7-methyl-4-oxooct-5-ene (258l) (0.112 g, 85%) as a colourless oil. νmax/cm−1 
(neat) 3356 (NH), 2970 (CH), 1690 (C=O), 1512, 1366, 1250, 1165, 1049;  [α]D
29 +9.4 (c 1.2, CHCl3); 
δH (400 MHz, CDCl3) 1.02 (6H, d, J 6.8 Hz, 7-CH3 and 8-H3), 1.15 (3H, d, J 6.8 Hz, 1-H3), 1.38 (9H, s, 
3 × CH3), 2.35–2.47 (1H, m, 7-H), 2.60 (1H, dd, J 16.0, 6.6 Hz, 3-HH), 2.81 (1H, dd, J 16.0, 4.8 Hz, 3-
HH), 3.90–4.05 (1H, m, 2-H), 4.97 (1H, br s, NH), 5.99 (1H, dd, J 16.0, 1.2 Hz, 5-H), 6.76 (1H, dd, J 
16.0, 6.7 Hz, 6-H); δC (101 MHz, CDCl3) 20.6 (CH3), 21.3 (2 × CH3), 28.5 (3 × CH3), 31.2 (CH), 43.7 
(CH), 45.8 (CH2), 79.1 (C), 127.8 (CH), 154.3 (CH), 155.2 (C), 199.4 (C); m/z (ESI) 278.1722 (MNa+. 
C14H25NNaO3 requires 278.1727). 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxo-6-phenylhex-5-ene (258m) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (274) (0.251 g, 0.810 mmol), benzaldehyde (0.160 mL, 1.62 
mmol) and potassium carbonate (0.246 g, 1.78 mmol) in acetonitrile (8 mL). Purification by flash 
column chromatography using silica gel, eluting with 20% ethyl acetate in petroleum ether (40–
60) gave (2R,5E)-2-(tert-butoxycarbonylamino)-4-oxo-6-phenylhex-5-ene (258m)  (0.227 g, 97%) 
as a white solid. Mp 59–62 °C; νmax/cm−1 (neat) 3345 (NH), 2976 (CH), 1687 (C=O), 1655 (C=O), 
1608 (C=C), 1495, 1365, 1247, 1166;  [α]D
23 +10.0 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.25 (3H, d, J 
6.8 Hz, 1-H3), 1.43 (9H, s, 3 × CH3), 2.77 (1H, dd, J 15.8, 6.8 Hz, 3-HH), 3.00 (1H, dd, J 15.8, 4.6 Hz, 
3-HH), 4.05–4.18 (1H, m, 2-H), 5.04 (1H, br s, NH), 6.73 (1H, d, J 16.2 Hz, 5-H), 7.36–7.41 (3H, m, 3 
× ArH), 7.52–7.54 (2H, m, 2 × ArH), 7.56 (1H, d, J 16.2 Hz, 6-H); δC (101 MHz, CDCl3) 20.6 (CH3), 28.4 
193 
 
(3 × CH3), 43.8 (CH), 46.6 (CH2), 79.2 (C), 126.4 (CH), 128.4 (2 × CH), 129.0 (2 × CH), 130.6 (CH), 
134.4 (C), 143.2 (CH), 155.2 (C), 198.9 (C); m/z (ESI) 312.1558 (MNa+. C17H23NNaO3 requires 
312.1570). 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-8,8-dimethyl-4-oxonona-5-ene (258p) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (274) (0.100 g, 0.323 mmol), 3,3-dimethylbutanal (0.081 
mL, 0.647 mmol) and potassium carbonate (0.0469 g, 0.339 mmol) in acetonitrile (4 mL). 
Purification with flash chromatography using silica gel, eluting with 20% diethyl ether in petroleum 
ether (40–60) gave (2R,5E)-2-(tert-butoxycarbonylamino)-8,8-dimethyl-4-oxonona-5-ene (258p) 
as a clear oil (0.015 g, 16%). νmax/cm−1 (neat) 3353 (NH), 2960 (CH), 1695 (C=O), 1514, 1366, 1248, 
1172, 1054; [α]D
20 +6.8 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 0.94 (9H, s, 2 × 8-CH3 and 9-H3), 1.20 (3H, 
d, J 6.7 Hz, 1-H3), 1.43 (9H, s, 3 × CH3), 2.09 (2H, dd, J 7.8, 1.3 Hz, 7-H), 2.63 (1H, dd, J 15.8, 6.6 Hz, 
3-HH), 2.86 (1H, dd, J 15.8, 4.8 Hz, 3-HH), 3.89–4.14 (1H, m, 2-H), 4.93 (1H, s, NH), 6.07 (1H, dt, J 
15.7, 1.3 Hz, 5-H), 6.88 (1H, dt, J 15.7, 7.8 Hz, 6-H); δC (101 MHz, CDCl3) 20.6 (CH3), 28.4 (3 × CH3), 
29.4 (3 × CH3), 31.5 (CH2), 43.8 (CH), 45.9 (CH2), 46.7 (C), 79.3 (C), 132.5 (CH), 145.8 (CH), 155.2 (C), 
198.8 (C); m/z (ESI) 306.2043 (MNa+. C16H29NNaO3 requires 306.2045). 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-8-methoxy-4-oxoocta-5-ene (258r) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (274) (0.0498 g, 0.161 mmol), 3-methoxypropanal (0.032 
mL, 0.322 mmol) and potassium carbonate (0.0245 g, 0.177) in acetonitrile (4 mL). Purification 
with flash chromatography using silica gel, eluting with 30% diethyl ether in petroleum ether (40–
60) gave (2R,5E)-2-(tert-butoxycarbonylamino)-8-methoxy-4-oxoocta-5-ene (258r) as a clear oil 
(0.0093 g, 21%). νmax/cm−1 (neat) 3348 (NH), 2976 (CH), 1696 (C=O), 1518, 1366, 1171, 1117; [α]D
20 
+10.3 (c 0.3, CHCl3); δH (400 MHz, CDCl3) 1.20 (3H, d, J 6.8 Hz, 1-H3), 1.43 (9H, s, 3 × CH3), 2.48 (2H, 
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br qd, J 6.6, 1.5 Hz, 7-H2), 2.65 (1H, dd, J 16.1, 6.5 Hz, 3-HH), 2.85 (1H, dd, J 16.1, 4.8 Hz, 3-HH), 
3.34 (3H, s, OCH3), 3.50 (2H, t, J 6.6 Hz, 8-H2), 3.85–4.21 (1H, m, 2-H), 4.93 (1H, s, NH), 6.14 (1H, 
dt, J 16.0, 1.5 Hz, 5-H), 6.84 (1H, dt, J 16.0, 6.6 Hz, 6-H); δC (101 MHz, CDCl3) 20.5 (CH3), 28.4 (3 × 
CH3), 32.8 (CH2), 43.7 (CH), 45.8 (CH2), 58.7 (CH3), 70.7 (CH3), 79.2 (C), 132.0 (CH), 144.5 (CH), 155.1 
(C), 198.8 (C); m/z (ESI) 294.1674 (MNa+. C14H25NNaO4 requires 294.1681). 
 
tert-Butyl (2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (264a) and tert-butyl 
(2R,6S)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (265a) 
 
 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxonona-5-ene (258a) (0.0756 g, 0.296 mmol) was 
dissolved in methanol (7.4 mL) and cooled to −78 °C. 2 M Hydrochloric acid in diethyl ether (0.148 
mL, 0.296 mmol) was added and the solution stirred at this temperature for 1 h and, then at room 
temperature for 1 h. Upon completion, the mixture was concentrated in vacuo. Purification by 
flash column chromatography using silica gel, eluting with 30% diethyl ether in petroleum ether 
(40–60) gave tert-butyl (2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (264a) (0.0369 
g, 49%) and tert-butyl (2R,6S)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (265a) (0.0253 g, 
33%) as colourless oils. Data for (2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (264a): 
νmax/cm−1 (neat) 2964 (CH), 1726 (C=O), 1688 (C=O), 1389, 1174, 1101;  [α]D
22 +151.7 (c 1.0, CHCl3); 
δH (400 MHz, CDCl3) 0.90 (3H, t, J 7.2 Hz, 3’’-H3), 1.20–1.39 (6H, m, 1’-H3, 1’’-HH and 2’’-H2), 1.49 
(9H, s, 3 × CH3), 1.65–1.78 (1H, m, 1’’-HH), 2.35 (1H, dd, J 17.7, 2.0 Hz, 3-HH), 2.52 (1H, dd, J 17.9, 
2.0 Hz, 5-HH), 2.70 (1H, ddd, J 17.9, 6.3, 1.4 Hz, 5-HH), 2.81 (1H, dd, J 17.7, 6.3 Hz, 3-HH), 4.10–
4.22 (1H, m, 6-H), 4.29–4.40 (1H, m, 2-H); δC (101 MHz, CDCl3) 14.0 (CH3), 20.1 (CH2), 22.9 (CH3), 
28.6 (3 × CH3), 39.4 (CH2), 41.4 (CH2), 44.7 (CH2), 46.6 (CH), 51.0 (CH), 80.0 (C), 154.7 (C), 208.3 (C); 
m/z (ESI) 278.1730 (MNa+. C14H25NNaO3 requires 278.1727). Data for tert-butyl (2R,6S)-2-methyl-
4-oxo-6-propylpiperidine-1-carboxylate (265a): νmax/cm−1 (neat) 2969 (CH), 1719 (C=O), 1690 
(C=O), 1403, 1354, 1174, 1116;  [α]D
22 −14.2 (c 0.5, CHCl3); δH (500 MHz, CDCl3) 0.91 (3H, t, J 7.3 Hz, 
3’’-H3), 1.16–1.38 (5H, m, 1’-H3 and 2’’-H2), 1.40–1.52 (10H, m, 1’’-HH and 3 × CH3), 1.54–1.62 (1H, 
m, 1’’-HH), 2.23–2.35 (2H, m, 3-HH and 5-HH), 2.65 (1H, dd, J 15.0, 7.5 Hz, 5-HH), 2.70 (1H, dd, J 
15.0, 8.0 Hz, 3-HH), 4.52–4.62 (1H, m, 6-H), 4.64–4.76 (1H, m, 2-H); δC (126 MHz, CDCl3) 14.0 (CH3), 
20.2 (CH2), 22.8 (CH3), 28.6 (3 × CH3), 39.3 (CH2), 43.9 (CH2), 45.6 (CH2), 48.5 (CH), 52.6 (CH), 80.3 
(C), 154.9 (C), 208.9 (C); m/z (ESI) 278.1715 (MNa+. C14H25NNaO3 requires 278.1727). 
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tert-Butyl (2R,6R)-6-butyl-2-methyl-4-oxopiperidine-1-carboxylate (264b) and tert-butyl 
(2R,6S)-6-butyl-2-methyl-4-oxopiperidine-1-carboxylate (265b) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of tert-butyl 
(2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (264a) using (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxodec-5-ene (258b) (0.0616 g, 0.229 mmol). Purification by flash 
column chromatography using silica gel, eluting with 20% diethyl ether in petroleum ether (40–
60) gave tert-butyl (2R,6R)-6-butyl-2-methyl-4-oxopiperidine-1-carboxylate (264b) (0.0320 g, 52%) 
and tert-butyl (2R,6S)-6-butyl-2-methyl-4-oxopiperidine-1-carboxylate (265b) (0.0189 g, 31%) as 
a colourless oils. Data for  tert-butyl (2R,6R)-6-butyl-2-methyl-4-oxopiperidine-1-carboxylate 
(264b): νmax/cm−1 (neat) 2961 (CH), 1727 (C=O), 1691 (C=O), 1390, 1175;  [α]D
20 +131.8 (c 0.2, CHCl3); 
δH (400 MHz, CDCl3) 0.88 (3H, t, J 7.0 Hz, 4’’-H3), 1.17–1.39 (8H, m, 1’-H3, 1’’-HH, 2’’-H2 and 3’’-H2), 
1.49 (9H, s, 3 × CH3), 1.68–1.86 (1H, m, 1’’-HH), 2.35 (1H, dd, J 17.7, 1.9 Hz, 3-HH), 2.52 (1H, dd, J 
17.9, 2.1 Hz, 5-HH), 2.72 (1H, ddd, J 17.9, 6.2, 1.4 Hz, 5-HH), 2.81 (1H, dd, J 17.7, 6.4 Hz, 3-HH), 
4.04–4.24 (1H, m, 6-H), 4.30–4.44 (1H, m, 2-H); δC (101 MHz, CDCl3) 14.0 (CH3), 22.5 (CH2), 22.7 
(CH3), 28.5 (3 × CH3), 28.9 (CH2), 36.9 (CH2), 41.3 (CH2), 44.6 (CH2), 46.5 (CH), 51.2 (CH), 79.9 (C), 
154.6 (C), 208.0 (C); m/z (ESI) 292.1886 (MNa+. C15H27NNaO3 requires 292.1889). Data for tert-
butyl (2R,6S)-6-butyl-2-methyl-4-oxopiperidine-1-carboxylate (265b): νmax/cm−1 2929, 1692 (C=O), 
1367, 1175; [α]D
20 −9.2 (c 0.1, CHCl3); δH (500 MHz, CDCl3) 0.89 (3H, t, J 7.1 Hz, 4’’-H3), 1.26 (3H, t, J 
7.0 Hz, 1’-H3), 1.29–1.38 (4H, m, 2’’-H2 and 3’’-H2), 1.44–1.53 (10H, m, 3 × CH3 and 1’’-HH), 1.55–
1.66 (1H, m, 1’’-HH), 2.24–2.37 (2H, m, 3-HH and 5-HH), 2.62–2.75 (2H, m, 3-HH and 5-HH), 4.48–
4.64 (1H, m, 6-H), 4.64–4.80 (1H, m, 2-H); δC (126 MHz, CDCl3) 14.1 (CH3), 22.6 (CH2), 22.8 (CH3), 
28.6 (3 × CH3), 29.3 (CH2), 36.8 (CH2), 44.0 (CH2), 45.7 (CH2), 48.5 (CH), 52.9 (CH), 80.3 (C), 155.0 
(C), 208.9 (C); m/z (ESI) 292.1887 (MNa+. C15H27NNaO3 requires 292.1889). 
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tert-Butyl (2R,6R)-2-methyl-4-oxo-6-pentylpiperidine-1-carboxylate (264c) and tert-butyl 
(2R,6S)-2-methyl-4-oxo-6-pentylpiperidine-1-carboxylate (265c) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of tert-butyl 
(2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (264a) using (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxoundec-5-ene (258c) (0.0852 g, 0.301 mmol). Purification by flash 
column chromatography using silica gel, eluting with 20% diethyl ether in petroleum ether (40–
60) gave tert-butyl (2R,6R)-2-methyl-4-oxo-6-pentylpiperidine-1-carboxylate (264c) (0.0402 g, 
47%) and (2R,6S)-2-methyl-4-oxo-6-pentylpiperidine-1-carboxylate (265c) (0.0302 g, 35%) as a 
colourless oils. Data for tert-butyl (2R,6R)-2-methyl-4-oxo-6-pentylpiperidine-1-carboxylate 
(264c): νmax/cm−1 (neat) 2932 (CH), 1728 (C=O), 1690 (C=O), 1366, 1173; [α]D
25 +139.9 (c 0.4, CHCl3); 
δH (500 MHz, CDCl3) 0.86 (3H, t, J 6.8 Hz, 5’’-H3), 1.17–1.35 (10H, m, 1’-H3, 1’’-HH, 2’’-H2, 3’’-H2 and 
4’’-H2), 1.49 (9H, s, 3 × CH3), 1.67–1.80 (1H, m, 1’’-HH), 2.36 (1H, dd, J 17.7, 1.9 Hz, 3-HH), 2.53 (1H, 
dd, J 17.9, 2.0 Hz, 5-HH), 2.71 (1H, ddd, J 17.9, 6.2, 1.3 Hz, 5-HH), 2.80 (1H, dd, J 17.7, 6.4 Hz, 3-
HH), 4.05–4.22 (1H, m, 6-H), 4.25–4.40 (1H, m, 2-H); δC (126 MHz, CDCl3) 14.1 (CH3), 22.7 (CH2), 
22.9 (CH3), 26.6 (CH2), 28.6 (3 × CH3), 31.7 (CH2), 37.3 (CH2), 41.4 (CH2), 44.7 (CH2), 46.6 (CH), 51.3 
(CH), 80.0 (C), 154.7 (C), 208.3 (C); m/z (ESI) 306.2034 (MNa+. C16H29NNaO3 requires 306.2040). 
Data for (2R,6S)-2-methyl-4-oxo-6-pentylpiperidine-1-carboxylate (265c): νmax/cm−1 2931, 1690 
(C=O), 1350, 1173;  [α]D
20 −20.8 (c 0.2, CHCl3); δH (500 MHz, CDCl3) 0.81 (3H, t, J 7.1 Hz, 5’’-H3), 
1.15–1.30 (9H, m, 1’-H3, 2’’-H2, 3’’-H2 and 4’’-H2), 1.38–1.47 (10H, m, 3 × CH3 and 1’’-HH), 1.49–
1.57 (1H, m, 1’’-HH), 2.16–2.33 (2H, m, 3-HH and 5-HH), 2.53–2.72 (2H, m, 3-HH and 5-HH), 4.43–
4.57 (1H, m, 6-H), 4.58–4.74 (1H, m, 2-H); δC (126 MHz, CDCl3) 14.1 (CH3), 22.7 (CH2), 22.8 (CH3), 
26.8 (CH2), 28.6 (3 × CH3), 31.7 (CH2), 37.1 (CH2), 44.0 (CH2), 45.7 (CH2), 48.5 (CH), 52.9 (CH), 80.3 
(C), 155.0 (C), 209.0 (C); m/z (ESI) 306.2039 (MNa+. C16H29NNaO3 requires 306.2040). 
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tert-Butyl (2R,6R)-2-methyl-6-octyl-4-oxopiperidine-1-carboxylate (264d) and tert-butyl (2R,6S)-
2-methyl-6-octyl-4-oxopiperidine-1-carboxylate (265d) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of tert-butyl 
(2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (264a) using (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxotetraadec-5-ene (258d) (0.0977 g, 0.300 mmol). Purification by flash 
column chromatography using silica gel, eluting with 20% diethyl ether in petroleum ether (40–
60) gave tert-butyl (2R,6R)-2-methyl-6-octyl-4-oxopiperidine-1-carboxylate (264d) (0.0495 g, 51%) 
and tert-butyl (2R,6S)-2-methyl-6-octyl-4-oxopiperidine-1-carboxylate (265d) (0.0318, 33%) as a 
colourless oils. Data for tert-butyl (2R,6R)-2-methyl-6-octyl-4-oxopiperidine-1-carboxylate (264d): 
νmax/cm−1 (neat) 2924 (CH), 1728 (C=O), 1690 (C=O), 1366, 1172;  [α]D
30 +158.2 (c 0.6, CHCl3); δH 
(400 MHz, CDCl3) 0.87 (3H, t, J 6.9 Hz, 8’’-H3), 1.15–1.35 (16H, m, 1’-H3, 1’’-HH, 2’’-H2, 3’’-H2, 4’’-
H2, 5’’-H2, 6’’-H2, and 7’’-H2), 1.49 (9H, s, 3 × CH3), 1.65–1.80 (1H, m, 1’’-HH), 2.36 (1H, dd, J 17.8, 
1.9 Hz, 3-HH), 2.53 (1H, dd, J 17.9, 2.0 Hz, 5-HH), 2.72 (1H, ddd, J 17.9, 6.2, 1.3 Hz, 5-HH), 2.81 (1H, 
dd, J 17.8, 6.4 Hz, 3-HH), 4.05–4.20 (1H, m, 6-H), 4.28–4.45 (1H, m, 2-H); δC (101 MHz, CDCl3) 14.2 
(CH3), 22.8 (CH2), 22.9 (CH3), 26.9 (CH2), 28.6 (3 × CH3), 29.3 (CH2), 29.6 (CH2), 29.7 (CH2), 32.0 (CH2), 
37.3 (CH2), 41.4 (CH2), 44.7 (CH2), 46.6 (CH), 51.3 (CH), 80.0 (C), 154.7 (C), 208.3 (C); m/z (ESI) 
348.2515 (MNa+. C19H35NNaO3 requires 348.2509). Data for tert-butyl (2R,6S)-2-methyl-6-octyl-4-
oxopiperidine-1-carboxylate (265d): νmax/cm−1 2924, 1690 (C=O), 1350, 1173;  [α]D
20 −15.4 (c 0.2, 
CHCl3); δH (500 MHz, CDCl3) 0.87 (3H, t, J 7.0 Hz, 8’’-H3), 1.15–1.39 (15H, m, 1’-H3, 2’’-H2, 3’’-H2, 4’’-
H2, 5’’-H2, 6’’-H2 and 7’’-H2), 1.48–1.54 (10H, m, 3 × CH3 and 1’’-HH), 1.54–1.64 (1H, m, 1’’-HH), 
2.24–2.37 (2H, m, 3-HH and 5-HH), 2.62–2.76 (2H, m, 3-HH and 5-HH), 4.49–4.64 (1H, m, 6-H), 
4.64–4.80 (1H, m, 2-H); δC (126 MHz, CDCl3) 14.2 (CH3), 22.8 (CH2), 22.9 (CH3), 27.1 (CH2), 28.6 (3 
× CH3), 29.3 (CH2), 29.5 (CH2), 29.7 (CH2), 32.0 (CH2), 37.2 (CH2), 44.0 (CH2), 45.7 (CH2), 48.5 (CH), 
52.9 (CH), 80.3 (C), 154.9 (C), 209.0 (C); m/z (ESI) 348.2494 (MNa+. C19H35NNaO3 requires 348.2509). 
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tert-Butyl (2R,6R)-2-methyl-6-nonyl-4-oxopiperidine-1-carboxylate (264e) and tert-butyl 
(2R,6S)-2-methyl-6-nonyl-4-oxopiperidine-1-carboxylate (265e)217 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of tert-butyl 
(2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (264a) using (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxopentadec-5-ene (258e) (0.0996 g, 0.148 mmol). Purification by flash 
column chromatography using silica gel, eluting with 20% diethyl ether in petroleum ether (40–
60) gave tert-butyl (2R,6R)-2-methyl-6-nonyl-4-oxopiperidine-1-carboxylate (264e) (0.0444 g, 55%) 
and tert-butyl (2R,6S)-2-methyl-6-nonyl-4-oxopiperidine-1-carboxylate (265e) (0.329 g, 33%) as a 
colourless oils. Data for tert-butyl (2R,6R)-2-methyl-6-nonyl-4-oxopiperidine-1-carboxylate (264e):  
νmax/cm−1 (neat) 2925 (CH), 1726 (C=O), 1691 (C=O), 1389, 1175, 1094; [α]D
23 +102.4 (c 1.1, CHCl3); 
δH (400 MHz, CDCl3) 0.87 (3H, t, J 6.8 Hz, 9’’-H3), 1.16–1.36 (18H, m, 1’-H3, 1’’-HH, 2’’-H2, 3’’-H2, 4’’-
H2, 5’’-H2, 6’’-H2, 7’’-H2 and 8’’-H2), 1.49 (9H, s, 3 × CH3), 1.68–1.80 (1H, m, 1’’-HH), 2.35 (1H, dd, J 
17.7, 1.8 Hz, 3-HH), 2.52 (1H, dd, J 18.0, 1.8 Hz, 5-HH), 2.71 (1H, ddd, J 18.0, 5.5, 0.8 Hz, 5-HH), 
2.80 (1H, dd, J 17.7, 6.4 Hz, 3-HH), 4.08–4.19 (1H, m, 6-H), 4.29–4.40 (1H, m, 2-H); δC (101 MHz, 
CDCl3) 14.1 (CH3), 22.7 (CH2), 22.7 (CH3), 26.8 (CH2), 28.5 (3 × CH3), 29.3 (CH2), 29.4 (CH2), 29.5 
(CH2), 29.6 (CH2), 31.9 (CH2), 37.2 (CH2), 41.3 (CH2), 44.6 (CH2), 46.5 (CH), 51.2 (CH), 79.9 (C), 154.5 
(C), 208.2 (C); m/z (ESI) 362.2662 (MNa+. C20H37NNaO3 requires 362.2666). Data for tert-butyl 
(2R,6S)-2-methyl-6-nonyl-4-oxopiperidine-1-carboxylate (265e): Spectroscopic data was 
consistent with the literature.217 νmax/cm−1 (neat) 2926, 1690 (C=O), 1353, 1173; [α]D
23 −13.4 (c 0.9, 
CHCl3), lit.217 [α]D −21.5 (c 1.1, CHCl3); δH (500 MHz, CDCl3) 0.87 (3Η, t, J 7.0 Hz, 9’’-Η3), 1.17–1.40 
(17Η, m, 1’-Η3, 2’’-Η2, 3’’-Η2, 4’’-Η2, 5’’-Η2, 6’’-Η2, 7’’-Η2 and 8’’-Η2), 1.44–1.55 (10Η, 3 × CΗ3 and 
1’’-ΗΗ), 1.55–1.65 (1Η, m, 1’’-ΗΗ), 2.24–2.36 (2Η, m, 3-ΗΗ and 5-ΗΗ), 2.61–2.76 (2Η, m, 3-ΗΗ and 
5-ΗΗ), 4.53–4.62 (1Η, m, 6-Η), 4.66–4.76 (1Η, m, 2-Η); δC (126 MHz, CHCl3) 14.2 (CΗ3), 22.8 (CΗ2), 
22.8 (CΗ3), 27.1 (CΗ2), 28.6 (3 × CΗ3), 29.4 (CΗ2), 29.5 (CΗ2), 29.6 (CΗ2), 29.7 (CΗ2), 32.0 (CΗ2), 37.2 
(CΗ2), 44.0 (CΗ2), 45.7 (CΗ2), 48.5 (CΗ), 52.9 (CΗ), 80.3 (C), 154.9 (C), 209.0 (C); m/z (ESI) 362 (MNa+, 
100%). 
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tert-Butyl (2R,6R)-2-methyl-4-oxo-6-undecylpiperidine-1-carboxylate (264f) and tert-butyl 
(2R,6S)-2-methyl-4-oxo-6-undecylpiperidine-1-carboxylate (265f)217 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of tert-butyl 
(2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (264a) using (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxoheptadec-5-ene (258f) (0.113 g, 0.307 mmol). Purification by flash 
column chromatography using silica gel, eluting with 20% diethyl ether in petroleum ether (40–
60) gave tert-butyl (2R,6R)-2-methyl-4-oxo-6-undecylpiperidine-1-carboxylate (264f) (0.0551 g, 
49%) and tert-butyl (2R,6S)-2-methyl-4-oxo-6-undecylpiperidine-1-carboxylate (265f) (0.0270 g, 
24%) as a colourless oils. Data for tert-butyl (2R,6R)-2-methyl-4-oxo-6-undecylpiperidine-1-
carboxylate (264f): νmax/cm−1 (neat) 2924 (CH), 1726 (C=O), 1691 (C=O), 1389, 1174, 1095; [α]D
24 
+92.7 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 0.88 (3H, t, J 6.9 Hz, 11’’-H3), 1.18–1.38 (22H, m, 1’-H3, 
1’’-HH, 2’’-H2, 3’’-H2, 4’’-H2, 5’’-H2, 6’’-H2, 7’’-H2, 8’’-H2, 9’’-H2 and 10’’-H2), 1.49 (9H, s, 3 × CH3), 
1.66–1.80 (1H, m, 1’’-HH), 2.36 (1H,  dd, J 17.7, 1.9 Hz, 3-HH), 2.53 (1H, dd, J 17.9, 2.0 Hz, 5-HH), 
2.71 (1H, ddd, J 17.9, 6.2, 1.3 Hz, 5-HH), 2.81 (1H, dd, J 17.7, 6.5 Hz, 3-HH), 4.07–4.23 (1H, m, 6-H), 
4.27–4.43 (1H, m, 2-H); δC (101 MHz, CDCl3) 14.3 (CH3), 22.8 (CH2), 22.9 (CH3), 26.9 (CH2), 28.7 (3 
× CH3), 29.5 (CH2), 29.6 (CH2), 29.7 (3 × CH2), 29.8 (CH2) 32.1 (CH2), 37.3 (CH2), 41.4 (CH2), 44.7 
(CH2), 46.6 (CH), 51.3 (CH), 80.0 (C), 154.7 (C), 208.3 (C); m/z (ESI) 390.2963 (MNa+. C22H41NNaO3 
requires 390.2979). Data for tert-butyl (2R,6S)-2-methyl-4-oxo-6-undecylpiperidine-1-carboxylate 
(265f): Spectroscopic data was consistent with the literature.217 νmax/cm−1 (neat) 2924, 2854, 1691 
(C=O), 1353, 1172; [α]D
24 −11.0 (c 0.9, CHCl3), lit.217 [α]D −19.7 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 
0.88 (3Η, t, J 6.9 Hz, 11’’-Η3), 1.18–1.40 (21Η, m, 1’-Η3, 2’’-Η2, 3’’-Η2, 4’’-Η2, 5’’-Η2, 6’’-Η2, 7’’-Η2, 
8’’-Η2, 9’’-H2 and 10’’-H2), 1.45–1.55 (10Η, 3 × CΗ3 and 1’’-ΗΗ), 1.55–1.65 (1Η, m, 1’’-ΗΗ), 2.24–
2.37 (2Η, m, 3-ΗΗ and 5-ΗΗ), 2.62–2.77 (2Η, m, 3-ΗΗ and 5-ΗΗ), 4.51–4.64 (1Η, m, 6-Η), 4.65–
4.80 (1Η, m, 2-Η); δC (101 MHz, CHCl3) 14.2 (CH3), 22.8 (CH3), 22.8 (CH2), 27.1 (CH2), 28.6 (3 × CH3), 
29.5 (2 × CH2), 29.7 (4 × CH2), 32.0 (CH2), 37.2 (CH2), 44.0 (CH2), 45.7 (CH2), 48.5 (CH), 52.9 (CH), 
80.3 (C), 154.9 (C), 208.9 (C); m/z (ESI) 390 (MNa+, 100%). 
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tert-Butyl (2R,6R)-6-(4’’-chlorobutyl)-2-methyl-4-oxopiperidine-1-carboxylate (264g) and tert-
butyl (2R,6S)-6-(4’’-chlorobutyl)-2-methyl-4-oxopiperidine-1-carboxylate (265g) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of tert-butyl 
(2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (264a) using (2R,5E)-2-(tert-
butoxycarbonylamino)-10-chloro-4-oxodec-5-ene (258g) (0.0484 g, 0.0159 mmol). Purification by 
flash column chromatography using silica gel, eluting with 20% diethyl ether in petroleum ether 
(40–60) gave tert-butyl (2R,6R)-6-(4’’-chlorobutyl)-2-methyl-4-oxopiperidine-1-carboxylate (264g) 
(0.0269 g, 56%) as a white solid and tert-butyl (2R,6S)-6-(4’’-chlorobutyl)-2-methyl-4-
oxopiperidine-1-carboxylate (265g) (0.0160 g, 33%) as a clear oil. Data for tert-butyl (2R,6R)-6-(4’’-
chlorobutyl)-2-methyl-4-oxopiperidine-1-carboxylate (264g): Mp 58–59 °C; νmax/cm−1 (neat) 2975 
(CH), 1725 (C=O), 1688 (C=O), 1390, 1366, 1174, 1097; [α]D
22 +120.1 (c 1.0, CHCl3); δH (400 MHz, 
CDCl3) 1.25 (3H, d, J 6.6 Hz, 1’-H3), 1.30–1.47 (3H, m, 1-HH and 2’’-H2), 1.49 (9H, s, 3 × CH3), 1.69–
1.84 (3H, m, 3’’-H2 and 1’’-HH), 2.37 (1H, dd, J 17.8, 1.9 Hz, 3-HH), 2.52 (1H, dd, J 18.0, 2.0 Hz, 5-
HH), 2.73 (1H, ddd, J 18.0, 6.0, 0.8 Hz, 5-HH), 2.78 (1H, dd, J 17.8, 6.4 Hz, 3-HH), 3.51 (2H, t, J 6.5 
Hz, 4’’-H2), 4.09–4.24 (1H, m, 6-H), 4.26–4.43 (1H, m, 2-H); δC (101 MHz, CDCl3) 22.8 (CH3), 24.1 
(CH2), 28.6 (3 × CH3), 32.3 (CH2), 36.5 (CH2), 41.5 (CH2), 44.7 (CH2), 44.8 (CH2), 46.7 (CH), 51.0 (CH), 
80.2 (C), 154.7 (C), 207.9 (C); m/z (ESI) 326.1480 (MNa+. C15H2635ClNNaO3 requires 326.1493). Data 
for tert-butyl (2R,6S)-6-(4’’-chlorobutyl)-2-methyl-4-oxopiperidine-1-carboxylate (265g): 
νmax/cm−1 (neat) 2970 (CH), 1720 (C=O), 1682 (C=O), 1350, 1165; [α]D
24 −10.2 (c 1.2, CHCl3); δH (400 
MHz, CDCl3) 1.26 (3Η, d, J 7.0 Hz, 1’-Η3), 1.41–1.57 (12Η, m, 3 × CH3, 1’’-HH and 2’’-H2), 1.60–1.69 
(1Η, m, 1’’-ΗΗ), 1.73–1.86 (2H, m, 3’’-H2), 2.23–2.35 (2Η, m, 3-ΗΗ and 5-ΗΗ), 2.64–2.76 (2Η, m, 3-
ΗΗ and 5-ΗΗ), 3.52 (2 H, t, J 6.5 Hz, 4’’-H2), 4.53–4.66 (1Η, m, 6-Η), 4.67–4.80 (1Η, m, 2-Η); δC (101 
MHz, CDCl3) 22.7 (CH3), 24.2 (CH2), 28.4 (3 × CH3), 32.1 (CH2), 36.2 (CH2), 43.8 (CH2), 44.8 (CH2), 
45.5 (CH2), 48.6 (CH), 52.5 (CH), 80.4 (C), 154.8 (C), 208.5 (C); m/z (ESI) 326.1480 (MNa+. 
C15H2635ClNNaO3 requires 326.1493). 
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tert-Butyl (2R,6R)-6-(2’’-cyclohexylethyl)-2-methyl-4-oxopiperidine-1-carboxylate (264i) and 
tert-butyl (2R,6S)-6-(2’’-cyclohexylethyl)-2-methyl-4-oxopiperidine-1-carboxylate (265i) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of tert-butyl 
(2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (264a) using (2R,5E)-2-(tert-
butoxycarbonylamino)-8-cyclohexyl-4-oxodec-5-ene (258i) (0.0269 g, 0.0830 mmol). Purification 
by flash column chromatography using silica gel, eluting with 20% diethyl ether in petroleum ether 
(40–60) gave tert-butyl (2R,6R)-6-(2’’-cyclohexylethyl)-2-methyl-4-oxopiperidine-1-carboxylate 
(264i) (0.0149 g, 55%) and tert-butyl (2R,6S)-6-(2’’-cyclohexylethyl)-2-methyl-4-oxopiperidine-1-
carboxylate (265i) (0.0108 g, 40%) as a colourless oils. Data for tert-butyl (2R,6R)-6-(2’’-
cyclohexylethyl)-2-methyl-4-oxopiperidine-1-carboxylate (264i): νmax/cm−1 (neat) 2924 (CH), 1721 
(C=O), 1690 (C=O), 1389, 1366, 1173, 1096; [α]D
25 +105.9 (c 0.4, CHCl3); δH (400 MHz, CDCl3) 0.75–
0.95 (2H, m, CH2), 1.05–1.38 (11H, m, 1’-H3, 1’’-HH, 2’’-H2, 3’’-H, and 2 × CH2), 1.49 (9H, s, 3 × CH3), 
1.60–1.84 (5H, m, 1’’-HH and 2 × CH2), 2.36 (1H, dd, J 17.8, 1.9 Hz, 3-HH), 2.52 (1H, dd, J 17.9, 2.0 
Hz, 5-HH), 2.71 (1H, ddd, J 17.9, 6.2, 1.2 Hz, 5-HH), 2.80 (1H, dd, J 17.8, 6.4 Hz, 3-HH), 4.03–4.17 
(1H, m, 6-H), 4.28–4.44 (1H, m, 2-H); δC (101 MHz, CDCl3) 22.8 (CH3), 26.4 (2 × CH2), 26.7 (CH2), 
28.7 (3 × CH3), 33.4 (CH2), 33.6 (CH2), 34.6 (CH2), 34.7 (CH2), 37.7 (CH), 41.4 (CH2), 44.7 (CH2), 46.6 
(CH), 51.7 (CH), 80.0 (C), 154.7 (C), 208.3 (C); m/z (ESI) 346.2345 (MNa+. C19H33NNaO3 requires 
346.2353). Data for tert-butyl (2R,6S)-6-(2’’-cyclohexylethyl)-2-methyl-4-oxopiperidine-1-
carboxylate (265i): νmax/cm−1 (neat) 2924, 1689 (C=O), 1358, 1173; [α]D
25 −12.3 (c 0.3, CHCl3); δH 
(400 MHz, CDCl3) 0.78–0.95 (2Η, m, CΗ2), 1.04–1.35 (10Η, m, 1’-CH3, 2’’-H2, 3’’-H and 2 × CH2), 
1.40–1.48 (1Η, m, 1’’-ΗH), 1.48 (9H, s, 3 × CH3), 1.60–1.74 (5H, m, 1’’-HH and 2 × CH2), 2.20–2.36 
(2Η, m, 3-ΗΗ and 5-ΗΗ), 2.60–2.77 (2Η, m, 3-ΗΗ and 5-ΗΗ), 3.52 (2 H, t, J 6.5 Hz, 4’’-H2), 4.46–4.62 
(1Η, m, 6-Η), 4.63–4.78 (1Η, m, 2-Η); δC (101 MHz, CDCl3) 22.7 (CH3), 26.1 (CH2), 26.6 (CH2), 26.7 
(CH2), 28.4 (3 × CH3), 33.3 (CH2), 33.4 (CH2), 34.3 (CH2), 34.7 (CH2), 37.5 (CH), 43.9 (CH2), 45.6 (CH2), 
48.4 (CH), 53.1 (CH), 80.0 (C), 154.7 (C), 208.8 (C); m/z (ESI) 346.2341 (MNa+. C19H33NNaO3 requires 
346.2353). 
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tert-Butyl (2R,6R)-2-methyl-4-oxo-6-(2’’-phenylethyl)piperidine-1-carboxylate (264j) and tert-
butyl (2R,6S)-2-methyl-4-oxo-6-(2’’-phenylethyl)piperidine-1-carboxylate (265j) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of tert-butyl 
(2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (264a) using (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxo-8-phenyloct-5-ene (258j) (0.090 g, 0.284 mmol). Purification by flash 
column chromatography using silica gel, eluting with 20% ethyl acetate in petroleum ether (40–
60) gave tert-butyl (2R,6R)-2-methyl-4-oxo-6-(2’’-phenylethyl)piperidine-1-carboxylate (264j) 
(0.041 g, 46%) as a white solid and tert-butyl (2R,6S)-2-methyl-4-oxo-6-(2’’-
phenylethyl)piperidine-1-carboxylate (265j) (0.0276 g, 31%) as a clear oil. Data for tert-butyl 
(2R,6R)-2-methyl-4-oxo-6-(2’’-phenylethyl)piperidine-1-carboxylate (264j): Mp 76–78 °C; 
νmax/cm−1 (neat) 2973 (CH), 1724 (C=O), 1687 (C=O), 1389, 1366, 1173, 1096; [α]D
18 +97.7 (c 1.0, 
CHCl3); δH (400 MHz, CDCl3) 1.27 (3H, d, J 6.7 Hz, 1’-H3), 1.49 (9H, s, 3 × CH3), 1.58–1.70 (1H, m, 1’’-
HH), 2.04–2.16 (1H, m, 1’’-HH), 2.38 (1H, dd, J 17.8, 2.0 Hz, 3-HH), 2.54–2.69 (3H, m, 5-HH and 2’’-
H2), 2.77 (1H, dd, J 17.5, 5.6 Hz, 5-HH), 2.82 (1H, dd, J 17.8, 6.8 Hz, 3-HH), 4.20–4.30 (1H, m, 6-H), 
4.31–4.43 (1H, m, 2-H), 7.12–7.32 (5H, m, Ph); δC (101 MHz, CDCl3) 22.7 (CH3), 28.5 (3 × CH3), 33.2 
(CH2), 39.0 (CH2), 41.4 (CH2), 44.6 (CH2), 46.6 (CH), 50.9 (CH), 80.1 (C), 126.1 (CH), 128.3 (2 × CH), 
128.5 (2 × CH), 141.0 (C), 154.5 (C), 207.7 (C); m/z (ESI) 340.1875 (MNa+. C19H27NNaO3 requires 
340.1883). Data for tert-butyl (2R,6S)-2-methyl-4-oxo-6-(2’’-phenylethyl)piperidine-1-carboxylate 
(265j): νmax/cm−1 (neat) 2974 (CH), 1719 (C=O), 1687 (C=O), 1353, 1169; [α]D
19 +6.1 (c 1.0, CHCl3); 
δH (400 MHz, CDCl3) 1.31 (3H, d, J 6.9 Hz, 1’-H3), 1.48 (9H, s, 3 × CH3), 1.74–2.02 (2H, m, 1’’-H2), 
2.25–2.42 (2H, m, 3-HH and 5-HH), 2.54–2.78 (4H, m, 3’-HH 5-HH and 2’’-H2), 4.61–4.83 (2H, m, 2-
H and 6-H), 7.13–7.33 (5H, m, Ph); δC (101 MHz, CDCl3) 22.8 (CH3), 28.4 (3 × CH3), 33.4 (CH2), 39.0 
(CH2), 43.7 (CH2), 45.5 (CH2), 48.4 (CH), 52.6 (CH), 80.4 (C), 126.1 (CH), 128.3 (2 × CH), 128.5 (2 × 
CH), 141.2 (C), 154.8 (C), 208.3(C); m/z (ESI) 340.1878 (MNa+. C19H27NNaO3 requires 340.1883). 
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tert-Butyl (2R,6R)-2-methyl-6-(2’’-methylpropyl)-4-oxopiperidine-1-carboxylate (264k) and tert-
butyl (2R,6S)-2-methyl-6-(2’’-methylpropyl)-4-oxopiperidine-1-carboxylate (265k) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of tert-butyl 
(2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (264a) using (2R,5E)-2-(tert-
butoxycarbonylamino)-8-methyl-4-oxonon-5-ene (258k) (0.0804 g, 0.298 mmol). Purification by 
flash column chromatography using silica gel, eluting with 20% diethyl ether in petroleum ether 
(40–60) gave tert-butyl (2R,6R)-2-methyl-6-(2’’-methylpropyl)-4-oxopiperidine-1-carboxylate 
(264k) (0.032 g, 40%) and tert-butyl (2R,6S)-2-methyl-6-(2’’-methylpropyl)-4-oxopiperidine-1-
carboxylate (265k) (0.032 g, 40%) as colourless oils. Data for tert-butyl (2R,6R)-2-methyl-6-(2’’-
methylpropyl)-4-oxopiperidine-1-carboxylate (264k): νmax/cm−1 (neat) 2960 (CH), 1726 (C=O), 
1688 (C=O), 1389, 1369, 1175; [α]D
28 +34.4 (c 0.2, CHCl3); δH (500 MHz, CDCl3) 0.89 (3H, d, J 6.3 Hz, 
3’’-H3), 0.92 (3H, d, J 6.3 Hz, 2’’-CH3), 1.26 (3H, d, J 6.7 Hz, 1’-H3), 1.27–1.33 (1H, m, 2’’-H), 1.50 (9H, 
s, 3 × CH3), 1.52–1.58 (2H, m, 1’’-H2), 2.36 (1H, dd, J 17.8, 2.0 Hz, 3-HH), 2.52 (1H, dd, J 17.9, 2.0 
Hz, 5-HH), 2.72 (1H, ddd, J 17.9, 6.1, 1.0 Hz, 5-HH), 2.82 (1H, dd, J 17.8, 6.5 Hz, 3-HH), 4.22–4.30 
(1H, m, 6-H), 4.31–4.39 (1H, m, 2-H); δC (126 MHz, CDCl3) 21.4 (CH3), 22.9 (CH), 23.9 (CH3), 25.5 
(CH3), 28.7 (3 × CH3), 41.5 (CH2), 44.7 (CH2), 45.8 (CH2), 46.7 (CH), 49.4 (CH), 80.1 (C), 154.6 (C), 
208.2 (C); m/z (ESI) 292.1877 (MNa+. C15H27NNaO3 requires 292.1883). Data for tert-butyl (2R,6S)-
2-methyl-6-(2’’-methylpropyl)-4-oxopiperidine-1-carboxylate (265k): νmax/cm−1 (neat) 2961 (CH), 
1721 (C=O), 1686 (C=O), 1352, 1171, 1125; [α]D
28 −4.0 (c 0.3, CHCl3); δH (500 MHz, CDCl3) 0.91 (3H, 
d, J 6.5 Hz, 3’’-H3), 0.94 (3H, d, J 6.5 Hz, 2’’-CH3), 1.26 (3H, d, J 7.0 Hz, 1’-H3), 1.33–1.44 (2H, m, 1’’-
H2), 1.48 (9H, s, 3 × CH3), 1.51–1.59 (1H, m, 2’’-H), 2.25–2.33 (2H, m, 3-HH and 5-HH), 2.59–2.73 
(2H, m, 3-HH and 5-HH), 4.58–4.82 (2H, m, 2-H and 6-H); δC (126 MHz, CDCl3) 22.2 (CH3), 23.0 (CH), 
23.2 (CH3), 25.4 (CH3), 28.6 (3 × CH3), 44.1 (CH2), 45.6 (CH2), 46.0 (CH2), 48.4 (CH), 50.8 (CH), 80.4 
(C), 154.8 (C), 208.8 (C); m/z (ESI) 292.1877 (MNa+. C15H27NNaO3 requires 292.1883). 
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tert-Butyl (2R,6R)-2-methyl-6-(1’’-methylethyl)-4-oxopiperidine-1-carboxylate (264l) and tert-
butyl (2R,6S)-2-methyl-6-(1’’-methylethyl)-4-oxopiperidine-1-carboxylate (265l) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of tert-butyl 
(2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (264a) using (2R,5E)-2-(tert-
butoxycarbonylamino)-7-methyl-4-oxooct-5-ene (258l) (0.103 g, 0.403 mmol). Purification by 
flash column chromatography using silica gel, eluting with 20% diethyl ether in petroleum ether 
(40–60) gave tert-butyl (2R,6R)-2-methyl-6-(1’’-methylethyl)-4-oxopiperidine-1-carboxylate (264l) 
(0.027 g, 27%) and tert-butyl (2R,6S)-2-methyl-6-(1’’-methylethyl)-4-oxopiperidine-1-carboxylate 
(265l) (0.027 g, 27%) as colourless oils. Data for tert-butyl (2R,6R)-2-methyl-6-(1’’-methylethyl)-4-
oxopiperidine-1-carboxylate (264l): νmax/cm−1 (neat) 2968 (CH), 1724 (C=O), 1688 (C=O), 1381, 
1366, 1354, 1175; [α]D
27 +171.1 (c 0.2, CHCl3); δH (500 MHz, CDCl3) 0.92 (3H, d, J 6.5 Hz, 2’’-H3), 0.97 
(3H, d, J 6.5 Hz, 1’’-CH3), 1.26 (3H, d, J 6.5 Hz, 1’-H3), 1.49 (9H, s, 3 × CH3), 1.60–1.72 (1H, m, 1’’-H), 
2.33 (2H, dd, J 17.5, 2.2 Hz, 3-HH), 2.59 (1H, dd, J 18.0, 2.6 Hz, 5-HH), 2.66 (1H, dd, J 18.0, 5.8 Hz, 
5-HH), 2.79 (1H, dd, J 17.5, 6.5 Hz, 3-HH), 3.95–4.10 (1H, m, 6-H), 4.31 (1H, quin.d, J 6.5, 2.2 Hz, 2-
H); δC (126 MHz, CDCl3) 19.3 (CH3), 20.4 (CH3), 22.8 (CH3), 28.6 (3 × CH3), 35.1 (CH), 41.5 (CH2), 44.8 
(CH2), 47.0 (CH), 56.3 (CH), 80.1 (C), 155.5 (C), 208.6 (C); m/z (ESI) 278.1722 (MNa+. C14H25NNaO3 
requires 278.1727). Data for tert-butyl (2R,6S)-2-methyl-6-(1’’-methylethyl)-4-oxopiperidine-1-
carboxylate (265l): νmax/cm−1 (neat) 2972 (CH), 1718 (C=O), 1687 (C=O), 1365, 1172, 1120, 1066; 
[α]D
23 −47.6 (c 0.5, CHCl3); δH (500 MHz, CDCl3) 0.93 (3H, d, J 6.5 Hz, 2’’-H3), 0.97 (3H, d, J 6.5 Hz, 
1’’-CH3), 1.30 (3H, d, J 6.8 Hz, 1’-H3), 1.48 (9H, s, 3 × CH3), 1.76–1.84 (1H, m, 1’’-H), 2.29 (1H, ddd, 
J 15.5, 5.4, 0.9 Hz, 3-HH), 2.53–2.57 (2H, m, 5-H2), 2.67 (1H, dd, J 15.5, 7.7 Hz, 3-HH), 4.15–4.35 
(1H, m, 6-H), 4.52–4.75 (1H, m, 2-H); δC (126 MHz, CDCl3) 20.2 (CH3), 20.4 (CH3), 22.6 (CH3), 28.4 
(3 × CH3), 33.0 (CH), 42.0 (CH2), 45.5 (CH2), 48.1 (CH), 58.5 (CH), 80.2 (C), 155.3 (C), 208.8 (C); m/z 
(ESI) 278.1720 (MNa+. C14H25NNaO3 requires 278.1727). 
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(+)-Myrtine (244)198 
 
 
 
To a solution of tert-butyl (2R,6R)-6-(4’’-chlorobutyl)-2-methyl-4-oxopiperidine-1-carboxylate 
(264g) (0.049 g, 0.161 mmol) in tetrahydrofuran (2 mL) was added 2 M hydrochloric acid solution. 
The reaction mixture was stirred at room temperature for 4 h. The reaction mixture was 
concentrated in vacuo to afford a yellow residue. This was dissolved in acetone (5 mL) and 
saturated sodium hydrogen carbonate solution (3 mL) and water (2 mL) were added. The reaction 
mixture was stirred at room temperature for 48 h. The reaction mixture was poured onto 
saturated sodium hydrogen carbonate solution (50 mL), which was extracted with 
dichloromethane (3 × 50 mL). The combined organic layers were combined and washed with brine 
(50 mL), dried (MgSO4) and concentrated in vacuo to give the crude product as a yellow oil. 
Purification by flash column chromatography using silica gel, eluting with 4% methanol in 
dichloromethane gave (+)-myrtine (244) as a pale yellow oil (0.017 g, 62%). [α]D
24 +8.9 (c 0.3, CHCl3), 
lit.198 [α]D
22 +10.5 (c 0.9, CHCl3); δH (500 MHz, CDCl3) 0.95 (3H, d, J 6.8 Hz, 1’-H3), 1.15–1.35 (2H, m, 
2’’-HH and 3’’-HH), 1.52–1.76 (4H, m, 1’’-H2, 2’’-HH and 3’’-HH), 2.14–2.28 (3H, m, 3-HH and 4’’-
H2), 2.46 (1H, td, J 11.6, 2.8 Hz, 5-HH), 2.60–2.69 (1H, m, 6-H), 2.74–2.80 (1H, m, 5-HH), 2.83 (1H, 
dd, J 13.4, 6.8 Hz, 3-HH), 3.37 (1H, quin.d, J 6.8, 2.3 Hz, 2-H); δC (126 MHz, CDCl3) 11.2 (CH3), 23.5 
(CH2), 26.0 (CH2), 34.4 (CH2), 48.2 (CH2), 48.8 (CH2), 51.5 (CH2), 53.6 (CH), 57.2 (CH), 209.7 (C); m/z 
(ESI) 168 (MH+, 100%). 
 
(8R,10R)-8-Methyl-10-undecyl-1,5-dithia-9-azaspiro[5.5]undecane (280) 
 
 
 
A solution of tert-butyl (2R,6R)-2-methyl-4-oxo-6-undecylpiperidine-1-carboxylate (264f) (0.0570 
g, 0.136 mmol) in anhydrous dichloromethane (5 mL) was cooled to 0 °C and 1,3-propanedithiol 
(0.136 mL, 1.36 mmol) and boron trifluoride diethyl etherate (0.042 mL, 0.340 mmol) was added 
dropwise. The reaction was warmed to room temperature and stirred for 20 h. The reaction 
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mixture was then diluted with dichloromethane (50 mL), washed with 1 M sodium hydroxide (50 
mL) and brine (50 mL). The organic layer was dried (MgSO4) and concentrated in vacuo to give the 
crude product as a yellow oil. Purification by flash column chromatography using silica gel, eluting 
with 5% methanol in dichloromethane gave (8R,10R)-8-methyl-10-undecyl-1,5-dithia-9-
azaspiro[5.5]undecane (280) as a clear oil (0.0500 g, 90%). νmax/cm−1 (neat) 2922 (CH), 1465, 721; 
[α]D
24 +6.4 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 0.88 (3H, t, J 6.9 Hz, 11’’-H3), 1.16–1.41 (21H, m, 1’-
H3, 2’’-H2, 3’’-H2, 4’’-H2, 5’’-H2, 6’’-H2, 7’’-H2, 8’’-H2, 9’’-H2 and 10’’-H2), 1.58–1.76 (2H, m, 1’’-H2), 
1.86 (1H, dd, J 14.0, 7.4 Hz, 7-HH), 1.90–2.04 (3H, m, 3-H2 and 11-HH), 2.24 (1H, dd, J 14.2, 4.4 Hz, 
11-HH), 2.29 (1H, dd, J 14.0, 3.9 Hz, 7-HH), 2.77–2.94 (4H, m, 2-H2 and 4-H2), 3.08–3.21 (1H, m, 10-
H), 3.27–3.41 (1H, m, 8-H); δC (101 MHz, CDCl3) 14.3 (CH3), 21.7 (CH3), 22.8 (CH2), 25.6 (CH2), 26.6 
(2 × CH2), 26.8 (CH2), 29.7 (3 × CH2), 29.8 (2 × CH2), 32.1 (CH2), 35.1 (CH2), 41.3 (CH2), 44.0 (CH2), 
45.0 (CH), 47.9 (CH2), 50.2 (CH); m/z (ESI) 358.2583 (MH+. C20H40NS2 requires 358.2597). 
 
(−)-Solenopsin A (246)191 
 
 
 
To a solution of (8R,10R)-8-methyl-10-undecyl-1,5-dithia-9-azaspiro[5.5]undecane (280) (0.0710 
g, 0.155 mmol) in ethanol (10 mL) was added a suspension of Raney nickel (1.58 g) in ethanol (10 
mL). The reaction mixture was heated under reflux whilst purging with hydrogen for 0.5 h. The 
reaction was then stirred under reflux, under an atmosphere of hydrogen for a further 3 h. After 
cooling to room temperature, the reaction mixture was filtered through a Celite pad and then 
concentrated in vacuo. The resulting residue was dissolved in dichloromethane (50 mL) and 
washed with 2 M sodium hydroxide (50 mL) and brine (50 mL). The organic layer was dried (MgSO4) 
and concentrated to give the crude product as a yellow oil. Purification by flash column 
chromatography using silica gel, eluting with 20% methanol in chloroform gave (−)-solenopsin A 
(246) as a clear oil (0.0301 g, 77%). [α]D
25 −1.0 (c 0.5, MeOH), lit.191 [α]D −1.21 (c 0.94, MeOH); δH 
(400 MHz, CDCl3) 0.88 (3H, t, J 6.9 Hz, 11’’-H3), 1.07 (3H, d, J 6.5 Hz, 1’-H3), 1.19–1.70 (26H, m, 3-
H2, 4-H2, 5-H2, 1’’-H2, 2’’-H2, 3’’-H2, 4’’-H2, 5’’-H2, 6’’-H2, 7’’-H2, 8’’-H2, 9’’-H2 and 10’’-H2), 2.87 (1H, 
qd, J 6.8, 4.4 Hz, 6-H), 3.06 (1H, quin.d, J 6.5, 3.6 Hz, 2-H); δC (101 MHz, CDCl3) 14.3 (CH3), 19.7 
(CH2), 21.4 (CH3), 22.8 (CH2), 26.6 (CH2), 29.5 (CH2), 29.7 (3 × CH2), 29.8 (3 × CH2), 29.9 (CH2), 32.1 
(CH2), 33.1 (CH2), 46.0 (CH), 51.0 (CH); m/z (EI) 253 (M+, 11%), 238 (36), 210 (5), 126 (6), 111 (8), 
98 (100). 
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